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Abstract 
 
Mutations in RHBDF2, the gene encoding inactive rhomboid protein iRHOM2, result in 
the dominantly inherited condition Tylosis with oesophageal cancer (TOC). TOC causes 
plamoplantar keratoderma, oral precursor lesions and up to a 95 % life-time risk of 
oesophageal squamous cell carcinoma (SCC). The role of iRHOM2 in the epidermis is 
not well characterised, although we previously showed dysregulated epidermal growth 
factor receptor (EGFR) signalling and accelerated migration in TOC keratinocytes, and 
a role for iRHOM2 was shown in trafficking the metalloproteinase ADAM17. Substrates 
of ADAM17 include EGFR ligands and adhesion molecules.  
iRHOM2 localisation and function were investigated in frozen sections and keratinocyte 
cell lines from control and TOC epidermis. Although iRHOM2 was predicted to be an ER-
membrane protein, it showed cell-surface expression in control epidermis, with variable 
localisation in TOC. Increased processing and activation of ADAM17 was seen in TOC 
keratinocytes compared with control cells, suggesting that increased ADAM17-mediated 
processing of EGFR ligands may cause the changes in EGFR signalling. Downstream 
of iRHOM2-ADAM17, Eph/Ephrin and NOTCH signalling also appeared affected. 
Additionally, desmosomes in TOC epidermis lacked the electron-dense midline of the 
mature desmosomes seen in normal skin; this was accompanied by increased 
processing of desmoglein 2, a substrate of ADAM17. Expression and localisation of 
iRHOM2 was also investigated in TOC and sporadic SCC. iRHOM2 expression varied 
between SCC cell lines, and appeared to correlate with ADAM17 and NOTCH1 
expression in oesophageal SCC and head and neck SCC cells.  
In summary, iRHOM2 mutations in TOC appear to be gain-of-function in nature, resulting 
in increased ADAM17 processing and enhanced EGFR signalling. Questions remaining 
include the reason why iRHOM2 is found at the plasma membrane. Future study of the 
iRHOM2-ADAM17 pathway may provide additional insight into the mechanism of 
epidermal wound healing and the pathogenesis of oesophageal SCC.  
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Chapter 1: Introduction 
1.1 The Skin 
The skin is critical for functions including formation of the permeability barrier, innate 
immune defence, insulation and structural functions. The skin consists of three layers – 
the epidermis, dermis and hypodermis (figure 1.1 A; Chu, 2008). The hypodermis 
comprises mostly adipocytes, and is important in maintaining mechanical integrity, 
insulating the body and forming a reserve energy supply; the hypodermis also contains 
many blood vessels, lymphatic vessels and nerves. The dermis forms the bulk of the skin 
and is important for elasticity, tensile strength, and as the major structural element of the 
skin. The dermis also contains nerve endings, blood vessels, capillaries, and lymphatic 
vessels and a number of resident cells such as fibroblasts, macrophages and transient 
circulating immune cells (Chu, 2008).  
The epidermis forms the permeability barrier and the outermost layer of the skin. It has 
key roles in adhesion, immune function and protection against ultraviolet (UV) radiation 
(Kalinin et al., 2001; Chu, 2008; Fuchs, 2009). The epidermis joins to the dermis via the 
dermal-epidermal junction, a semi-permeable basement membrane barrier important in 
providing resistance against external shearing forces, directing cytoskeletal organisation 
and developmental signals, and in determining the polarity of growth (Chu, 2008). The 
basement membrane allows epidermal keratinocytes to adhere through integrins, which 
form interactions between adjacent cells and components of the extracellular matrix. 
Keratinocytes of the basal epidermal layer express the integrins α3β1 and α6β4 which bind 
laminin V, a major component of the basement membrane (Kulukian and Fuchs, 2013).     
1.1.1 The Epidermis 
The epidermis has a stratified structure with four layers: the basal layer, spinous layer, 
granular layer and stratum corneum (figure 1.1 B). Keratinocytes account for 
approximately 80% of the epidermis, and are interspersed with other cell types including 
melanocytes, langerhans cells and merkel cells (Chu, 2008). Melanocytes produce the 
pigment of the skin in melanosomes, which are vacuoles that may be transferred to 
surrounding keratinocytes, and give skin its overall pigmentation (Haass and Herlyn, 
2005). Langerhans cells are dendritic cells found predominantly in the suprabasal layer 
as well as in the spinous, granular and basal layers (Mutyambizia et al., 2009). They 
process antigens and present them to T-cells in the epidermis, and are therefore 
associated with allergic conditions such as atopic dermatitis. Merkel cells are slow-
adapting mechanoreceptors found among keratinocytes of the basal layer in areas of 
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high-tactile sensitivity, with the majority of Merkel cells forming close associations with 
nerve endings (Halata et al., 2003).     
The basal layer (stratum basale) comprises predominantly proliferating transit-amplifying 
cells: keratinocytes with a columnar shape that undergo a specific number of cell 
divisions before entering the differentiation pathway (Barrandon and Green, 1987; Fuchs 
and Raghavan, 2002). There is also a population of stem cells within the hair follicle that 
can contribute cells to the interfollicular epidermis, particularly during wound healing 
(Clayton et al., 2007; Mascré et al., 2012).   
The suprabasal layer, or stratum spinosum, consists of cells with many desmosomal 
‘spines’. Desmosomes are cell surface modifications attached to the keratin intermediate 
filaments, and are important in cell-cell adhesion and providing resistance to mechanical 
stress (Fuchs, 2009). Spinous cells located closer to the basal layer have rounded nuclei 
and a polyhedral shape and as they differentiate, they develop a flatter shape and begin 
to produce lamellar granules and keratohyalin granules. Organelles found in cells of the 
granular layer contain precursors of lipids and proteins needed for formation of the 
cornified envelope in the stratum corneum (Candi et al., 2005; Fuchs, 2009).   
1.1.1.1 Expression of keratins 
Expression of keratins in the epidermis and other epithelia changes with the 
differentiation status of the cells (Fuchs and Green, 1980). Keratins form the intermediate 
filaments, which anchor the epidermis to the basement membrane at hemidesmosomes 
in the basal layer, and to neighbouring epidermal cells via desmosomes (Yin and Green 
2004; Fuchs 2009). Proliferating basal cells express the smaller molecular weight 
keratins K5 and K14. Spinous cells retain keratins K5 and K14, but do not produce any 
more of these keratins under normal conditions. They begin to synthesise keratins K1 
and K10, which are known as differentiation-specific keratins (Fuchs and Green, 1980; 
Fuchs, 1995; Blanpain and Fuchs, 2009). In hyperproliferative disorders, K1 and K10 are 
down-regulated and keratinocytes produce the K6 and K16 keratins (Fuchs, 1995). 
Specific keratins may be expressed in particular regions of skin, for example K9 
expression is restricted to the palms and soles (Candi et al., 2005).  
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Figure 1.1 Structure of the skin and epidermis. The skin comprises three layers: the 
hypodermis; dermis and epidermis (A). The dermis attaches to the epidermis via the 
dermal epidermal junction, and contains fibroblasts, blood vessels, and circulating 
immune cells. B: The stratified structure of the epidermis, formed by the progressive 
differentiation of keratinocytes from the basal layer. The keratinocytes gain a flatter 
morphology as they move through the epidermal layers, and eventually undergo terminal 
differentiation. Expression of proteins, such as keratins, change during the differentiation 
process. The purple structures on the cells of the spinous layer, or stratum spinosum, 
are desmosomes, important for the mechanical integrity of the epidermis. Images are 
adapted from Chu, 2008 
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1.1.1.2 Differentiation 
Keratinocytes in the epidermis follow a program of progressive differentiation with 
mitotically active cells in the basal layer developing into the terminally differentiated 
corneocytes of the stratum corneum (Fuchs, 1990). Proliferation in the basal layer is 
balanced by desquamation of the cornified cell layer at the cell surface in a process of 
epidermal homeostasis (Candi et al., 2005; Blanpain and Fuchs, 2009). Lineage tracing 
experiments in the epidermis have shown that the keratinocytes form vertical columns of 
progressively differentiating cells within the epidermis, with keratinocytes from the basal 
layer providing cells to the more differentiated upper layers of the epidermis  (Clayton et 
al., 2007; Poulson and Lechler, 2010; Mascré et al., 2012). Stratification occurs through 
asymmetric cell divisions of the progenitor cells in the basal layer, with a balance of 
symmetric and asymmetric cell division maintaining epidermal development and 
homeostasis (Lechler and Fuchs, 2005; Clayton et al., 2007; Mascré et al., 2012). 
Around 80 % of basal cell divisions result in production of both a differentiating and a 
proliferating cell, thus maintaining the basal population (Clayton et al., 2007; Mascré et 
al., 2012).  
1.1.1.3 Terminal differentiation and formation of the stratum corneum 
Keratinocytes of the granular layer generate many of the structural proteins and lipids 
needed to form the stratum corneum (Candi et al., 2005; Fuchs, 2009). The cells contain 
basophilic keratohyalin granules containing predominantly profilaggrin, keratin filaments, 
loricrin and small proline rich proteins (SPR), components of the stratum corneum (Candi 
et al., 2005; Fuchs, 2009). Once profilaggrin is released from the keratohyalin granules, 
it is cleaved in a Ca2+-dependent manner, and subsequently aggregates the keratin 
intermediate filaments, forming macrofilaments and resulting in the flattened structure of 
the upper epidermal cells (Candi et al., 2005). Filaggrin is eventually degraded into 
molecules such as urocanic acid and pyrrolidone carboxylic acid, which aid hydration of 
the stratum corneum and protect against UV rays (Chu, 2008).  
Release of loricrin from keratohyalin granules allows it to bind to desmosomal structures. 
It is then cross-linked to the plasma membrane by tissue transglutaminases. Filaggrin 
and loricrin provide a scaffold for the cross-linking of other cornified envelope proteins, 
including involucrin, trichohyalin and SPRs (Candi et al., 2005). Complex cornified 
envelope lipids such as ceramides are also synthesised and covalently attached to 
cornified envelope proteins such as loricrin, reinforcing the barrier layer (Serre et al., 
1991; Steinert, 1998). Corneocytes are attached to each other by corneodesmosomes, 
which are proteolytically degraded in the uppermost layers of the cornified envelope to 
allow desquamation (Serre et al., 1991; Simon et al., 1996; Candi et al., 2005).     
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1.2 Cell-cell adhesion and communication in the skin 
The epidermis is subjected to high levels of mechanical stress, so cell-cell connectivity 
is critical for resisting mechanical forces and barrier function. Cell-cell adhesion and 
communication is mediated by adherens junctions (AJ) and tight junctions (TJ) which 
bind the actin cytoskeleton (Niessen, 2007); desmosomes, which bind the intermediate 
filament networks (Yin and Green 2004); and Gap junctions (GJs), which allow cells to 
communicate through transfer of small molecules and ions (Scott et al., 2012). The 
structures of the junctions are represented in figure 1.2. Further functions of cell-cell 
adhesion complexes in cell signalling include direct signalling via activity of junctional 
components. Junctions may also act as “landmarks” in the membrane for cell-signalling 
molecules (Niessen, 2007).  
Junctional proteins have multiple, overlapping roles, but the major functional types 
include structural roles critical for initiation and maintenance of the junctions, plaque 
proteins which associate with the cytoskeleton, and proteins that regulate signalling and 
polarity (Niessen, 2007). Regulation of cell-cell junctions can occur via transcriptional 
mechanisms, and by post-translational and signalling modifications such as 
phosphorylation of junctional components by growth factor signalling, cleavage of 
junction molecules by proteases, and endocytosis (Niessen, 2007).  
1.2.1 Gap junctions 
GJs are channels that allow the passage of small molecules and ions between the 
cytoplasm of adjacent epithelial cells, thus mediating the chemical coupling of the cells 
(Scott et al., 2012). GJs form by the joining of two hexameric hemichannels at the surface 
of adjacent cells (figure 1.2 A). The hemichannels cluster to form cell surface plaques 
which contain several hemichannels, ranging in number from a few channels to 
thousands of hemichannels per plaque (Goodenough and Paul, 2009).  
The hemichannels are formed by connexins, which are integral membrane proteins with 
four transmembrane domains (TMD); 6 connexins join to form the hexameric 
hemichannel (connexon), which can consist of a homomeric or heteromeric combination 
of connexins (Goodenough and Paul, 2009). There are 21 members of the connexin 
gene family named after their molecular weight, and most tissues express at least one 
type of connexin protein (Scott et al., 2012). The epidermis expresses a number of 
connexins, including connexins 26, 30, 30.3, 31, 37 and 43 (Wiszniewski et al., 2000; 
Di et al., 2001), and mutations in a number of these connexins are associated with 
syndromic and non-syndromic inherited skin diseases (Scott et al., 2012). The number 
of connexin channel subunits, and their homophilic or heterophilic assembly, results in 
an array of combinations that allow fine-tuning of the GJ channel properties 
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(Goodenough and Paul, 2009), such as charge selectivity and conductance (Bukauskas 
and Verselis, 2004; Rackauskas et al., 2007; Goodenough and Paul, 2009). 
The opening and closing of the GJ channel may be regulated by a number of 
mechanisms including voltage gating, changing unitary conductance of single channels, 
or altering the channel open probability. These properties may also vary between the 
two hemichannel components of the GJ, providing further diversity in channel properties. 
Slower methods of regulating channel properties include controlling the number of 
channels at the cell surface, the rate of synthesis and assembly of the hemichannels; 
and channel degradation and turnover. A number of these steps are dependent on post-
translational modifications such as phosphorylation, which can also stabilise the 
channels in a range of conductance states (Goodenough and Paul, 2009).  
1.2.2 Tight junctions 
Tight junctions are specialised structures that form a semi-permeable diffusion barrier 
between the apical and basolateral membrane domains of polarised cells (Niessen, 
2007). A diagram representing the structure of TJs is shown in figure 1.2 B.  
The major TJ proteins include junctional adhesion molecules (JAMs), claudins, occludins 
and the scaffolding proteins ZO-1 to 3 (Niessen, 2007). The precise role of occludins in 
tight junctions is unclear. TJs still form in the absence of occludins, however, loss of 
occludins in knock-out mice results in phenotypes associated with loss of barrier function 
(Saitou et al., 2000; Niessen, 2007). Furthermore, knock-down of occludins results in a 
number of changes in cell phenotype and TJ function in epithelial cells in vitro (Yu et al., 
2005). There are at least 24 members of the claudin family (Angelow et al., 2008), which 
are expressed in a tissue-specific manner. Claudins appear to be able to initiate tight 
junction formation, as exogenous expression of claudins intiated Ca2+-independent 
initiation of cell-cell adhesion (Furuse et al., 1998; Van Itallie et al., 2001; Nitta et al., 
2003). Specific expression of these claudins regulates ion size and charge selectivity of 
the semipermeable junctions (Van Itallie et al., 2001), with charge selectivity regulated 
by differences in the isoelectric point in the claudin extracellular loop (Colegio et al., 
2002).  
JAM proteins include JAM-A, B and C, and some more distantly related JAM proteins 
such as adenovirus receptor, endothelial cell-selective molecule and JAM4 (Niessen, 
2007). JAMs can form homo- or heterophilic interactions. JAM proteins are also found 
on the surface of cells that do not form TJ, such as leukocytes, to help mediate 
transendothelial migration (Ebnet et al., 2004). A role for JAM-4 has also been shown in 
recruiting polarity complexes (Gliki et al., 2004).  
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The cytoplasmic binding ZO proteins ZO-1 to 3 act as scaffolds for the formation of tight 
junctions (Niessen, 2007). The ZO family are membrane associated guanylate kinase-
like homologues, containing 3 N-terminal PDZ domains, and SH3 domain and a 
guanylate kinase (GUK) domain. ZO proteins interact with occludins and claudins via the 
PDZ domain, while their C-terminus can associate with actin, forming a direct link with 
the cytoskeleton (Schneeberger and Lynch, 2004). ZO-1 localisation to TJ is largely 
dependent on its actin binding domain (Fanning et al., 2002). ZO-1 can interact with 
JAMS directly, and forms homodimers or heterodimers with ZO-2 or ZO-3. Furthermore, 
ZO-1 and 2, but not ZO-3 have been shown to be important for tight junction clustering, 
strand formation and barrier function. Other scaffolding proteins include MUPP1 and 
MAG1 proteins, which associate with the TJ cytosolic plaque (Schneeberger and Lynch, 
2004). Cingulin, a non-PDZ TJ protein, interacts with ZO proteins, JAMs and actins via 
its head domain, while its central rod domain is required for homodimerization and 
interaction with myosin (Cordenonsi et al., 1999; Bazzoni et al., 2000; Guillemot et al., 
2004), providing a further link to the cytoskeleton.  
1.2.3 Adherens junctions 
AJ are critical in the initiation and maintenance of cell-cell adhesion, and are dynamic 
complexes even in fully polarised epithelia (Niessen, 2007). A representation of the AJ 
structure is shown in figure 1.2 C. AJ comprise two major units – the cadherin-catenin 
complex, and the nectin-afadin complex, which likely interact via interactions between 
afadin, α-catenin and the actin cytoskeleton (Tachibana et al., 2000; Ooshio et al., 2010). 
The nectin-afadin complex is also necessary for the recruitment of tight junction proteins 
to the apical side of the AJ (Yamada et al., 2006; Ooshio et al., 2010).  
There are four main nectin proteins (nectin 1-4), and also multiple splice variants of these 
proteins (Irie et al., 2004). Nectins are immunoglobulin (IgG)-like adhesion receptors 
containing a PDZ domain, which may provide the first scaffold for AJ and TJ formation 
(Irie et al., 2004; Niessen, 2007). Nectins form lateral homodimers and may also form 
intercellular interactions with other nectins in a homophilic or heterophilic manner, which 
varies depending on the individual nectin (Irie et al., 2004). Nectins form a unit with 
afadin, an actin binding protein also known as AF-6, which can also bind to the actin 
cytoskeleton (Irie et al., 2004).   
The cadherin-catenin complex component of AJ comprises type 1 classical cadherins 
such as epithelial cadherin (E-cadherin), neuronal cadherin (N-cadherin) and 
P-cadherin, which contain a typical cadherin extracellular repeat (Niessen, 2007). There 
are a number of other members of the cadherin family including the desmosomal 
cadherins desmoglein and desmocollin (Getsios et al., 2004). The catenins p120-catenin 
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and β-catenin bind to the cadherins via their Armadillo repeat domains (Niessen, 2007). 
α-catenin connects to the complex via β-catenin. In addition to its role at the AJ, β-catenin 
is a critical mediator of the Wnt signalling pathway, it can mediate signal-induced 
changes in cadherin adhesive contacts, and can directly interact with signalling proteins 
including the epidermal growth factor receptor (EGFR; Nelson and Nusse 2004). 
Phosphorylation of β-catenin by EGFR can disrupt its binding to cadherins, allowing it to 
translocate to the nucleus and fulfil its signalling roles (Roura et al., 1999; Park et al., 
2005).   
P120-catenin is part of the subfamily of Armadillo-repeat containing proteins which 
includes the desomosomal plakophilins, with binding of p120-catenin regulating 
junctional stability by regulating endocytosis of the junctions (Xiao et al., 2007). P120-
catenin also regulates and integrates intracellular signalling via Rho small GTPases 
(Anastasiadis, 2007).  
Binding of α-catenin to actin or β-catenin is mutually exclusive (Drees et al., 2005), 
however actin polymerisation is partly dependent on α-catenin, and occurs close to the 
AJ (Drees et al., 2005; Gates and Peifer, 2005; Yamada et al., 2006). Afadin is another 
point at which AJ bind directly to the actin cytoskeleton (Niessen, 2007). Actin-binding 
proteins and other regulatory proteins may also associate with the AJ and regulate actin 
binding, for example, ZO-1, vinculin, spectrin and α-actinin (Gates and Peifer, 2005; 
Scott and Yap, 2006; Scott et al., 2006). Cadherin or nectin engagement can induce 
activity of Rho small GTPases, which are regulators of actin dynamics. The regulation of 
Rho GTPases may be via upstream Rap small GTPases and recruitment of guanine-
nucleotide exchange factors (GEFs). RapGEFs interact with E-cadherin, which activates 
Rap, resulting in a positive loop reinforcing adhesion (Irie et al., 2004; Braga and Yap, 
2005). 
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Figure 1.2 Cell-cell junctions in the epidermis. The components of cell-cell junctions 
and their assembly into A: Gap junctions, B: Tight junctions (adapted from Niessen 
2007), C: Adherens junctions (adapted from Niessen 2007), and D: Desmosomes 
(adapted from Getsios et al 2004 and Thomason et al 2010).  
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1.2.4 Desmosomes  
Desmosomes are found in many tissues and organs in the body, particularly in tissues 
that undergo high levels of mechanical stress, with the highest expression found in the 
skin and heart (Getsios et al. 2004; Yin and Green 2004; Garrod et al. 2002). 
Desmosomes are critical in functions including cell-cell adhesion and communication, 
and an increasing number of cell signalling roles are emerging for desmosomal proteins 
(Getsios et al., 2004; Thomason et al., 2010). Their function in both adhesion and 
signalling means disruption of desmosomal components or their regulatory proteins 
through genetic or environmental factors result in a range of diseases throughout the 
body.   
Desmosomes comprise three main classes of protein: the cadherins; the armadillo-family 
proteins; and the plakin protein desmoplakin (Thomason et al., 2010; Brooke et al., 
2012). Cadherins include desmogleins and desmocollins, while armadillo proteins 
include plakophilins and plakoglobin (PG). PG is also known as γ-catenin and can 
associate with AJ, although it has a stronger affinity for the desmosomes (Choi et al., 
2009). Distinct expression of the desmosomal proteins is seen in different tissues, and 
in different layers of the epidermis (figure 1.3A; Borrmann et al. 2000; Getsios et al. 
2004).   
The desmosomal cell-cell contacts are formed by the desmosomal cadherins, with 
cadherins from neighbouring cells binding in a Ca2+-dependent manner (Nollet, et al., 
2000), as occurs with the classical cadherins in AJ. Once the desmosomes have formed, 
the dependence on Ca2+ is lost, with adhesion in mature desmosomes showing 
resistance to the extracellular Ca2+ concentration, or to Ca2+ chelation (Watt, 1984; 
Mattey and Garrod, 1986). Reversion of the Ca2+-independence of desmosomes is seen 
upon wounding of confluent monolayers of cells. The process is rapid, occurring in 
around 15 min, and appears to depend on protein kinase C (PKC), as inhibition of PKC 
promotes Ca2+-independence (Wallis et al., 2000; Garrod et al., 2005).  
Electron microscopy has shown desmosomes to form dense plaques in regions of 
cell-cell contact. An electron-dense midline is visible in mature, hyperadhesive, 
Ca2+-independent desmosomes, which is lost upon wounding both in vitro and in vivo, 
accompanied by a decrease in the size of the intracellular space (Garrod et al., 2005). A 
diagram showing the structure of the assembled desmosome is shown in figure 1.4. The 
thicker, inner dense plaque is visible below the cell surface, where PKPs link DSP and 
cadherins via PG, with an outer dense plaque formed where DSP binds to keratin 
intermediate filaments (Getsios et al., 2004).  
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1.2.4.1 Desmosomal Cadherins 
Cadherins span the cell membrane, linking with cadherins from adjacent cells in the 
intracellular space to form the electron-dense midline seen in electron microscopy 
images of mature desmosomes (Garrod et al., 2005; Green and Simpson, 2007). There 
are three members of the desmocollin family (DSC1-3) and four members of the 
desmoglein family (DSG1-4). The structure of cadherin proteins shares about 30% 
similarity with each other and with the classical cadherins N-Cadherin and E-Cadherin 
(Garrod et al., 2002), allowing for variability and fine tuning of adhesion properties in 
different tissues. Desmocollins have two forms - ‘a’ and ‘b’ forms, that differ at the 
c-terminal as a result of alternative splicing. Cadherins are synthesised with a 
pro-peptide domain and signal sites in the N-terminus, which are cleaved during protein 
maturation (Collins et al., 1991; Getsios et al., 2004).  
Cadherin structure is shown in figure 1.3 B. All cadherins contain four extracellular 
cadherin repeats (EC), including Ca2+ binding sites and a cell-adhesion recognition 
(CAR) site; extracellular anchor (EA); TMD; and intracellular anchor (IA) (Getsios et al., 
2004; Thomason et al., 2010). The desmocollin a isoforms and desmogleins contain an 
intracellular cadherin repeat sequence (ICS) which binds PG. The shorter b form 
contains a shortened version of the ICS, which lacks the PG-binding domain (Collins et 
al., 1991). Desmogleins contain an additional region that includes an intracellular proline 
rich linker (IPL), repeat unit domain (RUD) and a DSG terminal domain (Garrod and 
Chidgey, 2008; Thomason et al., 2010).    
DSG2 and DSC2 are expressed predominantly in the intestine and heart (Legan et al., 
1994; Schäfer et al., 1996). They are expressed at low levels in the basal layer of 
stratified epithelia such as the epidermis (Schäfer et al., 1996; Garrod et al., 2002), with 
slightly stronger expression in skin of the palm in adults, and stronger basal layer DSG2 
expression in neonatal epidermis (Mahoney et al., 2006). DSG1 and 3 are more strongly 
expressed in stratified epithelia (Mahoney et al., 2006; figure 1.3 A).  
Binding between cadherins can be either homophilic or heterophilic (Marcozzi et al., 
1998; Tselepis et al., 1998; Runswick et al., 2001; Garrod and Chidgey, 2008), and 
cadherins from the same cell can also bind each other in lateral interactions. Inter-
cadherin interactions tend to form in cis on the same cell, or in trans with adjacent cells 
(Boggon et al., 2002; Getsios et al., 2004). Lateral interactions between different 
cadherin subtypes may also occur following Ca2+ depletion, for example between N-
cadherin and desmosomal cadherins (Troyanovsky et al., 1999; Lorch et al., 2004).  
The importance of the balance of desmosomal cadherin expression during and after 
development is shown by the effect of modulating their expression in mice: for example, 
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DSG2 knock-out mice die after implantation (Eshkind et al., 2002), while overexpression 
of DSG2 in the epidermis leads to hyperproliferation and formation of papillomas 
(Brennan et al., 2007), which will be discussed in more detail later. DSC3 knock-out leads 
to pre-implantation lethality in mice, despite being thought to be an epidermal specific 
cadherin (Den et al., 2006). However, truncated DSC1 lacking the PG and PKP binding 
tail was shown to be sufficient for a normal epidermal phenotype (Cheng et al., 2004).  
1.2.4.2 Armadillo proteins  
The Armadillo family of proteins contain a central domain containing a variable number 
of 42 amino acid repeats, or arm sequences, which have some variations in their 
sequences. PG contains 12 arm repeats, allowing its binding to desmosomes or AJ 
(figure 1.3 B; Choi et al. 2009). Within the desmosome structure, PG acts as an adaptor 
protein, binding to the desmosomal cadherins, DSP, PKP2 and 3, and p0071, an 
armadillo protein also known as PKP4 (Getsios et al 2004). The plakophilins PKP1-3 
contain 9 arm repeats and a flexible bend-causing insert between repeats 5 and 6 (Choi 
et al., 2009), and can bind to DSP and cadherins (Getsios et al., 2004). 
PG may play a role in the linking (lateral association) of desmosomes and AJ in cultured 
cells and regulating desmosome size (Palka and Green, 1997), with deletion of the C-
terminus of PG leading to formation of large desmosomes. Furthermore, mice lacking 
PG showed mixing of desmosomal and AJ proteins in cardiac muscle (Ruiz et al., 1996). 
PG may mediate cross-talk between AJ and desmosomes. The structure of PG is also 
shown in figure 1.3B. 
PKP1-3 are expressed in a tissue and differentiation-specific manner (Neuber et al., 
2010). Alternative splicing of PKP1 and 2 results in two isoforms of these proteins 
(Mertens et al., 1996; Schmidt et al., 1997). PKP1-3 can all be expressed in the nucleus 
as well as in the desmosomes, with PKP1b found only in the nucleus. PKP1b is the 
longer isoform, so the additional sequence may contain a nuclear localisation signal 
(Schmidt et al., 1997; Garrod and Chidgey, 2008). PKPs may also be regulated and 
targeted to the membrane by 14-3-3 proteins which bind to phosphoserine motifs 
(Darling et al., 2005). Other desmosomal accessory components include p0071, 
sometimes referred to as PKP4 (Hatzfeld and Nachtsheim, 1996; Garrod and Chidgey, 
2008), which can locate to desmosomes or AJ and may be involved in cross-talk between 
the two adhesion structures.  
 
 
 
37 
 
 
 
 
Figure 1.3 Desmosomal proteins in the skin. A: Diagram indicating relative 
expression levels of desmosomal components within the epidermis. B: Diagrams 
representing the approximate protein structure of the desmosomal components, 
including the cadherins, the armadillo proteins, and DSP. The different isoforms of the 
desmogleins, plakophilins and DSP are also indicated. Adapted from Getsios et al 2004, 
Garrod and Chidgey 2005, Thomason et al 2010 and Chu, 2008. 
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1.2.4.3 Desmoplakin  
The plakin linker protein DSP is critical in anchoring the desmosome to the cytoskeleton 
via keratin intermediate filaments (Green et al., 1990), and is essential for desmosome 
formation (Getsios et al., 2004). Knock-out of DSP in mice is lethal by E6.5, with defects 
in desmosome assembly and/or stabilisation, and effects were seen on the tissue 
architecture (Gallicano et al., 1998), showing the importance of DSP and desmosomes 
in development.   
There are two DSP isoforms, formed by alternative splicing (Green et al., 1990) and a 
minor isoform, DSP 1a, has also been identified (Cabral et al., 2010). DSPI and II are 
expressed at equal levels in stratified epithelia (Angst et al., 1990). Cabral et al (2012) 
showed decreased levels of PKP1, DSC2 and DSC3 but not of other desmosomal 
proteins in HaCaT keratinocytes after DSP1 or DSPI and II knock-down. They showed 
greater importance of isoform II in maintaining cell-cell adhesion in HaCaT monolayers 
after mechanical stretching and in dispase adhesion assays, and a reduced number of 
desmosomes with less well defined inner and outer dense plaques (Cabral et al., 2012).   
The DSP structure comprises globular head and tail domains surrounding a coiled-coil 
rod region which is shorter in the DSPII isoform (figure 1.3 B). The coiled-coil rod region 
is thought to allow dimerization of DSP. The head is the plakin domain, which is important 
for protein-protein interactions, and which contains two pairs of spectrin repeats either 
side of a Src 3 homology domain (Jefferson et al., 2007; Garrod and Chidgey, 2008). 
The C-terminal tail has three plakin repeat domains (A, B and C) which each have 4 ½ 
copies of a 38 amino acid sequence. Repeats B and C are globular structures containing 
grooves that may allow binding of intermediate filament proteins (Choi et al., 2002). 
Association of DSP with intermediate filaments may be negatively regulated by a 
phosphorylation site in the glycine-serine-arginine rich domain at the C-terminal of DSP 
(Stappenbeck et al., 1994). In addition to anchoring the IFs, DSP associates with 
microtubule anchoring protein ninein, and plays an important role in differentiation-
specific microtubule organisation (Lechler and Fuchs, 2005).  
1.2.4.4 Other desmosomal proteins 
Other plakin proteins include envoplakin and periplakin, whose expression are 
concentrated in the upper layers of the epidermis, particularly in the cornified envelope 
(Ruhrberg et al., 1996, 1997). Envoplakin and periplakin have a similar structure to 
desmoplakin, with the periplakin N-terminal localising to the desmosomal membranous 
space, and the C-terminal localising with keratin intermediate filaments when transfected 
into cells (DiColandrea et al., 2000). Envoplakin predominantly forms aggregates with 
the intermediate filaments, in a process mediated by its rod domain (DiColandrea et al., 
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2000). The C-terminus of periplakin can stabilise the interaction of both periplakin and 
envoplakin with the intermediate filaments (Karashima and Watt, 2002).   
Corneodesmosin, expressed in the upper layers of the epidermis, is a secreted 
glycoprotein that is added to desmosomes before they are converted into 
corneodesmosomes in the upper layers of the epidermis. Corneodesmosin is thought to 
act as an adhesion protein (Simon et al., 2001; Jonca et al., 2002; Garrod and Chidgey, 
2008), and is necessary for desquamation.  
Perp is a more recently identified desmosomal-associated protein (Ihrie et al., 2005; 
Marques et al., 2005), although it is debated whether it is a direct desmosomal 
component, or plays a regulatory role (Ihrie and Attardi, 2005; Ihrie et al., 2005). Perp 
does not appear to be necessary for the function of desmosomes in simple epithelia, but 
seems to be important in desmosomal regulation in stratified epithelia as a target of p63 
(Ihrie et al., 2005). Perp has also been shown to play a role in apoptosis as a target of 
the p53-mediated apoptosis pathway (Attardi et al., 2000): in mouse embryonic 
fibroblasts (MEFs), expression of perp was sufficient to induce cell death.  
1.2.4.5 Desmosome assembly 
Desmosome formation in keratinocytes nearly always forms following AJ formation 
(Vasioukhin et al., 2000), with communication between the two types of adhesion 
junctions critical in mediating and regulating cell adhesion. Continuous assembly of 
hemi-desmosomes occurs in low calcium, and the hemi-desmosomes are constantly 
recycled by endocytosis (Demlehner et al., 1995). When extracellular Ca2+ 
concentrations increase, within 5 minutes, cell-cell contact is initiated mostly by AJ. 
E-Cadherin in the AJ can bind PKG/γ-catenin, p120-catenin, β-catenin or α-catenin at 
specific sites. Interactions with actin filaments are then formed (Pokutta and Weis, 2007).  
PG is thought to mediate the initial communication, as it binds to both AJ and 
desmosomes (Lewis et al., 1997; Getsios et al., 2004). E-Cadherin and PG may then 
recruit PKP3 to the cell border to initiate desmosome formation (Gosavi et al., 2011), 
with these three proteins present at low levels at the cell membrane even in low levels 
of Ca2+ (Gosavi et al., 2011). This assembly step is followed by recruitment of the rest of 
the desmosomal components, for example, the plakophilins can recruit DSP to cell-cell 
borders (Kowalczyk et al., 1999; Bornslaeger et al., 2001; Bonné et al., 2003; Koeser et 
al., 2003; Getsios et al., 2004). Plakophilins may also mediate lateral interactions 
between desmosomal components (Kowalczyk et al., 1999).  
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Figure 1.4 Structure of the desmosome and location of desmosomal proteins 
within the structure. This cartoon represents the structure of the desmosome, showing 
Ca2+-dependent cell-cell adhesion mediated by homophilic or heterophilic binding of 
cadherins, which forms the electron-dense midline seen in electron microscopy images 
of mature desmosomes. The cytoplasmic tail of the cadherins is bound to the 
desmoplakin head domain via plakophilin and plakoglobin-mediated adhesion, forming 
the desmosomal outer dense plaque. The tail domain of desmoplakin binds to keratin 
intermediate filaments, forming the translucent outer dense desmosomal plaque and 
connecting the desmosomes to the cytoskeleton. Adapted from Getsios et al 2004, 
Garrod et al 2008 and Thomason et al 2010.  
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1.2.4.6 Desmosomal signalling 
Desmosomes also regulate tissue organisation and morphogenesis, and an increasing 
number of signalling roles are being identified for desmosomal proteins Some examples 
include DSG1-mediated differentiation in the epidermis by suppression of EGFR- 
extracellular signal-related kinase (ERK)1/2 signalling (Getsios et al., 2009; Lin et al., 
2010). PG also interacts with receptor tyrosine kinases (RTKs) including the EGFR; and 
RTK-mediated phosphorylation regulates the interaction of PG with AJ and 
desmosomes, and likely also downstream signalling events (Gaudry et al., 2001; Miravet 
et al., 2003).  
PG (γ-catenin) can compensate for β-catenin at AJ (Wickline et al., 2013), however PG 
and β-catenin appear to have differing signalling roles. PG could not fulfil the roles of 
β-catenin in Wnt signalling in β-catenin knock-out mice or β-catenin null cells (Wickline 
et al., 2013). However, although it was not as effective as β-catenin, PG was able to 
regulate TCF/LEF transcription activity (Hu et al., 2003; Shimizu et al., 2008; Al-Jassar 
et al., 2013). Furthermore, overexpression of the two proteins in developing epidermis 
resulted in different outcomes: β-catenin induced a hyperproliferative phenotype with 
increased hair follicle differentiation, while PG overexpression suppressed both these 
phenotypes (Gat et al., 1998; Charpentier et al., 2000; Getsios et al., 2004).  
The plakophilins also have important roles in cell signalling, with PKPs found in the 
nucleus as well as in junctions (Bonné et al., 1999, 2003). Their function has been related 
to that of p120-catenin, and include regulation of trafficking, stabilisation, clustering and 
recycling of cadherins at the cell surface. PKPs have also been associated with RNA 
Polymerase III and RNA binding proteins (Mertens et al., 1996; Müller et al., 2003; 
Garrod and Chidgey, 2008), and PKP2 has been suggested to play a role in regulating 
cell shape, which is also a function of p120-catenin (Getsios et al., 2004). 
The wide range of adhesion and signalling roles of desmosomes mean that genetic 
mutations in the proteins result in a range of syndromic and non-syndromic phenotypes, 
in particular affecting the skin and the heart (Brooke et al., 2012; Nitoiu et al., 2014).  
1.3 Inherited Skin Diseases 
There are many inherited diseases affecting the skin and epidermis, which result from 
mutations in a number of genes, including those encoding proteins of the desmosome 
(Maruthappu et al., 2014; Nitoiu et al., 2014). Monogenic mutations may result in 
conditions such as keratodermas, ichthyoses, and blistering conditions, and result from 
mutations in a diverse range of genes via a number of mechanisms. These include 
barrier proteins such as filagrin and transglutaminase; structural and adhesion proteins 
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such as desmosomal components and collagens; cell-cell communication proteins such 
as the connexins; proteases and their inhibitors (Nagy and McGrath, 2010; Fine et al., 
2014; Maruthappu et al., 2014; Nitoiu et al., 2014).  
Inherited skin conditions can also be syndromic, for example loss of the 
metalloproteinase A Disintegrin and Metalloproteinase 17 (ADAM17) leads to 
inflammatory skin and bowel disease (Blaydon et al. 2011), and mutations in 
desmosomal proteins lead to an array of syndromic and non-syndromic conditions 
including arrhythmic right ventricular cardiomyopathy (Nitoiu et al., 2014). Tylosis with 
oesophageal cancer (TOC) is a form of palmoplantar keratoderma (PPK) associated with 
a high life-time risk of developing oesophageal cancer (Ellis et al., 1994; Hennies et al., 
1995; Stevens et al., 1996).  
1.3.1 Mutations in desmosomal proteins 
A number of diseases arise from mutations in desmosomal proteins, including 
palmoplantar keratoderma (PPK), ectodermal dysplasia, hair disorders and 
cardiomyopathies, such as arrhythmic right ventricular cardiomyopathy (ARVC) (Brooke 
et al., 2012; Al-Jassar et al., 2013). The pathologies resulting from desmosomal 
mutations are complex – different mutations in the same desmosomal protein can cause 
different phenotypes, with no obvious clustering of mutations in the protein structure (Al-
Jassar et al., 2013; Nitoiu et al., 2014).  
The phenotype typically reflects tissue-specific expression and the adhesion properties 
of desmosomal components; phenotypes include acantholysis and blistering, thickening 
and epidermal hyperproliferation. However, desmosomal dysregulation may also result 
in disrupted intracellular organisation and signalling (Al-Jassar et al., 2013), reflecting 
the diverse roles of desmosomal proteins. For example, PKP2 mutations have recently 
been linked to the dysregulated trafficking of sodium channels in cardiomyopathy and 
Brugada syndrome (Cerrone and Delmar, 2014).  
There are a number of genetic mechanisms by which desmosomal mutations cause 
disease. For example, autosomal dominant mutations in DSP (Armstrong et al., 1999) 
and DSG1 (Kljuic et al., 2003) were identified in striate PPK, with the conditions 
appearing to cause disease through a mechanism of haploinsufficiency. However, 
homozygous loss-of-function (LOF) mutations in DSG1 resulted in a syndrome of severe 
dermatitis, allergies and metabolic wasting, with the patients’ parents suffering from the 
less severe non-syndromic striate PPK resulting from heterozygous DSG1 mutations 
(Samuelov et al., 2014).  
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Recessive DSP mutations are found in conditions such as Carvajal syndrome, which is 
characterised by ARVC with dilated cardiomyopathy, woolly hair, striate PPK and 
hyperkeratosis. The symptoms of Carvajal syndrome reflect the keratin binding 
properties of DSP, with hyperkeratosis occurring at sites of stress in the skin such as the 
joints, caused by loss of the keratin binding site affecting the intermediate filaments as 
well as cell adhesion (Norgett et al., 2000; Huen et al., 2002; Getsios et al., 2004). Loss 
of PG results in a reduction in the number of desmosomes, and loss of adhesion 
structures between keratinocytes in a lethal condition resulting from homozygous 
mutations in JUP, the gene encoding PG (Pigors et al., 2011). Recessive mutations in 
JUP were also found in patients with skin fragility, diffuse PPK and woolly hair, but these 
patients did not have any signs of ARVC (Cabral et al. 2010). 
1.3.2 Mutations causing defects in protein folding  
Cutaneous disease also arises from mutations in desmosomal regulatory proteins. 
Darier’s disease results from mutations in the ATP2A2 gene, which encodes the 
SERCA2 Ca2+ pump (Sakuntabhai et al., 1999). Symptoms of Darier’s disease include 
acantholysis, abnormal keratinisation and mucosal lesions, with formation of papules 
and plaques in seborrheic regions (Beck et al., 1977; Sakuntabhai et al., 1999). SERCA2 
maintains endoplasmic reticulum (ER) Ca2+ stores, which are required for post-
translational processing, folding and export of proteins such as DSP to the plasma 
membrane upon cell-cell contact (Jamora and Fuchs, 2002). If the Ca2+ store is depleted, 
misfolded proteins accumulate in the ER, leading to induction of the unfolded protein 
response (UPR) (Yoshida, 2007).   
The impaired adhesion and acantholysis associated with Darier’s disease appear to 
result from impaired trafficking of DSP (Dhitavat et al., 2003; Hobbs et al., 2011; Celli et 
al., 2012), which was associated with dysregulation of AJ and other desmosomal 
proteins, and enhanced further by treatment with thapsigargin, a specific inhibitor of 
SERCA pumps (Thastrup et al., 1994). Keratinocytes from patients with Darier’s disease 
showed constant activation of the UPR (Savignac et al., 2014), which could be reversed 
by treatment with α-glucosidase inhibitor Miglustat, allowing normal formation of AJ and 
desmosomes (Savignac et al., 2014).   
The condition Erythrokeratoderma Variabilis (EKV) is caused by mutations in the 
Gap-junction proteins Connexin 31 and Connexin 30.3 (Richard et al., 1998; Wilgoss et 
al., 1999; Macari et al., 2000; Gottfried et al., 2002; Terrinoni et al., 2004). EKV also 
results from protein misfolding, defective trafficking and activation of the UPR (Di et al., 
2002; Tattersall et al., 2009). EKV is characterised by fixed hyperkeratotic plaques, 
mainly on the extensor surfaces of the limbs, and transient erythematous patches. The 
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erythematous patches can last from a few hours to a few weeks and can sometimes 
migrate, when they are followed by fine white scaling. Around 50% of patients also suffer 
from PPK (Common et al., 2005). Activation of the UPR in HeLa cells and keratinocytes 
was shown by increased expression of UPR markers activating transcription factor 6 
(ATF6), and ER chaperone GRP78, also known as BiP (binding protein; Tattersall et al., 
2009). UPR activation results in up-regulation of factors to assist the cell with protein 
folding and alleviate the ER stress. However, if activation of the UPR does not resolve 
the ER stress, it eventually leads to cell death (Yoshida, 2007). Consistent with this, a 
high level of cell death was seen in cells transfected with EKV-causing mutant 
connexin 31 (Di et al., 2002; Diestel et al., 2002; Tattersall et al., 2009).  
1.3.3 Ichthyoses, including Harlequin Ichthyosis 
Ichthyoses are characterised by scaling of the skin, often covering the whole surface of 
the epidermis, hyperkeratosis, or a combination of both conditions, and may also present 
in a syndromic or non-syndromic manner (Oji et al., 2010). Identified genes associated 
with ichthyoses include TGM-1, encoding transglutaminase-1; FLG, encoding filagrin; 
CYP4F22, a member of the cytochrome p450 family; and ALOX12B, which codes for an 
epidermal-type lipoxygenase enzyme (Oji et al., 2010). Autosomal recessive ichthyoses 
(ARCI) comprise three main groups: ichthyosiform erythroderma; lamellar ichthyosis; 
and the most severe form of ichthyosis, Harlequin Ichthyosis (HI) (Maruthappu et al.. 
2014). Babies with ARCI are often born with a collodion membrane, which is shed during 
the first months of life (Ahmed and O’Toole, 2014).  
HI results from recessive LOF mutations in the lipid transporter ABCA12 gene (Kelsell et 
al., 2005), which may be homozygous or compound heterozygous (Akiyama et al., 2006, 
2007; Thomas et al., 2006). The type and position of the mutations affects the severity 
of the HI phenotype (Ahmed and O’Toole, 2014). At birth, babies born with HI have hard 
scale plate with deep fissures, eclabium, and bilateral ectropion, with a high perinatal 
mortality rate (Kelsell et al., 2005; Oji et al., 2010). Those that survive the perinatal period 
develop a severe, highly scaling erythroderma (Oji et al., 2010; Ahmed and O’Toole, 
2014).  
ABCA12 encodes the ATP-binding cassette family of transporters, and transports 
glucosylceramides through the lamellar granules to the extracellular space (Scott et al., 
2013). As ABCA12 protein function is severely disrupted in HI, lamellar granules are 
distorted, reduced or absent, and the lipid layer is severely reduced (Ishida-Yamamoto 
et al., 2005; Akiyama et al., 2006; Akiyama, 2011; Scott et al., 2013). Severe 
hyperkeratosis occurs as a compensatory mechanism for the loss of lipids, and the skin 
barrier is impaired; this likely explains why HI is associated with increased incidence of 
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infection and dehydration (Radner and Fischer, 2014). Although HI is associated with a 
high mortality rate in the first few weeks of life, understanding and treatment of the 
condition are improving and survival rates are increasing (Ahmed and O’Toole, 2014).  
1.3.4 Mutations in proteases and their inhibitors 
Another form of Ichthyosis, Exfoliative Ichthyosis, results from mutations in the CSTA 
gene encoding protease inhibitor Cystatin A (Blaydon et al. 2011b). An increasing 
number of proteases and their regulatory proteins are being identified as the cause of 
cutaneous diseases and syndromes (Curtis and Kelsell, 2013). Exfoliative ichthyosis, 
also known as peeling skin syndrome, is an autosomal recessive condition characterised 
by peeling of the skin of the palms and soles and dry scaly skin (Blaydon et al. 2011b). 
Cystatin A inhibits proteases including the Cathepsins B, H and L (Pavlova et al., 2002; 
Jenko et al., 2003; Renko et al., 2010). The mechanism by which Cystatin A mutations 
lead to Exfoliative Ichthyosis appear to involve detachment of the skin in the basal and 
suprabasal layers, and knock-down of the Cystatin A protein in vitro in keratinocytes 
results in impaired adhesion, in particular following mechanical stress (Blaydon et al. 
2011b).  
Protease activity, including that of the Cathepsins, is also important for the barrier 
function of the skin and in wound healing (Brocklehurst and Philpott, 2013; Curtis and 
Kelsell, 2013; Martins et al., 2013). In addition, increases in protease activity are 
frequently associated with inflammatory disease (Curtis and Kelsell, 2013). Homozygous 
LOF mutations in ADAM17, the gene encoding ADAM17, were identified in two siblings 
suffering from an inflammatory skin and bowel disease. The boy has survived into 
adulthood and leads a relatively normal life. The girl died aged 12 from fulminant 
parvovirus B19-associated myocarditis, and the boy was later found to have left 
ventricular dilatation (Blaydon et al. 2011). The skin and bowel symptoms associated 
with loss of ADAM17 function include perioral and perianal lesions with a generalised 
pustular rash, flares of erythema and scaling, frequent skin and bowel Staphylococcus 
aureus infections, wiry and disorganised hair, and nail abnormalities (Blaydon et al. 
2011).  
ADAM17 is a metalloproteinase responsible for shedding of a wide range of substrates, 
including cell-cell adhesion proteins (Pruessmeyer and Ludwig, 2009), and will be 
described in more detail in section 1.5. In contrast to ADAM17 LOF in inflammatory skin 
and bowel disease (Blaydon et al. 2011), the autosomal dominantly inherited syndrome 
TOC, caused by gain of function (GOF) variants in the inactive rhomboid protein 
iRHOM2, appears to result from a gain of ADAM17 function (Blaydon et al., 2012; Brooke 
et al., 2014) and will form the focus of this thesis.  
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1.3.5 Tylosis with oesophageal cancer 
Recently, our group identified mutations in the RHBDF2 gene, which encodes the 
inactive Rhomboid protein iRHOM2, in patients with the syndrome Tylosis with 
Oesophageal Cancer (TOC; OMIM 148500; Blaydon et al., 2012). TOC is an autosomal 
dominant condition characterised by symptoms including PPK, oral leukoplakia (figure 
1.5 A), follicular papules and nail abnormalities. The patients also suffer from 
oesophageal lesions and have up to a 95% life time risk of developing oesophageal 
squamous cell carcinoma (OSCC), which develops by age 65 (Ellis et al., 1994; Hennies 
et al., 1995; Stevens et al., 1996).   
The TOC mutations were found in three families from the UK, the US, and Germany, 
with the UK and US families having large pedigrees. The c.557T>C (p.Ile186Thr) 
mutation was identified in both the UK and US families, and the mutation c.566C>T 
(p.Pro189Leu) was found in the German family (Blaydon et al., 2012). Subsequently, the 
c.562G>A (p.Asp188Asn) mutation was identified in a Finnish family suffering from TOC 
(Saarinen et al., 2012). The mutations occur within 9 base pairs of the RHBDF2 gene, 
or four amino acids of the protein, in a region of the iRHOM2 protein that is highly 
conserved in a number of different species, and also conserved between iRHOM1 and 
iRHOM2 (figure 1.5 B; Blaydon et al. 2012).   
1.4 Rhomboid proteins 
Rhomboid proteins were first identified in drosophila and named due to the misshapen 
heads of mutant larvae (Urban et al., 2001). Drosophila Rhomboid protein (now known 
as Rhomboid-1 or dRho-1) was shown to be involved in EGFR signalling through 
cleavage of Spitz, an EGFR ligand and homologue of human TGF-α (Wassermanet al., 
2000; Freeman, 2009). The rhomboid protein family is conserved in all eukaryotes and 
many prokaryotes, and involvement of the rhomboid proteases has been reported in 
processes such as quorum sensing in bacteria, invasion of host cells by parasites and in 
mitochondrial fusion and remodelling (Freeman, 2009). Rhomboids typically contain 
7TMD and act as serine proteases, cleaving substrates in their transmembrane region.   
There are four subgroups of mammalian rhomboids: Secretase A and B; PARL; and 
iRHOMs (Lemberg and Freeman, 2007b). Secretase-A type rhomboids are named for 
their predicted localisation in the secretory pathway. They have 7TMD and include 
dRho1 and human RHBDL2. Secretase-B, or basic rhomboids, have six TMD and 
include E. coli GlpG and Human RHBDL4. PARL-type rhomboids such as drosophila 
Rhomboid-7 and human Presenilin-Associated-Rhomboid Like (PARL) contain the 
7TMD characteristic of rhomboid proteins, and are all predicted to be found in the 
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mitochondria. The final rhomboid group is the inactive rhomboids, iRHOM1 and 2, which 
are encoded by the genes RHBDF1 and RHBDF2 respectively (Lemberg and Freeman, 
2007b; Freeman, 2009).   
1.4.1 The Inactive Rhomboids 
iRHOMs have the typical rhomboid 7TMD, with an extended N-terminus and large loop 
L1 (figure 1.5 C; Lemberg and Freeman 2007; Freeman 2008). The physiological role of 
the iRHOMs is just beginning to be understood, with the iRHOM2 mutations in TOC 
providing insight into the importance of iRHOM2 in the skin and oesophagus (Blaydon et 
al., 2012). A likely role for iRHOM2 in rheumatoid arthritis was also recently 
demonstrated (Issuree et al., 2013). iRHOM1 and iRHOM2 lack the catalytic residues 
present in active rhomboids proteases (Koonin et al., 2003; Nakagawa et al., 2005; 
Freeman, 2009; Adrain et al., 2011). Instead, iRHOMs contain a highly conserved proline 
residue N-terminal to the catalytic serine, with a critical sequence of GPx rather than the 
GxS motif found in active proteases (Zettl et al., 2011). Substituting the proline residue 
into the sequence of RHBDL2 significantly lowered its catalytic activity. Zettl et al (2011) 
also demonstrated the lack of catalytic activity of iRHOM1 and iRHOM2 in a proteolytic 
activity assay. The N-terminal of the iRHOMs does not appear to be similar to any other 
proteins; the N-terminal of iRHOM1 contains a PEST (protein domain enhanced in serine 
and threonine) domain which is likely to be used for rapid proteolytic degradation 
(Rechsteiner, 1988; Nakagawa et al., 2005).   
iRHOM1 has been shown to be highly expressed in heart, lung, skeletal muscle and 
placenta with low levels in the colon, kidney and small intestine. It is barely detectable in 
the brain and peripheral blood monocytes (PBMCs) and not seen in any other tissues 
tested (Nakagawa et al., 2005). iRHOM2 appears most highly expressed in 
macrophages (Christova et al. 2013; Su et al. 2004, 
www.biogps.org/#goto=genereport&id=79651). Both iRHOMs are reported to localise to 
the ER and golgi in cultured cells (Nakagawa et al., 2005; Zou et al., 2009; Zettl et al., 
2011; Hosur et al., 2014).  
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Figure 1.5 Tylosis with oesophageal cancer (TOC) is caused by mutations in 
RHBDF2, the gene encoding the inactive rhomboid protein iRHOM2. A: Pictures 
showing two of the clinical symptoms of TOC: plantar keratoderma and oral leukoplakia. 
B:  Sequence alignment showing that the mutations in the RHBDF2 gene are found in a 
highly conserved region of the iRHOM2 protein (Blaydon et al., 2012). C: The protein 
structure of iRHOM2, showing the 7TMD, large loop L1 and long N-terminus, which 
accounts for approximately half of the protein. The numbers on the diagram indicate the 
amino acid numbers for each predicted region of the iRHOM2 protein (Uniprot database; 
www.uniprot.org). References for RHBDF2 mutations: 1. Blaydon et al 2012. 2. Saarinen 
et al., 2012.   
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Reflecting tissue-specific expression of the iRHOMs, murine knock-out of iRhom1 and 2 
has very different consequences. iRhom1-/- mice were indistinguishable from their 
littermates at birth, but failed to gain weight and died within 9 days or 6 weeks of birth, 
depending on the background strain (Christova et al., 2013). The mixed background 
mice, who survived longer, suffered a number of phenotypic effects, including myocardial 
infarction which likely resulted from thrombi development. All iRhom1-/- mice suffered 
brain haemorrhages, and the mice also suffered bone marrow, spleen, thymus and 
pancreatic defects (Christova et al., 2013). In contrast, iRhom2 knock-out mice appear 
healthy, and are fertile with no morphological defects, showing only an altered response 
to infection despite a normal immune cell distribution (McIlwain et al., 2012). Double 
knock-out of both iRhoms was embryonic lethal (Christova et al., 2013). 
1.4.2 Rhomboid Proteases 
A number of studies have contributed to elucidation of the rhomboid protease 
mechanism (Lemberg and Freeman, 2007a). Two highly conserved residues critical for 
Rhomboid catalytic activity were first identified as Ser201 and His254 in the E. coli 
rhomboid GlpG (Wang et al., 2006) and in H. influenzae GlpG (Lemieux et al., 2007). 
Rhomboid substrate specificity involves recognition of a ‘partially disordered 
conformation’ caused by several helix de-stabilising residues, particularly glycines and 
alanines, found in the luminal region of the substrate TMD (Urban and Freeman, 2003).  
1.4.2.1 RHBDL2 
The expression profile of RHBDL2 shows variable levels of expression between different 
mammalian tissues (Adrain et al. 2011; Su et al. 2004, http://www.biogps.gnf.org/).  
Variation in expression levels of RHBDL2 was seen between tumour cell lines (Adrain et 
al., 2011), suggesting that there may be different modes of regulating EGFR signalling 
in different tissues. A role for the human rhomboid protease RHBDL2 in EGFR signalling 
has been demonstrated (Adrain et al., 2011), suggesting that at least some of its function 
is conserved from dRho1. RHBDL2 is activated by proteolytic cleavage in loop L1 by an 
unidentified protease, which is sensitive to high doses of the gamma-secretase 
sulphonamide inhibitor GS118, but not to other gamma secretase inhibitors (Lei and Li, 
2009). In cultured cells, the N-terminal fragment translocates to the cell membrane 
following cleavage while the C-terminal portion seems to remain in the ER membrane.  
Staining of human cell lines demonstrated that RHBDL2 exists almost completely in the 
cleaved, activated state in those cell lines (Lei and Li, 2009). Substrates of RHBDL2 
identified thus far contain an epidermal growth factor (EGF)-like domain and include EGF 
(Adrain et al., 2011), thrombomodulin (Lohi et al., 2004) and members of the Ephrin B 
family, in particular Ephrin B3 (Pascall and Brown, 2004).   
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1.4.2.1.1 RHBDL2 substrates - Thrombomodulin 
Thrombomodulin is a type-1 transmembrane glycoprotein expressed on the surfaces of 
endothelial cells and epidermal keratinocytes (Esmon, 1995; Lager et al., 1995; Weiler 
and Isermann, 2003) and is involved in many physiological and pathophysiological 
processes. Lohi et al (2004) identified thrombomodulin as a potential substrate of 
RHBDL2 due to its EGF-like domain and because it contained a rhomboid recognition-
like region (based on the protein conformation). They demonstrated a low-level of 
cleavage of thrombomodulin by RHBDL2 but not RHBDL1. Cleavage was unaffected by 
the metalloprotease inhibitor batimastat, and was dependent on the cytoplasmic domain 
of thrombomodulin (Lohi et al., 2004). The RHBDL2-thrombomodulin pathway has been 
demonstrated to be relevant to cutaneous wound healing (Cheng et al., 2011).   
1.4.2.1.2 RHBDL2 substrates – Ephrin B3 
Ephrins are ligands for the Eph tyrosine kinase receptors. Eph-Ephrin signalling is 
bi-directional, affecting both the signal-sending and signal-receiving cell. Eph-Ephrin 
signalling is involved in processes including cell-cell communication, adhesion and 
migration (Pasquale, 2005, 2008) and can be dysregulated in cancer (Pasquale, 2010). 
Pascall and Brown (2004) first identified Ephrin B2 as a potential substrate of RHBDL2 
due to close sequence similarity in the luminal region with Spitz. Ephrin B1 and 3 do not 
contain this sequence but have many helix-destabilising alanines and glycines in the 
transmembrane region. RHBDL2 was shown to cleave a small amount of Ephrin B1, 
cleaved slightly higher levels of Ephrin B2 and showed robust cleavage of Ephrin B3. 
The cleavage of EphrinB3 appeared specific to RHBDL2 and dRho1, as no cleavage 
was seen in the presence of RHBDL1 or RHBDL4 (Pascall and Brown 2004). Ephrin B3 
cleavage probably occurs in the transmembrane region of the protein, and was 
independent of the cytoplasmic domain, in contrast to thrombomodulin cleavage (Pascall 
and Brown 2004; Lohi et al. 2004).   
1.4.2.1.3 RHBDL2 substrates - EGF 
The third protein reported as a substrate of RHBDL2 is EGF, which binds to the EGFR. 
This is consistent with the EGFR signalling role of dRho1 in drosophila (Wasserman et 
al., 2000), indicating conservation of rhomboid function in mammals. EGFR signalling is 
critical in development and is dysregulated in many cancers (Salomon et al., 1995). 
Adrain et al. (2011) demonstrated cleavage of Myc-tagged EGF; only slight cleavage of 
betacellulin and rat Nrg1; and no cleavage of other EGF-like ligands. This indicates that 
RHBDL2 signalling has a degree of specificity in the EGFR pathway. These findings 
contrast with previous findings by Pascall and Brown (2004), who did not see cleavage 
of any mammalian EGF-like ligand. However, Adrain et al (2011) explained that this may 
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be because the chimeras used by Pascall and Brown (2004) were missing EGF residues 
in the juxtamembrane region needed for cleavage by RHBDL2. 
EGF cleavage by RHBDL2 was independent of ADAM metalloproteinases, shown by 
experiments carried out in the presence and absence of the metalloprotease inhibitor 
BB94. The cleavage occurred at Ala1031, a different site to EGF cleavage by ADAM17. 
EGFR was also activated when ADAMs were inhibited, with a similar efficiency to 
ADAM17-mediated EGFR activation (Adrain et al., 2011). Cleavage of EGF by RHBDL2 
was also possible when ADAM17 was active, indicating independent proximal pathways 
that lead to EGF cleavage and EGFR activation (Adrain et al., 2011). In addition, 
ADAM17-independent secretion of EGF was impaired in cells transduced with four 
different RHBDL2 shRNAs, but ADAM17 mediated cleavage was unaffected. A 
combination of BB94 and RHBDL2 shRNA blocked cleavage and secretion of EGF 
completely (Adrain et al., 2011).   
1.4.3 iRHOM protein signalling 
A role for iRHOM1 in EGFR signalling and the NOTCH signalling pathway was 
suggested by studies expressing iRHOM1 in drosophila (Nakagawa et al., 2005). The 
shorter 52KDa iRHOM1 resulted in a severe wing phenotype, resembling the phenotype 
seen with mutations in Notch (e.g. Rabinow & Birchler 1990), and expression of targets 
downstream of Notch such as cut was reduced (Nakagawa et al., 2005). Co-expression 
of iRHOM1 with heparin-binding EGF (HB-EGF) resulted in a more severe wing 
phenotype, providing further evidence for involvement of iRHOM1 in this pathway. No 
obvious effect was seen with full length iRHOM1, perhaps because another protein not 
present in drosophila was needed for its activity (Nakagawa et al., 2005). Drosophila 
expresses a single iRHOM, diRhom, expressed only in neuronal cells. Knock-out of 
diRhom in flies caused a ‘sleep-like’ phenotype, with a significant decrease in daytime 
activity but no change in the ability of the flies to move. In contrast to Nakagawa et al 
(2005), however, no change was seen in other developmentally significant pathways, 
including the Notch pathway (Zettl et al., 2011). This could be because human iRHOM1 
has gained more functions compared to diRhom. The sleep-like phenotype seen with 
diRhom knock-out is consistent with increased activation of the EGFR pathway by 
transient overexpression of dRho1 and Star (Foltenyi et al., 2007), again suggesting that 
diRhom is involved in the regulation of this pathway.       
iRHOM1 siRNA knock-down affected pathways downstream of EGFR, shown by 
reduced levels of phosphorylated extracellular signal-related kinase (phospho-ERK) and 
phospho-Akt in MDA-MDB-435 breast cancer cells and head and neck squamous cell 
carcinoma (HNSCC) 1483 cells (Yan et al., 2008). In addition, knock-down of iRHOM1 
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reduced levels of phospho-EGFR and its downstream target p44/p42 mitogen activated 
protein kinase (MAPK) following stimulation with gastrin-releasing peptide (GRP) (Zou 
et al., 2009). Basal levels of p44/p42 MAPK phosphorylation were also reduced as well 
as the ability of serum-starved HNSCC 1483 cells to migrate into matrigel in response to 
GRP (Zou et al., 2009).   
Cutaneous keratinocytes from TOC patients were unresponsive to removal of 
exogenous EGF in proliferation and migration experiments (Blaydon et al., 2012). In 
control keratinocytes, both proliferation and migration were significantly reduced in the 
absence of exogenous EGF. This reduction in cell growth and wound healing was not 
seen in two cell lines derived from TOC cutaneous keratinocytes, which may suggest 
that the TOC keratinocytes are endogenously producing higher levels of EGFR ligands, 
so that the exogenous EGF does not affect their proliferation and migration. These 
findings also provide further evidence for a physiological role for iRHOM2 in EGF 
signalling (Blaydon et al., 2012). The hyperproliferative phenotype seen in the TOC cells 
is consistent with the hyperproliferative PPK and dysregulated wound healing seen in 
TOC patients. 
Zettl et al (2011) also demonstrated direct regulation of EGF by human iRHOM1 and 
mouse iRhom2. Both iRHOM1 and iRhom2 reduced the release of co-expressed EGF 
and other EGF-family ligands in COS-7 cells, which have no endogenous rhomboid 
activity and also in HeLa cells, which do express RHBDL2 endogenously (Adrain et al., 
2011). The ADAM family of metalloproteases was not inhibited in these experiments, 
and the release of control proteins prolactin and delta was unaffected. These findings 
suggest that iRHOMs act directly on rhomboid substrates rather than inhibiting the 
protease (Zettl et al., 2011). iRHOM-mediated reduction in EGF levels occurred through 
targeting the proteins for ER-associated degradation (ERAD) via the proteasome (Zettl 
et al., 2011). ERAD is a pathway often induced as a result of ER quality control 
mechanisms, especially following ER stress and induction of the UPR (Vembar and 
Brodsky, 2008). Furthermore, FLAG-tagged EGF co-immunoprecipitated with HA-
tagged human iRHOM1 and mouse iRhom2 but not control proteins (Zettl et al., 2011). 
Further regulation of EGFR signalling by iRHOMs also results through regulation of 
ADAM17 (Adrain et al., 2012; McIlwain et al., 2012; Christova et al., 2013), which cleaves 
a number of ligands for the EGFR (Pruessmeyer and Ludwig, 2009).  
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1.5 ADAM17 
ADAM17 (also known as TNF-α converting enzyme; TACE), is a type 1 transmembrane 
protein first identified as the enzyme responsible for catalysing the cleavage and 
shedding of transmembrane TNF-α (Black, 2002). ADAM17 has since been identified as 
the sheddase for a wide range of substrates, including a number of ligands for the EGF 
receptor and cell-adhesion molecules; ADAM17 has also been shown to mediate ligand-
independent cleavage of NOTCH (Bozkulak and Weinmaster, 2009; Pruessmeyer and 
Ludwig, 2009).  
1.5.1 ADAM17 structure and expression 
The ADAM17 protein comprises the pro-domain, the disintegrin domain, an EGF-like 
domain, TMD and the C-terminal cytoplasmic domain (figure 1.6 A; Black, 2002; 
Horiuchi, 2013). The disintegrin domain is thought to play a role in cell-cell adhesion 
through binding to the integrin α5β1, while the EGF-like domain is thought to facilitate the 
activation of ADAM17 though removal of the pro-domain, and also regulates the 
substrate specificity of ADAM17 (Horiuchi et al., 2009). ADAM17 cleaves its substrates 
in the extracellular juxtamembrane region, and the metalloproteinase catalytic activity is 
dependent on the presence of zinc ions (Black, 2002; Horiuchi et al., 2007, 2009). The 
inhibitory pro-domain contains a cysteine residue thought to interact with the zinc of the 
active site; this must be displaced to allow ADAM17 metalloproteinase activity. This pro-
domain is cleaved during ADAM17 maturation by furin proteases in the golgi (Schlondorff 
et al., 2000), activating ADAM17 before it is trafficked to the cell surface. Only active 
ADAM17 reaches the cell surface (Doedens and Black, 2000).   
ADAM17 appears to be synthesised and activated constitutively in many tissues, but its 
activity usually requires stimulation, for example with physiological stimuli such as 
lipopolysaccharide (LPS) or pharmacologically with phorbol esters (Pruessmeyer and 
Ludwig, 2009). The stimulation occurs downstream of MAPK and constitutively active 
kinases such as PKC (Black, 2002), as MAPK inhibitors prevented the increase in 
ADAM17 sheddase activity seen upon stimulation (Fan and Derynck, 1999). ADAM17 
appears to form multimers at the cell surface (Lorenzen et al., 2011), which are 
necessary for its catalytic activity: a dominant negative form of ADAM17 inhibited the 
activity of WT ADAM17. The association is dependent on the ADAM17 EGF-like domain 
(Lorenzen et al., 2011)   
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1.5.2 iRHOMs traffick ADAM17 from ER to Golgi 
A role for iRHOM2 in the trafficking of ADAM17 and regulation of TNF-α shedding was 
demonstrated in iRhom2 knock-out mice (iRhom2-/-) (Adrain et al., 2012; McIlwain et al., 
2012), with the same role later demonstrated for iRhom1, also in knock-out mice 
(Christova et al., 2013). iRHOM2 expression is up-regulated in response to LPS 
stimulation, which mimics bacterial infection. LPS also increases expression of ADAM17 
substrate, TNF-α (Adrain et al. 2012; McIlwain et al. 2012). TNF-α production was nearly 
completely abolished in iRhom2-/- mice, and there appeared to be an accumulation of 
TNF-α protein on the cell surface, which was mimicked by metalloprotease inhibitors 
(Adrain et al., 2012; McIlwain et al., 2012). LPS caused an increase in mRNA levels of 
iRhom2, ADAM17 and TNF-α in control cells, and levels of TNF-α and ADAM17 were 
increased even further in iRhom2-/- cells. No differences were seen in levels of other 
cytokines including IL-6 and IL-12 (McIlwain et al., 2012).   
The location of ADAM17 in the secretory pathway was shown using its glycosylation 
status (Adrain et al., 2012). Under normal conditions, ADAM17 undergoes N-linked 
glycosylation, which is sensitive to Endo-H. It is then trafficked to the golgi, where the 
sugars are elaborated and the glycosylation becomes resistant to Endo-H before the 
inhibitory pro-domain is cleaved by Furin later in the trans-golgi network (Schlondorff et 
al., 2000). In WT and iRhom2-/- mice, most ADAM17 was located in the ER. However, 
ADAM17 never became resistant to endo-H in iRhom2-/- mice, suggesting that it did not 
reach the golgi. Furin-cleavage of the pro-domain was also abolished in iRhom2-/- cells, 
with no mature ADAM17 seen iRhom2-/- macrophages, splenocytes or Bone Marrow 
Derived Macrophages (BMDM) (Adrain et al., 2012; McIlwain et al., 2012). Conversely, 
overexpression of iRhom2 in HEK293T cells increased the amount of ADAM17 exiting 
the ER, as more furin-cleaved ADAM17 was present in cell lysates, suggesting that this 
function of iRhom2 is conserved between humans and mice (Adrain et al., 2012). A 
mislocalisation of ADAM17 was also seen in iRhom2-/- BMDMs to ‘granular vesicular 
compartments’, shown by confocal microscopy and a count of the number of cells with a 
granular appearance (McIlwain et al., 2012).   
Interaction between iRhom2 and ADAM17 was seen in macrophages and mouse 
embryonic fibroblasts (MEFs) (Adrain et al., 2012; McIlwain et al., 2012). Interaction with 
both full length and mature ADAM17 was seen in both studies, but the interaction with 
mature, cleaved ADAM17 was weaker (Adrain et al., 2012; McIlwain et al., 2012). No 
interaction was seen between iRhom2 and other ADAM family members (McIlwain et al., 
2012). Catalytically active ADAM17 was also found in iRhom2-/- cells, showing that its 
production and folding is not affected by the absence of iRhom2 (Adrain et al., 2012). 
Overall, these findings suggest that iRhom2 is required for the trafficking of ADAM17 
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from the ER to the golgi, where it is cleaved into its active form before it travels to the 
cell surface (Adrain et al., 2012). iRhom2 in macrophages also contains golgi-specific 
(Endo-H resistant) glycans, suggesting that it is itself trafficked beyond the ER (Adrain 
et al., 2012). 
As iRHOM1 also trafficks ADAM17 and regulates its activation (Christova et al., 2013), 
the wider tissue distribution of iRHOM1 may explain why the phenotype of iRhom2-/- mice 
is much less severe than that of iRhom1-/- or  ADAM17-/- mice (McIlwain et al., 2012; 
Christova et al., 2013; Hosur et al., 2014). However, there is a clear reduction in mature 
ADAM17 levels in iRhom2-/- mice in a number of tissues (McIlwain et al., 2012), which 
may suggest that further iRHOM1 and iRHOM2 functions are involved in the 
pathogenesis associated with iRhom1 knock-out.  
1.5.3 ADAM17 substrates 
ADAM17 cleaves its substrates proximal to the cell membrane in a process known as 
ectodomain shedding. ADAM17, and its most closely related metalloproteinase ADAM10 
(Kuzubian or Kuz in drosophila) mediate a number of processes via cleavage of a diverse 
range of substrates (Pruessmeyer and Ludwig, 2009). The balance of the shedding and 
signalling of ADAM17 substrates is critical, as dysregulation of substrates such as EGFR 
ligands and TNF-α may have pathological consequences such as inflammation and 
cancer. Loss of ADAM17 function results in severe consequences, both in mice and 
humans (Peschon et al., 1998; Blaydon et al., 2011). ADAM17 signalling is therefore 
tightly regulated, including its expression via micro-RNAs (Schlondorff et al., 2000; 
Adrain et al., 2012; McIlwain et al., 2012), and also by protease inhibitors at the cell 
surface, such as tissue inhibitor of metalloproteinase 3 (TIMP3) (Amour et al., 1998).  
1.5.3.1 Tumour Necrosis Factor-α (TNF-α)  
TNF-α is targeted in a number of therapies for inflammatory conditions such as 
rheumatoid arthritis (Moss et al., 2008; Arribas and Esselens, 2009). Shedding of TNF-
α by ADAM17 is stimulated by LPS, which mimics infection, and by PKC activator phorbol 
myristate acetate (PMA) (Black et al., 1997; Moss et al., 1997; Rosendahl et al., 1997). 
A role for iRHOM2 was also shown in regulating ADAM17 in the pathogenesis of 
rheumatoid arthritis (Issuree et al. 2013). The TNF receptor (TNFR) is also shed by 
ADAM17, resulting in production of soluble TNFR (sTNFR); an important mechanism of 
regulating the TNF pathway through reducing availability of the receptor to circulating 
TNF-α. The sTNFR also binds to circulating TNF-α thus sequestering the inflammatory 
molecule form binding to the cell surface (Pruessmeyer and Ludwig, 2009).  
 
56 
 
 
Figure 1.6. Activation of matrix metalloproteinase ADAM17 is dependent on 
iRHOM activity. The diagram shown in A indicates the structure of the ADAM17 protein, 
including the inhibitory pro-domain. The pro-domain contains a cysteine amino acid 
residue that interacts with the Zn2+ of the metalloproteinase domain. The diagram in B 
shows some of the steps required for ADAM17 processing and activation. iRHOM1 or 2 
interact with ADAM17 in the ER, then facilitate its trafficking from the ER to the golgi, 
where its pro-domain is cleaved by furin-like pro-protein convertases. Cleavage of the 
protease activates the protein, allowing its trafficking to the cell surface where it cleaves 
substrates such as EGFR ligands and adhesion molecules.  
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1.5.3.2 Adhesion molecules  
ADAM17-mediated shedding of adhesion molecules by ADAM17 may also result in 
regulation of pro-inflammatory effects, particularly in the vascular endothelium. Adhesion 
molecules shed by ADAM17 include vascular cell adhesion molecule 1 (VCAM1), JAM-
A, and L-selectin. Shedding of L-selectin, for example, mediates recruitment of 
leukocytes to the blood vessel endothelium (Hafezi-Moghadam and Ley, 1999; Hafezi-
Moghadam et al., 2001; Venturi et al., 2003). Desmosomal cadherin DSG2 is also a 
substrate of ADAM17, and appears to be cleaved in response to changes in EGFR 
signalling (Lorch et al., 2004; Bech-Serra et al., 2006). Another possible role for ADAM17 
in cell-cell adhesion may include binding of ADAM17 to integrins via its disintegrin 
domain (Horiuchi et al., 2009).   
1.5.3.3 EGFR ligands 
EGFR ligands cleaved by ADAM17 include amphiregulin (AREG), transforming growth 
factor-α (TGF-α), heparin-binding EGF (HB-EGF), and epigen (Borrell-Pagès et al., 
2003; Sahin et al., 2004; Sahin and Blobel, 2007; Pruessmeyer and Ludwig, 2009; 
Schneider and Wolf, 2009). ADAM10 is responsible for shedding of EGF itself, and also 
betacellulin (Sahin et al., 2004; Sanderson et al., 2005; Schneider and Wolf, 2009). 
Shedding of these EGFR ligands was shown to be induced by ligands for G-protein 
coupled receptors (GPCRs) (Gschwind et al., 2003; Hart et al., 2004).  
Each ligand mediates different cellular effects in addition to spatio-temporal regulation of 
EGFR ligands through tissue-specific expression (Berasain and Avila, 2014). The 
ligands have different affinities for binding to the EGFR, for example, AREG has a lower 
affinity than EGF or TGF-α (Shoyab et al., 1989; Neelam et al., 1998). This seems to 
result in differential intensity and length of EGFR stimulation, which may affect the 
kinetics of downstream signalling pathways (Berasain and Avila, 2014): more transient 
EGFR activation, for example by AREG, may result in transient activation of downstream 
signalling components (Gilmore et al., 2008; Wilson et al., 2012), ultimately leading to 
differential biological effects (Andreu-Pérez et al., 2011). In support of this, TGF-α and 
HB-EGF stimulation resulted in different levels of phosphorylation and activation of the 
EGFR in Hep2 cells (Roepstorff et al., 2009).  
1.5.3.3.1 Amphiregulin 
AREG is synthesised as a type 1 transmembrane protein, known as pro-AREG, which is 
trafficked to the cell surface. AREG is expressed in a number of cell-types and tissues, 
and regulates cellular processes through binding to the EGFR, including proliferation, 
migration and apoptosis (Berasain and Avila, 2014). Mice lacking AREG have 
demonstrated a number of roles mediated by AREG, including mammary gland 
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development and aspects of the female reproductive system (Luetteke et al., 1999; 
Sternlicht and Sunnarborg, 2005; Schneider and Wolf, 2008), bone development (Qin et 
al., 2005), functions in the immune system (Zaiss et al., 2006), and also a role in 
epidermal homeostasis (Liu et al., 2008), including regulation of wound healing and 
production of antimicrobial peptides (Berasain and Avila, 2014).  
The balance of AREG, and other growth factor signalling is critical, with its hyperactivity 
leading to diseases including asthma, where increased AREG levels were seen in airway 
epithelial cells and circulating basophils (Enomoto et al., 2009; Kim et al., 2009; Qi, et 
al., 2010; Hirota et al., 2012). Other conditions in which AREG has been implicated 
include rheumatoid arthritis (Yamane et al., 2008) and psoriasis (Cook et al., 1992, 2004; 
Bhagavathula et al., 2005). AREG dysregulation has also been seen in a wide range of 
cancers including liver, lung, breast, colon, and pancreatic cancer (e.g. Johnson et al. 
1991; Funatomi et al. 1997; Hurbin et al. 2002; Shao et al. 2003; Willmarth & Ethier 
2006).  
1.5.3.3.2 Transforming Growth Factor Alpha 
TGF-α was the second EGFR ligand to be discovered, and also has roles in a number 
of cellular processes, and a pathological role for TGF-α over-activity has been 
demonstrated, particularly in epithelial cancers (Singh and Coffey, 2014). The TGF-α 
knock-out mouse displays eye defects at birth and corneal inflammation, and most 
strikingly a wavy hair phenotype (Luetteke et al., 1993; Mann et al., 1993; Singh and 
Coffey, 2014). This phenotype resembles that of mice with mutations in the RTK domain 
of the EGFR (Luetteke et al., 1994), reflecting the role of TGF-α in EGFR signalling. A 
number of studies overexpressing TGF-α under a variety of promoters have 
demonstrated a role for TGF-α in mammary gland development, and in regulating cell 
proliferation, with overexpression of the EGFR ligand resulting in hyperplasia or 
metaplasia in tissues including the liver, stomach and gastrointestinal system (Jhappan 
et al., 1990; Matsui et al., 1990; Sandgren et al., 1990). Furthermore, a critical role for 
TGF-α in skin proliferation was demonstrated, by overexpression under the skin-specific 
K14 promoter, where psoriasis-like lesions, stunted hair growth and occasional 
papillomas were seen, indicating the oncogenic potential of overactive TGF-α signalling 
in the epidermis (Vassar and Fuchs, 1991; Singh and Coffey, 2014).  
1.6 EGF receptor signalling 
The role of ADAM17 in cleaving ligands for the EGFR makes it an important regulator of 
EGFR signalling. EGFR signalling is critical in development, growth and wound healing, 
and regulates a wide range of cellular signalling processes, including proliferation, 
migration, and cell survival (Jones and Rappoport, 2014). EGFR signalling is 
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dysregulated in many cancers (Salomon et al., 1995; Blobel, 2005), and also in TOC 
keratinocytes (Blaydon et al., 2012), consistent with a role for iRHOM2 in regulating 
EGFR signalling.  
1.6.1 The EGFR / ErbB family of receptor tyrosine kinases 
The EGFR, also known as ErbB1, is one of four members of the ErbB family of RTKs 
(Jones and Rappoport, 2014). The ErbB RTK structure contains an extracellular domain, 
single TMD and an intracellular domain. Soluble forms of EGFR lacking the TMD and 
intracellular domain (ICD) also exist, and can be biomarkers for cancer (Salomon et al., 
1995; Jones and Rappoport, 2014). Following ligand stimulation, ErbB receptors at the 
plasma membrane form homo- or heterodimers (Tzahar et al., 1996; Olayioye et al., 
2000). Each ICD then phosphorylates the other in a process of autophosphorylation 
(Zhang et al., 2006), resulting in activation of a wide range of downstream signalling 
cascades (Mendoza et al., 2011; Jones and Rappoport, 2014). Following activation and 
phosphorylation, the receptor is internalised by endocytosis and targeted for recycling or 
degradation, for example through ubiquitination (Eden et al., 2012; Jones and 
Rappoport, 2014).  
The formation of homo- or hetero-dimers depends on the ligand, and on the complement 
of receptors expressed by a particular cell type. Each combination of receptors confers 
different properties to the RTK (Olayioye et al., 2000), providing one of the mechanisms 
of fine-tuning the signalling process depending on the specific situation (Jones and 
Rappoport, 2014). For example, in Hep2 laryngeal carcinoma cells, stimulation with 
TGF-α resulted in a weak phosphorylation and ubiquitination of EGFR, which resulted in 
complete recycling of the receptor, whereas HB-EGF or betacellulin stimulation caused 
persistant phosphorylation and ubiquitination of the receptor, leading to its degradation 
(Roepstorff et al., 2009). The method of internalisation may also be affected by the type 
of ligand, e.g. knock-down of clathrin inhibited internalisation of the receptor following 
stimulation with EGF, but caused only partial inhibition of the internalisation after 
stimulation with betacellulin or HB-EGF (Henriksen et al., 2013).  
1.6.2 Signalling Pathways downstream of EGFR activation 
Downstream signalling cascades activated by ligand binding to EGFR include MAPK, 
ERK, phosphoinositide-3-kinase (PI3K), Akt, Shc (p66), phospholipase C (PLC) γ, signal 
transducer adapter molecule (STAM), and Hrs, which may be activated through ligand 
binding at the plasma membrane (i.e. MAPK, ERK, Akt, Shc and PLCγ), or intracellularly 
following receptor internalisation (i.e. PI3K, ERk, Akt, STAM and Hrs) (Mendoza et al., 
2011; Park et al., 2012; Jones and Rappoport, 2014). The downstream signalling may 
also affect the trafficking of EGFR, providing feedback signals to the pathway (Jones and 
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Rappoport, 2014). The MAPK-Erk, PI3K-Akt and PLCγ pathways are shown in figure 
1.7. Other pathways include phosphorylation of caveolin, which regulates signalling 
through Grb7 (Lee et al., 2000), signal transducer and activator of transcription (STAT) 
signalling (Olayioye et al., 1999), and Src-focal adhesion kinase (FAK) signalling, which 
regulates cell migration (Biscardi et al., 1999; Ray et al., 2012).  
1.6.2.1 MAPK/ERK signalling 
A schematic of the major steps of ERK signalling are shown in (figure 1.7 A). ERK is a 
MAPK, and the major effector of the Ras oncoprotein, mediating and regulating cell 
survival, proliferation and motility (Mendoza et al., 2011). Ras belongs to the family of 
small GTPases, and stimulates ERK signalling via a cascade of kinase activity: 
MAPKKK, or MAP kinase kinase kinase (e.g. Raf), is a GTPase regulated kinase that 
phosphorylates MAPKK, or MAP kinase kinase (e.g. MEK), an intermediate kinase, 
which in turn phosphorylates a MAPK, or MAP kinase, i.e. ERK (Mendoza et al., 2011).  
Following growth factor binding to EGFR/ErbB RTKs, dimerisation and 
autophosphorylation, the adaptor protein GRB2 (growth factor receptor-bound protein 2) 
and guanine nucleotide exchange factor SOS (son of sevenless) are recruited to the cell 
surface, promoting increased levels of GTP-bound Ras, which activates Raf, which 
phosphorylates and activates MEK, which phosphorylates and activates ERK. ERK then 
phosphorylates p90 S6 kinase (RSK), and activates transcription factors which lead to 
transcription of immediate early genes such as c-Fos and c-Myc. These in turn signal to 
up-regulate late responsive genes, which in combination with RSK activity, lead to cell 
survival, proliferation and motility (Mendoza et al., 2011).  
Activated ERK also feeds back to earlier steps in the cascade to negatively regulate the 
pathway. Hormones, neurotransmitters or chemokines may bind to G-protein coupled 
receptors, leading to transactivation of ERK signalling via PKC and/or upstream RTKs. 
Phorbol esters, such as PMA which stimulates ADAM17 activity, mimic di-acyl glycerol 
(DAG), and bind and activate PKC. The signalling pathway may also be regulated 
through cross-talk with other signalling pathways such as the PI3K-Akt pathway 
(Mendoza et al., 2011).  
1.6.2.2 The PI3K-Akt cell survival pathway 
A PI3K-Akt cell-survival pathway (Rodrigues, 2000; Mendoza et al., 2011) schematic is 
shown in figure 1.7B. Growth factor stimulation of RTKs, for example by insulin and 
insulin-like growth factor 1 (IGF-1), leads to recruitment of insulin receptor substrate 
(IRS) and PI3K to the cell surface. PI3K then catalyses the conversion of phosphatidyl 
inositol biphosphate (PIP2), to phosphatidyl inositol tri-phosphate (PIP3) (Sengupta et al., 
2010). In quiescent cells, the tumour suppressor PTEN maintains low levels of PIP3 
61 
 
(Lemmon and Schlessinger, 2000). However, in the presence of PI3K, PIP3 levels 
increase, leading to recruitment of the protein kinase Akt and PDK1 (3-phosphoinositide-
dependent protein kinase 1) to the cell surface via pleckstrin homology domains 
(Sengupta et al., 2010; Mendoza et al., 2011). PDK1 activates Akt, which phosphorylates 
proteins needed for survival, proliferation and migration. Akt also phosphorylates 
tuberous sclerosis complex 2 (TSC2), a GTPase activating protein, or GAP. In quiescent 
cells, TSC2 and TSC1 maintain the GTPase RHEB (Ras homologue enriched in brain) 
in a primarily GDP-bound state. However, the phosphorylation of TSC2 releases this 
inhibition, allowing RHEB to activate mammalian target of rapamycin complex 1 
(mTORC1) (Mendoza et al., 2011).  
mTORC1 comprises mTOR (mammalian target of rapamycin), RAPTOR (regulatory 
associated protein of mTOR), and mammalian lethal with Sec13 protein 8 (mLST8). 
RAPTOR is a scaffolding protein, and tethers mTOR to substrates of mTORC1 (Alessi 
et al., 2009). mTORC1 phosphorylates and inhibits 4E-BP (eIF4E-binding protein; eIF4E 
is eukaryotic initiation factor binding protein 4E), preventing it from sequestering the 
eIF4E mRNA cap binding protein, which allows assembly of the cap-binding complex 
and initiation of translation (Mendoza et al., 2011). mTORC1 also phosphorylates S6K, 
resulting in its activation of transcription factors, ribosomal protein S6, RNA helicases, 
and other proteins involved in translation, initiation and elongation (Sengupta et al., 
2010). The net effect of these phosphorylation steps is promotion of ribosomal 
biogenesis as well as translation of cell growth and division proteins such as c-Myc and 
cyclin D (Mendoza et al., 2011).  
Akt may also be activated by mTORC2 (mammalian target of rapamycin complex 2), a 
second complex with which mTOR is associated, mTORC2 comprises mTOR, RICTOR 
(rapamycin-insensitive companion of mTOR), mLST8 and mSIN1 (mammalian stress-
activated protein kinase interacting protein). RICTOR is a scaffolding protein that tethers 
mTOR to mTORC2 substrates, as RAPTOR does in mTORC1 (Alessi et al., 2009). 
mTORC2 activation is involved in cytoskeletal reorganisation, cell survival and lipid 
metabolism (Mendoza et al., 2011).  
1.6.2.3 Cross-talk between the PI3K-Akt and Ras-MAPK/ERK pathways 
The dynamics of the pathways downstream of EGFR/ErbB activation are regulated by a 
number of factors, including the amount of the growth factor, the expression and cell-
surface localisation of the corresponding RTKs, and other RTK family members, and the 
co-expression of docking proteins (Lemmon and Schlessinger, 2000). Positive feed-
forward loops, and negative feedback loops provide regulation within a pathway, for 
example the inhibitory action of ERK-mediated phosphorylation of Ras-GTP, Raf and 
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MEK (Dhillon et al., 2007). S6K also provides negative feedback in the PI3K-Akt pathway 
through inhibition of PIP3 production by PI3K (Mendoza et al., 2011).  
Cross-talk between the pathways may also include cross-inhibition, cross-activation, and 
pathway convergence. ERK, RSK, Akt and S6K, for example, phosphorylate a number 
of proteins involved in the core signalling pathways, in addition to their activation or 
inhibition of downstream effectors of processes such as cell survival, proliferation or 
motility (Mendoza et al., 2011). 
1.6.2.4 PLCγ activation of PKC 
EGFR signalling also affects Ca2+ signalling (Margolis 1989), which can occur via the 
PLCγ pathway (Jones and Rappoport, 2014). A brief schematic of this pathway is shown 
in figure 1.8 C, the pathway forms one component of the complex, multi-layered 
phospho-lipase signalling network (Park et al., 2012). Binding of an EGFR ligand to the 
EGFR results in recruitment and phosphorylation of PLCγ, leading to hydrolysis of PIP2. 
This produces DAG and inositol triphosphate (IP3). Lipid mediators such as IP3 regulate 
a wide range of cellular processes, including actin cytoskeleton reorganisation, 
proliferation and migration (Suh et al. 2008; Wang et al. 2006; Park et al. 2012). DAG 
activates PKC (this effect is mimicked by PMA, another mechanism of cross-talk or 
feedback into the MAPK/ERK signalling pathway, while IP3 leads to the release of 
intracellular Ca2+ and Ca2+ signalling (Park et al., 2012; Jones and Rappoport, 2014). 
Ca2+ is also required for the activation of PKC.  
Ca2+ signalling is critical for a wide range of cellular processes, acting in part through 
activation of calmodulin, which acts on calcineurin (Park et al., 2012). Ultimately, this 
pathway results in activation of downstream proteins such as NFAT (Nuclear factor of 
activated T-cells) which provides a further mechanism of promoting cell growth and 
survival pathways (Park et al., 2012). DAG may also be phosphorylated by DAG kinase, 
producing the phospholipids phosphatidylserine, phosphatidylcholine and phosphatic 
acid, which ultimately result in production of prostaglandins and leukotrienes. The 
pathway also interacts with the Rho/ ROCK (Ras homologue/ Rho associated protein 
kinase) signalling pathway, which regulates cell migration via modulation of the actin 
cytoskeleton (Park et al., 2012). 
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Figure 1.7 Three components of the EGFR signalling pathway. Binding of a ligand 
to EGFR, or another RTK, results in homo- or heterodimerisation of the RTK followed by 
autophosphorylation. An array of signalling cascades occur downstream of this event, 
with crosstalk and feedback occurring between the pathways. Three of the pathways are 
illustrated above: A: The MAPK/ERK pathway; B: PI3K-Akt signalling; and C: PLCγ 
signalling, which mediates intracellular Ca2+ release and signalling and activation of PKC, 
which may also transactivate the MAPK/ERK signalling pathway downstream of GPCR 
activation. Adapted from Mendoza et al 2011 and Jones and Rappaport 2014.    
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1.7 NOTCH signalling 
NOTCH signalling is critical in a number of processes including development, regulation 
of proliferation, apoptosis and the cell cycle and in determining cell fate (Christian, 2012). 
NOTCH proteins were initially named after the wings of a female drosophila fly were 
described as being ‘notched’; which turned out to result from a dominant 
haploinsufficiency in the Notch gene (Poulson, 1939; Greenwald, 2012). Knock-out of 
Notch in mice is embryonic lethal, and ablation of Notch in mice after birth leads to skin 
tumours and hair loss (Nicolas et al., 2003; Demehri et al., 2008). The complex and 
heterogeneous nature of NOTCH signalling in different tissue types, and the importance 
of NOTCH in processes such as development and differentiation, are illustrated by the 
wide range of LOF and GOF somatic mutations found in NOTCH in cancers from 
different tissues and organs (South, 2012), which will be discussed in Chapter 5.   
1.7.1 NOTCH receptor Structure and Function  
NOTCH family receptors are Type 1 transmembrane proteins with 29-36 extracellular 
EGF-like repeats, three LIN cysteine-rich repeats, a linking region between the intra- and 
extra-cellular regions of the protein (the negative regulatory region; NRR), then a 
cytoplasmic RAM23 (Rbp associated protein) domain, six ankyrin repeats and a PEST 
domain in the C-terminal (Bray, 2006; Katoh and Katoh, 2007). Ligands for the NOTCH 
receptor bind at EGF repeats 11 and 12. The RAM domain is important in binding of 
NOTCH to the CSL transcription factor in the nucleus, and also contains a nuclear 
localisation signal (Bray, 2006). The ankyrin repeats may also allow binding of the 
intracellular domain to transcription factors in the nucleus (Mosavi et al., 2004). The 
PEST domain is needed for rapid degradation of NOTCH to allow for fast regulation of 
this highly dynamic pathway.  
Four NOTCH proteins have been identified in mammals (Ellisen et al., 1991; Weinmaster 
et al., 1991, 1992; Larsson et al., 1994; Li et al., 1998) and show specific cell-type specific 
expression patterns, for example NOTCH1 and NOTCH2 exhibit unique patterns of 
expression in human B-lineage cells (Bertrand et al., 2000). The four NOTCH proteins 
have different efficiencies at activating transcription (Bellavia et al., 2008), and induce 
different downstream genes (Bray, 2006; Ohashi et al., 2010; Wang, 2011). NOTCH3, 
for example, is important for HES5 induction in oesophageal differentiation (Ohashi et 
al., 2010), whereas HES1 is more predominant during epidermal differentiation (Blanpain 
et al., 2006). The different NOTCH isoforms can also work synergistically, for example, 
NOTCH1 and 3 co-ordinate in keratinocyte differentiation in the oesophagus (Ohashi et 
al., 2010). This provides considerable diversity in NOTCH signalling and downstream 
effects between different tissues (Bray, 2006).  
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1.7.2 The NOTCH Signalling Pathway 
NOTCH signalling can be canonical (ligand-dependent) or non-canonical (ligand-
independent), depending on the situation. In both cases, NOTCH activation is regulated 
by a number of processing steps (figure 1.8). Initially, the full-length NOTCH is cleaved 
by a furin-like convertase to remove the pro-domain (Logeat et al., 1998). This is known 
as S1 cleavage. NOTCH can then traffick to the cell surface where it is expressed as a 
heterodimer in canonical NOTCH signalling (Logeat et al., 1998). Whilst in the plasma 
membrane, NOTCH can be cleaved by ADAM10 or ADAM17 (S2 cleavage) (Brou et al., 
2000; van Tetering et al., 2009), which allows for S3 cleavage by γ-secretase and release 
of the NOTCH intracellular domain (NICD) (Saxena et al., 2001; Okochi et al., 2002). 
The NICD then trafficks to the nucleus (Iso et al. 2003; Lubman et al. 2004), where it 
results in altered expression of a number of genes (Bray, 2006; Wang, 2011; Christian, 
2012).  
In the nucleus, the NICD binds to a complex which includes CSL (CBF-1, Su(H), LAG-1) 
and Mastermind (MAM) (Petcherski and Kimble, 2000; Wu et al., 2001). CSL is a DNA-
binding protein complex, and MAM acts as a co-activator (Bray, 2006). In the absence 
of NOTCH, CSL proteins recruit co-repressor proteins to prevent inappropriate activation 
of NOTCH target genes (Bray, 2006). MAM also recruits histone acetylase p300, which 
promotes the assembly of initiation and elongation complexes and also controls the 
NICD turnover via the PEST domain (Fryer et al., 2004; Tsunematsu et al., 2004). 
NOTCH1 gene targets include E(spl)/HES class basic-helix-loop-helix (bHLH) proteins, 
which are well characterised NOTCH targets, although the response to NOTCH is 
dependent on the cell type and extracellular environment, and may be regulated through 
interactions with other pathways (Bray, 2006; Wang, 2011).  
1.7.2.1 Canonical and non-canonical NOTCH signalling  
Canonical NOTCH signalling is originated by binding of ligands on the signal-sending 
cell to NOTCH S1 on the signal receiving cell (Wang, 2011). Internalisation of the ligand 
then causes a conformational change in the NOTCH protein, allowing access of the 
ADAM metalloproteinases to the cleavage site at which S2 cleavage takes place (Brou 
et al., 2000; Wang, 2011). Canonical NOTCH signalling results in formation of the CSL-
NICD complex. Activated by MAM family of co-activators, and leads to transcription of 
HES1, HES5, HES7, HEY1, HEY2 and HEYL genes, which encode the bHLH/orange 
domain transcriptional repressors (Bray, 2006). In development, canonical NOTCH 
signalling is important in regulating cell fate, which depends on whether a cell is a signal-
sending cell expressing NOTCH ligands, or a signal receiving cell expressing the 
NOTCH receptor (Bray, 2006). 
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In non-canonical NOTCH signalling, alternative proteins may initiate NOTCH signalling 
in the absence of the typical ligands such as Delta-like and Jagged, with an increasing 
number of proteins are being discovered with roles in non-canonical NOTCH signalling 
(Wang, 2011). Some of these non-canonical ligands contain EGF repeat domains, 
similar to the canonical ligands, but others appear unrelated in structure (Wang, 2011). 
Mediators of non-canonical NOTCH signalling include thrombospondin 2 (Aho and Uitto, 
1998; Meng et al., 2010), which is dependent on low density lipoprotein receptor-related 
protein 1 (LRP1) to mediate NOTCH signalling (Meng et al., 2010), and EGF-like domain 
7 (EGFL7) (Schmidt et al., 2009), and Delta-Notch-like EGF-related receptor (Eiraku et 
al., 2005). In non-canonical signalling, the NICD may associate with CSL, NICD and 
Deltex instead of MAM. This results in amplification of a different group of target genes 
through MAG, a tissue-specific transcription factor, leading to terminal differentiation 
(Katoh and Katoh, 2007; Wang, 2011). The NOTCH NICD may also interact with p50 or 
c-Rcl in the nucleus to enhance the NF-κB pathway via p50 or c-Rcl (Shin et al., 2006). 
1.7.3 Is S2 cleavage mediated by ADAM10 or ADAM17? 
When NOTCH-S1 reaches the plasma membrane, its cleavage is regulated by the NRR, 
an internal inhibitory domain that prevents access of ADAM proteases to the S2 cleavage 
site (Bozkulak and Weinmaster, 2009; Gordon et al., 2009). A conformational change is 
required to reveal the S2 cleavage site and allow access by the ADAM proteases. This 
can be mediated by binding of ligands in neighbouring cells followed by endocytosis of 
the ligands, or by non-ligand mediated methods, which are less well understood but may 
result from changes in the cell microenvironment or through endocytosis of NOTCH, 
although this process is thought to be ADAM-independent (Bray, 2006; Wang, 2011; 
Christian, 2012).  
Whether S2 cleavage of NOTCH is mediated by ADAM10 or ADAM17 has been debated 
(Christian, 2012). Deficiency in ADAM10 homologue Kuz in flies, or Adam10 in mouse, 
resulted in the same phenotype as Notch1 deficiency in these species, whilst a different 
phenotype is seen in ADAM17-deficient flies and mice (Sotillos et al., 1997; Lieber et al., 
2002; Delwig and Rand, 2008), suggesting that ADAM10 is the major mediator of S2 
proteolysis in vivo, particularly ligand-dependent cleavage (Delwig and Rand, 2008; 
Christian, 2012). Further, Adam10 is essential for Notch signalling in the cardiovascular 
system and epidermis in mouse (Weber et al., 2011), and Adam10 endothelial knock-
out mice showed reduced expression of Notch1 target genes Snail (by 60 %) and Bmp2 
(by 30%) (Zhang et al., 2010). It remains to determine whether the remaining 40 % 
expression was due to Notch cleavage by ADAM17 (Christian, 2012).  
67 
 
Bozkulak and Weinmeister (2009) showed that ADAM10 is needed for ligand-dependent 
Notch cleavage in mouse embryonic fibroblasts (MEFs) in the signal-receiving cell, and 
expression of ADAM17 does not rescue the phenotype, demonstrating that ADAM10 and 
not ADAM17 is the main metalloprotease in ligand-dependent Notch cleavage. This was 
confirmed by ADAM10 and ADAM17 siRNA knock-down in C2C12 cells, although the 
western blot shows much higher levels of ADAM10 processing than ADAM17 
processing.  
However, MEFs expressing a mutated form of ADAM17, lacking the Zinc-binding domain 
and therefore protease activity (MEFΔZn/ΔZn), showed a 2-3 fold reduction in CSL reporter 
activity compared with WT ADAM17 MEFs (Sotillos et al., 1997; Delwig and Rand, 2008). 
However, reporter activity was not reversed by either anti-ADAM17 siRNA, or 
overexpression of active ADAM17 in the MEFΔZn/ΔZn, so differences may be due to clonal 
variation in cell lines (Bozkulak and Weinmeister 2009). ADAM17 is likely to be the major 
mediator of ligand-independent NOTCH cleavage: cells treated with EDTA to destabilise 
the NRR showed increased CSL-reporter activity, which was reversed by 
metalloprotease inhibitor and siRNA against ADAM17 but not by ADAM10 siRNA 
(Bozkulak and Weinmaster, 2009).  
Further supporting these findings, Kuz expression in cells lacking ADAM17 resulted in 
ligand-dependent Notch S2 cleavage, whereas high ADAM17 expression resulted in 
ligand-independent Notch cleavage in the same system (Sotillos et al., 1997; Lieber et 
al., 2002; Delwig and Rand, 2008).  
1.7.4 Regulation of NOTCH  
Other NOTCH regulators include Neuralised and Mindbomb in drosophila, and 
NEURL1/NEURL and NEURL2; MIB1 and MIB2 in humans and Mib1 and Mib2 in mouse 
(Katoh and Katoh, 2007). These proteins are E3-Ubiquitin Ligases, and are necessary 
for ligand activation at the cell surface (Lai, 2002; Le Borgne et al., 2005; Pitsouli and 
Delidakis, 2005; Bray, 2006). Other ubiquitin and E3 ligases that act on NOTCH include 
the Itch/NEDD4/Su(dx) family of HECT domain ubiquitin ligases, which may be involved 
in regulating NOTCH turnover and tend to negatively regulate NOTCH signalling (Qiu et 
al., 2000; Lai, 2002; Bray, 2006). Deltex is a RING finger protein and E3 ligase which 
positively regulates NOTCH in many tissues, including ligand-independent signalling 
(Matsuno et al., 1995; Hori et al., 2004; Bray, 2006). For example, in experiments with 
several genetically modified strains of yeast, Deltex was required for the presence of 
Notch in endocytic vesicles (Hori et al., 2004; Wilkin et al., 2004). In some cell types such 
as neurons, however, Deltex antagonises Notch (Sestan et al., 1999; Bray, 2006). 
Depending on a number of tissue and cell-dependent situation, the balance of negative 
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and positive NOTCH Regulators may determine the accessibility of NOTCH to ligands 
or γ-secretase, thus fine-tuning the rate of NOTCH signalling (Bray, 2006).  
 
The EGF-like repeats on the NOTCH extracellular domain are sites for glycosylation. 
Glycosylation by enzymes such as those of the Fringe family is essential for correct 
NOTCH function, and allows for a number of combinations of glycosylated NOTCH to 
further regulate signalling. Removing O-Fucosyltransferase, the enzyme that adds the 
first fucose to Notch, from drosophila or mice results in phenotypes similar to those seen 
with loss of Notch signalling e.g. through loss of a member of the γ-secretase complex 
(Shi and Stanley, 2003). O-Fucosyltransferase is also important in the folding and 
trafficking of NOTCH (Okajima et al., 2005), and glycosylation regulates the affinity of 
ligands for the NOTCH EGF repeats: The presence of Fringe enhances Notch binding 
to DLL instead of serrate in dorsal drosophila wing cells (Johnston et al., 1997; Sasamura 
et al., 2003) and this effect is abrogated when the EGF-12 repeat is mutated – serrate 
can then bind to Notch even in the presence of Fringe.  
1.7.4.1 NOTCH endocytosis and trafficking  
Further regulation of the NOTCH pathway is mediated through NOTCH ligand 
endocytosis and trafficking, and therefore spatial regulation of the signalling components 
(Bray, 2006). A large fraction of NOTCH is found in the endocytic pathway, co-localising 
with small RAB GTPases RAB5 and RAB7 (Jékely and Rørth, 2003; Wilkin et al., 2004). 
The short half-life of the downstream transcription factor proteins such as CSL is also 
important to allow fast dynamics of the pathway, in addition to rapid NOTCH degradation 
via the PEST domain (Gupta-Rossi et al., 2001; Oberg et al., 2001; Wu et al., 2001; Bray, 
2006). Further regulation may be mediated through regulation and modulation of the 
enzymes that cleave NOTCH, such as ADAM10 and ADAM17 and members of the 
γ-secretase complex.  
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Figure 1.8 The NOTCH signalling pathway. A schematic showing the basic steps of 
the NOTCH signalling pathway, including the activation by cleavage of the pro-domain 
by furin proteases (S1 cleavage), followed by trafficking of heterodimeric NOTCH to the 
cell surface. At the cell surface, S2 cleavage is mediated by ADAM metalloproteinases 
ADAM10 and ADAM17, often following NOTCH binding to a ligand on a neighbouring 
cell, but ligand independent signalling is also possible. ADAM10 appears to be the 
predominant metalloproteinase for ligand-dependent signalling. Once S2 cleavage has 
taken place, S3 cleavage is mediated by γ-secretases, which release the intracellular 
domain (NICD). This can then translocate to the nucleus and regulate the expression of 
target genes. NOTCH signalling is tightly regulated, and the NICD is rapidly degraded 
after activation via its PEST domain (Bray, 2006; Wang, 2011; Christian, 2012).  
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1.7.5 NOTCH signalling in the skin and gastrointestinal tract 
The multiple functions of NOTCH include self-renewal of stem cells, cell-fate 
determination of progenitor cells and initiating terminal differentiation of proliferating cells 
(Lowell et al., 2000; Nickoloff et al., 2002; Yamamoto et al., 2003; Blanpain et al., 2006; 
Ohashi et al., 2010). For example, activation of NOTCH1 signalling in the skin promotes 
exit of keratinocytes from the cell cycle and entry into the differentiation program 
(Rangarajan et al., 2001). Differences in the differentiation of different tissues, such as 
the skin and oesophagus, is in part mediated by tissue-specific expression of NOTCH 
and Delta-like and Jagged ligands and through interactions with other signalling 
pathways such as the EGFR pathway (Blanpain et al., 2006; Estrach et al., 2008; Ohashi 
et al., 2010; Nowell and Radtke, 2013). 
1.7.5.1 NOTCH signalling in the epidermis 
In the epidermis, NOTCH expression is highest in the suprabasal spinous and granular 
layers, where it appears to mediate both the initiation and maintenance of differentiation 
(Blanpain et al., 2006; Wang et al., 2008; Nowell and Radtke, 2013). Expression of 
NOTCH in specific cell clusters of the basal layer has also been identified (Lowell et al., 
2000), suggesting a role for NOTCH in regulating stem cell homeostasis. Expression has 
been seen of NOTCH1-4, and the ligands Jagged-1 and Jagged-2; expression of Delta-
like 1 has also been noted in stem cells in the basal layer, where it appears to negatively 
regulate NOTCH in stem cells, preventing early entry into the differentiation pathway 
whilst promoting differentiation of neighbouring cells (Lowell et al., 2000; Estrach et al., 
2008). Notch1 appears to be the major Notch isoform in murine epidermis, as knock-out 
of Notch1 had severe epidermal consequences that were only slightly compensated by 
the Notch2-4 isoforms (Nicolas et al., 2003; Vauclair et al., 2005). A role for NOTCH has 
also been implicated in inflammatory skin conditions such as atopic dermatitis (Ambler 
and Watt, 2010; Ziegler and Artis, 2010; Nowell and Radtke, 2013). 
In the basal layer, proliferation is driven by the activity of transcription factor p63, and 
also mediated by signalling pathways including the EGFR pathway (Nowell and Radtke, 
2013). EGFR signalling promotes Activator protein 1 (AP-1) transcription factor activity 
via C-Jun, and AP-1 and c-Jun negatively regulate NOTCH and p53 in these conditions. 
Indeed, overactivity of EGFR in the suprabasal layers impairs NOTCH activity and 
differentiation (Kolev et al., 2008). The balance of EGFR signalling appears to be 
regulated by the transcription factor ctip2, which positively regulates either EGFR or 
NOTCH signalling depending on the Ca2+ concentration (Zhang et al., 2012). The AP-1 
and NOTCH pathways appear to show reciprocal antagonism, as knock-out of Adam17 
in mouse resulted in high AP-1 activity and abnormalities associated with loss of Notch 
(Guinea-viniegra et al., 2012), which also further demonstrates the importance of 
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ADAM17 in skin homeostasis and differentiation, and may suggest a role for the NOTCH 
pathway in the epidermis (Nowell and Radtke, 2013).  
Following initiation of NOTCH signalling, which appears to be mediated predominantly 
by Jagged-1 (Estrach et al., 2006), the NOTCH pathway negatively regulates AP-1 (as 
just described) and also p63. NOTCH activity induces expression of the cell cycle 
inhibitor p21/CDKN1A (Rangarajan et al., 2001; Nguyen et al., 2006), which provides 
further inhibition of p63-induced proliferation. At the same time, NOTCH up-regulates or 
activates retinoic acid signalling, factors such as interferon response factor 6 (IRF6), and 
transcription of Hes/Hey transcriptional repressor proteins, in particular HES1 (Vauclair 
et al., 2005; Collins and Watt, 2008; Moriyama et al., 2008). In combination, these 
pathways promote differentiation in combination with other differentiation-promoting 
pathways (Nowell and Radtke, 2013) 
1.7.5.2 NOTCH signalling in oesophageal differentiation 
The oesophagus is also a stratified squamous epithelium, the structure of which will be 
discussed further in the next section. Oesophageal cells follow a similar pattern of 
differentiation to epidermal keratinocytes, which is dependent on NOTCH1 and NOTCH3 
(Katoh and Katoh, 2007; Ohashi et al., 2010). NOTCH3 induction was essential for the 
differentiation of oesophageal keratinocytes, and downstream NOTCH targets were 
activated following Ca2+-induced differentiation of telomerase-immortalised, non-
transformed oesophageal keratinocyte cell line EPC2-hTERT: Increased luciferase 
reporter activity of CSL was seen, in addition to increased HES5 mRNA and increased 
levels of the differentiation markers involucrin and cytokeratin 13 (Ohashi et al., 2010). 
In contrast to the epidermis, where HES1 appears to be a major downstream mediator 
of NOTCH activation, in the oesophagus, HES5 appears to be the major mediator 
(Ohashi et al., 2010). In the in vitro 3D model of oesophageal differentiation, NOTCH3 
expression was induced by the NOTCH1 NICD (Ohashi et al., 2010), suggesting that 
differentiation is initiated by NOTCH1, and that subsequent induction of NOTCH3 
follows.  
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1.8 The Oesophagus  
The morphology of normal oesophagus consists of three main layers – the basal layer, 
prickle cell layer, and superficial or functional layer (figure 1.9) (Hopwood, 1991; Kuo and 
Urma, 2006). The basal layer is clearly defined, comprising columnar-shaped basophilic 
cells, usually making up 10-15 % of the thickness of the epithelium. As in the skin, the 
basal layer of the oesophagus is important in regeneration, with a number of dividing 
cells scattered throughout the layer, and a few argyrophil cells, the number varying 
between individuals (Hopwood, 1991).  
Above the basal layer is the prickle cell layer, and above that the superficial or functional 
cell layer. These two layers are difficult to distinguish in paraffin-embedded tissue 
sections such as those shown in chapter 5. The cells of the functional layer are flatter 
than those of the prickle cell layer, and the prickle cell layer has wide spaces between 
the cells with more desmosomes than the functional layer, or the basal layer which has 
a number of hemidesmosomes (Logan et al., 1978; Hopwood, 1991; Kuo and Urma, 
2006). 
The oesophagus has a distinct pattern of keratins in each layer, similar to the epidermis, 
but the pattern of keratin expression is different to that seen in the epidermis 
(Banks Schlegel and Harris, 1983). The morphology can depend on the depth at which 
the biopsy was taken, as the cells are differentially affected by acid reflux, which can 
cause the cells to become leakier and less electron dense. Oesophageal submucosal 
glands can be seen in regions of connective tissue. These glands contain mucous and 
serous secreting cells and myo-epithelial cells which are similar to salivary glands. In 
addition, a number of papillae carrying blood vessels project into the lower half of the 
oesophagus. As in the skin, a number of infiltrating cells can be seen by electron 
microscopy including lymphocytes, granulocytes, and langerhans cells (Yassin and 
Toner, 1976).  
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Figure 1.9. The structure of the oesophagus. The oesophagus comprises three main 
layers: the muscularis externa, or tunica muscularis, the muscular, functional layer of the 
oesophagus; the submucosa, or lamina propria, which comprises loosely packed 
connective tissue, focal lymphocytes can be found in this layer; and the mucosal layer, 
a stratified squamous epithelium that surrounds the oesophageal lumen. The squamous 
layer cells migrate from the basal layer to the squamous layer at the oesophageal lumen 
in a process of terminal differentiation, similar to the process that occurs in the skin. The 
prickle cell layer contains a large number of desmosomes (shown in purple). As cells 
progress through the differentiation pathway, they gain a flatter shape and eventually 
form the flattened, squamous cells found at the oesophageal lumen.  
1. www.proteinatlas.org/dictionary/normal/esophagus+1, accessed 10.8.2014  
2. Kuo and Urma 2006, GI Motility Online PART 1: Oral cavity, pharynx and oesophagus, 
http://www.nature.com/gimo/contents/pt1/full/gimo6.html, accessed 5.9.2014. 
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1.9 Oesophageal Cancer 
Oesophageal cancer is currently one of most common cancers and causes of cancer 
mortality. According to estimates of global cancer incidence by the Globacan database 
in 2008 and 2012 (http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx accessed 
15/2/14), oesophageal cancer is the 8th most common cancer worldwide, and the 6th 
most common cause of cancer-related deaths internationally (4.9 % worldwide) 
(Pennathur et al., 2013). In the UK in 2011, oesophageal cancer was the 8th most 
common cancer in men, and 14th most common in women (CRUK, 
http://publications.cancerresearchuk.org/downloads/product/CS_REPORT_INCIDENC
E.pdf accessed 03.2014; office for national statistics, accessed 09.2014: 
http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-
mb1-/no--43--2012/index.html) and in 2012 was the 7th most common cancer in men and 
14th most common in women worldwide, based on age-standardised incidence rates 
which adjust for variations in the populations’ age structure (GLOBOCAN 2012, 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx accessed 03.2014).  
Areas with higher levels of deprivation show highest incidence of oesophageal cancer 
across the world and in the UK (GLOBOCAN 2012 and 2008; (Bray et al., 2013; Ferlay 
et al., 2014). Risk factors include alcohol, tobacco and exposure to nitrosamines 
(Pennathur et al., 2013). Mortality rates of oesophageal cancer are particularly high, with 
a mortality to incidence ratio of 0.88, and a 5-year survival of approximately 13 % (CRUK 
website, accessed 02.2014). A particular challenge in oesophageal cancer is early 
detection, with many cases being diagnosed at an advanced stage, making treatment 
difficult. Furthermore, metastasis occurs early in oesophageal cancer development even 
with the presence of a superficial primary tumour (Altorki et al., 2008; Pennathur et al., 
2009).  
1.9.1 Oesophageal Squamous Cell Carcinoma 
There are two major forms of oesophageal cancer: oesophageal adenocarcinoma, which 
originates in mucous-producing glandular cells lower in the oesophagus; and OSCC, 
which originates in the squamous cells lining the oesophagus. Together, these forms 
account for over 90 % of oesophageal cancer cases worldwide 
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-
oncology/esophageal-cancer/; CRUK; accessed 03.2014). OSCC is usually found in the 
upper two layers of the oesophagus. A change in epidemiology of OSCC compared with 
adenocarcinoma has been seen, with a large increase in adenocarcinoma in the UK and 
US. Nevertheless, OSCC accounted for about 28 % of oesophageal cancer cases in the 
UK(http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/incide
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nce/uk-esophageal-cancer-incidence-statistics#source1; 2008-2010;accessed 03.2014) 
and still accounts for a high proportion of cases worldwide (Pennathur et al., 2009).  
The initial stages of OSCC development at a histological level are described in Wang et 
al (2005): In the normal oesophagus, the basal layer accounts for less than 15 % of the 
thickness of the epithelium. With the onset of oesophagitis, infiltration of neutrophils and 
eusinophils is seen, with thickening of the basal layer to more than 15 % of the epithelia, 
but the cells seen are typical for the region of the oesophagus. With the onset of 
dysplasia, atypical cells are seen, firstly in the lower third of the epithelium with mild 
dysplasia, then progressing to the lower two-thirds of the epithelium in moderate 
dysplasia and finally covering all thirds of the epithelium, but not reaching full thickness 
in severe dysplasia. Carcinoma in situ is diagnosed when a full-thickness spread of 
atypical cells is seen throughout the oesophageal epithelium, without any metastasis or 
lymph node spread (Kuwano et al., 2003; Wang et al., 2005). Squamous cell carcinoma 
is diagnosed with invasion of the cells into the lamina propria (Wang et al., 2005).  
Lymph node metastasis is often seen early in the spread of OSCC due to the high 
number of lymphatic vessels found in the oesophagus (Kuwano et al., 2003; Pennathur 
et al., 2013). Other features of OSCC morphology can include glandular differentiation 
within the tumours, which is not normally seen in the oesophagus (Kuwano et al., 2003). 
Further, it is possible for multiple primary OSCC tumours to develop. 
Genetic predisposition has previously been implicated in OSCC development, for 
example mutations in enzymes that metabolise alcohol such as aldehyde 
dehydrogenase-2 (ALDH2) and alcohol dehydrogenase 2 (ADH2) may increase OSCC 
risk in Japan and China (Yokoyama et al., 1996; Pennathur et al., 2013). However, 
iRHOM2 represents the first highly penetrant gene associated with OSCC, with up to a 
95 % risk of developing the cancer associated with the condition (Stevens et al., 1996). 
iRHOM2 and other Rhomboid proteins and proteases are therefore of interest as targets 
for future research into oesophageal cancer and other forms of cancer. A role for 
iRHOM1 has also been demonstrated in breast cancer and head and neck SCC 
(HNSCC) (Yan et al., 2008; Zou et al., 2009; Zhou et al., 2014), and the ADAM17 and 
NOTCH pathways mediate pathogenesis of a range of cancers.  
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1.10 ADAM17 in Cancer 
There are many examples of ADAM17 dysregulation in a number of cancer types. 
ADAM17 overexpression in non-small-cell lung cancer (NSCLC) was associated with 
tumour grade, size, lymph node metastasis and overall poor patient survival (Ni et al., 
2013), and Warneke et al (2013) reported poor prognosis in gastric cancer patients 
associated with the EpCam pathway, in which EpCam is cleaved by ADAM17. 
Overexpression of ADAM17 has also been reported in ovarian, prostate, breast 
(Lendeckel et al., 2005; Sinnathamby et al., 2011; Narita et al., 2012),  pancreatic  (Ringel 
et al., 2006), colorectal, gastrointestinal (Blanchot-Jossic et al., 2005; Nakagawa et al., 
2009), non-small-cell lung cancer (Zhou et al., 2006) and head and neck cancer (Stokes 
et al., 2010; Kornfeld et al., 2011). Normal colony shape and cell polarity were restored 
in breast cancer cells following ADAM17 shRNA treatment, along with reduced AREG 
and TGF-α secretion (Kenny and Bissell, 2007). Kenny and Bissell (2007) also showed 
that high levels of ADAM17 and TGF-α were indicators of poor survival in breast cancer 
patients.   
1.11 NOTCH1 signalling in cancer 
A wide range of somatic mutations in NOTCH in cancer illustrate the complex and 
heterogeneous nature of NOTCH signalling in different tissue types and the importance 
of NOTCH in processes such as development and differentiation. Mutations can be LOF 
or GOF in nature depending on the tissue type (Wang, 2011; South, 2012). While knock-
out or mutation of Notch 1 or 2 in mice is embryonic lethal (Swiatek et al., 1994; Conlon, 
Reaume and Rossant, 1995; Hamada et al., 1999), ablation of Notch in mice after birth 
leads to hair loss, skin tumours susceptibility to chemical carcinogenesis (Nicolas et al., 
2003; Demehri et al., 2008). Total epidermal knock-out of Notch caused impaired barrier 
formation leading to systemic B-lympheroproliferative disease and death (Demehri et al., 
2008).  
The first NOTCH1 mutations identified in cancer were found in T-cell acute lymphoblastic 
leukaemia (T-ALL), where over 50 % of patients have mutations in the NRR or PEST 
domains leading to increased NOTCH activity and reduced protein turnover (Ellisen et 
al., 1991; Weng et al., 2004). Other cancers resulting from activating NOTCH1 mutations 
include chronic lymphocytic leukemia and diffuse large B-cell lymphoma (Di Ianni et al., 
2009; S. Lee et al., 2009; Fabbri et al., 2011; Puente et al., 2011). Furthermore, NOTCH1 
mutations were associated with worse prognosis in B-Cell chronic Lymphocytic 
Leukaemia (B-CLL) (Sportoletti et al., 2010; Fabbri et al., 2011; Rasi et al., 2012). 
Activating mutations result in up-regulation of NOTCH1 target genes such as HES1, 
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which prevents transcription of the tumour suppressor gene PTEN (Malecki et al., 2006; 
Psyrri et al., 2013). In a comparison of activating NOTCH mutations on CSL reporter 
activity, NOTCH mutants had significantly higher reporter activity than wild type (WT) 
NOTCH, but there was variation between mutants. Processing of the mutants showed 
some dependency on ADAM10, but ADAM17 appeared to be the major metalloprotease 
in processing GOF-mutant NOTCH in T-ALL (Bozkulak and Weinmaster, 2009; van 
Tetering et al., 2009).  
While in these situations NOTCH1 has a tumour promoting function, in other tissues 
NOTCH1 acts as a tumour suppressor (Nicolas et al., 2003; Demehri et al., 2008; South, 
2012), with inactivating mutations found in cutaneous squamous cell carcinoma (SCC), 
lung cancer (Wang, 2011; South et al., 2014) and HNSCC (Agrawal et al., 2011; Stransky 
et al., 2011). Inactivating mutations were mostly found in the EGF-repeat, ankyrin-repeat 
or heterodimerization domains or caused truncations of the protein, resulting in disrupted 
ligand binding and inactivation of the signalling cascade (Agrawal et al., 2011; Wang, 
2011). Further, inhibiting NOTCH signalling with γ-secretase inhibitors resulted in 
metaplasia in mouse goblet cells (Menke et al., 2010). 
Notch signalling has also been implicated in oesophageal cancer development: 40 % of 
3-month old transgenic mice expressing dominant-negative MAML1 (DN-MAML1; an 
inhibitor of Notch signalling), showed oesophageal basal cell hyperplasia/dysplasia, with 
a significantly higher Ki67 labelling index compared to the DNMAML1f/f and K14Cre 
generations of the mice. There was a reduction in involucrin staining and loss of filaggrin 
in keratohyalin granules in addition to loss of nuclear Notch3 staining (Ohashi et al., 
2010) suggesting altered differentiation. In addition, high NOTCH1 expression is a 
predictor of poor prognosis in OSCC (Ogawa et al., 2013) and is implicated in resistance 
to 5-FU treatment in OSCC cell line KYSE70 (Liu et al., 2013). Inactivating mutations 
were seen in 21 % of OSCCs but not in oesophageal adenocarcinomas (Agrawal et al., 
2012). 
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1.12 Aims 
The inactive rhomboids are relatively recently discovered proteins, with little known about 
their physiological roles. As mutations in RHBDF2, the gene encoding iRHOM2, affect 
the skin in TOC, this work firstly aims to investigate the expression and localisation of 
iRHOM2 in the epidermis. Secondly, initial investigation into the signalling function of 
iRHOM2 in epidermal keratinocytes will be performed, particularly focussing on iRHOM2-
mediated regulation of ADAM17 and EGF signalling and some potential downstream 
pathways. As RHBDF2/iRHOM2 is the first gene associated with highly penetrant 
inherited OSCC and as iRHOM2 regulates ADAM17 and EGFR signalling, the 
localisation and expression of iRHOM2 in OSCC and other SCCs will be investigated to 
see whether iRHOM2 dysregulation may be involved in the pathogenesis of sporadic 
cancers.  
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Chapter 2: Materials and Methods 
2.1 Cell Culture 
Keratinocyte cell lines, isolated from control, unaffected, skin (K17, NEB1) and TOC 
patient skin (TYLK1 and TYLK2), and immortalised with Human-papilloma virus (HPV), 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, Gillingham, 
UK) supplemented with: Penicillin/Streptomycin (P/S; 1 %);  L-glutamine (1 %; both from 
Invitrogen, Gillingham, UK); 10 % Foetal Calf Serum (FCS; Biosera, Boussens, France); 
and RM+ supplement (1 %; see below). Cells were cultured in a humidified incubator 
with 5 % CO2 in air at 37°C.   
TYLK1 and TYLK2 cells were isolated by Dr Andrew South, University of Dundee, as 
described in Blaydon et al., (2012): After gaining appropriate consent, primary 
keratinocyte cells were isolated from biopsies of affected papular skin from male (TYLK1) 
and female (TYLK2) tylosis patients. The primary keratinocytes were grown in the 
presence of a γ-irradiated 3T3 feeder-cell layer. Cells were immortalized with HPV16 
(E6/E7) and passaged until they could grow independently of the feeder cell layer. 
HeLa and HEK-293T cells were cultured in DMEM supplemented with 10 % FCS, 1 % 
L-glutamine and 1 % P/S and cultured in a humidified incubator at 5 % CO2 in air at 37°C. 
The OSCC cell lines TE-4, TE-8, KYSE270 and KYSE410 were cultured in RPMI 1640 
medium with 1 % L-glutamine and 10 % FCS at 37°C at 5 % CO2 in air. HNSCC cell lines 
were kindly provided by Helena Emich and Dr Adrian Biddle (Centre for Cutaneous 
Research (CCR), Blizard Institute, QMUL), and used only to make protein lysates. 
100X RM+ stock contains: EGF (1 µg/ml); transferrin (500 µg/ml); hydrocortisone 
(40 µg/ml); cholera toxin (84 ng/ml); insulin (500 µg/ml); L4 supplement (1.3 µg/ml). L4 
was prepared from 3,3’,5-Triiodo-L-thyronine sodium salt. All ingredients for RM+ were 
purchased from Sigma-Aldrich except EGF, which was purchased from ABD Serotec, 
(Kidlington, UK). Where cells were cultured in the absence of exogenous EGF, RM- 
supplement was included instead. RM- contains the same ingredients as RM+, but the 
EGF is omitted. All other cell culture equipment and consumables were purchased from 
Fisher Scientific (Loughborough, UK).  
2.1.1 Cell Passaging 
When cells reached approximately 90 % confluency, the medium was removed, cells 
washed with Phosphate-Buffered Saline (PBS; Sigma-Aldrich), and treated with trypsin-
EDTA (Invitrogen) in PBS until all cells detached from the flask: 1X concentration 
(0.05 %) for HeLa, HEK293T cells and OSCC Cell lines; 3X concentration (0.15 %) for 
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cutaneous keratinocytes. The trypsin reaction was quenched with serum-containing 
medium, the cells transferred to a 15 ml falcon tube, and centrifuged at 1200 rpm for 5 
min to pellet cells and allow complete removal of the trypsin. The supernatant was 
removed by aspiration, and the cells re-suspended in fresh medium. The required 
amount of cells was then seeded into a new flask with fresh medium. For example, for a 
1 in 10 split, 1/10th of the cell suspension was transferred into the new flask. The ‘split’, 
or the proportion of cells transferred to the new flask, was adjusted depending on the cell 
line and the growth rate of the cells.  
2.2 Transfection of cell lines  
2.2.1 Overexpression of DNA constructs 
Overexpression of DNA constructs was performed with Fugene 6 Transfection reagent 
(Roche, Welwyn Garden City, UK). Prior to transfection, 0.5 x 105 cells were plated per 
well of a 12-well cell culture dish containing coverslips for immunofluorescence 
experiments, or at 1.8 x 105 cells per well of a 6-well plate to make protein lysates. 
Transfections of HeLa and HEK-293T cells were carried out the following day and 
transfection of keratinocytes was carried out on the same day.   
Transfection complexes were formed in polystyrene tubes, as polypropylene decreases 
the activity of the Fugene 6 reagent. Per well of a 12-well dish, the reaction was set up 
as follows: 50 µl PBS was added to two separate tubes. 500 ng DNA was added to one 
tube and 1.5 µl Fugene added to the other. This was incubated for 5 min, and the DNA 
mixture transferred to the Fugene mixture and mixed by flicking. Reactions were 
incubated at room temperature for at least 20 min, then the DNA-fugene mixture added 
to the cells in a drop-wise manner. The cell culture medium was changed 6-24 h after 
transfection as the Fugene reagent can be toxic to the cells. This protocol was scaled up 
proportionately for transfection in a 6-well plate. Cells were used for experiments 48 h 
after transfection unless otherwise stated.   
2.2.2. siRNA Transfections 
Knock-down of RHBDF2 (iRHOM2) and ADAM17 was carried out using OnTarget plus 
SmartPool siRNA and Dharmafect transfection reagent (Dharmacon, Fisher 
Thermoscientific). All work was carried out in RNase free sterile conditions with surfaces 
cleaned with RNaseZap® beforehand (Ambion-Invitrogen, Paisley, UK). siRNA was 
resuspended to a concentration of 20 µM in siRNA resuspension buffer (Fisher 
Thermoscientific) according to the manufacturer’s instructions; aliquots were stored 
at -80°C.   
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Cells were plated into 6-well dishes at a density of 2 x 105 cells per well one day prior to 
transfection. For each well, 6 µl Dharmafect was added to 194 µl serum and antibiotic-
free medium in a polystyrene transfection tube. In a separate tube, 10 µl siRNA was 
added to 190 µl serum and antibiotic free medium for each well of cells. These mixtures 
were incubated for 5 min at room temperature, and then the diluted siRNA was added to 
the Dharmafect mixture. This was incubated for 20 min at room temperature. 
Antibiotic-free medium (1.6 ml; containing FCS) was added to the siRNA-Dharmafect 
complex, mixed by inverting, and added to the cells (2 ml per well). The transfection was 
left for a maximum of 24 h before medium was changed to complete medium containing 
antibiotics. It is important to change the medium within 24 h as the Dharmafect reagent 
can be toxic to the cells.  
 
2.3 Staining 
2.3.1 Immunocytochemistry (ICC) 
Cells were seeded onto coverslips in 12-well dishes and fixed for immunofluorescence 
staining once they had reached the desired level of confluency. In experiments involving 
transient overexpression of plasmid DNA, cells were transfected as described above, 
and fixed after approximately 48 h or when expression of the construct was optimal.   
Cells were fixed with either 4 % paraformaldehyde (PFA) in PBS for 30 min at room 
temperature, or in ice-cold methanol-acetone (1:1 mixture) at -20°C for 5 min. The 
following steps were all carried out at room temperature: cells were permeabilised with 
triton X100 (0.1 %) in PBS for 10 min, then blocked with Bovine Serum Albumin (BSA; 
3 %) for 30 min. Cells were incubated with primary antibody diluted in the blocking 
solution for 1 h at room temperature as indicated in Table 2.1. After the primary antibody 
incubation, cells were washed at least 3X in PBS, and then incubated for 1 h at room 
temperature with the appropriate AlexaFluor® fluorescently-conjugated secondary 
antibody (Invitrogen, UK) diluted 1 in 1000 in PBS. The secondary antibody targets the 
immunoglobulins of the host species of the primary antibody. The fluorescence 
conjugates used were AlexaFluor® 488, which is shown in the green channel; and 
AlexaFluor® 568, which shows in the red channel.  
Following incubation with the secondary antibody, the cells were washed thoroughly in 
PBS (at least 4 X 3 min), with 100 ng/ml 4',6-diamidino-2-phenylindole (DAPI) included 
in the second wash. Coverslips were then mounted onto slides with Shandon 
Immumount (Thermoscientific). Slides were left to set at 4°C, and then imaged on the 
Zeiss 510 Meta Confocal or the Zeiss LSM710 Meta Confocal microscope, as indicated.   
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2.3.2 Immunohistochemistry (IHC) 
Frozen skin sections were air-dried for 30-60 min. In some cases, sections were fixed 
with ice-cold methanol-acetone (MeAc; 1:1 mixture), which was added to the sections 
after air-drying and left to air-dry for approximately another 20 min. For staining with goat 
anti-EphA2 antibody, sections were fixed for 10 min with 4 % PFA in PBS at the end of 
the air-drying step. For further details of the conditions used for individual antibodies 
please see Table 2.1.   
Following drying and fixing, sections were permeabilised for 10 min in 
triton X100 (0.1 %), and blocked for 20 min in 3 % BSA in PBS. The primary antibody 
was diluted in the blocking solution and applied to the sections for an overnight 
incubation at 4°C. The following day, sections were washed in PBS, and then incubated 
for 1 h at room temperature with the appropriate Alexafluor® secondary antibody, diluted 
1 in 800 in PBS unless otherwise indicated. The sections were washed at least 3X with 
PBS, with DAPI nuclear stain (100 ng/ml) included in the second wash. Coverslips were 
mounted with Shandon Immumount mounting medium (Thermoscientific).  
2.3.3 Co-localisation 
For co-localisation experiments, the primary antibodies used were from two different 
species to ensure that the antibodies do not bind to each other and give a false-positive 
signal. The secondary antibodies, AlexaFluor® 488 and AlexaFluor® 568 had non-
overlapping emission spectra to minimise bleed-through between the channels and a 
false-positive result. In each experiment, the following control experiments were 
included:  
i) Negative control treated only with rabbit secondary antibody, negative control 
treated with only mouse secondary, and negative control treated with both 
secondary antibodies to detect non-specific binding of the secondary antibodies to 
the section or blocking solution. 
ii) Controls with each primary antibody stained individually and treated with the 
secondary targeting the host of that primary antibody only, which were used when 
choosing microscope settings, which were adjusted to avoid bleed-through. 
iii) Controls with each primary antibody stained individually and treated with both 
secondary antibodies to ensure the secondary antibodies are binding only to their 
target antibody, and that there is no false-positive signal resulting from non-specific 
binding of one secondary antibody to the wrong primary antibody.  
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Table 2.1 Table of antibodies and conditions for staining and western blots 
  
Protein Species Company Staining Conditions Western Blot Conditions
β-catenin Mouse BD Transduction Labs MeAc fix, 1in100 IHC n/a
ADAM17 - pro Rabbit AbCam n/a 10%, Milk block, 1in1000
ADAM17 - total Rabbit AbCam n/a 10%, Milk block, 1in2000
Anti-GFP Mouse AbCam 1in500 ICC n/a
Anti-GFP Rabbit AbCam 1in500 ICC n/a
CD68 Mouse AbCam MeAc fix, 1in500 IHC n/a
Desmocollin 2 Mouse ProGen MeAc fix, 1in500 ICC and IHC 10%, Milk block, 1in1000
Desmocollin 3 Mouse ProGen MeAc fix, 1in50 ICC and IHC 10%, Milk block, 1in250 
Desmoglein 1 Mouse ABD Serotec MeAc fix, 1in100 ICC and IHC n/a
Desmoglein 1 and 2 (3.10) Mouse ProGen 1in200 ICC and IHC n/a
Desmoglein 2 10D2 Mouse Kindly Provided by Pr My Mahoney 1in50 ICC and IHC n/a
Desmoglein 2 Ab10 Rabbit Kindly Provided by Pr My Mahoney n/a 10%, BSA block, 1in10,000
Desmoplakin 11-5F Mouse Kindly provided by Pr David Garrod MeAc fix1in100 ICC and IHC HMW protocol, Milk Block, 1in250
E-Cadherin Mouse AbCam MeAc fix1in100 ICC n/a
EphA2 Goat R&D Systems PFA fix, 1in50 10%, Milk block, 1in500
EphA4 Rabbit AbCam 1in50 10%, Milk block, 1in500
EphA4 (phospho-EphA4) Rabbit R&D Systems
1in50, use TBS instead of PBS 
at all steps
n/a
Ephrin A1 V18 Rabbit Kindly provided by Dr Spiro Getsios 1in50 IHC 12%, Milk block, 1in1000, 25KDa band
GRP78 (ET-21) Rabbit AbCam PFA fix, 1in100 n/a
iRHOM1 / RHBDF1 Rabbit AbCam 1in100 IHC n/a
iRHOM2 / RHBDF2 Rabbit Sigma MeAc fix, 1in100 ICC and IHC 10%, Milk block, 1in500
iRHOM2 / RHBDF2 Rabbit
Custom-made by Harlan laboratories, 
Oxon, UK
MeAc fix, 1i in 100 IHC n/a
NOTCH1 (ChIP grade) Rabbit AbCam MeAc fix 1in50 ICC HMW protocol, BSA block, 1in500
NOTCH1 (mN1A) Mouse AbCam MeAc fix 1in50 ICC n/a
NOTCH1 (Val1744) Rabbit AbCam MeAc fix 1in50 ICC n/a
Plakoglobin Mouse ABD Serotec MeAc fix 1in25 ICC and IHC 10%, Milk block, 1in100
Plakophilin 1 Mouse ProGen MeAc fix1in50 ICC and IHC 10%, Milk block, 1in100
Plakophilin 2 Mouse ProGen MeAc fix1in25 ICC and IHC 10%, Milk block, 1in250 
RHBDL2-N Terminal Rabbit AbCam 1in50 IHC n/a
Thrombomodulin Rabbit AbCam 1in100 IHC n/a
Tubulin Mouse AbCam 1in750 n/a
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2.3.4 Confocal microscopy 
Images were taken using the Zeiss 510 Meta Confocal or the Zeiss LSM 710 Meta 
Confocal microscopes using the LSM or Zen software respectively. Once the microscope 
system was running, the appropriate lasers were selected to detect the required 
wavelengths: 405 nm (DAPI), 488 nm (FITC) and 543 nm or 561 nm for the 510 and 710 
microscopes respectively (red channel). The laser power was set to 2.0% for each laser 
for each image on the LSM 710 micropscope. On the 510 microscope, the 488 nm laser 
was set to 12.0% and the 405 nm laser to 10.0%. Once the sample was identified using 
the eyepiece at a 10X magnification, the objective was changed to 40X, 63X or 100X as 
indicated with oil applied to the sample coverslip for all oil immersion lenses. 
With the Zen software for the 710 microscope, initial settings were determined using the 
Auto Exposure setting, while settings from a previous image were used as a starting 
point on the LSM 510 microscope. The focus was adjusted so that the region of brightest 
staining was in focus for each image. The pinhole was set to 1 airy unit (1 AU) for each 
channel; the detectors were aligned and the digital offset and gain settings were adjusted 
for each channel to avoid under- or overexposed pixels and to ensure the image was 
within the dynamic range of the detectors. The scanning parameters were then set: The 
frame size was 1024 x 1024 pixels; the scan speed was set to 7; data depth was 16 bit; 
and the scan average was set to 8. A single slice image was taken for each image. 
Microscope settings were kept the same for all images within an experiment to allow 
comparison between samples.  
2.4 Western Blotting 
2.4.1 Preparation of cell lysate 
Cells were lysed in 2X Laemelli buffer (0.1 M Tris-HCL (pH 6.8), 4 % sodium dodecyl 
sulphate (SDS), 20 % Glycerol, 0.001 % Bromophenol Blue, 1.44 M β-mercaptoethanol). 
Laemelli buffer is a denaturing buffer, making protein epitopes available to the probing 
antibodies. The SDS in the buffer gives the protein a negative charge, thereby allowing 
it to migrate through the gel in response to electrical charge. β-mercaptoethanol is a 
reducing agent, removing disulphide bridges from proteins and enabling them to move 
through the gel according to their size. Glycerol is included in the buffer to increase the 
density of the sample helping even loading of the gel. Bromophenol blue allows detection 
of the movement of the protein through the gel as it migrates through the gel faster than 
the other components of the sample.  
Before the lysis, the cell culture dish was placed on ice and the cells washed twice with 
PBS. The 2X Laemelli buffer was heated at 95°C for 5 min on a heat block, the PBS 
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removed from the cells and 150-250 µl heated 2X Laemelli buffer added to each well of 
a 6-well plate. A cell scraper was used to ensure the cells were detached from the plate, 
and the cell lysate transferred to a 1.5 ml eppendorf tube. The lysate was placed on the 
heat block at 95°C for 5 min and then immediately put back onto ice. The lysates were 
centrifuged at 13,000 rpm for 5-10 min and the supernatant transferred to a fresh ice-
cold tube (avoiding any pellet formed by the centrifugation, as this contains cell debris). 
If the supernatant was viscous, it was sonicated with the Soniprep 150 sonicator (MSE, 
Sydenham, UK) for 10-20 s. Protein lysates were stored at -80°C.   
2.4.2 Electrophoresis 
2.4.2.1 SDS-PAGE  
Sodium-dodecyl Sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using equipment from Bio-Rad (Hemel Hempsted, UK). All equipment was cleaned 
with hot water and 100 % ethanol before use. SDS-PAGE gels were prepared with an 
appropriate polyacrylamide percentage for the protein being detected (see Table 2.2), 
with higher percentage gels used for lower molecular weights. iRHOM2 is around 90 
KDa in size, so an 8 % gel was used for this antibody initially, then later, 10 % gels were 
used to allow visualisation of the ‘doublet’ seen in higher percentage gels. The resolving 
gel was made up first according to the recipe in Table 2.3. The basic ingredients are 
double distilled H2O (ddH2O), 30 % polyacrylamide mix (Protogel), tris (1.5 M, pH 8.8), 
SDS (10 %), ammonium persulphate (APS, 10 %; Sigma-Aldrich) and 
N,N,N,N-tetramethylethylenediamine (TEMED; Sigma-Aldrich). APS and TEMED act as 
polymerising agents in the gel. After pouring the gel, isopropanol was added to level the 
top of the gel and remove air bubbles. The gel was then left to set for around 20 min. 
The resolving gel has a higher resistance, so protein migration through the gel is slower, 
allowing separation of the proteins by size. As the gel percentage increases, the 
resistance also increases, allowing greater protein separation, and visualisation of 
smaller differences in size.  
Once the resolving gel was set, the isopropanol was removed and the top of the gel 
washed with ddH2O. The stacking gel was then prepared. The stacking gel has a lower 
resistance than the resolving gel, allowing the proteins to ‘stack up’ at the same point 
before entering the more resistant resolving gel. Each 5 ml stacking gel contained: 3.4 
ml ddH2O; 0.8 ml 30 % polyacrylamide mix; 0.63 ml Tris (1 M, pH6.8), 0.05 ml SDS 
(10 %), 0.05 ml APS (10 %) and 5 µl TEMED. The gel was poured around 10 or 15-well 
combs which form the loading wells at the top of the gel, avoiding the formation of air 
bubbles. This was left to set for approximately 30 min.   
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Once the gels had set, they were fitted into the tank and the combs removed. Running 
buffer (0.3 % Tris, 1.44 % Glycine and 0.1 % SDS in ddH2O) was poured in between the 
gels and outside the gel but without it touching to prevent a short circuit. The wells of the 
gel were rinsed to remove any gel debris or un-polymerised gel using a 1 ml pipette and 
running buffer. Protein samples were heated to 95°C or 5 min and then cooled on ice 
and spun at 13,000 rpm for 5 min in a bench top centrifuge before loading into the gels. 
Rainbow ladder (GE Healthcare) or HiMark high molecular weight protein ladder 
(Invitrogen) was also included in at least one well per gel to allow identification of protein 
size. The gel was then run for approximately 1 ½ h at 12 mA per gel until the dye front 
from the bromophenol blue in the loading buffer reached the bottom of the gel. The 
protein has a negative charge (from the SDS in the loading buffer), causing the protein 
to migrate from negative charge towards positive charge when the electrical current is 
run through the tank.   
2.4.2.2 Tris-acetate gradient gel electrophoresis 
DSP and NOTCH1 western blots were run on a pre-cast 3-8 % tris-hydroxymethyl amino 
ethane (TRIS)-acetate gradient gel (Invitrogen) due to their high molecular weight 
(HMW). The gels were prepared according to manufacturer’s instructions, and run with 
tris-acetate running buffer comprising: tricine (0.9 %), tris base (0.6 %) and SDS (1 %). 
HiMark HMW protein ladder (Invitrogen) was included in at least one well as a size 
marker.  
  
Protein size (kDa)  Gel percentage (%) 
4-40 20 
12-45 15 
10-70 12.5 
15-100 10 
25-200 8 
Table 2.2 SDS-PAGE gels  
Reagent 8 % 10 %  12 % 
H2O 4.6 ml 4.0 ml 3.3 ml 
30 % Acrylamide Mix 2.7 ml 3.3 ml 4.0 ml 
1.5 M Tris (pH 8.8)  2.5 ml 2.5 ml 2.5 ml 
10 % SDS 100 µl 100 µl 100 µl 
10 % APS 100 µl 100 µl 100 µl 
TEMED     4 µl     4 µl     4 µl 
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Table 2.3 Recipes for 10 ml resolving gel at 8 %, 10 % and 12 %   
 
2.4.3 Transfer 
The next step was to transfer the proteins from the gel onto a nitrocellulose membrane 
(GE Healthcare, Buckinghamshire, UK), which has a high affinity for proteins, allowing 
them to be retained during antibody incubation. For the transfer process, blotting paper, 
sponge pads and a piece of nitrocellulose membrane were soaked in transfer buffer 
(0.3 % tris, 1.4 % glycine, 20 % methanol in ddH2O). A cassette was used to sandwich 
in order: a sponge pad, two pieces of blotting paper, the gel, the nitrocellulose 
membrane, two pieces of blotting paper and another sponge pad, taking care to avoid 
air bubbles by rolling over the blotting paper on top of the gel and membrane with a 5 ml 
pipette. As with gel electrophoresis, the negatively charged protein migrates from 
negative charge towards positive charge when an electrical current is run through the 
tank. The gel was therefore placed towards the negative side of the tank and the 
membrane at the positive side. The tank was filled with transfer buffer, and an ice pack 
added to prevent overheating. A current of 300 mA for a 1½-2 h transfer, or 100 mA for 
overnight transfer, was run through the tank. HMW proteins were always transferred 
overnight at 100 mA using a buffer comprising: tris base (0.6 %), glycine (0.2 %) and 
methanol (5 %), without SDS.  
2.4.4 Blocking 
Once the transfer was complete, the nitrocellulose membranes were blocked in either 
10 % milk or 5 % BSA in tris-buffered saline-Tween (TBS-T) as indicated in table 2.1 for 
1 h, at room temperature. TBS-T comprises: Tris-HCl (0.2 %; Fisher Thermoscientific); 
NaCl (0.8 %) and Tween-20 (0.1 %; Sigma-Aldrich) in ddH2O. The pH was adjusted to 
7.5 in the 10X stock solution with concentrated hydrochloric acid (Sigma-Aldrich).   
2.4.5 Antibody incubation 
Primary antibodies were diluted in 5 % milk in TBS-T, or in 5 % BSA depending on the 
blocking solution. The conditions used for each antibody are shown in table 2.1. The 
membrane was incubated in the antibody overnight at 4°C, or for 2 h at room temperature 
where overnight transfer was carried out. A house-keeping gene of a different molecular 
weight to the protein of interest, such as glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), β-actin or vinculin, was included as a loading control to show whether the 
loading of proteins was equal.  
Following the primary antibody incubation, the membranes were washed in TBS-T, then 
incubated for 2 h in horseradish-peroxidase (HRP)-conjugated secondary antibody 
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(Dako, Ely, Cambridgeshire, UK) at a dilution of 1 in 3000 (swine-anti-rabbit secondary 
antibody), 1 in 2000 (rabbit-anti-mouse secondary antibody), or 1 in 2000 (rabbit-anti-
goat secondary antibody). Following the incubation with secondary antibody, 
membranes were washed at least 3X 5 min in TBS-T, and visualised using ECL plus or 
prime chemiluminescent reagent according to the manufacturer’s instructions (GE 
Healthcare) or Immobilon western chemiluminescence reagent (Millipore), also 
according to the manufacturer’s instructions.  
Chemiluminescence works using HRP conjugated to the secondary antibody, combined 
with peroxide, to catalyse the oxygenation of a lumigen substrate such as the PS-3 
Acridan substrate found in ECL plus. This generates acridinium ester intermediates 
which produce a sustained chemiluminescence in combination with the peroxidase and 
slightly alkaline conditions. The membranes were placed in a cassette and, in a dark 
room with only red light, photographic film (GE Healthcare) was exposed to the 
membrane for the appropriate amount of time to develop clear bands, then fixed and 
developed using the Compact X4 automated developing system (Xograph Imaging 
Systems, Gloucestershire, UK).   
 
 
2.4.6 Densitometry analysis 
Densitometrical analysis was carried out using Image J software (Rasband, W.S., Image 
J, U. S. National Institutes of Health, Maryland, USA) and Image Studio Lite software 
version 3.1 (LI-COR, Cambridge, UK). Film was scanned and images saved in JPEG 
format before importing into Image J or Image Studio Lite.  
For analysis with Image Studio Lite: The image was saved as a single colour file, and 
cropped to the appropriate size. Boxes were drawn around each band, and the integrated 
density calculated by the software as a measure of the intensity of the signal. The 
software measures the intensity of each pixel in the box, plotting a line graph of pixel 
number against intensity of the signal, giving a curve for each band. The software then 
measures the area under the curve to take into account the area and intensity of the 
band as integrated density. Any free rotations were carried out after the densitometry to 
avoid unwanted manipulation of the data. 
Analysis with Image J works in a similar way. JPEG files were imported into the 
programme and the images cropped and rotated in right angles to the right orientation. 
The ‘Analyse Gels’ tool was used: A box was drawn around each band, plots of the band 
intensity against pixel number generated and the area under the curve was measured.  
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The same process was carried out for GAPDH or other loading control bands in both 
software packages. The final band intensity is shown as a percentage of loading control 
signal to control for uneven protein loading.   
2.5 Phospho-Receptor Tyrosine Kinase arrays 
Phospho-RTK arrays were purchased from R&D systems and carried out according to 
the manufacturer’s instructions. Briefly, membranes were blocked with the blocking 
buffer provided. 500 µg protein from lysates of TYLK1 and TYLK2 TOC cells and NEB1 
control cells was diluted in 2 ml blocking buffer and applied to the membranes overnight 
at 4°C. Membranes were washed using the wash buffer provided, then incubated with a 
phospho-specific secondary antibody for 2 h at room temperature. Membranes were 
washed again with the buffer provided, and developed using ECL plus reagent 
(Amersham, GE Healthcare).   
2.6 ELISA  
2.6.1 Sample collection 
KYSE270, KYSE410 and TE-4 cells were plated in 12-well plates at a density of 3 x 105 
cells per well. The following day, once the cells had attached to the wells, the cells were 
washed with PBS and 1 ml fresh medium (RPMI 1640 with FCS, P/S, L-glutamine and 
RM+) added to each well of cells. Medium was collected immediately for the 0 h time 
point, then at 3 h, 6 h, 12 h, 24 h and 48 h time points. The medium was stored at -80°C 
until needed. At the 24 h time point, mRNA was also extracted from the cells with the 
RNeasy mini kit, protocol described in section 2.8.1.   
2.6.2 ELISA 
Enzyme-Linked Immunosorbent Assays (ELISAs) were carried out with the DuoSet 
ELISA development system (R&D Systems, Abingdon, UK) according to kit instructions. 
Briefly, the capture antibody was diluted to the working concentration specified by the 
manufacturer’s instructions (2 µg/ml for AREG; 0.4 µg/ml for TGF-α) and 100 µl added 
to each well of a 96-well ELISA plate. The plate was sealed and incubated at room 
temperature overnight.   
The following day, the wells were washed three times with wash buffer (0.05 % Tween-
20 in PBS; pH 7.2-7.4) and the wells dried by blotting the plate onto paper towels. Plates 
were blocked for 1 h at room temperature with 300 µl reagent diluent (1 % BSA in PBS; 
pH 7.2-7.4; 0.2 µm filtered), then the plate washed three times as described above. 
Standards were prepared by diluting in reagent diluent according to instructions for the 
particular kit: A high standard of 1000 pg/ml was used for AREG and 500 pg/ml for 
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TGF-α. Two-fold serial dilutions were then carried out to form a 7-point standard curve. 
Samples were diluted 1 in 4 for AREG ELISAs and 1 in 2 for TGF-α ELISAs in reagent 
diluent. Samples or standards were added to each well, 100 µl per well, each sample in 
duplicate. The samples and standards were incubated for 2 h at room temperature.   
Plates were washed 3 times, and detection antibody diluted in reagent diluent according 
to kit instructions. The diluted antibody was added to each well, 100 µl per well. This was 
incubated for a further 2 h at room temperature, then the wash step repeated. Further 
steps were carried out avoiding exposure to direct light. Firstly, 100 µl of the 1 in 200 
working dilution of streptavidin-HRP was added to each well and incubated for 20 min. 
The wash step was repeated, and 100 µl substrate solution added to each well. Substrate 
solution comprises a 1:1 mixture of colour reagent A (Hydrogen peroxide; H2O2) and 
colour reagent B (Tetramethylbenzidine). Stop solution (50 µl; 2 N sulphuric acid 
(H2SO4)) was then added and the optical density measured at 450 nm with a Synergy 
HT plate reader. Readings at 540 nm were subtracted from the readings to correct for 
background from the plate.  
2.6.3   ELISA analysis 
Data was imported into Microsoft Excel, and a standard curve generated from the 
absorbance of the standard protein concentration. A polynomial trend line was added 
with the order best fitting the data and achieving an R2 value as close to 1 as possible. 
The equation generated was used to determine protein concentrations in the individual 
samples. As each sample was run in duplicate, an average of the two readings was 
taken, and then an average of the triplicates for each condition calculated to determine 
the final protein reading for each experiment. The cells were counted at the 24 h 
timepoint and the concentration of AREG or TGF-α expressed as pg/ml/105 cells. 
2.7 Reverse-Transcriptase PCR 
2.7.1 mRNA extraction  
mRNA was extracted from cells using the RNeasy mini kit according to the 
manufacturer’s instructions (Qiagen, Crawley, UK). Cells were lysed directly in the cell 
culture dish using 350 µl buffer RLT with 3 µl β-mercaptoethanol included to inactivate 
endogenous RNases. Cells were removed from the cell culture dish with a cell scraper 
(Fisher Scientific), passed through a 20-gauge needle at least 5 times and transferred to 
an RNase/DNase-free tube. One volume of 70 % ethanol was added to the tube and 
mixed by pipetting. The lysate was then transferred to the RNeasy spin column and spun 
at 8,000 g for 30 s. Ethanol provides optimal conditions for the RNA to bind to the silica 
spin column. The flow-through from the spin was discarded, and the column washed with 
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700 µl buffer RW1 and spun at 8,000 g for 30 s. Two washes were then performed with 
buffer RPE, centrifuged for 30 s at 8,000 g for the first wash, then at 8,000 g for 2 min 
for the second wash. The column was transferred to a clean RNase/DNase-free tube, 
and centrifuged without solution for 1 min at maximum speed (~16,000 g) to remove all 
traces of ethanol, which can inhibit the elution step. Finally, the mRNA was then eluted 
in 30 µl RNase-free water and the concentration measured using the nanodrop 
spectrophotometer (Thermo Scientific).      
2.7.2 cDNA synthesis 
cDNA synthesis was performed with Superscript II reverse transcriptase enzyme 
(Invitrogen). Two tubes were included for each mRNA sample, one in which the reverse 
transcriptase enzyme is present (RT+) and one in which the enzyme is omitted (RT-). 
The RT- sample acts as a negative control, showing that there is no DNA or RNA 
contamination in the sample or reagents. For each sample, to make 20 µl cDNA, the 
following was added to a 0.2 ml RNase-free thin-walled PCR tube: 8 µl RNase free H2O, 
1 µl oligodT (short sequence of deoxy-thymine residues), 0.5 µl random 
primers/hexamers, 1 µl deoxynucleotide triphosphates (dNTP), and 1.5 µl RNA (diluted 
to 100 ng/µl). This mixture was incubated at 65˚C for 5 min and transferred quickly to 
ice. 5X first-strand buffer (4 µl), 2 µl dithiothrietol (DTT; 0.1 M) and RNase Out (1 µl) were 
then added and the tube incubated at 42˚C for 2 min. Finally, 1 µl Superscript II enzyme 
was added to each RT+ sample and 1 µl RNase free H2O added to each RT- sample 
and the tubes were incubated at 42˚C for 50 min. A polymerase chain reaction (PCR) for 
house-keeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) was 
then carried out to check the quality of the cDNA and check for contamination in the RT- 
samples.   
2.7.3 PCR  
Polymerase chain reactions (PCR) were carried out using either BioTaq DNA 
polymerase (Bioline, UK) or GoTaq DNA polymerase (Promega, UK) as indicated in 
Table 2.4. PCRs were carried out using primers from Sigma Genosys (UK). Primers were 
designed by Dr Diana Blaydon. The primer sequences, PCR conditions, annealing 
temperatures and the size of the PCR product are indicated in Table 2.4.   
A mastermix was prepared for each set of reactions. BioTaq mastermix contained: 10X 
buffer (2 µl); MgCl2 (50 mM; 0.6 µl); dNTP (0.4 µl); 0.2 µl each of forward and reverse 
primers and Taq polymerase (0.2 µl). Mastermix for reactions with GoTaq polymerase 
contained: 5X GoTaq buffer (4 µl); MgCl2 (25 mM; 1.2 µl); dNTP (0.4 µl); 0.2 µl each of 
forward and reverse primers; and Taq polymerase (0.2 µl). The primer stock solutions 
were at a concentration of 10 µM. Dimethylsulphoxide (DMSO) was added as indicated 
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in Table 2.4 to increase the specificity of some reactions. Finally, ddH2O was added to a 
total volume of 19.5 µl per reaction. Once the mastermix was prepared, it was transferred 
to separate 0.2 ml thin-walled PCR tubes or to the wells of a PCR plate, and 0.5 µl cDNA 
added to each well or tube. 0.5 µl ddH2O was added to one well/tube per reaction to act 
as a negative control and rule out contamination from the components of the PCR 
reaction.   
The tubes or plates were then put into a DNA engine Tetrad 2 Peltier thermocycler (MJ 
Research) and put through the following programme: 95°C for 30 s initial melting, 
followed by 35 cycles of the following: 95°C for 30 s to melt the double stranded DNA, 
exposing the bases for the primers to bind; X°C for 15 s to allow the primers to bind to 
the DNA – this annealing step was carried out at the temperature indicated in Table 2.4. 
An extension step of 1 min at 72°C was then carried out to allow further nucleotides to 
be added to the forming DNA strand. Finally, once the 35 cycles were complete, a final 
extension of 72°C for 10 min was carried out to ensure that all the PCR products were 
complete.    
Once the PCR cycle was finished, a 1 % agarose gel was prepared by boiling a solution 
of agarose in Tris-Borate-EDTA buffer (TBE) in a microwave until the agarose dissolved. 
The agarose solution was then cooled until comfortable to touch, then 0.5 µg/ml ethidium 
bromide was added. The gel was poured into a tray with a comb to form wells for loading 
the PCR products. The products were mixed in a 1:1 ratio with loading dye and run 
through the gel in a DNA electrophoresis tank (Horizon 11.14, Gibco BRL). Because 
DNA is negatively charged, when a current is run through the gel, the DNA migrates 
away from the negative charge at one side of the gel towards the positive charge at the 
other end of the gel. Smaller proteins will migrate faster through the gel, allowing 
separation of the PCR products by size. The 1 Kb plus DNA ladder (Invitrogen) was 
included in at least one well of each gel as a size marker. The ethidium bromide in the 
gel interchelates with the DNA and fluoresces under UV light when it is bound to the 
double stranded DNA allowing visualisation of the PCR products. Pictures of the gels 
were taken with the UviDoc system (Uvitec). 
2.7.4 qPCR 
Semi-quantitative real-time PCR (qPCR) was carried out using Taqman technology and 
the Rotorgene Q thermocycler (Qiagen). Taqman chemistry works using a sequence-
specific probe. The probe is fused to a fluorescent reporter at the 5’ end and a quencher 
at the 3’ end. When the probe is in its unbound state, the quencher and reporter are in 
close proximity, so that any fluorescent energy emitted by the reporter is absorbed by 
the quencher by fluorescence resonance energy transfer (FRET) (Holland et al., 1991). 
94 
 
This prevents detection of any signal from the reporter. However, when the probe binds 
to its target sequence, the 3’ and 5’ ends are separated, so the quencher is too far from 
the reporter to absorb the signal. When the samples are exposed to light, signal from the 
reporters of any bound probes may be detected by the machine. Thus as the target 
sequence is amplified by gene-specific primers, the amount of probe bound to the target 
sequence increases, as does the signal detected from the reporter.  
To set up the reactions, a mastermix was made using the Multiplex PCR Mastermix Kit 
(Qiagen). The mastermix contains the necessary ingredients for the qPCR including 
HotStarTaq DNA polymerase. The following was added for each reaction: Multiplex 
mastermix (10 µl); nuclease free H2O (6.5 µl); forward primer (10 µM, 1 µl); reverse 
primer (10 µM, 1 µl); Taqman probe (0.5 µl). The mastermix was transferred into 
individual 0.02 ml thin-walled PCR machines tailored for the rotorgene (19 µl per tube). 
Work was carried out on ice and nuclease-free conditions to preserve the enzyme, cDNA 
samples and other ingredients. cDNA was then added at a volume of 1 µl to give a total 
reaction volume of 20 µl. The qPCR reaction was carried out in triplicate for each sample, 
and a corresponding control reaction with RT- cDNA was included for each sample. 
Primers and probes against AREG, TGF-α and GAPDH were kindly provided by Dr 
Matthew Brooke, ordered from Sigma-Aldrich. The primer sequences are shown in table 
2.4. The reaction was run on the RotorGene Q qPCR machine (Qiagen). An initial 
denaturing step was carried out at 95°C for 10 min, followed by 45 cycles consisting of 
a 15 s denaturing step at 95°C and 50 s at 60°C for annealing and extension.  
qPCR results were analysed using the Rotorgene Q series software. Levels of each gene 
were expressed relative to housekeeping gene GAPDH using the ΔCT (change in cycle 
threshold) method (Livak and Schmittgen, 2001). A threshold was set using the software 
and the cycle number at which the signal for each sample crossed the threshold (the CT 
value) was recorded. The CT value for the gene of interest (AREG or TGF-α) was 
subtracted from the CT value for GAPDH to give the ΔCT value. This value was then 
expressed as 2 ΔCT to give a reading of the gene expression. 
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PCR 
 
Forward 
Primer 
 
Reverse Primer 
 
Conditions 
 
Annealing 
Temperature 
 
Product 
Size (bp) 
 
RHBDF2 
isoforms 
1 and 2 
 
RHBDF2ex2F 
GGGCAAACT
CAGACTCGA
AG 
 
RHBDF2ex5R 
CGCTGACTCC
AAACCACTG 
 
Bioline Taq 
5 % DMSO 
 
65°C 
 
429 and 
336 
 
RHBDF2 
isoform 1 
 
 
RHBDF2ex4F 
AGAAAAGCC
AGCCCAGGA
C 
 
RHBDF2ex6R 
AGGAGGTGAG
GGACAGGACT 
 
GoTaq 
10 % DMSO 
 
58°C 
 
492 
 
 
RHBDF2 
isoform 2 
 
 
RHBDF2ex3/4
-F 
CAGCATGCT
GCCTGAGAG
GA 
 
RHBDF2ex6R 
AGGAGGTGAG
GGACAGGACT 
 
Bioline Taq 
5 % DMSO 
 
60°C 
 
443 
 
AREG 
(For 
qPCR) 
 
 
 
AREG qPCR 
Forward 
AAGGACCAA
TGAGAGCCC
CG 
 
AREG qPCR 
Reverse 
TAATGGCCTG
AGCCGAGTAT
C 
 
qPCR Probe 
6FAM-
GCCGGCGC
CGGTGGTG
CTGT-BHQ1 
 
 
60°C 
(Green 
channel) 
 
 
TGFα 
(For 
qPCR) 
 
 
 
TGFa qPCR 
Forward 
AGCATGTGT
CTGCCATTC
TG 
  
  
TGFa qPCR 
Reverse 
TGTGATGATA
AGGACAGCCA
GG 
 
qPCR Probe 
6FAM-
TGGCCGTG
GTGGCTGC
CAGCCA-
BHQ1 
 
 
60°C  
(6FAM = 
Green channel 
reporter) 
 
 
GAPDH 
(For 
qPCR) 
 
 
 
GAPDH qPCR 
Forward 
TGGCCCCTC
CGGGAAACT
GT 
 
GAPDH qPCR 
Reverse 
CCTTGCCCAC
AGCCTTGGCA 
 
qPCR Probe 
HEX-
GCGTGATG
GCCGCGG
GGCTCTCC
A-BHQ1 
 
 
60°C 
(HEX = Yellow 
channel 
reporter) 
 
 
Table 2.4 PCR primers and reaction conditions. Anti-RHBDF2 primers were kindly 
provided by Dr Diana Blaydon, and qPCR primers provided by Dr Matthew Brooke.  
 
2.8 Migration assays 
Cells were plated in 6-well plates in triplicate for each cell line and condition and grown 
until confluent. Cells were incubated for 2 h at 37°C, 5 % CO2 with or without mitomycin 
C (MMC; 10 µg/mL; Sigma-Aldrich) which irreversibly inhibits proliferation, thus ensuring 
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that differences seen are due only to migration of the cells. Cells were washed 3X with 
PBS to remove the MMC, then two scratches placed perpendicular to each other to form 
a cross shape. The centre of the cross forms a guide to ensure images are taken at the 
same location in the scratch at each time point. Cells were again washed 3 times with 
PBS to remove any dead cells and cell debris formed by the scratch and medium without 
exogenous EGF (RM- medium) added to the cells. Images were then taken to show the 
scratch wounds at the 0 h time point with the Nikon Eclipse TE2000-5 microscope and 
Nikon digital Sight DSL1. Four pictures were taken of each well at the four regions 
adjoining the centre point of the scratches in each well. Further pictures were taken every 
24 h until the scratch was closed.  
2.9 Flow Cytometry  
NEB1 or HeLa cells were plated in 6-well dishes and transfected with Fugene 6 
transfection reagent as described in section 2.2. Cells were transfected with green 
fluorescent protein (GFP)-tagged wild type (WT) and mutant Connexin 31 or iRHOM2 
constructs. Approximately 48 h after transfection, the medium was collected and stored 
in a 15 ml falcon tube. The cells were washed with PBS and the PBS transferred to the 
falcon tube. The medium and PBS from the wash step were kept to allow collection of 
any dead cells that had detached from the culture dish. Next, 500 µl trypsin-EDTA in 
PBS  was added to each well of cells (0.05 % for HeLa cells, 0.15 % for keratinocytes) 
and the plates incubated at 37°C until the cells had detached from the dish. The trypsin 
was neutralised with warm serum-containing medium, and the medium and cells 
transferred to the falcon tube. The tube was centrifuged at 1200 rpm to collect the cells, 
the medium removed and the cells re-suspended in 500 µl PBS with 1 % FCS.   
Flow cytometry (FC) was carried out using the BD FACS Canto II machine at the BICMS 
core FACS facility with Dr Luke Gammon (CCR, QMUL). Immediately prior to FC, one 
drop of propidium iodide (PI; 500 µg/ml) was added to the cells and mixed with a Pasteur 
pipette, which also resuspended any pelleted cells. PI preferentially enters dead cells 
and fluoresces at approximately 600 nm upon binding nucleic acids within the cells 
(Nicoletti et al., 1991). Cells were then transferred to a polystyrene tube of the 
appropriate size for flow cytometry. At least 10,000 events were recorded for each 
sample, and each transfection was carried out in duplicate.   
For each experiment and each cell line, control tubes were prepared including: 
1) Untransfected cells to allow exclusion of any cell fragments or clusters. Cell size 
can be determined using the forward scatter and side scatter measurements and 
a gate set to include only cells of the desired size.   
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2) Untransfected cells plus PI to allow compensation for any bleed-through from the 
red (PI) channel into the green channel (known as the FITC, or fluorescein 
isothyocyanate channel, which detects emission signals at the GFP emission 
wavelength). 
3) Cells transfected with plasmids coding for enhanced green fluorescent protein 
(pEGFP), to allow a gate to be set for GFP-positive cells and compensation set 
to avoid recording any bleed-through from the green channel into the red channel.   
4) pEGFP transfected cells plus PI to allow gates to be set for detection of GFP-
positive cells.   
2.9.1 Flow Cytometry Analysis 
A plot of forward scatter vs side scatter was generated. Forward scatter detects cell size, 
and side scatter measures cell density, allowing detection of distinct cell populations. In 
this case, a gate was drawn to select single cells and exclude any cell debris and clumps 
of cells from the analysis. A plot of GFP / FITC intensity vs side scatter was then drawn 
using GFP-transfected control cells to allow determination of GFP-positive and negative 
populations, and the same performed for PI-positive and negative populations. 
Quadrants were then drawn to show:  
1) GFP-negative, PI-negative populations (untransfected, alive cells) 
2) GFP-negative, PI-positive populations (untransfected, dead cells) 
3) GFP-positive, PI-negative populations (transfected, alive cells) 
4) GFP-positive, PI-positive populations (transfected, dead cells)  
 
Compensation was carried out to account for any bleed-through from GFP into the red 
channel and from PI into the green channel. Gates were adjusted slightly for each sample 
to account for subtle differences in fluorescence intensity as distinct populations were 
visible. Finally, the percentage of transfected, dead cells was calculated for each sample. 
For analysis of iRHOM2-GFP transfected cells, the green fluorescent intensity of 
PI-negative cells was also taken into account, with the mean intensity plotted against cell 
number.     
 
 
 
98 
 
 
 
 
Chapter 3: iRHOM2 
expression and 
localisation in the 
skin 
 
 
 
 
  
99 
 
Chapter 3: iRHOM2 localisation and 
expression in normal and TOC Skin 
3.1 Introduction and Aims 
The inactive rhomboid protein iRHOM2 (and its homologue iRHOM1) are members of a 
relatively recently discovered family of proteins and are not well characterised in the skin 
and other squamous tissues. The iRHOMs are predicted to be localised to the ER, and 
an ER and golgi localisation has been seen in cultured cells (Nakagawa et al., 2005; Zou 
et al., 2009; Zettl et al., 2011; McIlwain et al., 2012), with the highest iRHOM2 expression 
levels reported in macrophages (Adrain et al., 2012; McIlwain et al., 2012). We recently 
identified germline mutations in iRHOM2 as the underlying cause of autosomal dominant 
inherited condition TOC (Blaydon et al., 2012). This chapter aims to investigate iRHOM2 
localisation and expression in normal and TOC skin and keratinocytes, to look at the 
desmosomal structure of TOC skin via electron microscopy (EM) imaging, and to 
investigate the protein expression and localisation of desmosomal proteins. 
3.2 Results 
3.2.1 iRHOM2 localisation in the skin 
To study the epidermal localisation of iRHOM2, IHC was performed in frozen skin 
sections and MeAc fixed keratinocytes.  
3.2.1.1 iRHOM2 in the epidermis 
iRHOM2 in normal skin sections was localised predominantly to the cell periphery, 
suggesting a plasma membranous localisation (figure 1 A and B), unlike the previously 
predicted ER localisation of iRHOM2 in cultured cells. Some fainter punctate intracellular 
staining was also seen, which could represent ER-iRHOM2 localisation. iRHOM2 
staining could also be seen in individual cells within the dermis.  
In NEB1 keratinocytes cultured in monolayer, the localisation of iRHOM2 appeared more 
intracellular, with punctate staining, particularly in the perinuclear region of the cells 
(figure 3.2.1 C), suggesting an ER-localisation of iRHOM2. Some cell-surface staining 
was sometimes also visible in NEB1 keratinocytes (figure 3.2.1 C), but the appearance 
of the membranous staining varied between experiments, perhaps suggesting that 
iRHOM2 localisation varies within the cell depending on the situation. Further evidence 
for cell-surface iRHOM2 is suggested by overexpression of GFP-tagged iRHOM2 in 
NEB1 keratinocytes (figure 3.2.1 D), which shows cell-surface staining in addition to 
fainter intracellular staining which sometimes appeared punctate in nature. 
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Negative control staining in which the primary antibody was omitted did not show any 
positive staining, indicating that staining was not due to non-specific binding of the 
secondary antibody to proteins in the skin or cells (figure 3.2.1 Aii, Bii and Cii). In addition, 
a similar cell-surface iRHOM2 localisation was seen in staining with another antibody 
against iRHOM2 in frozen skin sections (appendix A1), suggesting that the staining 
pattern does not result from non-specific binding of the anti-iRHOM2 antibody. 
Furthermore, western blotting of protein lysate from NEB1 keratinocytes showed a band 
at around 90 KDa which was of a reduced intensity in lysates from cells treated with 
siRNA targeting iRHOM2 (figure 3.2.1 E). The full length western blot is shown in 
appendix A1, including two faint additional bands at approximately 150 KDa and 52 KDa, 
which will be discussed later in the chapter. 
3.2.1.2 iRHOM2 is expressed in infiltrating macrophages 
iRHOM2 has previously been shown to be predominantly expressed in murine 
macrophages (Adrain et al., 2012; McIlwain et al., 2012). As some individual cells in the 
human epidermis stained brightly for iRHOM2, co-localisation was performed with 
antibodies against iRHOM2 and macrophage marker cluster of differentiation 68 (CD68) 
to confirm whether the individual iRHOM2-expressing cells in the dermis were indeed 
macrophages. CD68 staining in normal frozen skin sections was seen in a number of 
individual cells in the dermis and epidermis, which often had a spindle-like shape (figure 
3.2.2 A). iRHOM2 expression was seen adjacent to CD68 staining in many of the cells 
(figure 3.2.2 B-D), suggesting that iRHOM2 was expressed in the same cells as CD68 in 
the dermis, which are likely to be infiltrating macrophages. The iRHOM2 and CD68 
staining sometimes appeared to co-localise in the perinuclear region of the cells, but in 
general, the staining was distinct, with iRHOM2 appearing perinuclear and CD68 staining 
closer to the cell surface in most cells. This suggests iRHOM2 may be found in the ER 
in human macrophages, consistent with the localisation reported in the mouse.  
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Figure 3.2.1 iRHOM2 has a plasma membrane and perinuclear localisation in 
human epidermis and keratinocytes. A and B: iRHOM2 IHC in frozen skin 
sections from facelift skin in the absence (A) and presence (B) of DAPI nuclear 
stain. Images were taken at 40X magnification (n=6), and the regions marked with 
white boxes at 100X (n=1), shown to the right. C: ICC of iRHOM2 in NEB1 
keratinocytes in the presence (ii) and absence (i) of DAPI (n=6). Negative controls 
are shown in Aii, Bii and Cii. D: NEB1 cells overexpressing GFP-tagged iRHOM2-
WT, fixed with MeAc and stained with anti-GFP antibody (n=3). Imaging of frozen 
skin sections was carried out on the LSM510 confocal microscope, and of NEB1 
cells on the Zeiss Meta 710 confocal microscope. iRHOM2 staining is shown in 
green, DAPI nuclear staining in blue. E: Western blots showing iRHOM2 protein in 
NEB1 keratinocytes after treatment with iRHOM2 siRNA or non-targeting pool 
siRNA. 
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Figure 3.2.2 iRHOM2 is expressed in macrophages in normal skin. Co-
localisation of iRHOM2 and macrophage marker CD68 in normal frozen breast skin 
sections (n=3). A: Green channel, showing CD68 staining, B: Red channel showing 
anti-iRHOM2 staining C: CD68 and iRHOM2 (red and green channel merge). D: 
Merge of iRHOM2, CD68 and DAPI nuclear stain, shown in blue. Images were taken 
with the Zeiss LSM 710 Confocal microscope. Please see Appendix A2 for control 
staining performed at the same time as the above experiment.  
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3.2.1.3 iRHOM2 localisation in the oesophagus 
The localisation of iRHOM2 in the oesophagus was also investigated. IHC against 
iRHOM2 in normal oesophagus was performed by Dr Laura Gay, Centre for Digestive 
Diseases, QMUL. iRHOM2 also appeared to show a cell-surface expression in the 
oesophagus (figure 3.2.3), perhaps with some intracellular staining in some cells. This is 
consistent with iRHOM2 localisation in the epidermis, and suggests that iRHOM2 may 
be predominantly at the cell-surface in stratified squamous epithelia.  
3.2.2 iRHOM2 mRNA expression in keratinocytes  
The mRNA expression of iRHOM2 was investigated in a panel of human cells lines, 
including NEB1, HaCaT and N/TERT human keratinocyte cell lines, primary human 
keratinocytes (1˚HK), HeLa and HEK293T cells, to further confirm iRHOM2 expression 
in the skin. The RHBDF2 gene is 19 exons long and has two splice variants, isoforms 1 
and 2, which differ by 85 base pairs (bp) missing from the beginning of exon 4 in isoform 
2 (figure 3.2.4 A). Primers targeting RHBDF2 exons 2-5, spanning the region that differs 
between isoforms, produced two PCR products at around 336 bp and 423 bp, the sizes 
predicted for RHBDF2 isoforms 1 and 2 (figure 3.2.4 B). The RT-PCR was not 
quantitative, but, the smaller band likely representing isoform 2 appeared more intense 
in all the cell lines tested, with lower expression in N/TERT cells compared with the other 
cell lines. The 423 bp band for isoform 1 varied in intensity between the cell lines, with 
stronger expression in HaCaT, 1oHK and HeLa cells and a faint band present in NEB1 
cells.  
To confirm these results, primers specific to isoforms 1 and 2 were designed. The isoform 
2 PCR produced robust bands at approximately the correct size (443 bp) in all cell lines 
tested (figure 3.2.4 D), and showed lower isoform 2 levels in N/TERT cells, consistent 
with figure 3.2.4 B. A second faint band was visible in HeLa and HEK293T cells, however, 
suggesting detection of a non-specific product during the PCR. The isoform 1 PCR was 
less robust, but showed variable expression of RHBDF2 isoform 1 between cell lines 
(figure 3.2.4 C), also consistent with the PCR of both isoforms (figure 3.2.4 B). A band 
was also present at around 1 Kb in some samples. Overall, these results suggest that 
isoform 2 is the major isoform in keratinocytes, with isoform 1 expression more variable.  
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Figure 3.2.3 iRHOM2 localisation in normal oesophagus. Plasma membranous 
staining of iRHOM2 in normal oesophagus at magnifications of 20X (A) and 40X (B) 
in the presence (i) and absence (ii) of DAPI nuclear stain, shown in blue. Images 
were taken by Dr Laura Gay. Brightness and contrast increased by 10 % from 
original image.  
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Figure 3.2.4 Variable expression of iRHOM2 isoforms 1 and 2 at the mRNA level in 
human keratinocytes. A: An alignment of the first section of the cDNA sequence of 
iRHOM2 isoforms 1 and 2 was performed (Multiple sequence alignment with hierarchical 
clustering; Corpet 1988, http://multalin.toulouse.inra.fr/multalin/). B: RT-PCR was carried 
out with primers detecting both isoforms 1 and 2 of iRHOM2 (B; n=1)), isoform 1 specific 
primers (C; n=2)) and isoform 2 specific primers (D; n=2).  
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3.2.3 iRHOM2 localisation in Tylosis with Oesophageal Cancer 
IHC was performed against iRHOM2 in TOC frozen skin biopsies to determine whether 
the RHBDF2 mutations affect the localisation of the iRHOM2 protein. Initial IHC 
experiments were carried out in an older frozen skin biopsy from a TOC patient, who will 
be referred to as patient 4. (The majority of IHC in this thesis was performed in three 
newer biopsies.) iRHOM2 in normal facelift skin stained at the same time showed the 
same plasma membranous localisation seen previously, with some fainter intracellular 
staining and expression in the macrophages (figure 3.2.5 A). In TOC patient 4, however, 
the intensity of iRHOM2 at the cell surface was reduced and much more intracellular 
staining was seen (figure 3.2.5 B), suggesting that iRHOM2 localisation is altered in 
TOC.  
The IHC was repeated in newer biopsies from three female TOC patients from three 
generations of the same family. Patient 1 is the mother of patient 2 and grandmother of 
patient 3; patient 2 is the mother of patient 3. In contrast to patient 4, IHC in TOC patients 
2 and 3 (figure 3.2.6 C and D) showed a localisation of iRHOM2 very similar to that seen 
in normal epidermis (figure 3.2.6 A), with plasma-membranous staining and fainter 
punctate intracellular staining. Patient 1, however, had dysregulated iRHOM2 staining, 
with less staining at the cell surface and increased intracellular staining which appeared 
more diffuse (figure 3.2.6 B), similar to the localisation seen in patient 4. 
3.2.3.1 iRHOM2 co-localises with β-catenin at the cell surface in normal 
and TOC skin 
IRHOM2 co-localisation experiments were performed with β-catenin to assess protein 
expression at the cell surface (figure 3.2.7). In normal epidermis, β-catenin appeared at 
the plasma membrane, with some intracellular staining in a couple of cells, but this was 
absent from most epidermal cells (figure 3.2.7 A and B). β-catenin appeared to co-
localise with iRHOM2, shown by yellow plasma-membranous staining where the signal 
from both secondary antibodies was emitted from the same region of the tissue. Control 
staining is shown in appendix A3, showing that the signal was not a result of non-specific 
binding of the anti-mouse secondary antibody to the iRHOM2 primary antibody, or vice 
versa, and that there was no signal in the negative control.  
In the epidermis of TOC skin, iRHOM2 still appeared to co-localise with β-catenin, 
particularly in patients 2 and 3 (figure 3.2.7 D and E), with strong yellow staining seen at 
the plasma membrane. In epidermis from patient 1, which showed dysregulated iRHOM2 
staining, there still appeared to be some faint co-localisation at the cell surface (figure 
3.2.7 C), but the staining was much weaker and the signal from the co-localisation 
appeared more orange in colour. This indicates that iRHOM2 still reaches the plasma 
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membrane in TOC when iRHOM2 is dysregulated, but suggests that cell-surface levels 
of iRHOM2 are reduced.  
3.2.3.2 iRHOM2 expression in macrophages appears unaffected in TOC 
To see whether iRHOM2 expression in the macrophages was affected by the TOC 
RHBDF2 mutations, co-localisation with macrophage marker CD68 was performed in 
TOC skin (figure 3.2.8). There were no clear differences in CD68 or iRHOM2 staining in 
the macrophages of TOC skin compared with normal skin, and iRHOM2 still appeared 
to be found in the same cells as CD68. Perhaps iRHOM2 staining appeared a little more 
diffuse in the macrophages in patient 1 epidermis (figure 3.2.8 B).  
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Figure 3.2.5 Variable iRHOM2 localisation and lower expression TOC skin. IHC of 
iRHOM2 in normal frozen sections from facelift skin. A: Normal skin and B: TOC skin 
(patient 4). Images were taken initially at 40X (n=4), then the regions indicated by white 
boxes imaged at 100X (n=1), shown on the right, and in the presence of DAPI nuclear 
stain in Aii and Bii. C: Negative control shown in the absence (i) and presence (ii) of 
DAPI nuclear stain. Images were taken on the LSM 510 confocal microscope. iRHOM2 
staining is shown in green and DAPI nuclear stain in blue.   
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Figure 3.2.6 Variable iRHOM2 localisation in TOC skin, part 2. IHC of iRHOM2 
in three TOC frozen skin biopsies taken at a later date than the original biopsy. iRHOM2 
staining is shown in the absence (i) and presence (ii) of DAPI nuclear stain. A: Normal frozen 
facelift skin B: TOC patient 1 (n=2), C: TOC patient 2 (n=3), D: TOC patient 3 (n=2). E: 
Negative control. Images were taken on the Zeiss Meta 710 confocal microscope. iRHOM2 
staining is shown in green and DAPI nuclear stain in blue. 
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Figure 3.2.7 iRHOM2 still reaches the cell surface in TOC skin. Co-localisation of 
iRHOM2 and β-Catenin in TOC frozen skin sections compared to control skin (n=2). A: 
Normal skin (same settings as TOC patient 2 in E) B: Normal skin (same settings as 
TOC patients 1 and 3 in C and D). C: TOC patient 1, D: TOC patient 3, E: TOC patient 
2. iRHOM2 staining is shown in green, β-catenin is shown in red, DAPI nuclear stain is 
shown in blue. Images were taken on the Zeiss Meta 710 confocal microscope. Control 
staining can be seen in Appendix A3. 
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Figure 3.2.8 iRHOM2 appears unaffected in macrophages in TOC skin. IHC showing 
co-localisation of iRHOM2 and CD68 as indicated in A: Normal skin, B: TOC patient 1, 
C: TOC patient 2, D: TOC patient 3. CD68 is shown in green, iRHOM2 in red, and DAPI 
nuclear staining in blue. N=1. Please see Appendix A4 for control images. Images were 
taken on the Zeiss Meta 710 confocal microscope.  
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3.2.3.3 iRHOM2 localisation in TOC keratinocytes 
The localisation of iRHOM2 in cutaneous keratinocytes was also investigated by ICC 
(figure 3.2.9). ICC was highly variable between a number of staining experiments, as 
seen in staining of NEB1 keratinocytes, so this figure represents one example. The 
variation may suggest that small changes in culture conditions and perhaps cell 
confluence levels can impact on iRHOM2 localisation, which may reflect changes in its 
activity in different situations. This may also reflect the differentiation status of the cells, 
as the cells were cultured in high Ca2+ medium.  
As described in section 3.2.1, in NEB1 control keratinocytes, iRHOM2 showed a 
predominantly punctate perinuclear localisation, which was consistent between different 
experiments. Some faint plasma membranous staining can be seen here (figure 3.2.9 
A), which occurred in many but not all experiments. Staining in K17 control keratinocytes 
was also punctate and predominantly perinuclear, with some even fainter cell-surface 
staining, but the intensity of the staining appeared reduced. TYLK1 and TYLK2 
keratinocytes also showed punctate iRHOM2 staining, but this appeared to be found 
throughout the cell, reaching to the plasma membrane. Staining was also seen in the 
plasma membrane in TYLK1 but not TYLK2 cells (figure 3.2.9), although again, there 
was variation in the plasma membranous staining between different experiments.  
Figure 3.2.9 B shows the staining at a higher magnification, allowing clearer visualisation 
of the cell-surface staining. Negative control staining is shown in figure 3.2.9 C. K17, 
TYLK1 and TYLK2 cells were perhaps at a lower confluence level than NEB1 cells for 
this experiment, and did not form the same block-like morphology, possibly explaining 
some variation within this experiment.  
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Figure 3.2.9 iRHOM2 localisation in TOC and control keratinocytes. A: An example 
of ICC of iRHOM2 in control and TOC keratinocytes as indicated in the absence (i) and 
presence (ii) of DAPI nuclear stain (n=5). B: Control and TOC cells at a higher digital 
zoom. C: Negative control. Images were taken on the Zeiss Meta 710 confocal 
microscope. 
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3.2.4 iRHOM2 expression appears reduced in TOC 
IHC in frozen skin sections appeared reduced in TOC epidermis compared with control 
epidermis (figures 3.2.5-3.2.8). It is difficult to accurately determine expression levels 
from immunofluorescence, but similar results were seen in western blots with lysates 
from NEB1 cells overexpressing WT and TOC-mutant GFP-tagged iRHOM2, (figure 
3.2.10 A), where the intensity of the higher band representing GFP-tagged iRHOM2 was 
much lower for both iRHOM2-I186T and iRHOM2-P189L. Repeats of this experiment are 
shown in appendix A5. The expression levels of iRHOM2-GFP were variable between 
experiments, but the overall trend appears consistent in NEB1 cells. Interestingly, the 
same difference was not seen in HEK293T cells overexpressing iRHOM2 (appendix A5).  
Flow cytometry was performed on NEB1 cells overexpressing both isoforms of iRHOM2. 
Flow cytometry counts individual cells, allowing selection of all GFP-expressing 
keratinocytes and exclusion of untransfected cells. Flow cytometry measurements were 
performed with the help of Dr Luke Gammon, Centre for Cutaneous Research, QMUL. 
Consistent with the western blotting results in figure 3.2.10 A, the fluorescence intensity 
appeared slightly lower in mutant iRHOM2-expressing cells than WT overexpressing 
cells (figure 3.2.10 B). Interestingly, the fluorescence intensity of isoform 2-transfected 
cells appeared slightly higher than the intensity of cells transfected with isoform 1, which 
would be consistent with the intensity of the RT-PCR bands for iRHOM2 mRNA levels in 
figure 3.2.4.   
Cells were stained with PI immediately before flow cytometry analysis to determine cell-
death levels in the cells, and whether cell death was the cause of the lower 
overexpression levels seen. There was a slight trend towards increased cell death in 
cells overexpressing isoform 2 (figure 3.2.10 C) shown by the percentage of cells positive 
for propidium iodide, which could explain some of the difference seen. However, flow 
cytometry measures individual cells and the cells included in the analysis for 
fluorescence were negative for propidium iodide. Furthermore, increased cell death was 
not seen in cells overexpressing mutant iRHOM2 compared to cells overexpressing wild 
type iRHOM2, so cell death does not appear to account for the reduced intensity. Cells 
transfected with Connexin 31 WT and the C86S mutant were included as negative and 
positive controls for cell death. Connexin 31 C86S is a GJB3 mutation associated with 
autosomal dominant erythrokeratoderma variabilis (EKV), and its expression causes 
activation of the UPR and cell death (Tattersall et al., 2009). 
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Figure 3.2.10 iRHOM2 harbouring TOC mutations expresses at a lower level when 
overexpressed in NEB1 keratinocytes. NEB1 cells were transfected as indicated with 
iRHOM2 WT or TOC mutant, pEGFP, or were untransfected control cells. A: Western blot 
showing expression of iRHOM2-GFP isoform 2, and endogenous iRHOM2 (n=3). B: Graph 
of a flow cytometry experiment showing average FITC intensity for each event for cells 
overexpressing isoform 1 and isoform 2 of iRHOM2 (n=3). C: Percentage of cells in flow 
cytometry experiments that are positive for PI staining, i.e. dead cells (n=3). Connexin 31 WT 
and EKV-mutant expressing cells were included as positive and negative controls for cell 
death. D: Graph showing the percentage of GFP-positive cells of all the total events in flow 
cytometry experiments (n=3). E: Western blot showing iRHOM2 and GAPDH loading control 
in lysates from 3D raft cultures with control (K1 and K17) and TOC (TYLK1 and TYLK2) 
keratinocytes (n=1). 3D cultures and western blot was performed by Dr Nihal Kaplan and Dr 
Spiro Getsios, Northwestern University, Chicago, US.  
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It is also possible that the differences seen by western blot could have resulted from 
lower transfection efficiency with mutant iRHOM2. To determine whether this was the 
case, the transfection efficiency in the flow cytometry experiments was estimated by the 
percentage of GFP-positive cells in the population (figure 3.2.10 C). The transfection 
efficiency did appear to be slightly greater for isoform 2, and also appeared to be lower 
for iRHOM2-P189L isoforms 1 and 2. However, the reduction in transfection efficiency 
does not appear to correlate closely with the reduction in protein expression in figure 
3.2.10 A, particularly for iRHOM2-I186T. The flow cytometry experiments measure the 
intensity of individual cells that have taken up the GFP-tagged plasmid, which should in 
part control for this possibility unless there was a large variation in the number of 
plasmids taken up by the cells in each experiment.  
Further evidence for a reduction in iRHOM2 expression in TOC is shown by western 
blots in lysates from 3D raft cultures with the TOC keratinocytes by Dr Spiro Getsios and 
Dr Nihal Kaplan, Northwestern University, Chicago (figure 3.2.10 E), which show 
reduced levels of iRHOM2 in raft cultures from TOC keratinocytes compared with control 
keratinocytes. Interestingly, western blots of TOC keratinocytes grown in monolayer 
culture did not always show reduced levels of iRHOM2, which will be discussed further 
later in this chapter and in the next chapter.  
3.2.5 Is expression of iRHOM2 specific to keratinocytes? 
Overexpression of GFP-tagged WT and mutant iRHOM2 constructs in both NEB1 and 
HeLa cells showed variable distributions of iRHOM2 (figure 3.2.11). In NEB1 
keratinocytes (figure 3.2.11 A), iRHOM2 appeared to localise predominantly to cell-cell 
borders, as seen in normal epidermis (figure 3.2.1) with some intracellular localisation 
particularly in the perinuclear region of the cells. There was perhaps a slight increase in 
perinuclear localisation of iRHOM2 in some cells expressing iRHOM2-P189L, but there 
were no striking differences in WT and mutant iRHOM2 localisation.  
In HeLa cells (figure 3.2.11 B), both WT and mutant iRHOM2 appeared to be present 
throughout the cell (figure 3.4A), with some aggregation of iRHOM2 in the perinuclear 
areas of some cells. This may suggest that there is something specific to keratinocytes 
that leads to iRHOM2 localisation at the plasma membrane. However, HeLa cells were 
derived from cervical cancer, and have been passaged many times so do not represent 
a normal non-keratinocyte cell line. Therefore, overexpression in a wider range of cell 
lines and staining in endogenous tissues could be performed. Other groups have also 
shown an ER-localisation of iRhom2 in non-keratinocyte cells including COS-7 cells 
(Zettl et al 2011), L929 cells (McIlwain et al 2012 supplementary information) and MEFs 
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(Hosur et al 2014). Furthermore, iRHOM1 does not go to the plasma membrane in 
keratinocytes (chapter 4), suggesting that cell-surface localisation of iRHOM2 in 
keratinocytes and squamous tissue is specific to iRHOM2. The cell surface localisation 
of iRHOM2 in the epidermis and in the oesophagus will be discussed further later in the 
thesis.  
To confirm that iRHOM2-GFP is indeed reaching the cell surface, co-localisation of 
iRHOM2-GFP with the cell-surface proteins E-Cadherin and PG was performed (figure 
3.2.12). Though the level of cell-surface iRHOM2 expression appeared variable, where 
it reached the plasma membrane, co-localisation was seen with both E-Cadherin and 
PG. Negative controls and repeats with the iRHOM TOC mutants not shown in figure 
3.2.12 can be seen in Appendix A6. 
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Figure 3.2.11 Expression of iRHOM2-GFP at cell-cell borders in keratinocytes but 
not HeLa cells is unaffected by mutations found in TOC. GFP-tagged WT and TOC-
mutant iRHOM2 was overexpressed in A: NEB1 keratinocytes (n=3) B: HeLa cells (n=1). 
Imaging was performed on the Zeiss Meta 710 Confocal Microscope.  
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Figure 3.2.12 Co-localisation of overexpressed iRHOM2 with membrane protein E-
Cadherin and membrane-associated desmosomal protein PG. A and B: 
Co-localisation in NEB-1 cells of overexpressed iRHOM-WT-GFP (A) and iRHOM2-
I186T-GFP (B) with membrane protein E-cadherin (n=1); C and D: Co-localisation of 
iRHOM2-WT-GFP (C) and iRHOM2-P189L-GFP (D) with PG, which can associate with 
both desmosomes and AJ at the cell-surface (n=1). Images were taken on the Zeiss 
Meta 710 LSM confocal microscope. iRHOM2-GFP is shown in green, E-Cadherin and 
PG are shown in red, DAPI nuclear staining is shown in blue.  
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3.2.6 Desmosomes are dysregulated in TOC 
To look more closely at the structure of TOC epidermis and investigate epidermal 
structures such as the desmosomes, biopsies from TOC patients 1, 2 and 3 were fixed 
in gluteraldehyde. The biopsies were processed for electron microscopy by Mr Graham 
McPhail, Pathology department, Barts and the London School of Medicine and Dentistry. 
Electron microscopy was performed by Professor Akemi Ishida-Yamamoto, Tokyo, 
Japan.  
Desmosomes in all layers of TOC epidermis lacked the electron-dense midline seen in 
mature desmosomes in normal epidermis (figure 3.2.13), suggesting that they are in the 
immature form seen in wound healing (Garrod et al 2005). To look further at which 
desmosomal proteins were affected, western blotting was performed in lysates of control 
(NEB1 and K17), and TOC (TYLK1 and TYLK2) keratinocytes after culture in the 
presence and absence of exogenous EGF (figure 3.2.14), as desmosomal proteins are 
regulated by EGF signalling (Lorch et al., 2004; Klessner et al., 2009). A summary of all 
western blots and GAPDH loading control are shown in appendix A7.  
There was some variation in expression of desmosomal proteins between the different 
cell lines, but the majority of the proteins did not show a distinction in expression between 
control and TOC keratinocytes. The exception was DSG2, which was consistently 
reduced in TOC keratinocytes after culture in the absence of EGF, but this difference 
was much less clear after culture in the presence of EGF (figure 3.2.14). Increased 
expression of PKP1, PKP2 and PG was seen in NEB1 cells after culture in the absence 
of EGF relative to the other three cell lines. Western blots of lysates from the absence 
and presence of EGF were carried out separately, however, and so cannot be compared 
directly.  
DSP isoforms I and II, PG, both DSC2 isoforms and DSG2 appeared at approximately 
the size expected. PKP1 and PKP2 appeared slightly lower than the expected size 
(PKP1 was ~70-76 KDa compared with the predicted 87 KDa, and PKP2 was ~76 KDa, 
while it was predicted to be 97 KDa). Some of the size differences may be explained by 
uneven running of the gel, but it is surprising that PKP1 and 2 appeared ~15 KDa smaller. 
PKP2 appeared closer to 100 kDa after culture in RM-, suggesting that the size 
difference may be an issue with the marking of the ladder used in the western blots.  
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Figure 3.2.13 TOC skin lacks mature desmosomes. Electron microscopy showing 
desmosomes in A: Normal skin and B-D: Three TOC patients. White arrows in A indicate 
electron dense midlines seen in desmosomes of normal skin but not TOC skin. Scale 
bars represent 200 nm. Electron microscopy was performed by Dr Akemi Ishida-
Yamamoto, Asahikawa Medical University, Japan.  
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Figure 3.2.14 Variable expression of desmosomal proteins in control and TOC 
keratinocytes. Western blots showing levels of several desmosomal proteins in control 
and TOC keratinocytes after culture in the presence and absence of exogenous EGF, 
as indicated. Please see appendix A7 for repeats of the western blots in two more sets 
of protein lysates.  
 
  
123 
 
3.2.6.1 Increased desmoglein 2 processing in TOC 
As levels of full-length DSG2 protein appeared reduced in TOC keratinocytes after 
culture in the absence of EGF, and DSG2 is of interest as a substrate of ADAM17 (Lorch 
et al., 2004; Bech-Serra et al., 2006), the DSG2 western blots were analysed further. 
The antibody used to detect DSG2 protein is Ab10, a polyclonal antibody raised against 
the extracellular domain of DSG2 closest to the membrane (Brennan and Mahoney, 
2009). DSG2 is cleaved by ADAM17 in the juxtamembrane region to give a 100 KDa 
fragment, the intensity of which is reduced in the presence of siRNA targeting ADAM17 
(Klessner et al., 2009). The 100 KDa fragment comprises the entire DSG2 cytoplasmic 
tail, transmembrane domain, and an extracellular juxtamembrane domain.  
The anti-DSG2 western blot detected fragments at approximately the reported sizes for 
full-length and ADAM17-cleaved DSG2 (Klessner et al., 2009) (figure 3.2.15 A). There 
were no clear differences in the intensity of the bands for cleaved DSG2 in control and 
TOC keratinocytes after culture in the presence of exogenous EGF, as described for full-
length DSG2 in the previous figure. However, the reduction in full-length DSG2 in TOC 
keratinocytes after culture in the absence of EGF was accompanied by an increase in 
the intensity of the 100 KDa band representing cleaved DSG2, particularly in TYLK1 cells 
(figure 3.2.15 A). The other bands seen may represent DSG2 cleavage products 
mediated by other enzymes such as ADAM10 (Klessner et al., 2009). Graphs showing 
densitometry analysis of three repeats of the experiments are shown in figure 3.2.15 B. 
There is some variation between experiments, but there is a clear trend, and the findings 
are consistent with further repeats by Dr Matthew Brooke, and with increased ADAM17 
activity in TOC which is discussed in the next chapter.  
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Figure 3.2.15 Reduced levels of ADAM17 substrate DSG2 in TOC cells. Control and 
TOC cells were cultured in the presence and absence of exogenous EGF. A: Western 
blots of DSG2, including full length DSG2 (DSG2 FL), cleaved DSG2 and GAPDH 
loading control in the control and TOC cells. The band thought to represent ADAM17-
cleaved DSG2 (Klessner et al., 2009) is indicated as ‘DSG2 Cl’. B: Densitometry of 
DSG2 FL (i) and DSG2 Cl (ii) in cells after culture in the presence and absence of EGF, 
n = 3. Densitometry was carried out with Image J.  
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3.2.6.2 DSG2 localisation in monolayer keratinocytes  
ICC of DSG2 in keratinocytes after culture in the presence and absence of EGF is shown 
in figure 3.2.16. After culture in the presence of EGF, DSG2 appeared to be localised in 
a thin line around the plasma membrane (figure 3.2.16A) with no clear differences 
between control and TOC cells. There was also punctate staining throughout the cell, 
which may have been due to inclusion of the cell surface in the confocal image. After 
culture in the absence of EGF (figure 3.2.16 B), the plasma membrane localisation 
appeared slightly different, with projections crossing the membrane in some cells as if 
the cells were being ‘stitched together’ by DSG2, which would be consistent with 
increased desmosome formation in the absence of EGF, and the formation of 
desmosomal links between cells. Again, there were no clear differences between control 
and TOC keratinocytes.  
The cells were confluent in both experiments, but may have been more tightly packed 
after culture in the presence of EGF, which could influence DSG2 localisation. ICC of 
DSG2 was performed with the monoclonal antibody 10D2, which recognises a specific 
region of DSG2 EC1 region (Keim et al., 2008), so staining with Ab10 would be of interest 
for future work to see whether a change in DSG2 localisation is seen in TOC 
keratinocytes. Further repeats are needed to confirm whether there is a consistent 
difference. A z-stack, or whole cell imaging and co-localisation with a cell-surface, or lipid 
raft marker, would also allow collection of a complete picture of DSG2 localisation in 
control and TOC keratinocytes in future imaging.  
IHC of DSG2 in TOC frozen skin sections was also performed with antibody 10D2. 
However, the staining was very faint and difficult to see and therefore not shown. DSG2 
has been reported to be expressed at low levels in the basal layer of the epidermis 
(Brennan and Mahoney, 2009), which could explain why little staining was seen in skin 
sections. Keratinocyte cell lines are proliferative and represent cells of the basal layer, 
perhaps explaining why differences in DSG2 were seen in monolayer. One example of 
DSG2 IHC with antibody 10D2 is shown in appendix figure A8, which shows intracellular 
DSG2 staining in the epidermis and cell-surface DSG2 in the hair follicle of the same 
tissue section, so future work staining DSG2 with 10D2, and perhaps Ab10 IHC would 
be of interest to determine DSG2 localisation in the epidermis.  
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Figure 3.2.16 DSG2 localisation in cells cultured in the presence and absence of 
exogenous EGF. ICC of DSG2 in cells after culture in RM+, with EGF (A) (n=2) and 
RM- (n=2), without EGF (B). A and B were carried out in separate staining and imaging 
experiments. C: Negative controls for A are shown in (i) and B are shown in (ii). Images 
were taken on the Zeiss Meta 710 Confocal microscope. DSG2 is shown in green, DAPI 
nuclear stain shown in blue.  
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3.2.6.3 Localisation of desmosomal proteins in normal and TOC skin 
These findings may suggest that another cadherin is affected in the upper layers of the 
epidermis, so IHC of a panel of desmosomal proteins was also performed in skin biopsies 
(figure 3.2.17 and appendix A9-A22). IHC in control skin and patient 1 is shown in figure 
3.2.17. There were no clear differences in the localisation of most of the desmosomal 
proteins stained. There were perhaps some subtle differences in staining intensity in 
patient 1, for example staining of DSG1 and 2, PG and DSP was possibly slightly reduced 
in patient 1 (figure 3.2.17 B, D and F) and perhaps PKP1 was slightly increased in the 
upper epidermal layers, which was also seen in the other TOC patients (figure 3.2.17 E 
and appendix A20). Interestingly, DSC2 appeared up-regulated in patient 2, but not 
patients 1 or 3 (figure 3.2.17 G). The localisation did not appear to be significantly altered, 
shown in figure 3.2.17 H, which has increased digital zoom and reduced gain to allow 
visualisation of the localisation.  
3.2.6.3.1 Desmosomal proteins in cell monolayer 
The localisation of desmosomal proteins was also investigated in keratinocyte 
monolayers by ICC after culture in the presence of EGF (figure 3.2.18 parts A and B). 
There did not appear to be any striking differences in the localisation of any of the 
desmosomal components between control and TOC keratinocytes, although there was 
some variation in the staining. DSG1 appeared at lower intensity in NEB1 keratinocytes, 
with little membranous staining in TYLK2 cells (figure 3.2.18 A), but it would perhaps be 
expected at low levels in the basal layer and monolayer keratinocytes. There perhaps 
appeared to be less membranous staining of DSC2 in TYLK1 cells (figure 3.2.18 B), but 
NEB1 cells appeared at a higher density than the other cell lines. DSC3 membranous 
staining appeared variable, with perhaps lower intensity in NEB1 cells as seen by 
western blotting. PG membranous staining perhaps appeared more diffuse in TOC 
keratinocytes (figure 3.2.18 D), but again, NEB1 cells were more densely packed in 
staining of PG, which could affect desmosomal proteins. Very low staining levels of PKP1 
were seen in all cell lines (figure 3.2.18 E), perhaps because it is expressed minimally in 
the basal layer. No clear differences could be seen in PKP2 or DSP staining (figure 
3.2.18 F and G).  
Overall, more work is needed to investigate desmosomal proteins in TOC. Perhaps 
future experiments after culture in the absence of EGF would highlight any subtle 
differences, as was the case for DSG2. Culture was in high Ca2+ medium, which should 
encourage the formation of cell-cell adhesion complexes and desmosomes.  
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Figure 3.2.17 Localisation of desmosomal proteins in normal and TOC skin. IHC 
was performed against a panel of desmosomal proteins in frozen skin sections from 
normal (i) and TOC (ii) skin. A-F: Staining in normal skin and patient 1 of A: DSG1 (n=2), 
B: DSG1 and 2 (DSG3.10 antibody) (n=2) C: DSC3 (n=1), D: PG (n=1), E: PKP1 (n=2), 
F: DSP (n=2). G: DSC2 (n=1) in normal skin from breast (i); patient 1 (ii), patient 2 (iii), 
H, DSC2 in patient 2 at lower digital gain and exposure to allow visualisation of protein 
localisation. Further staining of the desmosomal proteins in all three patients can be seen 
in appendix A9-B22.
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Figure 3.2.18 part 1: Desmosomal proteins in control and TOC cells. ICC showing 
desmosomal proteins in control (NEB1 and K17) and TOC (TYLK1 and TYLK2) cell lines 
(n=1). A: DSG1, B: DSC2, C: DSC3, D: PG. Images were taken on the Zeiss Meta 710 
Confocal microscope. Desmosomal proteins are shown in green and DAPI nuclear stain 
in blue.  
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Figure 3.2.18 part 2: Desmosomal proteins in control and TOC cells. E: PKP1 (n=1), 
F: PKP2 (n=1), G: DSP (n=3). Images were taken on the Zeiss Meta 710 Confocal 
microscope. Desmosomal proteins are shown in green and DAPI nuclear stain in blue.  
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3.3 Discussion 
 
3.3.1 Summary of results: 
1) iRHOM2 is localised at the cell-surface in the skin and oesophagus 
2) iRHOM2 localisation may be dysregulated in some instances in TOC 
3) iRHOM2 expression may be reduced in TOC 
4) Desmosomes in TOC epidermis lack electron-dense midlines 
5) There appears to be increased processing of desmosomal cadherin DSG2 in TOC 
keratinocytes  
3.3.2 iRHOM2 at the cell-surface 
iRHOM2 was predicted to be an ER-membrane protein, and previously described 
functions of iRHOM2, including targeting of EGF for ERAD and trafficking of ADAM17, 
appear to be performed primarily from an ER localisation. However, IHC in the skin and 
oesophagus has not previously been described, and iRHOM2 appeared to show a 
predominantly plasma-membranous localisation in these tissues. The role of iRHOM2 at 
the cell surface in keratinocytes of the epidermis and oesophagus is unknown and could 
reflect an additional unknown function of iRHOM2. Another theory could be that excess 
iRHOM2 is ‘stored’ at the cell surface, which would be consistent with the variation in 
cell-surface iRHOM2 between overexpression experiments (figure 3.2.1D and 3.2.12), 
where there is likely to be more iRHOM2 than is needed in the cell. During imaging of 
cells strongly expressing iRHOM2 at the plasma membrane, fainter intracellular staining 
may have been missed as the microscope settings were adjusted for the bright staining 
seen at the plasma membrane. The often punctate localisation of iRHOM2 could also 
suggest localisation to a particular region of the cell membrane such as lipid rafts, where 
desmosomes are located, and/or in vesicles in intracellular staining.  
Staining of monolayer keratinocytes did appear to show a mostly perinuclear punctate 
localisation, suggesting ER-localised iRHOM2 with some faint cell-surface staining. 
iRHOM2 did not co-localise with ER markers, however, but appeared ‘next to’ staining 
with ER markers (work by Dr Daniel Tattersall). iRHOM2 has 7TMD and a long 
N-terminus and loop L1, so the antibody could be recognising a portion of the iRHOM2 
protein outside of the ER. The antibody epitope is shown in appendix A1. The cells shown 
in figure 3.2.1 were quite confluent, so perhaps cell contact or contact inhibition are 
affecting the appearance of cell-surface iRHOM2.  
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Previous studies reporting ER-localisation of iRHOM2 have predominantly been 
performed in monolayer culture using tagged versions of overexpressed iRHOM2 (Zettl 
et al., 2011). Some tumour biopsies shown in chapter 5 show cell-surface localisation, 
for example lung carcinoma, also suggesting that iRHOM2 may show plasma membrane 
localisation in other squamous tissues. iRHOM2 localisation in cancer will be discussed 
further in chapter 5.  
The striking cell-surface staining seen in the skin and oesophagus (keratinocytes) 
perhaps suggests that something specific to these cells encourages a cell-surface 
localisation of iRHOM2. The protein unique to keratinocytes is keratin. A yeast-two-
hybrid screen was performed with the N-terminal of iRHOM2, and results included three 
type I keratin proteins. This is currently being followed up by Dr Thiviyani Maruthappu in 
the group, so it will be interesting to see whether a link with keratins turns out to be a 
reason for cell-surface iRHOM2 localisation.  
Also, perhaps there is a further link between iRHOM2 and the desmosomes additional 
to processing by ADAM17: DSP is the anchor protein that links the keratin cytoskeleton 
to the plasma membrane. In one experiment, DSP knock down in HaCaT keratinocytes 
resulted in a striking up-regulation of iRHOM2 (appendix A24). This result was not shown 
in this chapter as further repeats did not produce the same results, although the knock 
down was effective. Perhaps something specific to the conditions in the first experiment 
(e.g. there was a lot of cell death) could have caused up-regulation of iRHOM2. The 
appearance of cell-surface iRHOM2 in staining of keratinocyte monolayers was highly 
variable, and iRHOM2 localisation appears to be dynamic and to depend on the cell 
conditions.  
3.3.3 iRHOM2 processing (Different iRHOM2 fragments in 
western blotting) 
Nakagawa et al (2005) showed that iRHOM1 undergoes proteolytic cleavage to give a 
fragment around 52 KDa and likely an undetectable N-terminal cleaved fragment, which 
may be degraded due to the presence of the PEST sequence. A band potentially 
representing a processed form of iRhom2 was also detected in co-immunoprecipitation 
experiments (McIlwain et al., 2012) suggesting that iRHOMs themselves may be 
regulated by proteolytic cleavage. Processing of active rhomboid protease RHBDL2 has 
been shown – RHBDL2 is cleaved, then the N-terminus goes to the cell surface while 
the C-terminal portion remains in the ER membrane (Lei and Li, 2009).   
iRHOM2 western blots often showed a band at approximately 52 KDa in cutaneous 
keratinocytes, which was also seen in HNSCC cells (chapter 5). This band was 
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sometimes increased in intensity in cells overexpressing iRHOM2, although this was 
again variable. Co-immunoprecipitation experiments also suggested iRHOM1 exists as 
a homodimer or oligomer (Nakagawa et al., 2005). An additional band at approximately 
150 KDa was also often seen in iRHOM2 western blots which could reflect an iRHOM2 
dimer or complex, although perhaps the molecular weight would be expected to be 
slightly higher. Also, this band was not affected by siRNA against iRHOM2, but a 
reduction in protein levels after siRNA transfection is dependent on the half-life of the 
protein, so an iRHOM2 dimer could be a more stable form of the protein less susceptible 
to degradation.  
3.3.4 iRHOM2 isoforms 
Additionally, there are two isoforms of iRHOM2 that may behave in slightly different 
ways. The two isoforms have not previously been discussed in detail in the literature. 
RT-PCR appeared to suggest that isoform 2 is the dominantly expressed isoform in most 
cutaneous keratinocyte cell lines, with more variable expression of isoform 1. This could 
suggest that isoform 1 is less stable or more tightly regulated than isoform 2. However, 
isoform 2 was focussed on in overexpression experiments as it appeared to be the major 
isoform of iRHOM2. Future work to improve the RT-PCR technique and avoid the non-
specific bands seen would be of interest, and qPCR could be performed to quantify the 
differences in expression. Further investigation of both isoforms and their roles in the 
epidermis and different tissues would be interesting - DSP, for example, has two 
isoforms, which have different roles in different tissues, with isoform II being the critical 
isoform for adhesion in the epidermis (Cabral et al., 2010).   
3.3.5 Desmosome dysregulation in TOC 
There appeared to be a general dysregulation of desmosomes in TOC epidermis, 
including increased processing of DSG2. The 100 KDa DSG2 fragment detected in 
western blots is likely detecting DSG2 after endocytosis. Lorch et al (2004) also detected 
a 60 KDa fragment in the supernatant, representing the extracellular portion of DSG2. 
Further processing of DSG2, producing other cleavage fragments, has also been 
reported (Klessner et al. 2009; Nava et al., 2007). Future work with ELISA assays for 
DSG2, or western blotting of the supernatant would determine whether this fragment was 
found in medium from TOC cells.   
Otherwise, there appeared to be subtle changes in desmosomal proteins but no clear 
differences in each patient as was seen in the electron-dense midline in the desmosomes 
of all three patients in the same biopsies. This perhaps suggests general dysregulation 
of desmosomes in TOC epidermis rather than a dramatic effect on one or two 
desmosomal components. There are some drawbacks of the IHC analysis: staining is 
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not easily quantifiable; there could be variation in the point in the section the confocal 
image was taken (although the image was focussed at the point of brightest staining for 
all sections); MeAc fixation may have masked some cytoplasmic staining. Western 
blotting of monolayer keratinocytes does not represent all of the epidermal layers and 
may therefore miss some differences.  
Perhaps DSG1 or 3, or DSC1, which were not tested by western blotting are affected - 
DSC1 and DSG1 are associated with differentiation, although there was no clear 
difference in DSG1 specific IHC. Cadherins form the electron dense midline, so it seems 
likely that a cadherin is affected. Desmosomal dysregulation could be mediated through 
increased DSG2 cleavage by ADAM17 and/or increased EGFR signalling. The lack of 
midlines in TOC desmosomes is indicative of desmosomes in a wound healing state (as 
described in Garrod et al. 2005), and suggests that there may be accelerated wound 
healing in TOC.  
3.3.5.1 ADAM17  
Staining with an antibody against DSG1 and 2 in skin from a patient homozygous for 
LOF mutations in ADAM17 showed an increase in staining intensity, implying a reduction 
in DSG2 shedding by ADAM17 in this patient (Blaydon et al., 2011). In contrast, TOC 
appears to result in increased processing and activity of ADAM17, and increased EGFR 
signalling (Chapter 4, Brooke et al., 2014; Blaydon et al., 2012). Loss of the electron-
dense midline in TOC desmosomes is consistent with desmosomes in a wound-healing 
state (Garrod et al., 2005), and appeared to be accompanied by increased processing 
of DSG2 in TOC cutaneous keratinocytes, which could be mediated by ADAM17 and 
EGFR signalling (Lorch et al., 2004; Getsios et al., 2009; Klessner et al., 2009) causing 
alterations in desmosomal composition and Ca2+-dependence.  
The increased DSG1 and 2 staining in epidermis with homozygous LOF mutations in 
ADAM17 was seen throughout the epidermis, despite previous reports of DSG2 
expression being restricted to the basal layer (Brennan and Mahoney, 2009). This is 
consistent with staining in patient 1 (figure 3.2.17) and patient 4 (appendix A24) showing 
reduced DSG1 and 2 throughout the epidermis, but no obvious difference in DSG1 
staining. The staining is very weak in the basal layer, which may suggest that the 
antibody is recognising predominantly DSG1. It is possible that MeAc fixation before 
staining masked signal from cytoplasmic DSG2 in the basal layer. There could also be 
differences in expression levels of the desmosomal proteins between skin from different 
body sites, and recognition of different forms of the desmogleins by different antibodies 
raised against different epitopes. 
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3.3.5.2 EGFR regulation of desmosomes   
EGFR signalling results in phosphorylation of desmosomal cadherins followed by 
subsequent cleavage and endocytosis, e.g. DSG2 (Lorch et al., 2004; Klessner et al., 
2009). Internalisation of other adhesion complex proteins can occur in clathrin-
dependent and independent manners, for example E-cadherin internalisation (Le et al., 
1999; Paterson et al., 2003; Bryant and Stow, 2004; Ivanov et al., 2004; D’Souza-
Schorey, 2005; Bryant et al., 2007), with the many internalisation and trafficking 
pathways contributing to its regulation of the proteins through degradation or recycling 
(Bryant and Stow, 2004). Less is known about desmosomal trafficking.  
EGFR inhibition increases adhesion between cells (Lorch et al., 2004; Brennan and 
Mahoney, 2009; Klessner et al., 2009) and results in accumulation of ADAM17 at the 
cell-surface in the highly invasive SCC68 cell line (Klessner et al., 2009). As there is 
increased EGFR signalling in TOC (Blaydon et al., 2012) and increased ADAM17 
processing and activity (Brooke et al., 2014; chapter 4), it suggests that desmosomal 
dysregulation in TOC may be mediated by EGFR signalling.   
Furthermore, an increase in a 100 KDa cleavage fragment of DSG2 was seen in SCC8 
cells, which was inhibited by ADAM17 siRNA, but not ADAM10 siRNA (Klessner et al., 
2009). This is consistent with the findings in this chapter (published in Brooke et al., 
2014) which suggest increased levels of a 100 KDa DSG2 fragment in TOC 
keratinocytes potentially resulting from increased DSG2 cleavage by ADAM17. In SCC8 
cells, the pool of DSG2 was shifted away from the ADAM17-rich cell compartment upon 
EGFR inhibition, reducing DSG2 cleavage despite increased levels of the protease 
(Klessner et al., 2009). Interestingly, siRNA knock down of ADAM10 in the SCC68 cells 
increased levels of the 100 KDa fragment, suggesting that ADAM10 may further regulate 
DSG2 downstream of ADAM17 cleavage (Klessner et al., 2009). 
In contrast to Klessner et al (Santiago-Josefat et al., 2007; Klessner et al., 2009), 
Santiago-Josefat et al (2007) saw stabilisation of ADAM17 protein following EGF 
treatment in the cell lines T47D and A431, resulting in increased protein levels of mature 
ADAM17 at the cell surface (Bech-Serra et al., 2006). Santiago-Josefat et al (2007) also 
saw an increase in DSG2 cleavage products associated with the increase in ADAM17 
protein levels, which was reduced by metalloproteinase inhibition, consistent with the 
findings in this chapter, and with Klessner et al (2009).  
3.3.5.3 EGFR signalling in diseases targeting desmogleins  
Further evidence for involvement of EGFR signalling in desmosome regulation comes 
from the autoimmune disease pemphigus. Pemphigus pathology is mediated by 
auto-antibodies which target desmogleins, resulting in severe blistering phenotypes. 
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Pemphigus foliaceus (PF) occurs due to autoantibodies against DSG1 (Koulu et al., 
1984; Stanley et al., 1986; Eyre and Stanley, 1988; Ishii et al., 2000), while Pemphigus 
vulgaris (PV) results from auto-antibodies against DSG3 (Amagai et al., 1991), or against 
both DSG1 and DSG3 (Ding et al., 1997). The disease can switch from PV to PF or vice 
versa, which is accompanied by a change in the autoantibodies in patient serum (Komai 
et al., 2001; Harman et al., 2002).  
The phenotype of PV and PF correlate with tissue-specific expression of DSG1 and 3 
and with the epidermal layers in which DSG1 and 3 are expressed (Amagai et al., 1991; 
Payne et al., 2004; Mahoney et al., 2006): PV is characterised by blistering of both the 
skin and mucous membranes, particularly at the suprabasal layers, and epidermal cell-
cell detachment (acantholysis) occurs in these layers due to loss of cell-cell contact. PF 
causes superficial blisters and scales resulting from acantholysis in the granular layer of 
the epidermis, with no blistering in the mucous membranes (Amagai and Stanley, 2012; 
Kitajima, 2013). DSG1 and 3 can compensate for each other in the epidermal layers in 
which they are co-expressed (Shirakata et al., 1998; Mahoney et al., 1999). 
There are three main theories to describe the mechanism of pemphigus autoantibodies 
disrupting desmosomal integrity: Steric hindrance, where the antigen causes 
desmosome splitting (Iwatsuki et al., 1989; Shimizu et al., 2004); the non-assembly and 
depletion hypothesis (e.g. Calkins et al. 2006; Oktarina et al. 2011); and desmosome 
remodelling impairment where DSG is internalised and sequestered from reassembly 
into the desmosome (Kitajima, 2013). However, a number of lines of evidence now point 
away from the steric hindrance model (Koch et al., 1997; Chernyavsky et al., 2007; 
Aoyama et al., 2010; Kitajima, 2013).  
3.3.5.3.1 Non-assembly and depletion hypothesis  
The non-assembly and depletion hypothesis suggests that sequestration of DSGs 
prevents desmosome assembly, leading to the depletion of the desmosomal proteins 
(e.g. Calkins et al., 2006; Oktarina et al., 2011). PV-IgG disrupts the desmosome 
structure, followed by internalisation of desmosomal components into intracellular 
vesicles and retraction of intermediate filaments, resulting in decreased cell-cell 
adhesion (Calkins et al., 2006; Yamamoto et al., 2007). PG co-internalised with DSG3 
after PV-IgG treatment, and DSG3 total levels were specifically reduced (Calkins et al., 
2006). Depletion of DSG3 by PV-IgG appeared to prevent Ca2+-induced desmosome 
assembly, and DSG3 was detected in early endosomes (Mao et al., 2009). DSG3 
sequestration in the cytoplasm means it is unavailable for reassembly into the 
desmosome (Mao et al., 2009).  
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3.3.5.3.2 Desmosome-remodelling impairment 
There is increasing evidence that the internalisation and sequestration of DSG and 
depletion of desmosomal components after binding of pemphigus IgG is mediated 
through an outside-in signalling cascade. The final model for Pemphigus pathology is of 
desmosomal remodelling due to a cascade of signalling events resulting from PV-IgG 
binding, including DSG3 phosphorylation, the Ca2+/PKC pathway, apoptosis signalling, 
PG modulation, p38MAPK, EGFR and heat shock protein (HSP) 27 (Kitajima, 2013).  
The Ca2+-dependent form of desmosomes is required for internalisation upon PV-IgG 
binding (Eyre and Stanley, 1987; Cirillo, et al. 2010; Spindler et al., 2014). The Ca2+-
dependent depletion is dependent on PKC (Osada et al., 1997; Cirillo et al., 2010; 
Spindler et al., 2014). Schulze et al (2012) showed that AK23, a pathogenic anti-DSG3 
antibody, activates EGFR, leading to increased Myc levels causing proliferation and 
acantholysis in injected mice (Schulze et al., 2012). They hypothesised that binding of 
the PV-IgG and/or DSG3 depletion interferes with the cross-talk between AJ and 
desmosomes, impairing the control of desmosome remodelling (Schulze et al., 2012). 
Some insight into the order of signalling events following PV-IgG binding in keratinocytes 
was gained by time-course studies showing peak activation of Src 30 min after PV-IgG 
binding, EGFR 60 min after EGFR binding, and p38 MAPK after 240 min (Chernyavsky 
et al., 2007). 
A number of studies have demonstrated a role for p38MAPK in regulating retraction of 
the cytoskeleton and mediating Pemphigus pathology (Berkowitz et al., 2005, 2006; 
Chernyavsky et al., 2007; Berkowitz et al., 2008; Berkowitz et al., 2008; Lee et al., 2009; 
Jolly et al., 2010), which is perhaps mediated via blocking RhoA (Waschke et al., 2006). 
Inhibition of p38MAPK prevented DSG3 internalisation and depletion of DSG3 in both 
detergent soluble and insoluble cell fractions in human keratinocytes (Jolly et al., 2010) 
and also prevented retraction of the cytoskeleton (Lee et al., 2009). 
Lee et al (2009) also saw increased apoptosis in mouse skin after injection with PF-IgG, 
and in human keratinocytes. P38MAPK has also been shown to regulate apoptosis in 
the skin (Hildesheim et al., 2002; Laethem et al., 2004) as have DSG2 and desmosomal 
regulator Perp (Attardi et al., 2000). Nguyen et al (Nguyen et al., 2009) showed that 
PERP is internalised with DSG3 and PG upon treatment with PV-IgG in human 
keratinocytes. Loss of PERP enhances adhesion defects in response to PV-IgG (Bektas 
and Rubenstein, 2009; Nguyen et al., 2009).  
These pathways may be of interest in future work to determine the mechanism of 
desmosome dysregulation and whether it is mediated by EGFR signalling. A blistering 
phenotype is not seen in TOC, despite alterations in desmosomes, suggesting that a 
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more subtle dysregulation of the desmosomes is taking place, and that cell-cell adhesion 
is not dramatically affected in TOC. Further investigation of the emerging signalling roles 
of desmosomes may also be interesting in relation to iRHOM2, EGFR signalling and 
TOC.  
3.3.6 Conclusion 
iRHOM2 appears to be localised at the plasma membrane in the epidermis and 
oesophagus, although it was previously reported to be an ER protein. TOC mutant 
iRHOM2 is able to traffick to the plasma membrane, but appears to be dysregulated/ 
re-localised in some instances, as shown in frozen skin biopsies from 2 out of 4 TOC 
patients. iRHOM2 localisation was variable in keratinocytes cultured in monolayer. 
Furthermore, iRHOM2 expression appears reduced in TOC IHC, flow cytometry, and 
western blots of NEB1 cells overexpressing iRHOM2, consistent with reduced iRHOM2 
expression seen in 3D cultures. Desmosomes in TOC skin lack the electron-dense 
midline usually formed by binding of cadherins from adjacent cells, suggesting a wound-
healing phenotype. This appeared to be accompanied by increased processing of DSG2, 
which may be mediated by metalloproteinase ADAM17.  
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Chapter 4: iRHOM2 signalling pathways  
in the skin 
4.1 Introduction 
In the previous chapter, EM imaging showed that TOC skin lacks the electron-dense 
midline formed by cadherins in mature desmosomes in normal skin, which could be 
associated with increased processing of the desmosomal cadherin DSG2 in TOC 
keratinocytes (chapter 3; Brooke et al., 2014). Increased DSG2 processing could result 
from a combination of ADAM17-mediated DSG2 shedding (Lorch et al., 2004; Klessner 
et al., 2009), and/or desmosomal remodelling resulting from changes in EGFR signalling 
(Lorch et al., 2004; Brennan and Mahoney, 2009; Getsios et al., 2009; Klessner et al., 
2009).    
Previously described functions of iRHOM2 (and iRHOM1) include a role in EGFR 
signalling through targeting of EGF for ERAD (Zettl et al., 2011), and trafficking of 
ADAM17 from the ER to the golgi (Adrain et al., 2012; McIlwain et al., 2012) where it is 
activated. Further regulation of ADAM17-mediated shedding by iRHOM2 has also been 
demonstrated through direct regulation of ADAM17 substrates (Maretzky et al., 2013), 
including EGFR ligands. Dysregulation of EGFR signalling has also been implicated in 
TOC by our group (Blaydon et al., 2012), shown by increased proliferation and migration 
in TOC keratinocytes, especially after culture in the absence of exogenous EGF. 
ADAM17 has also been shown to cleave NOTCH at the S2 stage of processing, 
predominantly in a ligand-independent manner (Bozkulak and Weinmaster, 2009). 
NOTCH signalling plays an important role in differentiation in squamous tissues such as 
the skin and oesophagus (Rangarajan et al., 2001; Ohashi et al., 2010), and inactivating 
mutations in NOTCH underlie a number of SCCs (Agrawal et al., 2011; Stransky et al., 
2011; Wang, 2011; South, 2012). A role for iRHOM1 in NOTCH signalling was suggested 
by studies expressing a 52 KDa truncated version of iRhom1 in drosophila, causing a 
wing phenotype resembling that associated with Notch mutations. The phenotype was 
associated with reduced expression of downstream Notch targets such as cut, although 
no obvious effect was seen when full length iRHOM1 was expressed (Nakagawa et al., 
2005). Zettl et al (2011) did not see any genetic interactions between drosophila iRhom 
and Notch.  
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4.1.1 Aims 
This chapter aimed to investigate the iRHOM2-ADAM17 pathway in normal and TOC 
epidermis, TOC plus tissue from a patient harbouring homozygous LOF mutations in 
ADAM17. Investigation of how downstream signalling is affected in TOC was also carried 
out, including a protein array against phosphorylated RTKs and preliminary 
investigations into the Eph/Ephrin pathway and NOTCH1 expression. Finally, IHC was 
performed against iRHOM1, rhomboid protease RHBDL2 and its substrate 
thrombomodulin to determine how mutations in iRHOM2 may affect localisation/function 
of these other rhomboid proteins in the skin.  
4.2 Results 
4.2.1 Increased migration in TOC cells in the absence of EGF 
We previously demonstrated an increased rate of migration in TOC keratinocytes, 
particularly in the absence of exogenous EGF, in experiments performed by Dr Andrew 
South, University of Dundee (Blaydon et al., 2012). However, a slight increase in the rate 
of proliferation was also seen in these cells, which could account in part for some of the 
increased scratch-wound closure seen. Therefore, to confirm that the scratch-wound 
closure was due to migration of the cells, scratch-wound assays were performed in the 
absence of exogenous EGF, with and without pre-treatment with MMC, which irreversibly 
inhibits proliferation (figure 4.2.1).  
Consistent with previous findings, TYLK1 TOC keratinocytes migrated faster than control 
K17 keratinocytes, covering more of the scratch than K17 cells after 24 h, and completely 
closing the scratch wound at the 48 h time point. The increased migration was seen in 
TOC cells with and without pre-treatment with MMC (figure 4.2.1), confirming that the 
results seen in previous scratch assays were due to migration, and not a result of 
increased proliferation in these cell lines.  
4.2.2 Regulation of ADAM17 and iRHOM2 expression may be 
linked 
IHC was performed against iRHOM2 in skin from a patient homozygous for LOF 
mutations in ADAM17 (figure 4.2.2) to see how loss of ADAM17 impacts on iRHOM2 
expression and localisation. iRHOM2 in LOF ADAM17 skin was localised to the plasma-
membrane as seen in normal epidermis. However, the intensity of the staining appeared 
reduced, suggesting that loss of ADAM17 expression and/or activity results in a reduction 
of iRHOM2 expression levels.  
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Figure 4.2.4 A shows western blots against iRHOM2 and ADAM17 in control and TOC 
keratinocytes after treatment with non-targeting pool (NTP), ADAM17 or iRHOM2 siRNA. 
Levels of iRHOM2 and ADAM17 were reduced by the respective siRNA treatments 
(figure 4.2.3 B and C), though there was some variability in the efficiency of the knock 
down, particularly for iRHOM2 (shown in figure 4.2.3 B). The upper band of the iRHOM2 
doublet appeared to be preferentially knocked down, though the lower band also 
appeared reduced with iRHOM2 knock down in a number of the samples.  
ADAM17 knock down also appeared to lower iRHOM2 protein levels in control (NEB1 
and K17) and TOC (TYLK1 and TYLK2) keratinocytes compared to keratinocytes treated 
with NTP siRNA (figure 4.2.3 A and B). In some cases, the reduction appeared greater 
than that seen after treatment with iRHOM2 siRNA. This is consistent with reduced 
iRHOM2 expression in ADAM17 LOF patient skin, and suggests that regulation of 
iRHOM2 and ADAM17 expression may be related. 
4.2.3 iRHOM2 processes ADAM17 in normal and TOC skin  
siRNA knock down of iRHOM2 appeared to result in reduced levels of mature ADAM17 
in all four cell lines (figure 4.2.3 A and C; appendix B1). In K17 cells in two experiments, 
and NEB1 cells in one experiment, the reduction in mature ADAM17 also appeared to 
be accompanied by a slight increase in pro-ADAM17 protein, but expression of pro-
ADAM17 appeared to stay at a relatively similar level in the other NEB1 cells and was 
variable in TYLK1 and TYLK2 cells. Surprisingly, iRHOM2 protein expression appeared 
to be slightly increased in the TOC cells compared to NEB1 cells, in contrast to findings 
in chapter 3 and Blaydon et al (2012), which will be discussed further later in the chapter. 
Although there was high variability between samples, perhaps relating to variability in 
the efficiency of the knock down, the reduction of mature ADAM17 levels were consistent 
with additional western blots performed by Dr Matthew Brooke (Brooke et al., 2014). 
ANOVA analysis comparing the cell lines did not show a significant difference in mature 
ADAM17, perhaps due to the variation in results. However, including the further repeats 
by Dr Brooke showed that anti-iRHOM2 siRNA significantly reduced mature ADAM17 
levels in TYLK1 and TYLK2 cells (p<0.01 for both cell lines) (Brooke et al., 2014). 
4.2.3.1 Increased ADAM17 processing in TOC 
Increased levels of mature ADAM17 in TOC epidermis (figure 4.2.3) is supported by the 
observed increased levels of mature ADAM17 and the free ADAM17 pro domain in TOC 
keratinocyte monolayers compared to NEB1 cells (figure 4.2.4 A; Dr Matthew Brooke), 
and in 3D raft cultures of TOC keratinocytes compared to K17 rafts (figure 4.2.4 B; 
Dr Nihal Kaplan and Dr Spiro Getsios, Northwestern University, Chicago). 
Immunofluorescence experiments also showed increased cell-surface ADAM17 in 
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monolayer and 3D culture (figure 4.2.4 C and D, Brooke et al. 2014). Together, the data 
suggest that the mutations in iRHOM2 found in TOC are GOF in nature and lead to 
increased trafficking, processing and activation of ADAM17. 
 
 
Figure 4.2.1 Accelerated wound closure in TOC cells is independent of 
proliferation Scratch-wound migration assays were performed in control (K17) and TOC 
(TYLK1) cell lines in the absence of exogenous EGF (n=2). Cells were incubated with 
MMC (10 µg/ml) or vehicle (H2O) as indicated prior to scratch wounding. MMC 
irreversibly inhibits proliferation.   
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Figure 4.2.2 Reduced iRHOM2 staining in a patient with a homozygous Loss of 
Function ADAM17 mutations IHC of iRHOM2 in frozen sections from normal skin (A) 
and in skin from a patient with homozygous LOF mutation in ADAM17 (B). n=1 due to 
low availability of the sample. iRHOM2 staining is shown in green, DAPI nuclear stain in 
blue. Images were taken with the LSM510 confocal microscope at magnifications of 40X 
(left-hand images) and 100X (right hand images). 
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Figure 4.2.3 iRHOM2 knock down reduces ADAM17 processing in normal and TOC 
keratinocytes, and ADAM17 knock down reduces iRHOM2 protein levels. A: 
Western blots against iRHOM2, total ADAM17 and GAPDH loading control were 
performed with lysates from normal and TOC keratinocytes after treatment with 
ADAM17, iRHOM2 or Non-targeting pool (NTP) control siRNA (n=3). B-C: Bar graphs 
showing densitometry (relative to GAPDH) for iRHOM2 (B) and pro- and mature 
ADAM17 (C) as indicated. Densitometry was performed with Image J software. Both 
bands of the iRHOM2 doublet were included in analysis in B. 
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Figure 4.2.4 iRHOM2 mutations in TOC result in increased processing of ADAM17. 
Western blots and IHC of ADAM17 were performed in keratinocyte monolayers and 3D 
cultures. A: Western blot showing the free ADAM17 pro-domain and GAPDH loading 
control in protein lysates from control (NEB1) and TOC (TYLK1 and TYLK2) keratinocyte 
monolayers. B: Western blots in control (K1 and K17) and TOC (TYLK1 and TYLK2) 3D 
raft cultures, showing total ADAM17, the free ADAM17 pro-domain and GAPDH loading 
control. C: IHC showing total ADAM17 staining in NEB1 control cells and TYLK2 TOC 
keratinocyte monolayers, showing increased ADAM17 levels at the cell surface in TYLK2 
cells. D: Total ADAM17 staining in 3D raft cultures with control (K1 and K17) and TOC 
(TYLK1 and TYLK2) keratinocytes, also showing elevated cell-surface ADAM17 in TOC 
(magnification 63X). Monolayer IHC and western blots were performed by Dr Matthew 
Brooke. 3D raft cultures and associated staining and western blots were performed by 
Dr Nihal Kaplan and Dr Spiro Getsios, Northwestern University, Chicago, US. 
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4.2.4 Protein array against phosphorylated Receptor Tyrosine 
Kinases (RTKs) 
To investigate the effects of increased ADAM17 processing and dysregulated EGFR 
signalling in TOC (Blaydon et al., 2012; Brooke et al., 2014), a protein array was 
performed against phosphorylated RTKs to begin to identify which signalling pathways 
are affected downstream of EGFR (figure 4.2.5). The array was performed in lysates 
from TYLK1 and TYLK2 TOC keratinocytes and NEB1 control cells in collaboration with 
Dr Diana Blaydon (figure 4.2.5 A). Densitometry was performed on phospho-EGFR and 
the three proteins that showed striking differences between NEB1 control cells and the 
TOC keratinocytes relative to the control proteins included in the corners of the array. 
There was perhaps a slight increase in phospho-EGFR levels according to the 
densitometry analysis (figure 4.2.5 B) although the signal was very strong, which is likely 
to affect the accuracy of the densitometry measurements so further experiments would 
therefore be needed to confirm this. 
Clear differences were seen in three proteins between TOC and NEB1 keratinocytes: 
phospho-Insulin Receptor (figure 4.2.5 C) and phospho-IGF1R (Insulin-like Growth 
Factor 1 receptor; figure 4.2.5 D) were both up-regulated in TYLK1 and TYLK2 cells; and 
a decrease was seen in phosphorylation of the EphA4 receptor (figure 4.2.5 E). The 
Eph/Ephrin pathway was selected for further investigation.  
The Eph receptor family is the largest family of RTKs, with EphA receptors binding 
predominantly GPI-anchored Ephrin A ligands, while EphB receptors bind mostly Ephrin 
B ligands (Kullander and Klein, 2002). EphA4 is an exception, and binds both Ephrin A 
and B ligands, including Ephrin B3 (e.g. Gale et al. 1996; Bergemann et al. 1998; 
Kullander & Klein 2002), which is a substrate of rhomboid protease RHBDL2 (Pascall 
and Brown, 2004). EphA2 and its ligand Ephrin A1 were also chosen for further 
investigation as targets of EGFR signalling (Macrae et al., 2005; Larsen et al., 2007; 
Menges and McCance, 2008) and because the EphA2-EphrinA1 signalling axis is 
important in differentiation in the skin (Lin et al., 2010).  
4.2.5 EphA2 and EphA4 receptor expression may be affected 
downstream of EGFR in TOC keratinocytes and skin 
To investigate EphA2 and EphA4 expression in TOC keratinocytes, cells were cultured 
in the presence and absence of exogenous EGF, then lysates collected for western blot 
analysis. Protein levels of EphA4 (figure 4.2.6 A) and EphA2 (figure 4.2.6 B) appeared 
to be lower in NEB1 cells after culture with exogenous EGF compared with TOC control 
cells. However, after culture in the absence of EGF (RM-), levels of both EphA4 and 
EphA2 appeared reduced in control cells, but were reduced to a lesser extent in the 
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TYLK1 and TYLK2 cells, suggesting that the increased EGFR signalling in TOC 
keratinocytes may affect downstream EphA2 and EphA4 expression.  
The findings were highly variable, however, perhaps due to variation in cell density 
affecting EphA2 and EphA4 expression, although confluent monolayers were used each 
time, control cells grow more slowly than TOC cells in the absence of exogenous EGF 
and so may not have been as densely packed. The strong signal associated with the 
EphA2 western blot may also have affected the densitometry results, particularly after 
culture in the presence of EGF (figure 4.2.6 B) where there was also a strong signal 
below the western blot which likely results from processing of EphA2. Increased EphA2 
expression was also seen by Dr Spiro Getsios in 3D cultures of the TOC cells compared 
to 3D cultures of both K1 and K17 control keratinocytes (figure 4.2.6 F).  
Unfortunately, western blots for phospho-EphA4 did not work well (my findings, and 
personal communication from Dr Spiro Getsios) – this would have been useful to confirm 
the findings of the phospho-array. Expression of EphA2 ligand Ephrin A1 appeared to be 
variable between cell lines after culture in the presence and absence of EGF (figure 4.2.6 
E), perhaps suggesting that it is not directly affected in TOC keratinocyte monolayers. 
Ephrin A1 expression did not appear to be affected in the TOC keratinocyte 3D cultures 
(figure 4.2.6 F).   
4.2.5.1 EphA2 and EphA4 in the skin 
To further investigate EphA2 and EphA4 in the skin, IHC for EphA2, total EphA4 and 
phospho-EphA4 was performed in frozen skin biopsies from control and TOC skin, and 
in a number of other skin diseases, to see whether any changes in this pathway were 
specific to TOC skin.  
4.2.5.1.1 EphA4 localisation 
IHC against EphA4 in frozen skin biopsies is shown in figure 4.2.7. In normal skin, EphA4 
could be seen throughout the cell in the upper layers of the epidermis, with stronger 
plasma membrane staining in the upper epidermal layers, particularly the stratum 
granulosum. Staining was of brighter intensity in the basal layer, where the localisation 
appeared more cytoplasmic. Some small puncta could be seen in some cells, which 
appeared to co-localise with the DAPI staining, suggesting a nuclear localisation. 
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Figure 4.2.5 Protein array against phosphorylated Receptor Tyrosine Kinases in 
TOC keratinocytes compared to NEB1 controls. A: The three phospho-arrays 
performed with NEB1 control lysates and TYLK1 and TYLK2 TOC cell lysates (n=1). B-
E: Bar graphs showing densitometry of the spots representing phospho-EGFR (B) and 
the three proteins with the clearest differences are shown in C-E: Phospho-Insulin 
Receptor (C); phospho-IGF1-R (D); and Phospho EphA4 (E). Densitometry was carried 
out with the Image J Software. Densitometry of each phospho-protein is shown in 
Appendix B2. 
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Figure 4.2.6 Expression of Eph Receptors EphA2 and EphA4 and EphA2 ligand 
Ephrin A1. Cells were cultured in the presence and absence of exogenous EGF, and 
western blots were carried out against A: EphA4 receptor, B: EphA2 receptor. Densitometry 
was carried out with Image J Software of C: EphA4 (NEB1, TYLK1, TYLK2 n=3; K17 n=2 
(due to a broken gel for GAPDH)), D: EphA2 (n=3). E: Western blot showing EphA2 ligand 
Ephrin A1 and vinculin loading control in control and TOC cells after culture in the presence 
and absence of EGF (n=1). F: Western blots against EphA2, Ephrin A1 and GAPDH loading 
control in 3D cultures of control (K1 and K17) and TOC (TYLK1 and TYLK2) keratinocytes. 
3D cultures and western blots shown in F were by Dr Spiro Getsios and Dr Nihal Kaplan.  
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Figure 4.2.7 EphA4 receptor expression up-regulated, with nuclear translocation 
in the skin of a TOC patient with dysregulated iRHOM2 localisation. A: IHC of total 
EphA4 protein in normal skin from breast tissue (n=4), and TOC patients 2, 3 and 1 as 
indicated (n=1). Patient 1 is shown twice: 1) at the same settings as normal skin and patients 
2 and 3 to allow comparison of staining intensity with normal skin; and 2) at reduced 
brightness to allow clearer visualisation of EphA4 localisation. Skin from patient 1 showed 
altered iRHOM2 localisation, whereas patients 2 and 3 had cell-surface iRHOM2. 
B: Negative control staining. C: Digitally zoomed in images of EphA4 localisation in patient 
1. EphA4 is shown in green and DAPI nuclear staining in blue. Images were taken on the 
Zeiss Meta 710 Confocal microscope.   
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In TOC patients 2 and 3, a similar staining pattern of EphA4 was seen, with larger puncta 
with potential localisation in patient 3. The stronger cell-surface staining perhaps 
appeared in lower epidermal layers in patient 2. The most striking differences in EphA4 
expression and localisation were seen in patient 1 (the patient showing dysregulated 
iRHOM2 localisation): EphA4 staining intensity was dramatically higher when imaged at 
the same settings as the other sections. This also appears to be the case in the dermal 
macrophages, visible below the epidermis in figure 4.2.8 A, which could be confirmed by 
co-localisation with macrophage marker CD68, as in Chapter 3.  
Imaging with a lower exposure in the green channel to allow clearer visualisation of the 
localisation showed clear cell-surface staining throughout the upper layers of the skin, 
reaching the suprabasal layers. EphA4 in the basal layer appeared nuclear and 
perinuclear, and membranous staining was less clear. Bright nuclear staining was also 
visible and appeared to co-localise with the DAPI stain. This nuclear staining was seen 
in all epidermal layers in patient 1, whereas it was only seen in the upper layers of the 
epidermis in normal skin and patients 2 and 3. The nuclear ‘puncta’ were much larger 
than in normal skin and patient 2, but more consistent with the size of the puncta in 
patient 3.  
IHC was also performed against phospho-EphA4 (figure 4.2.8). In normal skin, the 
phospho-EphA4 staining pattern was diffuse throughout the cells, with perhaps a slight 
increase in staining intensity in the basal layer (less difference than that seen for total 
EphA4 receptor). No nuclear puncta were visible. Phospho-EphA4 localisation in skin 
from TOC patient 2 showed a similar staining pattern to normal skin. Patient 3 showed 
the same diffuse staining throughout the cells of the epidermis, with increased staining 
intensity in the basal layer. A striking increase in phospho-EphA4 staining was seen in 
patient 1, however, consistent with the differences seen in expression and localisation of 
the total EphA4 receptor in this patient. A change in the localisation of phospho-EphA4 
was also seen in this patient: while diffuse staining throughout the cell and plasma 
membrane was seen in normal skin and in patients 1 and 3, EphA4 did not reach the 
plasma membrane in skin from patient 1. Furthermore, large puncta were visible with a 
nuclear or perinuclear localisation.  
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Figure 4.2.8 Variable localisation of phospho-EphA4 in TOC skin. IHC was performed 
against phospho-EphA4 in frozen skin sections (n=2). A: phospho-EphA4 in frozen skin 
sections from normal breast skin, and TOC skin from patients 2, 3 and 1. As in the previous 
figure, patient 1 is shown twice at two different exposures to allow both comparison of staining 
intensity with normal skin (1), and clearer visualisation of localisation (2). Patient 1 showed 
the most altered iRHOM2 localisation. B: Negative control staining. C: Phospho-EphA4 
staining in Patient 1 digitally zoomed to allow clearer visualisation of the localisation. Images 
were taken on the Zeiss Meta 710LSM confocal microscope. Phospho-EphA4 staining is 
shown in green, DAPI nuclear staining in blue. 
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Figure 4.2.9 EphA2 localisation in normal and TOC skin. IHC of EphA2 in frozen skin 
sections from normal skin and TOC skin showing variable staining intensity. A: 
Experiment 1 – EphA2 staining in normal skin from facelift, and TOC patients 1-3. B: 
Experiment 2 – EphA2 staining in normal skin from breast, and TOC patient 3. Normal 
skin sections from two different body sites were stained in case of variation in EphA2 
localisation between body sites, C: Negative control staining in experiment 1 (i) and 
experiment 2 (ii). EphA2 is shown in green, DAPI nuclear stain in blue. Images were 
taken on the Zeiss Meta 710LSM confocal microscope.  
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4.2.5.1.2 EphA2 localisation 
EphA2 appeared to be localised to the plasma membrane with some cytoplasmic 
staining in normal and TOC skin, with some small nuclear or perinuclear puncta as seen 
for EphA4 in normal skin (figure 4.2.9). Two separate staining experiments are shown to 
allow comparison of EphA2 in normal skin from facelift and breast. EphA2 in normal skin 
from facelift appeared to be expressed throughout the epidermis, but with lower 
expression in the upper epidermal layers (figure 4.2.9 A). In contrast, expression of 
EphA2 was seen throughout the epidermis in normal skin from breast (figure 4.2.9 B; 
see also figure 4.2.12 A) suggesting body-site-specific EphA2 expression patterns in the 
skin. The intensity of EphA2 staining was variable between different sections, but also 
between different staining experiments (n=3), so it is not possible to determine 
expression levels of EphA2 from this data. 
4.2.5.2 EphA2 and EphA4 in keratinocytes 
ICC against EphA2 and EphA4 was also performed in control and TOC keratinocytes 
after culture in the absence of EGF (figure 4.2.10). Strong membranous staining of 
EphA2 was seen in NEB1 and K17 control keratinocytes, and TYLK2 TOC keratinocytes 
(n = 2, also see appendix B3), with fainter cytoplasmic and perinuclear staining. There 
was no clear difference in EphA2 localisation between control and TOC cells.  
EphA4 appeared to be localised predominantly to the nucleus in control and TOC 
keratinocytes, with a punctate staining pattern. Some faint plasma membranous staining 
was visible, and also weaker punctate cytoplasmic staining which could perhaps 
represent EphA4 in trafficking vesicles. Staining intensity appeared lower in K17 cells, 
perhaps related to higher confluency of the cells in this experiment.  
4.2.5.3 Ephrin A1 
IHC was also performed against Ephrin A1 in normal and TOC frozen skin sections 
(figure 4.2.11). Ephrin A1 was expressed throughout the epidermis in normal skin, with 
more intense perinuclear staining in the basal layer. Staining in the upper layers of the 
epidermis appeared diffuse throughout the cell and plasma membrane, with some 
possible nuclear staining in some cells. In TOC patients 1 and 2, more epidermal cells 
appeared to show nuclear (or perinuclear) Ephrin A1. The staining was faint, and some 
of the sections appeared to contain holes around the nucleus, likely resulting from the 
freezing process. Some cell-surface Ephrin A1 was seen in the upper epidermal layers 
in patient 3. TOC skin also appeared to show nuclear staining in a greater number of 
basal cells in addition to perinuclear staining in the basal layer, particularly in patients 1 
and 2.  
156 
 
 
Figure 4.2.10 EphA2 and EphA4 localisation unaffected in control and TOC 
keratinocytes in the absence of EGF. ICC was carried out after culture in the absence 
of EGF (RM-). A: EphA2 in NEB1, K17 and TYLK2 cells as indicated (n=2). B: EphA4 in 
NEB1, K17, TYLK1 and TYLK2 cells as indicated (n=3). C: Negative controls for EphA4 
with anti-rabbit secondary antibody (i) and for EphA2 with anti-Goat secondary antibody 
(ii). EphA2 and EphA4 staining is shown in green, DAPI nuclear staining is shown in 
blue. Images were taken on the Zeiss Meta 710 LSM confocal microscope.  
 
 
 
157 
 
 
Figure 4.2.11 Ephrin A1 localisation appears unaffected in TOC skin. A: IHC against 
EphA2 ligand Ephrin A1 in frozen skin sections from normal and TOC patient skin as 
indicated (n=2). B: Negative control staining. Ephrin A1 is shown in green, DAPI nuclear 
stain in blue. Images were taken on the Zeiss Meta 710 confocal microscope.    
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4.2.5.4 EphA2 and Ephrin A1 in other genetic skin disease 
EphA2 and its ligand Ephrin A1 were also stained in frozen skin biopsies from the 
following genetic skin diseases: recessive inflammatory skin/bowel disease (ADAM17); 
dominant EKV (Cx31) and recessive Harlequin Ichthyosis (ABCA12) (figure 4.2.12 and 
4.2.13 C, D and E respectively). 
There was no clear difference in EphA2 localisation between normal skin and skin from 
the panel of different genodermatoses (figure 4.2.12). Ephrin A1 also showed a similar 
localisation in all the sections stained (figure 4.2.13), with stronger perinuclear staining 
in the basal layer and fainter, more diffuse staining in the upper epidermal layers. In the 
patient with homozygous LOF ADAM17 mutations, the strong perinuclear staining 
appeared to extend into the suprabasal layers of the epidermis, with strong nuclear 
staining seen in the basal layer (figure 4.2.13 C). As Ephrin A1 is associated with 
inhibiting differentiation, this could be consistent with a reduction in barrier function and 
increased incidence of infection associated with ADAM17 LOF (Blaydon et al., 2011; 
Brooke et al., 2014).  
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Figure 4.2.12 Localisation of EphA2 in a panel of genetic skin diseases. IHC against 
EphA2 in frozen skin sections, taken at magnifications of 40X (i) and 63X (ii). A: Control 
Skin, B: recessive inflammatory skin/bowel disease (ADAM17) (n=1); C: dominant EKV 
(Cx31) (n=1) and D: recessive Harlequin Ichthyosis (ABCA12) (n=1). Negative control 
staining is shown in E. Images are shown with and without DAPI nuclear stain (shown in 
blue), with EphA2 staining shown in green. Images were taken on the Zeiss Meta 710 
Confocal microscope.  
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Figure 4.2.13 Localisation of EphrinA1 in a panel of genetic skin diseases: LOF 
ADAM17 mutations may be associated with increased suprabasal Ephrin A1 
staining. Staining of EphA2 ligand EphrinA1 in frozen skin sections from control skin 
and genetic skin diseases taken at magnifications of 40X (i) and 63X (ii): A: Control skin, 
B: negative control with primary antibody omitted, C: recessive inflammatory skin/bowel 
disease (ADAM17), D: dominant EKV, E: Harlequin Ichthyosis (ABCA12). Ephrin A1 
staining is shown in green, and DAPI nuclear stain is shown in blue. Images were taken 
on the Zeiss Meta 710 Confocal microscope. Staining was only performed once due to 
limited availability of the frozen sections. 
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4.2.6 NOTCH1 expression 
In contrast to ADAM17 LOF skin, increased Transglutaminase 1 activity indicative of 
increased barrier function was seen in TOC (Brooke et al., 2014). An important mediator 
of differentiation is NOTCH, which can be cleaved by ADAM17 in the ligand-independent 
S2 cleavage step. Therefore, western blots, ICC and IHC were performed against 
NOTCH1 in control and TOC keratinocytes frozen skin biopsies.  
4.2.6.1 NOTCH1 protein expression 
Western blots against NOTCH1 in three sets of lysates are shown in figure 4.2.14 A. This 
was performed with the Abcam Chromatin immunoprecipitation (ChIP)-grade antibody, 
which recognises the whole NOTCH1 protein and detects full-length NOTCH1 at around 
460 KDa (not seen in these western blots), activated S1-cleaved NOTCH1 at around 
250 KDa (both bands of this doublet were measured for densitometry); and cleaved 
NOTCH1, seen at approximately 118-110 KDa, which includes S2-NOTCH1 cleaved by 
ADAM10 or ADAM17, and S3-NOTCH1 cleaved by γ-secretase. The lower band at 
approximately 80 KDa is reported as non-specific (Abcam website: 
http://www.abcam.com/notch1-antibody-chip-grade-ab27526-references.html; 
accessed 09.2014).  
Levels of NOTCH1 S1 fragment appeared to be increased in TYLK1 and TYLK2 TOC 
keratinocytes in lysate sets 2 and 3, and in TYLK1 cells in lysate set 1 (figure 4.2.14 A), 
suggesting increased overall NOTCH1 expression and activation. Densitometry was 
performed on lysate sets 1 and 2 (figure 4.2.14 B). Particularly in TYLK1 cells, the 
densitometry suggests increased expression of the NOTCH1 S1 fragment, with some 
increase in NOTCH1 expression in TYLK2 cells. However, the GAPDH loading control 
signal is strong with a lot of background in the first lane which may have affected the 
densitometry analysis. Lysate set 3 was excluded from analysis as the GAPDH signal 
was too strong for accurate densitometry. The signal did appear consistent between the 
cell lines, however, suggesting approximately equal protein loading.  
Cleaved NOTCH1 also appeared to be increased in expression in TOC keratinocytes 
(figure 4.2.14 A), which was again seen more strongly in TYLK1 cells, but a slight 
increase appeared in TYLK2 cells compared to NEB1 and K17 control keratinocytes. 
Densitometry for lysate sets 1 and 2 is shown in figure 4.2.14 C, supported elevated 
processing of NOTCH1 in TOC compared to controls although more experiments are 
needed to confirm this.  
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Figure 4.2.14 NOTCH1 expression and processing may be increased in TOC 
keratinocytes. A: Western blots showing full length and cleaved NOTCH1 in lysates 
taken from three sets of keratinocytes (labelled 1 to 3). Each sample set included NEB1 
and K17 control cell lines and TYLK1 and TYLK2 TOC cell lines. B: Densitometry of 
NOTCH1 S1 fragment, C: Densitometry of cleaved NOTCH1 (S2-S4 fragments). 
Densitometry was performed on lysate sets 1 and 2 because the GAPDH was too bright 
to get meaningful results in the third set of samples. The third experiment does, however, 
also suggest increased levels of NOTCH1 S1 and perhaps cleaved NOTCH1 in the TOC 
cell lines. Densitometry was carried out using Image J Software.  
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4.2.6.2 NOTCH1 localisation in keratinocyte cell lines 
Staining of total and cleaved NOTCH1 was carried out in confluent monolayers of TOC 
keratinocytes after culture in the presence of EGF. ICC with the ChIP grade antibody 
recognising total NOTCH1 showed punctate intracellular staining, with some staining at 
the cell surface, and larger puncta that appear to co-localise with DAPI nuclear staining 
(figure 4.2.15). The cell-surface staining appeared to be more intense in many areas of 
the monolayers in TOC keratinocytes compared to control cells, where plasma-
membranous staining was more difficult to locate during imaging (n=2). The increase 
was particularly clear in TYLK1 monolayers, shown at a higher zoom level in figure 
4.2.15 B alongside K17 control keratinocytes, consistent with western blotting of the S1 
fragment, which would be expected to be found at the plasma membrane.   
A similar result was seen with ICC with the mN1A antibody, which recognises S1 cleaved 
NOTCH1 (figure 2.16). Staining with the mN1A antibody gave a similar punctate staining 
pattern to the ChIP grade antibody, again showing slightly increased NOTCH1 at the cell 
surface in TOC keratinocytes compared to control cells although the differences are 
more subtle than those seen with the ChIP grade antibody.   
The antibody Val1744 recognises NOTCH1 cleaved at amino acid residue Val1744, a 
stable form of the NICD. ICC with this antibody showed a ‘speckled’ appearance 
throughout the cell, including in the nucleus (figure 4.2.17), with smaller more diffuse 
puncta than those seen in staining with the ChIP grade or mN1A antibodies. There 
appeared to be more intense staining in TOC keratinocytes than control keratinocytes, 
particularly in the nucleus. This was more pronounced in TYLK1 cells, also consistent 
with levels of cleaved NOTCH1 in the western blot in figure 2.14.      
4.2.6.3 Variability in localisation between NOTCH1 antibodies 
Although these findings suggest that it may be interesting to look further at NOTCH1 
localisation in TOC keratinocytes, it is not possible to reach a conclusion due to the low 
number of repeats and inconsistencies in the staining patterns between the different 
antibodies.  
For example, staining with the mN1A antibody showed weak staining at cell borders 
compared with the ChIP grade antibody although the S1 and S2 cell-surface fragments 
would be expected to be at the same levels and to be recognised by both antibodies. 
The staining pattern of the NICD also appeared much more diffuse with the NICD-
specific antibody compared to intracellular staining with the ChIP grade and mN1A 
antibodies. Further work is therefore needed to confirm the localisation of the different 
processed forms of NOTCH1 fragments within control and TOC cells e.g. with cell 
fractionation and additional antibodies.  
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Figure 4.2.15 Cell-surface NOTCH1 may be increased in TOC cutaneous 
keratinocytes. A: ICC in control (NEB1, K17) and TOC (TYLK1 and TYLK2) 
keratinocytes with an antibody recognising total NOTCH1 protein (AbCam ChIP-grade 
antibody) (n=1), B: Higher power images of cell-surface NOTCH1 staining in i) K17 
control cells and ii) TYLK1 TOC keratinocytes. NOTCH1 is shown in green, DAPI nuclear 
stain is shown in blue. Images were taken on the Zeiss Meta 710 Confocal Microscope.  
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4.2.6.3 NOTCH1 in the epidermis 
IHC was also performed in normal and TOC skin with the same antibodies to investigate 
NOTCH1 in differentiated epidermis. IHC with the mN1A antibody (figure 2.18) showed 
a punctate intracellular localisation in normal skin from breast and abdomen, similar to 
that seen in staining of keratinocyte monolayers with the same antibody. Some faint 
plasma-membranous staining was seen in the upper epidermal layers. The staining 
intensity of NOTCH1 was variable between IHC experiments and within IHC 
experiments: in experiment 1 (figure 2.18 A), TOC patients 1 and 2 appeared to show 
increased overall expression of NOTCH1, compared to normal breast skin stained and 
imaged in the same experiment, however, this was not replicable in experiment two. In 
experiment 2, staining of normal skin from breast and abdomen was performed, showing 
variability in staining intensity between skin biopsies taken from different body sites 
(figure 2.18 left hand side). Cell-surface expression of NOTCH1 was particularly faint in 
this experiment. This time, patient two appeared to have a similar staining intensity to 
that of normal breast skin (figure 4.2.18 B), with a similar localisation. Patient 3 showed 
the greatest differences in staining with this antibody, with increased staining intensity, 
and strong cell-surface staining in the upper epidermal layers (figure 4.2.18 C).  
Staining with the ChIP grade antibody was very faint in IHC, with no clear differences in 
the staining (appendix B4), so further optimisation may be required in future experiments, 
or perhaps the antibody is not suitable for use in IHC with frozen sections.   
Staining of cleaved NOTCH1 with the Val1744 antibody in normal and TOC skin (figure 
4.2.19) was more consistent with the western blotting data, with greater staining intensity 
in all three TOC biopsies compared to normal skin from breast and abdomen in two 
separate staining experiments. The staining was diffuse and cytoplasmic in both normal 
and TOC skin, and interestingly did not appear to be localised to the nucleus in many of 
the cells of the epidermis in contrast to staining of monolayer keratinocytes. Staining was 
much fainter in the basal layer of the epidermis with strong staining in the suprabasal 
layers in normal skin and TOC, perhaps consistent with increased NOTCH1 activity in 
differentiating keratinocytes. However, the variability and inconsistency in the staining 
means that the data should perhaps be interpreted with caution and confirmed by other 
methods, for example in 3D keratinocyte cultures and cell fractionation.   
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Figure 4.2.16 Increased processing of NOTCH1 may be taking place in TOC 
keratinocytes. A and B: ICC of NOTCH1 with an antibody that recognises NOTCH1 after 
S1 cleavage (mN1A) (n=1). B: NOTCH1 mN1A staining shown at a higher zoom level in (i) 
K17 control and (ii) TYLK1 TOC keratinocytes. C: Negative control staining. NOTCH1 is 
shown in green, DAPI nuclear stain is shown in blue. Images were taken on the Zeiss Meta 
710 Confocal Microscope.  
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Figure 4.2.17 Increased staining intensity and nuclear localisation of NOTCH1 
NICD in TOC keratinocytes. A: ICC in control (NEB1, K17) and TOC (TYLK1 and 
TYLK2) keratinocytes with an antibody that specifically recognises NOTCH1 cleaved at 
Valine residue 1744 – the NICD. B: K17 (i) and TYLK1 (ii) stained with anti Val1744 at a 
higher magnification. C: Negative control staining. NOTCH1 is shown in green, DAPI 
nuclear stain is shown in blue. Images were taken on the Zeiss Meta 710 confocal 
microscope. Please note that this is preliminary data from one experiment only.  
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Figure 4.2.18 NOTCH1 S1 fragment localisation is variable in TOC skin. IHC against 
S1 cleaved NOTCH1 (mN1A antibody) in frozen sections from normal and TOC skin. A: 
Experiment 1 – Normal breast skin and TOC patient 1, staining carried out in the same 
staining session. B and C: Experiment 2 (All sections shown in B and C were stained at 
the same time). B: Normal skin from breast tissue, TOC patient 2. C: Normal skin from 
abdomen, TOC patient 3. D: Negative control staining in experiment 1 (i) and experiment 
2 (ii). NOTCH1 is shown in green, DAPI nuclear stain is shown in blue. Images were 
taken on the Zeiss Meta 710 Confocal Microscope, and all images in this figure were 
taken with the same settings, although imaging for experiments 1 and 2 was performed 
on different days.   
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4.2.7 Are other rhomboid family proteins dysregulated in TOC? 
As rhomboid proteins are a relatively recently discovered family of proteins, little is known 
about their regulation and localisation in the skin. Preliminary IHC experiments were 
therefore performed against iRHOM1, RHBDL2 and the RHBDL2 substrate 
thrombomodulin. RHBDL2 was selected as it cleaves EGF, and because it has been 
shown to be important in wound healing in vitro. Thrombomodulin is also important in 
wound healing and is tightly regulated during differentiation. (Ephrin B3, another 
RHBDL2 substrate, may also have been interesting, but IHC was not consistent in frozen 
tissue sections.)  
iRHOM1 IHC in normal and TOC skin is shown in figure 4.2.20. In contrast to the plasma-
membranous iRHOM2 staining seen in the skin, iRHOM1 appeared to have a more 
cytoplasmic or perinuclear localisation, with more intense staining in the basal layer and 
some faint cell-surface staining in the granular layer. A similar localisation of iRHOM1 
was seen in skin from TOC patients, with the intense basal-layer staining appearing to 
reach further into the suprabasal layers, perhaps due to the hyperproliferative nature of 
TOC skin. In patients 2 and 3, the cell-surface staining in the stratum granulosum 
appeared more intense, and in patient 1, which shows the strongest alteration in iRHOM2 
localisation, some individual cells in the suprabasal layer appeared to show cell-surface 
staining (figure 4.2.20). IHC of RHBDL2 is shown in figure 4.2.21. IHC and western 
blotting were both inconsistent with this antibody. The experiment shown is the result of 
one experiment, with normal skin from facelift and TOC skin from patient 4, an older TOC 
skin biopsy. The staining in normal skin showed a diffuse localisation throughout the cell 
and plasma membrane (and in the macrophages), with brighter nuclear or perinuclear 
staining. In TOC patient 4 in this experiment, the staining appeared more cytoplasmic, 
with no staining at the cell surface, and much brighter, compact perinuclear staining was 
seen, perhaps consistent with a golgi-like localisation. This localisation was seen in 
normal skin to a lesser extent in one experiment.  
In normal frozen skin, thrombomodulin staining appeared diffuse throughout the 
cytoplasm and plasma membrane in the lower epidermal layers, and more cytoplasmic 
in the upper layers. In the frozen sections, there was perhaps some nuclear/stronger 
perinuclear staining in some cells of the basal layer, in contrast to IHC in paraffin-
embedded skin sections (figure 4.2.22; Raife et al. 1994; Lager et al. 1995), showing 
cell-surface staining in the spinous and granular epidermal layers. Patients 2 and 3 
appeared to show stronger perinuclear staining in the basal layer, but otherwise showed 
a similar localisation and staining intensity to normal skin with increased cytoplasmic 
staining in the upper layers of the epidermis. 
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Some plasma membrane staining was seen in Patient 1 sections, which appeared to 
show a reduced staining intensity compared to normal skin and the other TOC patients, 
particularly in the basal layer which would be more consistent with the normal skin 
staining reported by Lager et al. (1995). In the upper layer, the diffuse staining appeared 
to be of lower intensity, with some plasma membrane staining seen in these layers. The 
differences between patient 1 and the other patients and normal skin could suggest that 
RHBDL2 and thrombomodulin are affected by the altered iRHOM2-ADAM17-EGF 
signalling in TOC, but the inconsistencies with previous work (Lager et al., 1995) suggest 
that these findings may need to be repeated in paraffin-embedded skin. These findings 
are very preliminary, and further investigations of the rhomboid signalling pathway in the 
skin are warranted.  
  
171 
 
 
 
Figure 4.2.19 NOTCH1 NICD expression is increased in TOC skin. IHC against 
NOTCH1 cleaved at Val1744 (NICD) in frozen sections from normal and TOC skin. A: 
Experiment 1; normal breast skin and TOC patient 1. B and C: Experiment 2 (All sections 
shown in B and C were stained at the same time). B: Staining from normal skin from 
breast tissue and TOC patient 2. C: Normal skin from abdomen and TOC skin from 
patient 3. D: Negative control staining in experiment 1 (i) and experiment 2 (ii). NOTCH1 
is shown in green, DAPI nuclear stain is shown in blue. Images were taken on the Zeiss 
Meta 710 Confocal Microscope, and all images in this figure were taken with the same 
settings, although imaging for experiments 1 and 2 was performed on different days.   
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Figure 4.2.20 iRHOM1 localisation in normal and TOC skin. A: IHC in frozen skin 
sections from normal and TOC skin. B: negative control. iRHOM1 staining is shown in 
green, and DAPI nuclear stain is shown in blue. Staining was carried out on the Zeiss 
Meta 710 Confocal Microscope. N=2. 
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Figure 4.2.21 Rhomboid protease RHBDL2 in normal and TOC skin. IHC of RHBDL2 
in normal facelift skin (A) and TOC skin from patient 4 (B). Images were taken on the 
510 Meta LSM confocal microscope. RHBDL2 staining is shown in green, and DAPI 
nuclear stain in blue. Please note that staining results varied between experiments, and 
this result was seen only once this strikingly, and less clearly one other time in the same 
frozen sections despite a number of repeats. Further information is included in the results 
text.  
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Figure 4.2.22 Localisation of RHBDL2 substrate thrombomodulin in normal and 
TOC skin. IHC on frozen skin sections from normal and TOC skin (A), with negative 
control staining shown in B. Images were taken on the Zeiss Meta 710 microscope,  
Thrombomodulin staining is shown in green, and DAPI nuclear staining in blue. Staining 
was repeated twice for each biopsy.   
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4.3 Discussion   
This chapter investigated the iRHOM2-ADAM17 pathway in TOC and the effect of 
increased EGFR signalling on downstream pathways including Eph/Ephrin and NOTCH1 
signalling. Finally, preliminary investigation of other rhomboid proteins was performed.  
4.3.1 Summary of Results 
1) Increased migration in TOC cells appears to be independent of proliferation, shown 
by scratch assays carried out in the presence and absence of MMC.  
2) iRHOM2 appears to be important in processing metalloproteinase ADAM17 in 
cutaneous keratinocytes, shown by reduced mature ADAM17 levels after iRHOM2 
knock down.  
3) TOC mutations appear to increase ADAM17 processing, shown by increased cell-
surface ADAM17 and increased mature ADAM17 levels in TOC keratinocyte monolayers 
and 3D cultures (collaborative data).  
4) iRHOM2 expression may be partly regulated by ADAM17, as iRHOM2 protein levels 
appeared reduced after ADAM17 siRNA knock down, and the staining intensity of 
iRHOM2 appeared reduced in skin from a patient with a homozygous LOF ADAM17 
mutation.  
5) Eph-Ephrin signalling may be a downstream target of increased EGF signalling in 
TOC, shown by western blotting and IHC of EphA2 and EphA4 and a protein array 
against phospho-RTKs.  
6) NOTCH1 expression and processing appear increased in confluent TOC cells 
compared to control cell lines.  
7) Other rhomboid signalling pathways may also show some subtle dysregulation in 
TOC, shown by IHC of iRHOM1, RHBDL2 and thrombomodulin.   
 
4.3.2 Increased ADAM17 processing and EGFR signalling in TOC 
iRHOM2 mutations in TOC result in increased EGFR signalling (Figure 4.2.1; (Blaydon 
et al., 2012; Brooke et al., 2014), likely mediated by increased iRHOM2-dependent 
ADAM17 activation (figures 4.2.2-4.2.4; Brooke et al. 2014) and increased processing of 
EGFR ligands by ADAM17 (figure 4.2.4; Brooke et al. 2014).   
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4.3.2.1 ADAM17 processing 
Reduced mature ADAM17 levels after iRHOM2 knock down is consistent with results in 
human monocytes by Issuree et al. (2013) and with the role of iRHOM2 in ADAM17 
processing; collaborative data also shows increased mature ADAM17 levels and 
cell-surface ADAM17 in TOC keratinocyte monolayers and 3D cultures. Furthermore, 
ELISA assays show increased shedding of a number of EGFR ligands in TOC 
keratinocytes including AREG and TGF-α (Brooke et al. 2014; shown in figure 4.2.4). 
There was some variation in the western blotting data shown in figure 4.2.3 between sets 
of lysates, but results appear consistent with other methods used and with the literature 
showing iRHOM2-mediated ADAM17 processing (Adrain et al., 2012; McIlwain et al., 
2012). 
4.3.2.2 Increased TOC keratinocyte migration and EGF signalling 
Increased proliferation and migration was seen in the TOC cells, which was particularly 
apparent after culture in the absence of exogenous EGF (figure 4.2.1; Blaydon et al. 
2012). ADAM17 has been shown to be required for keratinocyte migration, for example 
FGF7-stimulated migration was blocked by ADAM17 siRNA and EGFR inhibition 
(Maretzky et al., 2011). The process was also dependent on ADAM17 substrate HB-
EGFR, as the migration was blocked by mutant diphtheria toxin CRM197, which 
selectively inhibits EGF. Furthermore, recent data in the group by Dr Matthew Brooke 
showed reduced migration in TOC keratinocytes after treatment with an ADAM17 
inhibitor (GW280264X) but not with an ADAM10 inhibitor, further suggesting that 
increased ADAM17-mediated shedding of EGFR ligands may be the mechanism for 
increased migration in TOC keratinocytes.  
Further research into the role of RHBDL2 would also be of interest, as RHBDL2 has also 
been shown to cleave EGF (Adrain et al., 2011) and RHBDL2 and its substrate 
thrombomodulin have been implicated in wound-healing (Cheng et al., 2011). IHC shown 
in this chapter is very preliminary and not easily reproduced, but if the dramatic re-
localisation seen was ‘real’, it perhaps suggests that this pathway may be affected in 
TOC and would be interesting for future research into EGF signalling, migration and 
wound healing in the skin. Adrain et al. (2011) showed that EGF cleavage by RHBDL2 
was independent of ADAM17 in experiments carried out in the presence and absence of 
the metalloproteinase inhibitor BB94, and that RHBDL2-mediated cleavage of EGF could 
occur while ADAM17 was active or inhibited. EGFR was activated when ADAMs were 
inhibited with a similar efficiency to ADAM17-mediated EGFR activation (Adrain et al., 
2011) demonstrating an additional pathway for regulation of EGFR signalling, and 
suggesting that this pathway would be interesting for further research in the skin.   
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4.3.2.3 Eph-Ephrin Signalling affected downstream of EGFR signalling 
Effectors of migration downstream of EGF signalling may include members of the 
Eph/Ephrin family of RTKs and ligands. The Eph/Ephrin family is involved in a number 
of cellular processes, including proliferation, adhesion, cell survival and differentiation 
(e.g. Guo et al., 2006; Yamada et al., 2008; Egawa et al., 2009; Furne et al., 2010; 
Genander et al., 2010; Genander and Frisén 2010; Lin et al., 2010; Kaplan et al., 2012), 
and a number of studies have implicated Eph/Ephrin signalling in migration (Larsen et 
al., 2007; Fukai et al., 2008; Miao et al., 2009; Hiramoto-Yamaki et al., 2010; Larsen, 
Stockhausen and Poulsen, 2010; Kaplan et al., 2012). 
4.3.2.3.1 EphA4 and EphA2 signalling in migration 
EphA4 has been shown to promote migration and proliferation in glioma cell lines (Fukai 
et al., 2008), inhibit migration in lung adenocarcinoma (Saintigny et al., 2012), and 
regulates migration in many processes in the nervous system, for example inhibiting 
Schwann Cell migration in peripheral nerve regeneration (Wang et al., 2013). Both 
EphA4 and EphA2 regulate migration through Rho-GTPase-dependent mechanisms 
(Fukai et al., 2008; Hiramoto-Yamaki et al., 2010).  
The Ephrin A1-EphA2 signalling axis is better characterised, particularly in the skin. 
EphA2 can act in a ligand (Ephrin A1)-dependent or independent manner (Miao et al., 
2009; Hiramoto-Yamaki et al., 2010), and appears to be constitutively active (Larsen et 
al., 2007) in contrast to other Eph receptors such as EphA4 (Binns et al., 2000; Wybenga-
Groot et al., 2001). The role of Ephrin A1 includes regulating EphA2 turnover at the 
plasma membrane.   
Ligand-independent EphA2 activation appears to stimulate migration, while Ephrin A1 
mediated activation of EphA2 results in phosphorylation, followed by internalisation and 
down-regulation of EphA2 and an inhibitory effect on migration (Larsen et al., 2007; Miao 
et al., 2009; Hiramoto-Yamaki et al., 2010; Larsen et al., 2010). Ligand-independent 
action of EphA2 stimulated serum-induced chemotaxis in glioma and prostate cancer 
cells, which was dependent on phosphorylation at S897 by Akt (Miao et al., 2009). The 
Ephrin A1/EphA2 pathway is also relevant to wound healing in the cornea, where 
elevated Ephrin A1 expression was seen in diabetic corneal cells and in corneal cells 
cultured in high glucose, and was associated with impaired migration and wound healing 
mediated by inhibition of Akt (Kaplan et al., 2012).  
4.3.2.3.2 EphA4 and EphA2 in TOC 
Decreased phospho-EphA4 was seen in a phospho-protein array against RTKs carried 
out with lysates from cells cultured in the presence of EGF in addition to changes in IGF-
1R and Insulin-R. Further pathways could potentially be identified after culture without 
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exogenous EGF, as potential (although variable) differences in total EphA2 and EphA4 
receptor expression were seen in TOC keratinocytes after culture without exogenous 
EGF but not after culture in the presence of EGF. The findings were supported by 
increased EphA2 in 3D cultures of TOC keratinocytes compared to control keratinocyte 
3D cultures (figure 4.2.6). Insulin-R and IGF-1R signalling have also been implicated in 
migration, proliferation and differentiation in the skin (Benoliel et al., 1997; Wertheimer 
et al., 2000; Sadowski and Dietrich, 2003; Sadagurski et al., 2006), and may be of 
interest in future investigations.  
IHC in frozen skin biopsies suggested increased EphA4 and phospho-EphA4 protein in 
patient 1, but not in the other TOC patients, suggesting that EphA4 may be affected 
downstream of dysregulated iRHOM2, but not in ‘normal’ circumstances. Some possible 
nuclear EphA4 was seen in some cells in patient 1 epidermis, and in ICC, perhaps 
suggesting an additional role for EphA4 in the skin. EphA2 appeared to be in the nucleus 
in serum-starved HEK293T cells (Miao et al., 2009), but EphA4 in mouse skin appeared 
to show a more intracellular localisation (Egawa et al., 2009), and IHC against EphA4 by 
Yamada et al (2008) in skin sections showed stronger expression at the plasma 
membrane. This could suggest variable EphA4 localisation between species and 
different body sites in human; recognition of cleavage products of EphA4 (for example, 
EphA4 is cleaved by Caspase 3 in adult neurogenesis, where it acts as a dependence 
receptor (Furne et al., 2010); or could represent inconsistencies between protocols and 
antibodies, so this requires further investigation, for example, by cell fractionation.   
An increase in phospho-EphA4 contrasts with the findings of the phospho-array, perhaps 
due to the different conditions in monolayer culture compared with differentiating cells in 
the upper layers of the epidermis. Further, the phospho-EphA4 antibody did not work 
well for western blotting (my experience and personal communication from Dr Spiro 
Getsios), so it is possible that the staining is non-specific. Changes were only in patient 1, 
consistent with the results seen with the total EphA4 antibody, however, suggesting that 
this pathway may be affected. Further work will be required to confirm these findings, 
perhaps including in vivo and 3D wound healing assays, and IHC in involved TOC skin.  
4.3.2.3.3 Effect of growth factors on EphA2  
Alterations in EphA2 expression downstream of EGF signalling have previously been 
shown in cancer cell lines with both ligand-dependent EGFR signalling and constitutively 
active EGFR mutant EGFRvIII (Larsen et al., 2007). This induction of expression was 
partly dependent on MEK and src family kinases (Larsen et al., 2007; 2010), and was 
dependent on cell adhesion and proteins of the extracellular matrix (Larsen et al., 2010). 
Furthermore, co-immunoprecipitation experiments in a number of cell lines showed 
increased association of EphA2 with EGFR upon stimulation of the cells with EGF, 
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suggesting that activation of EGFR is required for the association of the two RTKs to 
occur (Larsen et al., 2007). Growth-factor stimulation of cancer cell lines also induced 
phosphorylation of EphA2 residue S897, which was required for EphA2 localisation at 
the leading edge of the cell, and for cell polarisation (Miao et al., 2009).  
Growth factors and cytokines associated with psoriasis have been shown to affect 
epidermal morphology (Johnston et al., 2010; Gordon et al., 2013). Keratinocyte 
organisation in 3D cultures was disrupted in the basal and spinous layers by treatment 
with EGF and IL-1α, associated with a reduced number of keratohyalin granules and 
expanded stratum corneum and reduced expression of differentiation markers K10, 
DSG1, and loricrin (Johnston et al., 2010; Gordon et al., 2013). These changes were 
accompanied by up-regulation of members of the RTK family, including EphA2. More 
minor morphological changes were seen with TNF-α and IL17-α treatment despite similar 
changes in EphA2 (Gordon et al., 2013). Enhanced IL-1 expression and proliferation was 
seen in the skin of mice where Ephrin B2 was knocked out perinatally (Egawa et al., 
2009).  
4.3.2.3.4 RHBDL2 and thrombomodulin in epidermal wound healing 
Expression of RHBDL2 substrate thrombomodulin is closely regulated in epidermal 
wound healing (e.g. Raife et al., 1994; Lager et al., 1995; Raife et al., 1996; Mizutani et 
al. 1994; Senet et al., 1997) and may be interesting to study in future investigations. 
Thrombomodulin is cleaved by a number of proteases, and soluble thrombomodulin is 
released extracellularly; furthermore, recombinant thrombomodulin acts as a mitogenic 
factor (Hamada et al., 1995; Shi et al., 2005).   
Increased expression of soluble thrombomodulin and RHBDL2 was seen after wounding 
in HaCat cells and in mice after transdermal incision surgery (Peterson et al., 1999; 
Cheng et al., 2011). The increase in soluble thrombomodulin release in HaCaT cells was 
dependent on RHDL2, as its release was prevented by the non-specific serine protease 
inhibitor 3,4-dichloroisocoumarin (DCI) and also by shRNA directed against RHBDL2. 
Migration and proliferation were also reduced by RHBDL2 knock down, and the effects 
reversed by treatment with recombinant soluble thrombomodulin. Conversely, 
overexpression of RHBDL2 increased release of soluble thrombomodulin (Cheng et al., 
2011). These findings lead to the hypothesis that RHBDL2 cleaves thrombomodulin after 
wounding, releasing soluble thrombomodulin to induce proliferation and migration in 
keratinocytes to close the wound (Cheng et al., 2011).   
4.3.3 ADAM17-dependent regulation of iRHOM2 expression 
Two pieces of data from this chapter support ADAM17-mediated regulation of iRHOM2 
expression in the skin: reduced iRHOM2 protein after ADAM17 knock down, and 
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reduced iRHOM2 staining intensity in skin from a patient with a homozygous LOF 
ADAM17 mutation. Furthermore, a relationship between iRHOM2 and ADAM17 
expression is consistent with data in OSCC and HNSCC cell lines, which will be shown 
in the next chapter. The data contrasts with findings of Issuree et al (2013), who did not 
see down-regulation of iRHOM2 upon treatment with anti-ADAM17 siRNA in human 
monocytes. The result was seen at the mRNA level, however, so the regulation could 
take place at the post-translational level, or the time points of the experiments could have 
been different (the time point for sample collection was not stated in (Issuree et al., 2013). 
Alternatively, different regulatory pathways could be active in these tissues compared 
with the pathways dominant in immune cells, and the presence of iRHOM1 in 
keratinocytes may affect iRHOM2 regulation due to the overlapping functions of the two 
proteins. Other functions of the iRHOMs may play a role in regulating their expression, 
for example targeting EGF for ERAD (Zettl et al., 2011). Christova et al. (2013) also saw 
reduced ADAM17 levels in iRHOM double knock-out mouse cells, suggesting that 
iRHOM2 levels affect pro-ADAM17 expression, as well as the reverse situation shown 
here.  
4.3.3.1 iRHOM2 expression in TOC 
In IHC in the previous chapter, western blots of overexpressed iRHOM2 and 3D 
keratinocyte cultures appeared to show reduced iRHOM2 levels in TOC. However, in 
figure 4.2.3 in this chapter, iRHOM2 levels appeared higher in TYLK1 and TYLK2 cells 
than in control keratinocytes. There is no clear explanation for this inconsistency. The 
differences might reflect subtle differences in culture conditions such as the confluency 
of the cells when protein lysates were made, or interpretation of bands on western blot. 
iRHOM2 appears to be a highly dynamic protein, so subtle changes in conditions could 
cause variation in iRHOM2 activity. In addition to regulating ADAM17 processing, 
targeting EGF for ERAD (Zettl et al., 2011) and controlling substrate selectivity of 
ADAM17 (Maretzky et al., 2013), iRHOM2 may have a further undiscovered functions 
that could affect its expression, localisation and processing.  
As discussed in the previous chapter, the appearance of iRHOM2 as a doublet in western 
blots may be interesting. The iRHOM2 knock down appeared fairly weak, and to primarily 
affect the upper band of the doublet, whilst having a clear impact on ADAM17 
processing. However, some reduction in the lower band was seen after knock down in 
some lysates, and after ADAM17 knock down. This suggests either a non-specific effect 
of the siRNA, or that the lower band is a more stable form of iRHOM2. Alternatively, if 
the lower band represents isoform 2 of iRHOM2 and the upper band isoform1, perhaps 
the iRHOM2 pool of siRNAs preferentially targets isoform 1. Future work breaking down 
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the pool of siRNAs would be useful, and would confirm the specificity of the iRHOM2 
siRNA. 
4.3.4 NOTCH Signalling in TOC 
Expression of NOTCH1 S1 and cleaved NOTCH1 appeared increased in TOC 
keratinocytes. A potential increase in cell-surface total NOTCH1 in TOC keratinocytes 
(shown by two separate antibodies) and in the upper layers of skin from TOC patient 3 
were also seen. Furthermore, there appeared to be an increase in cleaved NOTCH1 in 
the nucleus in TOC keratinocytes and increased staining of cleaved NOTCH1 in the 
upper layers of TOC skin. However, the staining was not nuclear as seen in the cells, 
and as might be expected for NOTCH NICD. Expression in the upper layers of the 
epidermis would be consistent with a role of NOTCH in differentiation. However, further 
work is needed to confirm these preliminary results.    
NOTCH gene transcription has been reported to be negatively regulated by EGFR 
signalling (via suppression of p53 by c-jun; Kolev et al., 2008), so it is perhaps a little 
surprising to see increased NOTCH1 in TOC where increased shedding of EGFR ligands 
is seen. The increase in NOTCH1 expression could be a compensatory mechanism to 
balance the increase in EGFR signalling, or increased processing may be mediated by 
increased ligand-independent S2 cleavage by ADAM17. There is some evidence for a 
positive feedback loop in NOTCH expression, shown by reduced levels of Notch in 
zebrafish and mouse Notch pathway mutants (Del Monte et al., 2007). Positive feedback 
loops have also been suggested in the NOTCH pathway in several previous studies (e.g. 
de Celis et al. 1997; Deftos et al. 1998). This could mean that increased NOTCH1 
processing in TOC is leading to positive feedback and increased overall NOTCH1 
expression in some situations.  
4.3.5 Differentiation and skin barrier 
EphA4 staining appeared stronger in the upper epidermal layers in some of the TOC 
patients, with some variability in EphA2 IHC. There were no clear differences in Ephrin 
A1 in TOC, while there was perhaps an increase in Ephrin A1 associated with LOF 
ADAM17 mutations in the suprabasal layers, which could potentially be related to 
impaired differentiation. Ephrin A1 treatment has been shown to activate and down-
regulate EphA2 leading to colony compaction, stratification, and differentiation in 
keratinocytes cultured in low Ca2+ medium (Lin et al., 2010). The mechanism occurred 
via induction of DSG1 expression, which induces further differentiation including up-
regulation of keratin 10 and DSC1 a and b isoforms (Lin et al., 2010). EphA4 has also 
been shown to be up-regulated upon differentiation (Gordon et al., 2013).  
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In psoriasis, which is associated with abnormal differentiation of keratinocytes 
(Tschachler, 2007; Elder et al., 2010; Guttman-Yassky, Nograles and Krueger, 2011), 
changes were seen in the expression profile of Eph receptors and Ephrin ligands (Kulski 
et al., 2005; Piruzian et al., 2009; Jabbari et al., 2012; Gordon et al., 2013). EphA2 and 
EphA4 were both up-regulated compared to normal skin, while Ephrin A1 was down-
regulated (Gordon et al., 2013). This was replicated in 3D raft cultures after treatment 
with EGF ligands, where impaired induction of differentiation-associated proteins was 
seen. Treatment with the Ephrin A1-Fc peptide improved expression of many 
differentiation markers, including DSG1, DSC1 and K10, and rescued the disrupted 
morphology associated with treatment with EGF or IL-1α (Gordon et al., 2013). 
Interestingly, Gordon et al saw less disruption in epidermal morphology after treatment 
with TNF-α or IL-17a, suggesting that increased EphA2 expression alone is not enough 
to disrupt epidermal morphology. This may also explain why the epidermal morphology 
in TOC is not so disrupted, although it is often thicker due to hyperproliferation.  
Expression of RHBDL2 substrate thrombomodulin is also tightly regulated in 
differentiation as well as in wound healing (Mizutani et al., 1994; Raife et al., 1994; Lager 
et al., 1995; Raife, Demetroulis and Lentz, 1996; Senet et al., 1997). The exact role of 
thrombomodulin in this process is not well known, but thrombomodulin is up-regulated in 
keratinocytes by differentiation-inducing retinoic acid, and down-regulated by TNF-α in 
endothelial cells but not in keratinocytes (Raife et al., 1996).   
In addition, an increase was seen in transglutaminase 1 (TGM1) activity in TOC skin and 
3D cultures of TOC keratinocytes (Brooke et al., 2014), suggesting altered differentiation 
in TOC. Conversely, ADAM17 knock-out mouse epidermis had impaired TGM activity, 
impaired barrier function and atopic dermatitis, which was  which was improved by topical 
treatment with TGF-α (Franzke et al 2012) showing that TGM activity is regulated by the 
ADAM17-EGFR pathway. Further, reduced expression of TGM1 (Blaydon et al., 2011) 
and reduced TGM activity (unpublished data by Matthew Brooke) was associated with 
homozygous LOF ADAM17 mutations in human epidermis. This suggests that increased 
TGM1 activity in TOC skin may improve barrier function. 
4.3.5.1 The iRHOM2-ADAM17 pathway in infection 
Decreased TGM1 expression and activity in LOF ADAM17 skin is associated with an 
increased incidence of infection, suggesting that increased ADAM17 and TGM1 activity 
in TOC skin and keratinocytes may infer resistance to attack by pathogens. Consistent 
with this, a reduction in the adhesion and invasion efficiency of S. aureus was seen in 
TOC keratinocytes compared with control cells (Brooke et al. 2014, data by Dr Charlotte 
Simpson). ADAM17 knock down increased the efficiency of S. aureus adhesion and 
invasion in both control and TOC keratinocytes.  
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Furthermore, a physiological role for murine iRhom2 in the immune response was 
demonstrated (McIlwain et al., 2012). iRhom2-/- mice were protected against septic shock 
and liver damage, which was mimicked by co-injection of LPS and galactosamine (GalN). 
The mice had much reduced serum TNF-α levels following injection but normal levels of 
other cytokines, and also lower levels of CD62L-negative granulocytes in the spleen and 
blood. The knock-out mice had a less disrupted liver architecture than WT mice, and 
were much less likely to die in the 48 hours after treatment (McIlwain et al., 2012). 
However, defence against the bacterium Listeria monocytogenes was impaired in the 
iRhom2 knock-out mice, as the mice had higher levels of liver granulomas and 
succumbed to the infection much more quickly than WT mice, even at low titres of 
infection (McIlwain et al., 2012).    
4.3.6 Conclusion 
The data in this chapter and in Brooke et al (2014) suggest that the TOC mutations in 
iRHOM2 are GOF in nature and result in increased ADAM17 processing and ADAM17-
mediated shedding of EGFR ligands. This appears to lead to effects on EGFR signalling 
in TOC keratinocytes, and potentially the downstream Eph/Ephrin pathways. In addition, 
there appeared to be an increase in NOTCH1 expression in TOC keratinocytes and 
epidermis. The changes appear to affect migration and perhaps differentiation in TOC 
skin and may have a favourable effect on barrier function and resistance to S. aureus 
infection. Other members of the rhomboid protein family may be of interest for future 
investigation into EGFR signalling, differentiation and wound healing in the skin.    
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Chapter 5: A role for the iRHOM2-ADAM17 
pathway in Cancer 
5.1 Introduction 
iRHOM2 / RHBDF2 is the first gene associated with high-penetrance inherited OSCC 
(Blaydon et al., 2012; Saarinen et al., 2012), and iRHOM1 has previously been 
associated with HNSCC and breast cancers in cell lines, in vivo xenograft tumour 
experiments and breast cancer tumours (Yan et al., 2008; Zou et al., 2009). iRHOM2 
and iRHOM1 are important for the processing of ADAM17 (Adrain et al., 2012; McIlwain 
et al., 2012; Christova et al., 2013), which is a sheddase with substrates including EGFR 
ligands and cell adhesion molecules (Gschwind et al., 2003; Sahin et al., 2004; Bech-
Serra et al., 2006; Klessner et al., 2009; Pruessmeyer and Ludwig, 2009).  
ADAM17 has been implicated in the pathogenesis of a wide range of cancers, including 
non-small-cell lung cancer (NSCLC) (Ni et al. 2013; Zhou et al. 2006), ovarian, prostate, 
breast (Lendeckel et al., 2005; Sinnathamby et al., 2011; Narita et al., 2012), colorectal, 
gastrointestinal (Blanchot-Jossic et al., 2005; Nakagawa et al., 2009) and head and neck 
cancer (Stokes et al., 2010; Kornfeld et al., 2011). ADAM17-mediated shedding of AREG 
and TGF-α was also indicative of poor survival in breast cancer patients (Kenny and 
Bissell, 2007). 
NOTCH signalling has also been reported to be regulated by ADAM17 (Bozkulak and 
Weinmaster, 2009), and appeared dysregulated in TOC keratinocytes in the previous 
chapter. NOTCH acts as a tumour suppressor in a number of epithelia (Nicolas et al., 
2003; Demehri et al., 2008; South, 2012), with LOF mutations frequently found in 
cutaneous SCC, lung cancer (Wang, 2011; South et al., 2014) and HNSCC (Stransky et 
al. 2011; Agrawal et al. 2011). In addition, inactivating NOTCH mutations were seen in 
21 % of OSCCs but not in oesophageal adenocarcinomas (Agrawal et al., 2011), and 
whole exome sequencing revealed NOTCH1 mutations in further OSCC samples (Song 
et al., 2014). NOTCH1 has also been implicated in resistance to 5-FU treatment in OSCC 
cell line KYSE70 (Liu et al., 2013).  
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5.1.2 Aims 
This chapter aimed to investigate the iRHOM2-ADAM17 pathway in OSCC, focussing in 
particular on protein expression of iRHOM2, ADAM17 and NOTCH1 in OSCC and 
HNSCC cell lines. Further aims included investigation of iRHOM2 localisation in a wider 
range of cancer tissues by IHC, in particular to determine whether localisation was 
predominantly membranous or cytoplasmic and whether iRHOM2 localisation is 
dysregulated in different tumours. Finally, the catalogue of somatic mutations in cancer 
(COSMIC) database was searched for iRHOM1 and iRHOM2 mutations to determine the 
incidence of iRHOM mutation in different cancers. 
5.2 Results  
5.2.1 ADAM17 and iRHOM2 expression in OSCC biopsies and 
cell lines  
IHC for total ADAM17 and iRHOM2 was performed in adjacent TOC and sporadic OSCC 
sections by the BICMS core pathology facility. Protein levels appeared to vary between 
the stromal and tumour tissue in both TOC (figure 5.2.1 A) and sporadic (figure 5.2.1 B 
and C) OSCC sections, with both iRHOM2 and ADAM17 staining appearing to be of low 
intensity in stromal regions and of stronger intensity in the tumour tissue of the biopsies, 
for example in figure 5.2.1 B.   
To further investigate the link between iRHOM2 and ADAM17 in OSCC, western blots of 
iRHOM2 and ADAM17 were carried out in four commercially available OSCC cell lines: 
KYSE270; KYSE410; TE-4 and TE-8, which were kindly provided by Dr Janet Risk, 
University of Liverpool. The KYSE270 cell line was originally isolated from a well-
differentiated OSCC from a 79-year-old male Japanese patient and KYSE410 from a 
poorly-differentiated OSCC from a 51-year-old male Japanese patient (http://www.phe-
culturecollections.org.uk). TE-4 cells were isolated from a 48-year old male 
(http://cancer.sanger.ac.uk/cosmic/sample/overview?id=735828) but the differentiation 
status of the tumour is unknown. The TE-8 cell line originated from a moderately 
differentiated OSCC (Sakai et al., 2009). Mutations in EGFR have been reported in 
KYSE270 cells (Kato et al., 2013), while TE-4 and TE-8 cells have both been reported 
to not harbour EGFR mutations (Kimura et al. 2006; Sudo et al. 2007; COSMIC 
database). 
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Figure 5.2.1 ADAM17 expression mirrors iRHOM2 expression in tylotic and 
sporadic Oesophageal Squamous Cell Carcinoma. Sections cut from paraffin-
embedded oesophageal SCC (OSCC) biopsies were stained with Haematoxylin and 
Eosin (H&E) and diaminobenzylene (DAB) staining against iRHOM2 and ADAM17 as 
indicated. A: Tylotic OSCC, B and C: Sporadic OSCC. Staining was carried out by the 
Core Pathology Facility. Please note that this image was originally in JPEG format 
and is therefore of reduced quality. 
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During cell culture, KYSE270 cells grew with a block-like morphology similar to 
cutaneous keratinocytes, and grew the fastest of the four cell lines. KYSE410 cells had 
a spindle-like morphology. TE-8 cells grew with the spindle-like or epitheloid morphology 
of KYSE410 cells, but there appeared to be a fairly high level of cell death. 
5.2.1.1 iRHOM2 in OSCC cells: 
Western blots for iRHOM2 showed a wide range of expression between the four cell lines 
(figure 5.2.2 Ai), with particularly high expression in the KYSE270 cell line. As in 
cutaneous keratinocyte cell lines, the iRHOM2 band appeared as a ‘doublet’ with two 
bands at around 90 KDa. Densitometry (taking into account both bands; figure 5.2.2 C) 
showed moderate iRHOM2 expression in TE-4 and TE-8 cells, low expression in 
KYSE410 cells and the highest expression in KYSE270 cells. There was some variability 
between sample sets, perhaps due to differing exposure times between western blots. 
The upper band of iRHOM2 often appeared at a slightly higher molecular weight in TE-4 
cells compared to the other cell lines (figure 5.2.2 Ai), perhaps suggesting post-
translational modification. KYSE410 and TE-8 cell lysates appeared to have a greater 
proportion of the lower band of the iRHOM2 doublet.  
5.2.1.2 ADAM17 in OSCC cells: 
The intensity of bands representing ADAM17 also varied between the four cell lines 
(figure 5.2.2 Aii), with particularly high ADAM17 levels seen in the KYSE270 cell line 
corresponding with high iRHOM2 levels. The mature ADAM17 band was of particularly 
high intensity in KYSE270 cells, consistent with increased iRHOM2-mediated ADAM17 
processing. TE-8 cells showed lower total ADAM17 expression compared to TE-4 cells, 
despite similar levels of iRHOM2 expression (figure 5.2.2 D). KYSE410 cells had similar 
total ADAM17 levels to TE-4 cells, but the proportion of mature ADAM17 was lower 
(figure 5.2.2 D and E), corresponding with lower overall iRHOM2 protein expression, and 
a higher proportion of the lower iRHOM2 band (figure 5.2.2 Ai). This may suggest that 
the upper band of the ‘doublet’ may be important in ADAM17 processing, as it was 
strongly expressed in KYSE270 cells.  
The mature ADAM17 band consistently appeared at a slightly higher molecular weight 
in KYSE270 cells, perhaps due to N-linked glycosylation which has previously been 
reported for ADAM17 (Issuree et al., 2013; Chavaroche et al., 2014).  
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Figure 5.2.2 Variable iRHOM2 and ADAM17 levels in OSCC cell lines. A: Western 
blots against iRHOM2 and ADAM17 in four OSCC cell lines. B: Western blot against the 
pro-domain of ADAM17. The blue boxes indicate the bands of interest: the top band 
represents full length pro-ADAM17; the bottom band represents the free pro-domain. C-
E: Graphs representing densitometry analysis of the bands in the western blots in part 
A: C-D: Densitometry analysis was carried out to analyse the proportion of pro- and 
mature ADAM17 in each cell line in relation to the iRHOM2 expression. C: iRHOM2 
densitometry; D: Stacked bar graph showing ADAM17 densitometry. The band 
representing mature ADAM17 is shown in black and the band representing pro-ADAM17 
shown in white. E: The percentage of total ADAM17 protein accounted for by the band 
representing mature ADAM17 in each cell line. N = 2 for each densitometry analysis, but 
the same results were also seen in a third set of lysates for which no loading control is 
available. Densitometry was carried out with Image Studio Lite software.  
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Figure 5.2.2 B shows a western blot against pro-ADAM17 in the four OSCC cell lines. 
The antibody recognises the free pro-domain of ADAM17 and unprocessed pro-ADAM17 
(both highlighted by blue boxes), in addition to some non-specific bands. TOC cutaneous 
keratinocytes showed increased levels of the free ADAM17 pro-domain compared to 
control cutaneous keratinocytes (see Chapter 4). The OSCC cells did not appear to 
retain the free pro-domain to the same extent as cutaneous keratinocytes, however 
slightly elevated levels of the free pro-domain were seen in KYSE270 cells, along with 
slightly higher unprocessed pro-ADAM17 levels (figure 5.2.2 B).  
5.2.3 Correlation between iRHOM2 and ADAM17 expression in 
Head and Neck Squamous Cell Carcinoma cell lines 
Western blots in a panel of ten HNSCC cell lines isolated from primary tumour tissue 
were performed to study the potential relationship between iRHOM2 and ADAM17 
expression in another cancer type. The cell lines were made by Dr Helena Emich, Centre 
for Cutaneous Research, QMUL.  
5.2.3.1 iRHOM2 in HNSCC cell lines 
As seen in the OSCC cells, iRHOM2 levels varied between the different HNSCC cell 
lines in preliminary western blots (figure 5.2.3 A), with particularly high iRHOM2 levels in 
LUC4, 24n, NA and 50(2), and the lowest levels in Mkn, 57n, TUM57 and TUM59. As in 
keratinocytes and OSCC cells, a ‘doublet’ was often seen at around 90 KDa. In most 
cases the lower band of the doublet appeared more prominent, with the exception of 
TUM59 cells. There was some variability in the size of the iRHOM2 band at ~90 KDa in 
the cell lines, with a slightly smaller lower band present in NA cells accompanied by 
another fragment at approximately 76 KDa. 
The full length western blot of iRHOM2 in the HNSCC cell lines is shown in figure 5.2.3 B. 
As mentioned in Chapter 3, some extra bands were detected by the anti-iRHOM2 
antibody: one around 150 KDa, and one around 55 KDa. The intensity of these bands 
also varied between the HNSCC cell lines, with the 150 KDa band particularly strong in 
NA, LK and 24n cells, and the 55 KDa band particularly bright in NA, LM, 24n and LUC4 
cells; another band at around 50 KDa was seen in 57n cells (figure 5.2.3 B). These data 
could suggest non-specific binding of the anti-iRHOM2 antibody, as discussed in chapter 
3, or could potentially show different processing of iRHOM2 between the cell lines. 
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Figure 5.2.3 Variable expression of iRHOM2 and ADAM17 in HNSCC cell lines. A: 
Western blotting of iRHOM2 and ADAM17 in a panel of ten Head and Neck SCC 
(HNSCC) cell lines. B: Full length western blot of iRHOM2 to show all the bands present, 
perhaps indicating different processing of iRHOM2 between cell lines. Please note that 
this is preliminary data from one western blot of each protein. 
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5.2.3.2 Correlation between iRHOM2 and ADAM17 expression in HNSCC 
cell lines 
Preliminary western blots for ADAM17 in the HNSCC cell lines are shown in figure 5.2.3 
A, although this was only performed once in one set of lysates. ADAM17 expression was 
variable between cell lines, with higher levels appearing in cell lines with higher iRHOM2 
(figure 5.2.3 A). iRHOM2 and ADAM17 protein levels were analysed relative to GAPDH 
and plotted in a scattergraph with iRHOM2 protein expression on the X axis and ADAM17 
protein expression on the Y axis (figure 5.2.4). A polynomial best-fit curve was plotted, 
with the Pearson’s correlation coefficient, or r2 value, calculated using Microsoft Excel. 
An r2 value of 1 indicates a perfect positive correlation, a value of -1 indicates a perfect 
negative correlation and a value of 0 indicates that there is no correlation between the 
data sets.  
When iRHOM2 expression was plotted against total ADAM17 protein expression, there 
appeared to be a strong positive correlation between the levels of the two proteins (figure 
5.2.4 A), with an r2 value of 0.932 associated with the data. One outlier was excluded 
from the analysis - the LK cell line, shown in red. LK cells had low iRHOM2 and relatively 
high ADAM17 expression. The correlation appeared less strong when only pro-ADAM17 
levels were taken into account (figure 5.2.4 B), with an r2 value of 0.7239 associated with 
the curve when LK cells were excluded. However, taking into account the intensity of 
bands for mature, processed ADAM17 (figure 5.2.4 C), which is reliant on the action of 
iRHOM2, the r2 correlation value reached 0.918 excluding the LK cell line, and 0.8357 
including the LK cells: this indicates that the proportion of pro-ADAM17 in LK cells was 
higher than that of mature ADAM17, perhaps because the lower iRHOM2 levels meant 
reduced processing of ADAM17.  
Figure 5.2.4 D shows expression of both pro- and mature- ADAM17 in order of increasing 
iRHOM2 expression, showing the suggested trend toward increasing ADAM17 levels 
with iRHOM2 levels and the high proportion of pro-ADAM17 in outlier cell line LK. 
Interestingly, LK cells did not appear to express the upper band of the iRHOM2 doublet 
(figure 5.2.3 A), consistent with findings in OSCC cell lines (figure 5.2.2) suggesting that 
expression of the upper iRHOM2 band is required for production of mature ADAM17.   
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Figure 5.2.4 iRHOM2 and ADAM17 expression appears to correlate in HNSCC cell 
lines. Expression levels of iRHOM2 and ADAM17 protein were measured by 
densitometry relative to a GAPDH loading control. A-C: Scattergraphs showing iRHOM2 
protein expression on the X-axis against total levels of ADAM17 (A), pro-ADAM17 (B) 
and mature ADAM17 (C) on the Y-axis. D: Relative levels of pro-ADAM17 (white) and 
mature ADAM17 (black). Cell lines are presented in order of increasing iRHOM2 
expression. Densitometry was carried out with Image Studio Lite software. Please note 
that this is preliminary data from one western blot of each protein. 
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5.2.3.3 iRHOM2 levels and tumour characteristics 
Table 5.2.1 shows the cell lines in order of increasing iRHOM2 expression, alongside 
the characteristics of the original tumours. All the cell lines were from moderately 
differentiated, moderate to poorly differentiated, or poorly differentiated tumours, or from 
lymph node metastasis. The sample size was too small to determine a link between 
tumour stage and / or characteristics, but observational analysis suggested that there 
was not a clear correlation between iRHOM2 expression levels and differentiation status, 
tumour depth, perineural invasion or extracapsular spread.  
Two cell lines expressing fairly high iRHOM2 (LM and 50(2); 3rd and 4th highest iRHOM2 
expression) showed a cohesive invasion front while cell lines expressing lower iRHOM2 
had a discohesive invasion front. The two cell lines expressing highest iRHOM2 (24n 
and NA) had different properties: NA cells had a discohesive but infiltrative invasion front; 
and 24n cells were from a lymph node metastasis so invasion front was not applicable. 
Again, the sample size is much too small to form a conclusion from this, but further 
investigation of iRHOM2 and ADAM17 in invasion would be interesting, particularly as 
ADAM17 has previously been implicated in tumour invasion (Chen et al., 2013; 
Doberstein et al., 2013; Giricz et al., 2013).   
 
Table 5.2.1 iRHOM2 expression does not appear to correlate with tumour 
characteristics in HNSCC cell lines. Table showing cell lines in increasing order of 
iRHOM2 expression according to densitometry analysis against tumour grade, depth, 
perineural invasion, lymphovascular spread, extracapsular spread and invasion front. 
Please note that this is preliminary data from one set of lysates. 
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5.2.4 ADAM17 activity in OSCC cell lines 
To see whether active ADAM17 levels are related to shedding of ADAM17 substrates, 
ELISA assays were performed to measure shedding of AREG and TGF-α into the cell 
culture medium over a time period of 0 to 48 h. Semi-quantitative RT-PCR (qPCR) was 
performed on mRNA extracted at the 24 h time point to measure expression levels 
relative to housekeeping gene GAPDH. There was variation between levels of AREG 
and TGF-α in the medium from the three cell lines (figure 5.2.5 A and B respectively), 
but this did not appear to correspond with levels of mature ADAM17 in lysates from the 
cells.  
KYSE270 cells shed the lowest level of AREG (figure 5.2.5 A), despite having the 
greatest level of mature ADAM17 protein. KYSE410 cells had the lowest iRHOM2 and 
mature ADAM17 protein of the three cell lines, but medium from KYSE410 cells had an 
AREG concentration approximately 3.5X higher than medium from KYSE270 cells after 
48 h (figure 5.2.5 A). TE-4 cells shed particularly high levels of AREG (figure 5.2.5 A), 
while expressing moderate levels of mature ADAM17 protein. The results could in part 
be explained by the mRNA levels of AREG (figure 5.2.5 B), which were particularly high 
in KYSE410 cells. However, TE-4 cells, which shed the highest levels of AREG, had a 
moderate AREG expression at the mRNA level. Further investigation into regulation of 
AREG and ADAM17 expression will be required to explain these findings. 
TGF-α is shed by OSCC cells (and cutaneous keratinocytes; Brooke et al. 2014) at a 
much lower level than AREG (Figure 5.2.5 C). Variability was also seen in the shedding 
of TGF-α between the three cell lines, although the pattern was different to that of AREG: 
while TE-4 again shed the highest levels of TGF-α (associated with moderate mRNA 
expression), the TGF-α concentration was higher in medium from KYSE270 cells than 
KYSE410 cells (figure 5.2.5 C). This corresponded with higher mRNA levels of TGF-α 
and high mature ADAM17 protein levels in KYSE270 cells (figure 5.2.5 D). KYSE410 
cells showed a much lower mRNA expression of TGF-α than KYSE270 cells (combined 
with low iRHOM2/ADAM17 levels). Interestingly, the level of TGF-α decreased in 
medium from KYSE270 cells between the 24 h and 48 h time points (figure 5.2.5 C).   
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Figure 5.2.5 Variable shedding of ADAM17 substrates AREG and TGF-α in OSCC 
cell lines may be linked with differential mRNA expression  
Cells were cultured for up to 48 h, and the medium collected at a number of timepoints 
for ELISA analysis of AREG and TGF-α protein concentration. mRNA was extracted from 
cells at the 24 h timepoint and qPCR performed to estimate mRNA levels of AREG and 
TGF-α. N=2 for all experiments. A: Chart showing concentration of AREG in medium 
from KYSE-270, KYSE-410 and TE-4 cells, measured by ELISA (n=2). B: Semi-
quantitative RT-PCR (qPCR) showing relative mRNA levels of AREG (n=1). C: Protein 
concentrations of TGFα in medium from the three OSCC cell lines measured by ELISA 
(n=2). D: qPCR showing mRNA levels of TGF-α relative to GAPDH (n=1). Similar results 
were seen at 24 h and 48 h in preliminary ELISA experiments. 
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5.2.5 iRHOM2 and downstream proteins in OSCC and 
Oesophagitis 
To look further at iRHOM2 in OSCC, preliminary IHC experiments were carried out in 
paraffin-embedded oesophageal biopsies from a patient suffering from oesophagitis, 
OSCC from a TOC patient, and sporadic OSCC (figure 5.2.6 A-C respectively). IHC was 
carried out by the BICMS core pathology facility and images taken and selected by Dr 
Laura Gay and Professor David Kelsell.  
iRHOM2 staining was seen throughout the layers of the oesophagus, with the most 
intense staining in the basal layer and the faintest staining in the middle layers. Although 
it is more difficult to determine localisation in DAB-stained paraffin-embedded biopsies, 
iRHOM2 appeared to show a cell-surface localisation In the upper, more differentiated 
functional layers of the oesophagus, consistent with staining at the plasma membrane 
and with fluorescence staining of iRHOM2 in a normal frozen oesophageal tissue section 
in chapter 3 (figure 3.1.4). In the paraffin section, iRHOM2 appeared at lower levels in 
the middle prickle cell layer, where it appeared to show a more perinuclear localisation, 
perhaps consistent with iRHOM2 located in the ER (figure 5.2.6 A). The basal layer 
appeared to show intracellular iRHOM2 staining at a stronger intensity than the other 
oesophageal layers.   
In the sections from TOC and sporadic OSCC, the distinct morphology of the 
oesophagus was lost, with smaller, more compact cells consistent with increased 
proliferation in the cancer, particularly in the TOC OSCC (figure 5.2.5 B and C). iRHOM2 
staining was of variable intensity throughout the sections, consistent with staining in 
OSCC biopsies in figure 5.2.1. iRHOM2 staining in the upper oesophageal layers 
appeared to be more diffuse than that in control oesophagus, with no clear plasma 
membranous staining (figure 5.2.5 B and C), although this is a small number of samples 
and it is difficult to distinguish iRHOM2 localisation.      
5.2.5.1 Ephrin B3 in OSCC sections  
As Eph/Ephrin signalling was implicated by the phospho-RTK array and western blotting 
in TOC cutaneous keratinocytes (Chapter 4), IHC was performed against Ephrin B3, a 
substrate of RHBDL2. In oesophagitis, Ephrin B3 staining was very faint throughout the 
section, perhaps with slightly more intense staining in the basal layers of the oesophagus 
and some faint cell-surface staining in the upper layers (figure 5.2.6 A). In the TOC and 
sporadic OSCC sections, Ephrin B3 staining appeared at higher intensity than in control 
oesophagus, with a diffuse, cytoplasmic-like localisation (figure 5.2.6 B and C). Again, 
this is a small, preliminary sample set and the localisation of Ephrin B3 is difficult to 
distinguish, particularly in OSCC biopsies.  
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Figure 5.2.6 Altered localisation of iRHOM2 and expression of RHBDL2 substrate 
Ephrin B3 in Tylotic and Sporadic Oesophageal SCC. Sections from paraffin-
embedded TOC stained with iRHOM2 (Left panel) and Ephrin B3 (Right panel) in A: 
control oesophagus from a patient suffering from oesophagitis, B: oesophageal SCC 
(OSCC) from a TOC patient, C: Sporadic OSCC. IHC was kindly performed by the Core 
Pathology Facility. 
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5.2.6 A possible link between NOTCH1 expression and the 
iRHOM2-ADAM17 pathway in OSCC and HNSCC cell lines  
As LOF somatic mutations in NOTCH 1 are prevalent in SCC and NOTCH1 expression 
appeared up-regulated in TOC keratinocytes, western blots were carried out with an 
antibody against total NOTCH1 in OSCC and HNSCC cell lines with the AbCam ChIP 
grade antibody which recognises total NOTCH1.  
5.2.6.1 NOTCH1 in OSCC cell lines 
In OSCC and HNSCC cell lines where iRHOM2 and ADAM17 levels appeared higher, 
levels of full length and cleaved NOTCH1 also appeared increased (figure 5.2.7). Of the 
OSCC cell lines TE-4, KYSE270 and KYSE410 (figure 5.2.7 A), KYSE270 cells had the 
highest level of the NOTCH1 S1 and S2/S3 fragments, correlating with high iRHOM2 
and active ADAM17 protein expression seen in figure 5.2, while lower levels of NOTCH1 
S1 and S2/S3 fragments seen in KYSE410 cells were associated with the low iRHOM2 
and mature ADAM17 expression. TE-4 cells had no visible NOTCH1 S1, but interestingly 
had a higher level of NOTCH1 S2/S3 (figure 5.2.7 A) with a relatively high proportion of 
mature ADAM17 (figure 5.2.7 A).  
Another faint band is also visible in the NOTCH1 western blot in the OSCC cell lines at 
about 170 KDa in the two KYSE cell lines (figure 5.2.7 A), which is absent in the TE-4 
cell line and not seen in any other NOTCH1 western blots, perhaps indicating a non-
specific band or a differently processed but stable form of NOTCH1. However, the 
sample size is too small to determine a correlation between iRHOM2 and NOTCH1 
expression.  
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Figure 5.2.7 NOTCH1 expression appears to correlate with iRHOM2 and ADAM17 
levels in HNSCC cell lines. Western blots with an antibody against total NOTCH1 
(AbCam ChIP grade) in A:  Oesophageal SCC cell lines, B: HNSCC cell lines. C-E: 
Densitometry analysis of western blots in HNSCC cell lines shown in B: The integrated 
density of iRHOM2 in the HNSCC cell lines (western blot shown fig 5.2.4) was plotted 
against the integrated density of  bands representing NOTCH1 S1 fragment (C),  
NOTCH1 S2 fragment (D) and NOTCH1 S3 fragment (E), all shown relative to GAPDH 
loading control. F-G: Densitometry of mature ADAM17 against NOTCH1 fragments 
S1 (F) and S2 (G) (also from fig 5.2.4). Densitometry was performed with Image Studio 
Lite software. Please note that this is preliminary data from one western blot. 
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5.2.6.2 NOTCH1 in HNSCC cell lines 
There also appeared to be a possible correlation between iRHOM2 and NOTCH1 levels 
in the HNSCC cells in a preliminary western blot (figure 5.2.7 B-D), with cell lines with 
the highest levels of iRHOM2 (50(2), 24n and NA) also showing the highest levels of 
NOTCH1 S1 and S2 fragments. In this western blot, perhaps because of the running 
conditions or protein loading, the S2 and S3 bands appeared to be visible separately, 
allowing densitometry of the individual S2 and S3 fragments.  
A band at the predicted molecular weight as full length NOTCH1 was also visible in some 
cell lines, shown in figure 5.2.7 B, although there was high background, and transfer of 
high molecular weight proteins may not have been consistent. Two out of three of the 
cell lines with highest iRHOM2 (NA and 50(2) but not 24n) had clear bands at this size, 
however, much weaker bands or no bands were visible at this size in the other cell lines, 
perhaps suggesting a correlation between total NOTCH1 expression and iRHOM2 
expression.   
When iRHOM2 expression (from the western blot shown in figure 5.2.4) was plotted on 
the X-axis against the NOTCH1 S1 fragment (~260 KDa) on the Y axis, the data fitted a 
linear trendline with an r2 value of 0.6060 indicating a moderate positive correlation 
(figure 5.2.7 C). There also appeared to be a less strong correlation between NOTCH1 
S2 and iRHOM2 expression (figure 5.2.7 D) with an associated r2 value of 0.4174. 
Interestingly, the correlation between NOTCH1 S1 and S2 appeared linear, suggesting 
that the link between the proteins may be indirect, or depend on other factors, perhaps 
including γ-secretase activity. The correlation was not seen when iRHOM2 expression 
was plotted against the band that likely represents the NOTCH1 S3 fragment (figure 
5.2.7 E), which had an r2 value of 0.0191 when a linear trend-line was plotted.  
This preliminary work was in a small number of samples with only one set of lysates, and 
needs further investigation to confirm the findings, but overall could suggest that 
expression of the NOTCH1 S1 and S2 fragments but not the S3 fragment may be 
dependent on iRHOM2 expression. This would also be consistent with ADAM17-
mediated S2 cleavage of NOTCH1 being dependent on iRHOM2 expression and activity 
levels. 
Scattergraphs showing densitometry of mature ADAM17 against NOTCH1 S1 and S2 
fragments also fitted linear trendlines with a similar correlation between mature ADAM17 
and NOTCH1 S1 (r2=0.6149, figure 5.2.7F), suggesting a moderate correlation. The 
relationship between mature ADAM17 and NOTCH1 S2 also showed a linear, although 
slightly less strong correlation (r2=0.4299). Further investigation of this would be 
interesting as ADAM17 may be expected to cleave NOTCH1 at the S2 stage. The scatter 
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graph also appeared to show two distinct populations with low and high mature ADAM17 
expression. This may be due to the small sample size, and further investigation is 
needed, but overall these data support further correlation between NOTCH1 expression 
and the iRHOM2-ADAM17 pathway.  
5.2.7 iRHOM2 localisation in frozen cancer sections 
5.2.7.1 Cutaneous SCC  
Symptoms of TOC include hyperproliferation in the skin, particularly of the palms and 
soles. Furthermore, cutaneous SCCs frequently show chromosomal imbalance or LOH 
on Chromosome 17q (Purdie et al., 2007), the location of the RHBDF2 gene. Therefore, 
IHC for iRHOM2 was performed in a panel of frozen tissue sections from sporadic 
cutaneous SCC, kindly provided by Dr Karin Purdie, Centre for Cutaneous Research, 
QMUL (figure 5.2.8). Sections D, E, I and J showed loss of chromosome 17, while 
chromosomes F, G and H had normal chromosome 17 copy numbers. 
The cutaneous SCCs seemed to retain a plasma-membranous localisation of iRHOM2, 
with higher levels of punctate intracellular staining in some sections such as sections C, 
E and I. This may be because the surface of some cells was included in the confocal 
image and is often seen in normal skin. The overall staining intensity of iRHOM2 
appeared reduced compared to normal skin, with particularly low intensity in sections F 
and J, although it is difficult to judge expression levels from immunofluorescence.  
5.2.7.2 iRHOM2 Localisation in Frozen Tumour Biopsies  
To see whether iRHOM2 localisation or expression was affected in a number of other 
sporadic cancers, IHC was performed on frozen tissue sections from breast carcinoma, 
breast ductal carcinoma, breast lobular carcinoma, neuroblastoma, endometrial 
adenocarcinoma, cervical SCC and lung SCC kindly provided by the Core Pathology 
facility. Initially, images were taken with the same microscope settings to allow some 
comparison of the iRHOM2 staining intensity. Unfortunately, matched normal tissue 
sections from the correct body sites were not available for control staining in the same 
tissue. Additional staining not shown in this chapter can be seen in appendix figures C1-
C5.  
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Figure 5.2.8 iRHOM2 shows cell-surface localisation and variable staining 
intensity in cutaneous Squamous Cell Carcinomas (SCCs). IHC of iRHOM2 was 
carried out in a panel of SCCs and normal skin. Images were taken on the LSM 510 
confocal microscope at magnifications of 20X, 40X and 100X. The settings were kept 
the same for each image to allow comparison. Sections were labelled alphabetically. 
Ai-ii: section C; Bi-ii section D; Ci-ii: section E; E: section F; F: section G; G: section H; 
H: section I; I: Normal skin, image taken at 40X. J shows the negative control in which 
primary antibody was omitted. N=2 for each biopsy. iRHOM2 staining is shown in green, 
DAPI nuclear staining in the negative control is shown in blue (J ii).  
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Plasma membranous staining was seen in distinct regions in a number of the tumour 
sections (figure 5.2.11, indicated by white arrows) with particularly clear membranous 
staining seen in regions of breast carcinoma (figure 5.2.11 A, B) and lung SCC 
(figure 5.2.11 C). Some less clear cell-surface staining was also seen in breast ductal 
carcinoma (figure 5.11 D) and neuroblastoma (figure 5.11 E). Where there was plasma 
membranous staining, there was still strong intracellular staining.   
In tumour regions without plasma-membranous iRHOM2 staining, the localisation 
appeared diffuse throughout the cells/tissue, perhaps including a lower level of plasma 
membranous staining. Cells in regions of some sections included brighter perinuclear 
staining, for example neuroblastoma (figure 5.2.11 F) and breast lobular carcinoma 
(figure 5.2.11 G), which could suggest an ER-localisation of iRHOM2. In the cervical 
SCC (figure 5.12 A-D), regions with lower levels of iRHOM2 staining also showed a 
patchier staining pattern, perhaps indicating faint perinuclear staining.  
A few sections showed brighter iRHOM2 staining at the tissue edges, indicated by 
orange arrows in the figures, for example in breast duct carcinoma (figure 5.2.11 H) and 
endometrial carcinoma (figure 5.2.11 I, J). 
5.2.7.2.1 High iRHOM2 expression in infiltrating immune cells.  
In regions of the cervical SCC with fainter iRHOM2 staining, several individual cells 
showed bright iRHOM2 staining (figure 5.2.12 A, B), perhaps representing infiltrating 
macrophages as iRHOM2 is expressed predominantly in immune cells (Su et al., 2004), 
as seen in the dermis of the skin (Chapter 3). Some individual cells with brighter iRHOM2 
staining could be seen to a lesser extent in endometrial adenocarcinoma (figure 5.12 C), 
and a small number of infiltrating-like cells could perhaps be seen in lung Carcinoma 
(figure 5.12 D) although this staining is less distinct and has a lower intensity than in the 
cervical SCC section. Breast carcinoma sections also contained cells with particularly 
high iRHOM2 staining intensity (figure 5.12 E).   
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Figure 5.2.9 Variable iRHOM2 expression (staining intensity) in a panel of frozen 
tumour sections compared to normal skin. IHC against iRHOM2 in frozen sections 
from A: normal facelift skin, B: negative control (normal skin; no primary antibody), C: 
breast carcinoma, D: breast duct carcinoma, E: breast lobular carcinoma, F: 
neuroblastoma, G: endometrial adenocarcinoma,   H: cervical SCC, I: lung carcinoma. 
Images were taken on the LSM 510 Confocal microscope. Settings were the same as 
those used for normal skin.  N=2 for each biopsy. 
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Figure 5.2.10 iRHOM2 expression varies between distinct tumour regions. IHC of 
iRHOM2 in frozen sections from A: cervical SCC, B: breast ductal carcinoma, C: 
neuroblastoma, D: endometrial adenocarcinoma. Images were taken on the LSM510 
confocal microscope. iRHOM2 is shown in green and blue staining represents DAPI 
nuclear staining. N=2 for each biopsy. 
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Figure 5.2.11 Membranous, cytoplasmic and perinuclear localisation of iRHOM2 is 
seen in different tumour sections. IHC of iRHOM2 in breast carcinoma (A, B), lung 
carcinoma (C), breast ductal carcinoma (D), neuroblastoma (E and F; F focuses on 
brighter perinuclear staining). G: breast lobular carcinoma H: breast ductal Carcinoma, 
I-J: breast ductal carcinoma. iRHOM2 staining is shown in green, DAPI nuclear stain in 
blue. Images were taken with the LSM 510 Confocal microscope. White arrows indicate 
plasma membranous staining, orange arrows indicate brighter iRHOM2 staining at the 
tissue edge.  N=2 for each biopsy.  
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Figure 5.2.12 iRHOM2 is strongly expressed in infiltrating cells in tumours. IHC of 
iRHOM2 in Cervical SCC (A, B), Endometrial adenocarcinoma (C), Lung carcinoma (D) 
Breast carcinoma (E). Red arrows indicated brightly stained individual cells that may be 
infiltrating macrophages, or tumour-associated macrophages (TAM). iRHOM2 is shown 
in green, DAPI nuclear stain in blue. Images were taken on the LSM 510 confocal 
microscope. N=2 for each biopsy. 
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5.2.8 Somatic mutations in iRHOM1 and iRHOM2 
The COSMIC database (Catalogue of Somatic Mutations in Cancer; 
http://www.sanger.ac.uk/resources/databases/cosmic.html) stores the currently known 
information on somatic mutations across the genome, and information about the tumours 
in which the mutations were found. The location of mutations throughout the iRHOM1 
and iRHOM2 structures was studied, as well as the tissue distribution of the mutations. 
Coding mutations were selected and compared with the Exome Variant Server (EVS) to 
eliminate single nucleotide polymorphisms (SNPs; appendix C6 and C7). Somatic 
mutations were marked onto the sequence of iRHOM1 and iRHOM2, and the Uniprot 
protein database http://www.uniprot.org/ used to determine the approximate distribution 
of the mutations throughout the predicted regions of the iRHOM1 and iRHOM2 protein 
structures. 
A number of mutations/sequence variants were found throughout the sequence of both 
iRHOM1 and iRHOM2 (figure 5.2.13), with a similar number of variations found in both 
iRHOM1 and iRHOM2: 22 and 25 mutations respectively (figure 5.2.14 B). The mutations 
were predominantly missense mutations, but five LOF mutations were found: three 
frameshift mutations (one in iRHOM1 and two in iRHOM2), and one nonsense stop 
mutation in each protein.   
5.2.8.1 Distribution of mutations throughout the protein structure  
The approximate distribution of mutations throughout the structure of iRHOM1 and 
iRHOM2 is shown in figure 5.14 A, with the number of mutations in each protein region 
shown in figure 5.14 B. Approximately half of the mutations were found in the 
characteristic long N-termini of the proteins (figure 5.14 C), which account for around half 
the amino acid sequence. No mutations were seen in the conserved region of the 
N-terminal in which the TOC mutations are found in iRHOM2. A number of mutations 
were found in the extended loop L1: 8 mutations in iRHOM2, including both frameshift 
mutations and the nonsense mutation; and 4 mutations in iRHOM1 including the 
frameshift mutation. Two mutations were found in the TMD of iRHOM1, 5 in iRHOM2 
TMD, and 1 mutation in loop L6 of iRHOM2. iRHOM2 lacked mutations in the C-terminal, 
whereas 3 mutations were found in this region of iRHOM1, which comprises 30 amino 
acids.   
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5.2.8.2 Tissue distribution of mutations:  
Mutations in iRHOM1 and iRHOM2 were found in a number of tissues (figure 5.15). 
iRHOM1 mutations were particularly concentrated in large intestine (13 mutations, 
1.86 % of samples tested) and lung (9 mutations, 1 % of samples tested). One mutation 
was found in cervical cancer samples out of 14 samples tested (7.14 %), and one in soft 
tissue out of 15 samples tested (6.7 %). iRHOM2 mutations were most prevalent in lung 
(8 mutations, 0.96 of samples tested); large intestine (5 mutations, 1.76 of samples 
tested); breast (5 mutations, 0.52 % of samples tested), and prostate (4 mutations, 1.25 
% of samples tested).  
Interestingly, three mutations were seen in iRHOM1 in oesophageal cancer (1.73 % of 
samples tested), but no somatic mutations in iRHOM2 have yet been reported (Weaver 
et al., 2014). The LOF nonsense and frameshift mutations in iRHOM1 were both found 
in the large intestine. In iRHOM2, one frameshift deletion mutation in was found in large 
intestine, the other in ovary; the nonsense mutation in iRHOM2 was found in breast.  
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Figure 5.2.13 Somatic mutations in iRHOM1 and iRHOM2 are distributed 
throughout the protein structure. Somatic mutations in iRHOM1 and 2 were extracted 
from the Collection of Somatic Mutations in Cancer (COSMIC) database. Amino acid 
residues affected by Mutations in COSMIC, and not found on the Exome Variant Server 
(EVS) are highlighted in the sequence of iRHOM1 (A) and iRHOM2 (B). Missense 
mutations are highlighted in yellow, frameshift mutations in green and Nonsense 
mutations in pink. R107 on the second line of iRHOM1 is underlined, as two mutations 
were found in this residue: R107C and R107H. Red letters indicate residues already 
identified as variants in ENSEMBL. Bold, purple letters indicate COSMIC mutations 
found on the EVS. Blue letters highlight alternative exons, the long underline indicates 
the residues absent in isoform 2 of iRHOM2, and the pink underlined letters show the 
TOC mutations.  
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Figure 5.2.14 Location of somatic mutations throughout the structure of iRHOM1 
and iRHOM2. A: Schematic showing structures of iRHOM1 (i) and iRHOM2 (ii) in the 
ER membrane. Approximate locations of the somatic mutations listed in the collection of 
somatic mutations in cancer (COSMIC) database are indicated: missense mutations by 
yellow rectangles; frameshift mutations by green rectangles; and nonsense mutations by 
pink rectangles. The rough location of the region in which TOC mutations are found in 
iRHOM2 are indicated on both proteins with a purple rectangle. Amino acid residue 
numbers are written in black. B: Bar chart indicating the number of mutations in iRHOM1 
and 2 in the different regions of the proteins. C: The percentage of the total mutations 
found in each region of iRHOM1 and iRHOM2.  
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Figure 5.2.15 Tissue distribution of somatic mutations in iRHOM1 and iRHOM2. 
The tissues in which mutations were found in iRHOM1 and iRHOM2 in the collection of 
somatic mutations in cancer (COSMIC) database are shown. A: Number of mutations 
found in each tissue. B: Percentage of total samples of each tissue containing mutations 
in iRHOM1 or iRHOM2.  
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5.3 Discussion 
 
5.3.1 Summary of Findings 
The main findings from this chapter are as follows: 
1) iRHOM2 and ADAM17 expression levels are variable between different tumours, 
shown by western blotting of OSCC and HNSCC cell lines, and IHC of TOC and 
sporadic OSCC tumours  
2) iRHOM2 showed a variable localisation and expression pattern, both between 
tumours and within individual tumours, shown by preliminary IHC experiments in a 
panel of frozen tumour sections 
3) ADAM17 and NOTCH1 expression appeared to correlate with iRHOM2 protein levels 
in OSCC biopsies and cell lines, and in HNSCC cell lines   
4) The ligand Ephrin B3, which is a substrate of rhomboid protease RHBDL2, appeared 
to be up-regulated in OSCC in sporadic and TOC tumours 
5) Somatic mutations in iRHOM2 and its homologue iRHOM1 reported in the COSMIC 
database were found throughout the structure of iRHOM1 and 2 and in tumours 
originating from a number of different tissues, with highest frequencies in large 
intestine and lung   
5.3.2 iRHOM2 localisation in cancer 
In this preliminary work, IHC showed variable localisation and expression of iRHOM2 in 
several frozen tumour biopsy sections including neuroblastoma, cervical SCC, lung and 
breast cancer. A major drawback is the lack of a normal control sample for comparison 
of iRHOM2 localisation (and expression) at the particular body site, particularly as little 
is known about the tissue-specific localisation of iRHOM2. Nevertheless, iRHOM2 
localisation appeared to be variable between different tumours and also within individual 
tumour sections, perhaps indicating some dysregulation in cancer, or cell-specific 
iRHOM2 activity.    
A stronger staining intensity was seen at the edges of some sections. ADAM17 
expression has been reported at the invasion front in glioblastoma stem cells (Chen et 
al., 2013), and a role for ADAM17 in invasion and metastasis was reported in a number 
of studies (e.g. Chen et al. 2013; Doberstein et al. 2013; Giricz et al. 2013; Lu et al. 
2013). As iRHOM2 and ADAM17 expression appeared to correlate in keratinocytes, 
OSCC and HNSCC cell lines (Chapter 4 and figure 5.2.4), this expression pattern in 
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cancer may suggest a particular role for the iRHOM2-ADAM17 pathway in invasion 
(and/or migration) in these tumour regions.  
Staining of iRHOM2 and ADAM17 in paraffin-embedded TOC and sporadic OSCC 
biopsies potentially suggested a more cytoplasmic localisation of iRHOM2 compared to 
control oesophagus in some tumour regions (figures 5.2.1 and 5.2.6). The quality of the 
iRHOM2 staining in paraffin-embedded sections was fairly low, however, and the 
biopsies were a number of years old, which may have impacted on the staining quality. 
In addition, the number of tumours studied was small, but as a preliminary result, it 
suggests that further research into iRHOM2 localisation in OSCC and other cancers may 
be of interest.  
5.3.2.1 Tumour-Associated Macrophages 
iRHOM2 was predicted to be an ER-membrane protein with high expression in 
macrophages. There was indeed some bright staining in individual cells, particularly in 
cervical SCC (figure 5.2.12), indicative of infiltrating macrophages as seen in the dermis 
of normal and TOC skin (chapter 3). This could be confirmed in future by co-staining with 
macrophage marker CD68. Strong iRHOM2 staining in macrophages is consistent with 
previous reports of iRHOM2 expression (Adrain et al., 2012; McIlwain et al., 2012; 
Issuree et al., 2013), and with co-localisation of iRHOM2 and CD68 in the dermis of 
normal and TOC frozen skin biopsies in Chapter 3.  
Macrophages have been shown to play a particular role in tumour development, with a 
change in phenotype to Tumour Associated Macrophages (TAM). The cells seen may 
therefore represent classically activated (M1) macrophages, which play important 
cytotoxic anti-tumour roles, or tumour-associated macrophages (TAMs) which can be 
found at various stages towards the alternatively activated (M2) macrophages, which 
have a wound healing phenotype and pro-cancer properties (Biswas and Lewis, 2010; 
Biswas and Mantovani, 2010; Rego, Helms and Dréau, 2014).   
TAMs in breast cancer have been associated with worse clinical outcome (Finak et al., 
2008; Beck et al., 2009), and many ADAM17 substrates shed by cancer cells are 
important in recruiting macrophages to the tumour tissue (Kenny and Bissell, 2007; 
Talmadge, Donkor and Scholar, 2007; Scheller et al., 2011) and in driving the change in 
phenotype to pro-tumour M2 macrophages. These ligands include colony-stimulating 
factor (CSF-1), TNF-α, intercellular adhesion molecule 1 (ICAM1), Vascular Cell 
Adhesion Molecule 1 (VCAM1), soluble IL-6 receptor, AREG and TGF-α (Rego, Helms 
and Dréau, 2014). Pro-tumour roles of TAMs include promotion of angiogenesis, ECM 
degradation, promotion of tumour cell invasion, and suppression of anti-tumour immune 
responses (e.g. Lin et al. 2001; Lin et al. 2006; Ojalvo et al. 2009; Erreni et al. 2011).  
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TAMs are recruited to specific regions of the tumour microenvironment, and 
macrophages with different protein profiles are found in different tumour regions 
depending on local stimuli such as hypoxia and level of vascularisation (Lewis et al., 
2000; Mantovani et al., 2002; Biswas and Mantovani, 2010). Inflitration of macrophages 
into specific tumour areas is consistent with the localisation seen in the cervical SCC 
biopsy, with brightly-stained macrophages in regions of lower iRHOM2 expression.  
5.3.3 Correlation between iRHOM2 and ADAM17 levels in cancer 
cell lines 
iRHOM2 and ADAM17 both appeared at variable levels in OSCC and HNSCC cancer 
cell lines, consistent with variable iRHOM1 expression levels seen in HNSCC cell lines 
(Yan et al., 2008). Variation in iRHOM2 staining intensity was also seen in cutaneous 
SCC sections, although this could result from different processing of the biopsies, or 
bleaching of some sections during microscopy.  
Results in chapter 4 and this chapter suggest a correlation between iRHOM2 and 
ADAM17 expression: reduced iRHOM2 in cutaneous keratinocytes treated with ADAM17 
siRNA; higher ADAM17 and iRHOM2 staining in the same regions of OSCC tumour 
biopsies; reduced iRHOM2 in a patient with homozygous LOF mutations in ADAM17; 
and western blots of iRHOM2 and ADAM17 protein levels in OSCC and HNSCC cell 
lines. Ideally, a larger number of samples would be used, particularly of OSCC cell lines, 
to allow testing for the correlation between iRHOM2 and ADAM17 expression levels. 
Results for the HNSCC cell lines were also limited to one set of lysates. However, 
although preliminary, the data are consistent from several experiments, and because 
iRHOM2 is critical in the processing of ADAM17 (Adrain et al., 2012; McIlwain et al., 
2012), it would be logical for regulation of the expression of the two proteins to be linked.   
The lack of a normal control cell line for OSCC and HNSCC makes determination of 
normal iRHOM2 levels impossible in these tissues. However, there was clear variability 
in expression between cell lines. OSCC cells were all grown in RPMI 1640 medium with 
RM+ keratinocyte supplement. This may not have been optimal for the TE-8 cell line, as 
some cell death was seen, but was kept the same to allow comparison between the cell 
lines after culture in the same conditions. The addition of RM+ supplement may also 
have been unnecessary for cancer cells, but it would have been necessary to 
supplement at least EGF had we acquired a normal oesophageal cell line. These factors 
could be considered for future culture of these cell lines. 
As iRHOM2 levels vary between regions in tumours from a number of tissues, the 
variability could reflect the area of the tumours from which the cell lines originated, for 
example from fibroblasts or keratinocytes. This could further indicate organ or tissue-
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specific expression of iRHOM2. Christova et al., (2013) reported particularly high 
iRHOM2 mRNA expression in the skin and lungs of wild-type mice, which also correlated 
with ADAM17 mRNA expression levels in these tissues, consistent with the results in this 
chapter and chapter 4.  
In general, iRhom1 was expressed at higher levels than iRhom2, and the highest levels 
of all three proteins were seen in the skin, lungs, large intestine and stomach (Christova 
et al., 2013). Interestingly, the greatest number of somatic mutations in iRHOM1 and 
iRHOM2 reported in the COSMIC database were in the large intestine and lung, with 
both LOF mutations in iRHOM1 found in large intestine, and one of the three LOF 
mutations in iRHOM2 found in cancer of the large intestine. As ADAM17 deletion causes 
a gut phenotype in humans (Blaydon et al., 2011), it may suggest that this pathway is 
important in the gut, particularly the large intestine. This data may also highlight the 
tissue-specific expression of iRHOM2.  
The KYSE270 OSCC cell line, which showed particularly high iRHOM2 and ADAM17 
levels, originated from a well-differentiated tumour (Shimada et al., 1992). This may 
suggest an important role for iRHOM2 early in tumour development, which would be 
consistent with elevated iRHOM1 levels in breast cancer at stage 1 and 4 tumours, but 
not in stage 2 and 3 tumours (Yan et al., 2008).  
5.3.4 ADAM17 Activity 
ELISAs showed variable secretion of AREG and TGFα into culture medium between 
TE-4, KYSE270 and KYSE410 cells, and also variable mRNA expression of the proteins. 
The qPCRs had very little signal in RT- samples, and strong signal in samples where 
reverse transcriptase was included, suggesting that results were specific and not due to 
contamination. Use of ADAM17 inhibitors in future studies may help to clarify the 
variation seen between mature ADAM17 protein and AREG and TGF-α mRNA levels 
and shedding.  
The variability seen in AREG and TGF-α shedding is consistent with previous studies 
showing variable expression of TGF-α, AREG and other ADAM17 ligands between 
different cancers. For example, TGF-α up-regulation was seen in breast-cancer 
associated fibroblasts (Gao et al., 2013), and invasion of triple-negative breast cancer 
cells was mediated by ADAM17 shedding of TGF-α (Giricz et al., 2013). Another 
explanation for variability could come from further regulation of ADAM17 activity, such 
as by microRNAs (Ostenfeld et al., 2010; Chen and Chang, 2013) or by protein 
disulphide isomerase (PDI) which has been reported to reduce ADAM17 enzymatic 
activity by catalysing the formation of disulphide bonds in the membrane proximal region 
(Düsterhöft et al., 2013).  
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5.3.5 NOTCH1 
Consistent with the increased expression of full-length and cleaved NOTCH1 in TOC 
cutaneous keratinocytes described in Chapter 4, a positive correlation between iRHOM2, 
ADAM17 and NOTCH1 protein expression was seen in HNSCC cell lines. There is a 
high level of background in the NOTCH1 western blot, which could affect densitometry 
analysis. However, the Image Studio Lite software used for the analysis corrects for 
background.   
The correlation may imply regulation of NOTCH1 via ADAM17-mediated cleavage (likely 
ligand-independent cleavage), and NOTCH1 expression appeared to correlate with 
iRHOM2 and ADAM17 expression up to the S2 cleavage stage in the HNSCC cell lines. 
However, the correlation between mature ADAM17 and NOTCH1 appeared to be weaker 
than the iRHOM2-NOTCH1 and iRHOM2-ADAM17 correlations. This could reflect 
inaccuracies in densitometry measurements, as the pro- and mature ADAM17 bands are 
fairly close together. Alternatively, it could perhaps reflect an indirect association with 
Notch signalling. Future work using ADAM17 inhibitors may help to determine whether 
ADAM17 is directly affecting NOTCH1 expression. Investigation of ADAM10 in these 
cells would also be useful to determine whether its expression and activity is also related 
to NOTCH signalling. 
High NOTCH1 expression was also seen in the KYSE270 OSCC cell line, which 
expressed high iRHOM2 and mature ADAM17, consistent with the correlation seen in 
HNSCC cell lines, although the sample size was again very small and no loading control 
was included in this experiment. However, the differences between NOTCH1 in the cell 
lines are quite pronounced, and the same sets of lysates gave consistent loading in 
ADAM17-iRHOM2 western blots.   
The COSMIC cell line project has records of NOTCH1 substitution mutations in 
KYSE270 cells (http://cancer.sanger.ac.uk/cell_lines/sample/overview?id=753574; 
c.1393G>C, p.A465P; c.1393G>C, p.A465P) and two non-protein changing mutations). 
No NOTCH1 mutations were reported in KYSE410 
(http://cancer.sanger.ac.uk/cell_lines/sample/overview?id=753574; accessed 19.4.14) 
or TE-4 cells (http://cancer.sanger.ac.uk/cell_lines/sample/overview?id=1503371; 
accessed 19.4.14). Two NOTCH1 mutations were reported in TE-8 cells 
(http://cancer.sanger.ac.uk/cell_lines/sample/overview?id=753574; both c.1318T>C, 
p.C440R). However, most reported somatic NOTCH1 mutations in SCCs are LOF rather 
than missense mutations (e.g. Weaver et al. 2014). Further investigation of a wider range 
of OSCC cell lines and study of iRHOM2/ADAM17 inhibition on cell properties such as 
migration and invasion would be interesting.  
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5.3.6 Ephrin B3 in cancer 
Ephrin B3 appeared up-regulated in TOC and sporadic OSCC in IHC experiments. 
However, the staining was carried out on a small sample set, and western blots did not 
appear to work with this antibody. Increased Ephrin B3 expression in OSCC would be 
consistent with findings in epithelial ovarian cancer (Castellano et al., 2006), where 
arteriole-specific Ephrin B3 staining was seen in normal ovarian epithelial tissue and no 
staining in stromal cells, but increased Ephrin B3 staining intensity in cancerous tissue. 
The localisation was partly at the cell membrane and in the cytoplasm in the ovarian 
tumours, with some nuclear staining visible (Castellano et al., 2006); the staining in figure 
5.2 appeared to show Ephrin B3 staining throughout the cell in the tumour samples. In 
epithelial ovarian cancers, expression of the Ephrin B3-EphB4 ligand pair was 
associated with worse survival (Castellano et al., 2006). 
A role for Ephrin B3 in glioma cell migration and invasion was shown, with Ephrin B3 
required for EphB2/Fc-mediated migration in glioma cell lines via Rac1, an important 
regulator of cell motility (Nakada et al., 2006). Furthermore, increased Ephrin B3 
phosphorylation correlated with tumour grade in glioma specimens (Nakada et al., 2006). 
Knock down of Ephrin B3 in non-small-cell lung cancer (NSCLC) cells affected 
proliferation and cell morphology (Ståhl et al., 2011, 2013), and Ephrin B3 expression 
was associated with EphA2 phosphorylation at Ser-897, downstream of Akt 
phosphorylation in NSCLC (Ståhl et al., 2011). Further study of the wider Eph/Ephrin 
signalling pathway would be of interest in TOC and OSCC in association with iRHOM2-
ADAM17 signalling, as EphA2 and EphA4 appeared to be altered in TOC cutaneous 
keratinocytes. 
5.3.7 Conclusion 
Taken together, these findings show variation in iRHOM2 expression and localisation in 
a number of cancer tissues and cell lines, particularly OSCC and HNSCC, perhaps 
suggesting that iRHOM2 may be dysregulated in these cancers. Furthermore, the 
iRHOM2-ADAM17 pathway may play a role in modulating the immune response to 
cancer, as high expression of iRHOM2 was seen in infiltrating macrophage-like cells in 
cervical cancer and breast cancer, and ADAM17 and its substrates have been implicated 
in the tumour immune response in a number of previous studies. The results are 
preliminary and performed on a small number of samples, but suggest that iRHOM2 may 
be of interest for further investigation in cancer progression as a regulator of ADAM17, 
EGFR and growth factor signalling, and perhaps the NOTCH signalling pathway.  
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Chapter 6: Discussion 
This work began with investigation of the localisation and expression of iRHOM2 in 
normal and TOC skin. Following electron microscopy imaging of TOC epidermis showing 
desmosomal dysregulation, the expression and localisation of desmosomal proteins was 
investigated, including ADAM17 substrate DSG2. The function of iRHOM2 in relation to 
trafficking and activation of metalloproteinase ADAM17 was studied and preliminary 
work carried out to look at the pathways that may be affected in TOC downstream of 
ADAM17-EGFR signalling. Finally, preliminary work investigating the expression and 
localisation of iRHOM2, and expression of ADAM17 and NOTCH1 was carried out in 
OSCC and HNSCC cell lines and OSCC biopsies.   
6.1 Overview of findings 
Missense mutations in the N-terminus of iRHOM2 associated with the autosomal 
dominant condition TOC appear to be GOF in nature, resulting in increased processing 
and activation of metalloproteinase ADAM17. This leads to increased levels of cell-
surface ADAM17, and increased cleavage of ADAM17 substrates including EGFR 
ligands and DSG2. A schematic summarising this mechanism and possible downstream 
effects is shown in figure 6.1 A and B. 
Increased ADAM17-mediated cleavage of EGFR ligands including AREG and TGF-α 
leads to amplified EGFR signalling. This causes a wound healing phenotype in TOC 
epidermis, features of which include increased migration of TOC keratinocytes and 
desmosomal re-modelling. Increased migration may be mediated in part by changes in 
Eph/Ephrin signalling, and is also associated with increased proliferation of TOC 
keratinocytes (Blaydon et al., 2012). In the basal layer of the epidermis, desmosomal 
remodelling may also be mediated by increased processing of DSG2 by ADAM17, further 
affecting the formation and maintenance of desmosomes. Desmosomal remodelling may 
also be associated with effects on cell-cell adhesion.  
Increased ADAM17 activity also appears to result in increased activity of TGM1, leading 
to increased barrier formation in TOC epidermis, and reduced levels of infection (Brooke 
et al., 2014), which may be associated with changes in NOTCH1 activity.  
Further work is needed to determine why the TOC iRHOM2 mutations lead specifically 
to oesophageal SCC. The oesophagus is subjected to high levels of physical and 
chemical stress (e.g. alcohol, smoking and hot drinks), and ADAM17 and EGFR 
signalling are associated with the development and progression of a number of cancers, 
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as are Eph/Ephrin signalling and desmosomal dysregulation. Future investigation into 
these pathways may uncover some of the reasons for the occurrence of OSCC in TOC. 
6.2 How do iRHOM2 mutations lead to increased 
ADAM17 processing? 
The main mechanism by which the mutations in the N-terminus of iRHOM2 affect its 
signalling appears to be increased stability of the iRHOM2 protein, resulting in increased 
iRHOM2 activity. Hosur et al (2014) recently demonstrated increased stability of iRHOM2 
p.I186T, and showed increased stability of murine iRhom2 with an N-terminal truncation 
mutation found in mice suffering from a phenotype including hair loss, accelerated wound 
healing and tumour formation. The mutation, known as Cub (curly-bare), was previously 
described in Johnson et al (2003), and is caused by splicing of Rhbdf2 exons 1-7, 
resulting in production of an approximately 63.5 KDa protein, as the next start ATG is in 
exon 8.  
There was a greater reduction in iRHOM2 immunoreactivity of COS-7 cells 
overexpressing WT human iRHOM2 than in cells expressing either iRHOM2-p.I186T or 
the iRhom2-cub mutation following treatment with protein synthesis inhibitor 
cyclohexamide. Hosur et al (2014) also suggested that WT iRHOM2 itself may be 
regulated by targeting for ERAD (in addition to its targeting EGF for ERAD) as the half-
life (t1/2) of iRHOM2-WT was increased by treatment with proteasomal inhibitor MG-132, 
but the t1/2 of iRHOM2-cub was not affected. 
iRHOM1 has also been shown to be an unstable protein (Nakagawa et al 2005), with a 
PEST domain located in its N-terminal region. A PEST domain is a 12-60 amino acid 
long region rich in proline (P), glutamic acid (E), serine (S) and threonine (T), often 
flanked by positively charged amino acids (Rogers et al., 1986; Rechsteiner, 1988; 
Rechsteiner and Rogers, 1996), although the sequence itself does not contain positively 
charged amino acids. PEST domains are found in proteins such as enzymes and 
signalling molecules for which rapid changes in concentration are required (Rechsteiner, 
1988; Rechsteiner and Rogers, 1996), including NOTCH1 (Öberg et al., 2001; Weng et 
al., 2004; Bray, 2006). Interestingly, DSG1 also contains a PEST region (Garrod and 
Chidgey, 2008), likely relating to a signalling function of the cadherin such as its role in 
cell death.   
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Figure 6.1 A: Schematic showing hypothesis for the mechanism of iRHOM2 
mutations effect in TOC. Increased stabilisation of iRHOM2 results in its greater 
availability for trafficking of ADAM17 from the ER to the golgi, and ultimately 
increased levels of active ADAM17 at the cell surface. This results in enhanced 
shedding of ADAM17 substrates including EGFR ligands and desmosomal 
cadherin DSG2. Increases in EGFR signalling result in enhanced migration and 
hyperactive wound healing, and may also lead to desmosomal re-modelling, 
which is an important part of the wound healing response. Desmosomal 
remodelling may also be enhanced by ADAM17-mediated cleavage of DSG2, for 
example in the basal layers of the epidermis. There may also be some differences 
in downstream desmosomal signalling.  
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Figure 6.1 B: Pathways that may be affected downstream of enhanced EGFR 
signalling in TOC. Pathways affected in TOC, and affecting migration, proliferation, 
and likely adhesion may include Eph/Ephrin signalling, possibly mediated by EphA2 
and EphA4; increased transglutaminase activity and potentially NOTCH signalling, 
leading to enhanced barrier function and protection from infection. A major question 
remaining is the role of iRHOM2 at the cell-surface in squamous tissues, and 
whether this may involve interaction with and/or regulation of keratins. 
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Increased iRHOM2 stability is consistent with the apparent increase in iRHOM2 protein 
expression seen in some sets of lysates from TOC keratinocytes compared with control 
cells in the siRNA knock down experiments presented in Chapter 4. However, some 
results in this thesis suggested reduced levels of iRHOM2 protein in TOC (Chapter 3). 
This could perhaps result from signalling feedback and other regulatory mechanisms 
needed to tightly control iRHOM2 and ADAM17 expression and activity, which could 
mean that slight changes in conditions result in changes in iRHOM2 expression (and 
localisation), perhaps explaining some of the variability seen in results in the results 
shown this thesis.  
Hosur et al (2014) also demonstrated that iRhom2-cub was a GOF mutation of iRHOM2. 
They generated an Rhbdf2 knock-out mouse, which did not show a phenotype and had 
normal hair growth (consistent with the findings of McIlwain et al. 2012). They crossed 
the Rhbdf2 knock-out mice with Rhbdf2cub/cub mice to generate compound mutant mice. 
These mice had sparse hair, showing that expression of Rhbdf2cub rather than loss of the 
protein is the cause of the phenotype.  
6.2.1 The effect of increased iRHOM2 stability on EGFR 
signalling 
Increased ADAM17 trafficking resulting from N-terminal mutant iRHOM2 stability leads 
to elevated shedding of EGFR ligands by ADAM17. This leads to increased EGFR 
signalling, which is reflected in the TOC hyperproliferative phenotype (Blaydon et al., 
2012; Brooke et al., 2014). The Rhbdf2Cub/Cub truncation also resulted in increased 
migration and accelerated wound healing in MEFs and mouse ear punch wounds (Hosur 
et al., 2014). Increased proliferation was seen in Rhbdf2cub/cub MEFs (Hosur et al., 2014), 
consistent with increased proliferation and migration of TOC keratinocytes (Blaydon et 
al. 2012; Brooke et al. 2014; Chapter 4), and with hyperproliferation and thickening of 
skin in response to stress (Ellis et al., 1994; Hennies, Hagedorn and Reis, 1995; Stevens 
et al., 1996).  
The Rhbdf2Cub/Cub phenotype of accelerated wound healing was associated with 
increased phosphorylation of proteins of the EGFR signalling pathway, including Akt, 
mTOR, and p38MAPK, and also with increased EGFR internalisation, consistent with 
increased activation of the pathway (Hosur et al., 2014). This is also consistent with the 
findings in TOC (Blaydon et al. 2012; Brooke et al. 2014; Chapter 4). Interestingly, 
Rhbdf2+/cub heterozygotes also showed accelerated wound healing, without the defects 
in hair growth and coat formation (Hosur et al., 2014), consistent with the dominant mode 
of inheritance of the iRHOM2 mutations in TOC (Blaydon et al., 2012).  
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A large proportion of the wound healing phenotype seen in Rhbdf2Cub/cub mice appears 
to be mediated by Areg: a LOF point mutation was identified in Areg, known as AregMCub, 
which affects a splice site in exon 1. This results in gain of 22 extra nucleotides, disrupting 
the coding frame and adding a premature stop codon. Homozygous AregMCub reduced 
the hyperactive EGFR signalling and wound closure, while a single copy of the AregMCub 
gene prevented the hair loss phenotype seen in Rhbdf2cub mice. This genetic 
combination resulted in a wavy hair phenotype, suggesting that remaining phenotypic 
differences result from other changes in the EGFR pathway (Hosur et al., 2014).  
The accelerated wound healing phenotype in Rhbdf2cub/cub mice with N-terminal 
truncations of iRHOM2 therefore appear to result from increased Areg shedding rather 
than solely on ADAM17-EGFR ligand signalling, suggesting that increased AREG levels 
may also mediate the accelerated wound healing phenotype in TOC. Further evidence 
for the importance of growth factor balance in the skin and gastrointestinal system are 
demonstrated by the overlapping phenotypes associated with ADAM17 LOF mutation 
(Blaydon et al., 2011) and a LOF mutation in EGFR recently reported by Campbell et al 
(Campbell et al., 2014) in a patient suffering from an inflammatory bowel, lung and 
cutaneous syndrome, which resulted in death caused by infection at the age of two and 
a half.  
Overall, these findings suggest that iRHOM2 mutations in TOC stabilise the protein as 
seen with N-terminal truncation Cub mutation, but still allow trafficking of ADAM17, which 
is augmented through the increased longevity of iRHOM2 (Brooke et al., 2014; Hosur et 
al., 2014). Trafficking of ADAM17 appears to depend on the N-terminal of iRHOM2, as 
Rhbdf2Cub/cub mice showed defects in ADAM17 trafficking, but increased Areg secretion 
(Hosur et al., 2014). 
6.3 Regulation of iRHOM2 and ADAM17 expression 
In this work there appeared to be a correlation between iRHOM2 and ADAM17 protein 
expression levels, consistent with the findings of Christova et al (2013) in the mouse. 
The mechanisms of iRHOM regulation are beginning to be uncovered, with protein 
stability appearing to be a major factor regulating expression of both iRHOM1 and 
iRHOM2 (Nakagawa et al., 2005; Hosur et al., 2014). Expression could be further 
regulated by control of transcription and translation, regulatory proteins such as micro-
RNAs (miRNAs), and through feedback from various signalling pathways such as those 
downstream of EGFR signalling.   
Regulation of ADAM17 expression appears to vary depending on the cell type and 
situation. Two major pathways reported to be involved in up-regulation and activation of 
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ADAM17 include: TNF-α/ TLR-4–induced up-regulation of ADAM17, for example in 
response to LPS (e.g. Scott et al. 2011; Chanthaphavong et al. 2012); and hypoxia, 
which has been reported in conditions including rheumatoid arthritis and cancer 
(Charbonneau et al., 2007; Szalad et al., 2009; Wang, Feng and Li, 2013). 
6.3.1 Hypoxia-induced ADAM17 up-regulation 
ADAM17, along with TNF-α, is up-regulated by hypoxia through hypoxia-inducible factor-
1α (HIF-1α) in a number of cell types, including synovial cells (Charbonneau et al., 2007), 
vascular smooth muscle cells (VSMC) (Obama et al. 2014), the U87 glioma cell line 
(Szalad et al., 2009) and hepatocellular carcinoma cell lines (Wang, Feng and Li, 2013). 
Hypoxia results in up-regulation or activation of a number of transcription factors, 
including NF-κB (Koong, Chen and Giaccia, 1994) and HIF-1α (Wang and Semenza, 
1995; Wang et al., 1995).  
HIF-1α is usually degraded in normoxic conditions by oxygen-dependent prolyl 
hydroxylation, leading to ubiquitination and proteasomal degradation (Bruick and 
McKnight, 2001). In hypoxia, HIF-1α is regulated by RACK1, which forms a complex with 
Elongin C and E3 ubiquitin ligases, also leading to HIF-1α degradation. The molecular 
chaperone HSP90, however, competes with RACK1 for binding to HIF-1α, and when 
bound, stabilises HIF-1α (Liu et al. 2008). This allows it to be targeted to the nucleus 
where it regulates gene transcription in association with HIF-1β (Liu and Semenza, 2007; 
Liu et al., 2008), which is present constitutively in normoxic and hypoxic conditions 
(Wang and Semenza, 1995).  
 
Hypoxia-mediated regulation of ADAM17 appears in part to be mediated by iRHOM 
activity. iRHOM1 was recently shown to regulate HIF-1α in breast cancer, and its 
expression is associated with poor response to treatment (Zhou et al., 2014), suggesting 
the development of drug resistance with iRHOM1 expression. iRHOM1 was shown to 
regulate HIF-1α by binding RACK1, sequestering it from HIF-1α, and therefore 
preventing RACK1-mediated HIF-1α degradation. Zhou et al (2014) therefore suggested 
that iRHOM1 is part of a molecular switch controlling HIF-1α stability.  
This provides further insight into the link between regulation of iRHOM and ADAM17 
expression. The similarity in protein sequence and overlapping functions of iRHOM1 and 
2 suggest that this pathway, or a similar pathway, may be regulated by iRHOM2 and may 
be an area for future investigation.  
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6.3.2 Micro-RNA regulation of ADAM17 expression 
Micro-RNAs are emerging as important regulators of ADAM17. miR-122 and miR-145, 
for example, have been shown to be important in regulating ADAM17 expression in a 
number of cancer cell lines (Tsai et al., 2009; Chen and Chang, 2013). Micro-RNAs are 
highly conserved non-coding RNAs of approximately 20 nucleotides in length and 
predominantly function to regulate expression of a vast array of proteins by binding to 
the 3’ UTR of the mRNA (Ebert and Sharp, 2012). 
Hydroquinone-induced miRNA-122 down-regulation in human leukaemia cells caused 
up-regulation of ADAM17, likely via ERK activation (Chen and Chang, 2013); miR-122 
was also down-regulated in hepatocellular carcinoma with local intrahepatic metastases 
(Tsai et al., 2009). Restoring miR-122 expression in vitro or in vivo reduced invasion and 
migration of cell lines; and in vivo, reduced tumourigenesis, angiogenesis and 
development of intrahepatic metastases. Knock down of ADAM17 produced similar 
results, suggesting that this pathway may be a future therapeutic target (Tsai et al., 
2009).  
Yu et al (2013) demonstrated that miR-145 reduces expression of both ADAM17 and the 
SOX9 (SRY-box containing gene 9) transcription factor. ChIP assays demonstrated that 
SOX9 binds to the ADAM17 promoter (Yu et al., 2013), suggesting that it may be involved 
in mediating the effects of miR-145 on ADAM17 expression. Furthermore, miR-145 
expression was reduced in head and neck cancer, affecting proliferation, sphere 
formation and tumour volume (Yu et al., 2013).    
Recently, miR-152 was also shown to negatively regulate ADAM17 expression in human 
umbilical vein endothelial cells (HUVEC; Wu et al. 2014), reducing both proliferation and 
migration. A decrease in miR-152 expression may contribute to (or result from) the 
increase in ADAM17 expression in hypoxia, as miR-152 expression was decreased while 
ADAM17 mRNA and protein expression increased in hypoxic conditions. Furthermore, 
there was a reduction of circulating miR-152 in patients with atherosclerosis, while miR-
145 expression was unaffected, suggesting that the relationship between miR-152 and 
ADAM17 expression may be important in the pathogenesis of atherosclerosis (Wu et al., 
2014).   
6.4 Other functions of the iRHOMs 
Previously described functions of the iRHOMs include targeting of EGF for ERAD (Zettl 
et al., 2011), regulating substrate selectivity of protease substrates such as AREG and 
TGF-α (Nakagawa et al., 2005; Maretzky et al., 2013), and as described in the previous 
section, iRHOM1 has been shown to regulate HIF-1α stability (Zhou et al., 2014). This is 
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interesting as it suggests a further role for iRHOM1 in regulating ADAM17 expression 
and activity in addition to regulating ADAM17 trafficking. 
6.4.1 Substrate selectivity 
Both iRHOM1 and iRHOM2 have been shown to control substrate selectivity of EGFR 
ligands for shedding. iRHOM1 interaction with the unprocessed forms of TGF-α, with only 
a weak association with the mature, N-glycosylated TGF-α, was previously described by 
Nakagawa et al (2005). Interaction of iRHOM1 with one isoform of transmembrane HB-
EGF and with Spitz was also seen in transfected cells (Nakagawa et al., 2005). 
Interestingly, drosophila Star, which is needed for trafficking of Spitz in drosophila (Lee 
et al., 2001), co-localised with iRHOM1, but no interaction was seen between the two 
proteins (Nakagawa et al., 2005). No homologue of Star has been identified in the 
mammalian genome. As drosophila expresses a single iRHOM, it suggests that iRHOM1 
and 2 may have adapted to take the role of Star in mammalian cells, regulating EGFR 
ligand availability at the cell surface and providing a further mechanism for fine-tuning 
EGF signalling in different cell types.   
Maretzky et al (2013) identified the substrate selectivity of iRhom2, demonstrating in 
mouse embryonic fibroblasts (MEFs) that shedding of ligands including Hbegf, Areg, 
epiregulin and Kit ligand 2 is dependent on iRhom2, as shedding of these ligands was 
reduced in iRhom2 knock-out MEFs. Shedding of some other ADAM17 substrates such 
as TGF-α is dependent on iRhom1 (Maretzky et al., 2013). PMA-stimulated shedding of 
HB-EGF, which is needed for GPCR-mediated cross-talk with the EGFR/ERK1/2 
signalling axis (Prenzel et al., 1999; Maretzky et al., 2011), was almost completely 
abrogated in iRhom2 knock-out MEFS compared with WT controls, although mature 
ADAM17 was present in both WT and knock-out MEFs. iRhom2 did not appear to be 
involved with regulation of ADAM10-mediated ligand shedding (Maretzky et al., 2013).  
The difference in ligand shedding was seen in PMA-stimulated cells, but no great 
differences were seen in constitutive shedding in iRhom2 knock-out MEFs, or upon 
overexpression of iRhom2 although small differences may have been missed. This 
suggests that iRHOM2 is important in controlling substrate selectivity under stimulated 
conditions (Maretzky et al., 2013), and may act to regulate cellular response to specific 
situations, allowing fine tuning of signalling processes.   
Regulation of substrate selectivity was dependent on the N-terminal domain of iRhom2 
(Maretzky et al., 2013). Furthermore, Areg/AREG selectivity appeared to be controlled 
by iRHOM2 independently of ADAM17, as human or mouse Rhbdf2-Cub with the N-
terminal truncation was able to increase shedding of Areg, but was not able to traffick 
ADAM17 (Hosur et al., 2014). Expression of iRHOM2 p.I186T in HEK293T cells also 
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resulted in greater levels of AREG in conditioned medium and lower intracellular levels 
compared with Human WT iRHOM2 (Hosur et al., 2014).  
The regulation of Areg appears to be dependent on the rhomboid peptidase domain 
(Hosur et al., 2014), which is active in rhomboid proteases, but catalytically inactive in 
the iRHOMs (Lemberg and Freeman, 2007b; Adrain and Freeman, 2012). Deletion of 
the peptidase domain of Human iRHOM2 with the Cub N-terminal truncation diminished 
AREG secretion. Hosur et al (2014) also showed that the increased secretion of AREG 
and HB-EGF was dependent on the amino acid residues Glu-426 and Cys-432 in TMD 
4; and His-366 and His-475 in TMD2 and 6 respectively. These residues were also 
critical for the suppression of EGF via targeting for ERAD (Hosur et al., 2014). 
6.5 How might iRHOM2 dysregulation lead to cancer?  
iRHOM2 is involved in EGFR signalling through multiple mechanisms, including: direct 
regulation of ADAM17 activation; targeting EGF for ERAD (Zettl et al., 2011); and 
regulating ADAM17 substrate selectivity, including ADAM17-independent regulation of 
AREG (Maretzky et al., 2013). Increased EGFR signalling is known to mediate 
development and progression of many cancers, and ADAM17 has been implicated in a 
number of cancers through functions including shedding of EGFR ligands and adhesion 
proteins, and modulation of the immune response. The role of ADAM17 in cancer will be 
discussed further in the next section. It also seems likely that additional functions of 
iRHOM2 will be uncovered in future, which could provide further insight into the role of 
iRHOM2 in cancer.   
GOF in iRHOM2 resulted in increased susceptibility to tumour formation in a mouse 
model of human familial adenomatous polyposis (Hosur et al., 2014). ApcMin/+ mice 
heterozygous for iRhom2cub/cub showed decreased survival, as well as an increase in the 
number of polyps and tumour area. No increased incidence of cancer was seen in Rhbdf 
knock-out mice over two years, consistent with the Cub and TOC mutations being GOF 
in nature. Overall, this suggests that the more stable iRHOM2 increases the growth of 
epithelial tumours, but does not result in spontaneous incidence of cancer, i.e. provides 
a “conducive environment for, but does not drive” tumour development (Hosur et al., 
2014). 
This is consistent with the life-time risk of developing OSCC in TOC, which tends to occur 
by the age of 65, rather than patients developing oesophageal tumours early as seen 
with other cancer-driving mutations. The findings of Hosur et al. (2014), with regard to 
the effect of iRhom2 GOF on tumour development, provide further insight into the TOC 
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phenotype, and support the hypothesis of accelerated and dysregulated wound healing 
in tissues subjected to stress.  
6.5.1 ADAM17 in cancer development and progression 
As described in Chapter 1, ADAM17 expression and activity is dysregulated in a number 
of cancer types including NSCLC (Zhou et al., 2006; Ni et al., 2013), gastric cancer 
(Warneke et al., 2013), ovarian, prostate, breast (Lendeckel et al., 2005; Kenny and 
Bissell, 2007; Sinnathamby et al., 2011; Narita et al., 2012),  pancreatic (Ringel et al., 
2006), colorectal, gastrointestinal (Blanchot-Jossic et al., 2005; Nakagawa et al., 2005), 
and head and neck cancer (Stokes et al., 2010; Kornfeld et al., 2011). ADAM17 is also 
associated with tumour progression through immune modulation and recruitment of 
TAMs (e.g. Talmadge et al. 2007; Kenny & Bissell 2007; Scheller et al. 2011; Das et al. 
2012).  
ADAM17 has also been implicated in enhancing communication between tumour and 
stromal cells, thus mediating tumour progression. Cancer-associated fibroblasts isolated 
from breast tumours secreted higher levels of TGF-α than normal fibroblasts, and 
conditioned medium from the cells promoted growth of TGF-α-negative breast cancer 
cells (Gao et al., 2013). ADAM17, as well as ADAM10, may have a role in dampening 
the immune response by shedding major histocompatibility complex (MHC) class 1 
molecules required for tumour cell recognition by the immune system (Chitadze et al., 
2013).   
Recently, a role for ADAM17 in regulating stemness was also reported (Kamarajan et 
al., 2013; Hong et al., 2014). In HNSCC cell line UM-SCC-14A, orasphere formation (a 
marker of stemness) was inhibited by metalloprotease inhibitor TAPI-2 and by ADAM17 
shRNA, likely by inhibiting ADAM17-mediated cleavage of CD44. ADAM17 shRNA also 
reduced tumour incidence and volume (Kamarajan et al., 2013). RECK also inhibited 
expression of stemness markers in gastric cancer cells by suppressing ADAM17-
mediated NOTCH activation (Hong et al., 2014). In contrast, Guinea-Viniegra et al. 
(2012) reported suppression of skin cancer by ADAM17 through NOTCH-mediated 
differentiation.  
6.5.2 Eph/Ephrin signalling in cancer 
Results shown in chapters 4 and 5 suggested changes in EphA2 and EphA4 in TOC 
epidermis and keratinocytes, as well as a potential up-regulation of Ephrin B3 in 
preliminary IHC of OSCC biopsies. Further study of the wider Eph/Ephrin signalling 
pathway would be of interest in TOC and OSCC in association with iRHOM2-ADAM17 
signalling and downstream pathways. The Eph/Ephrin pathway has been implicated in 
proliferation, angiogenesis, invasion and metastasis in a number of cancers; Eph 
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receptors and Ephrin ligands also play complex roles in signalling and cross-talk with 
other pathways (Chen, 2012).  
EphA4 and EphA2 expression was reported as a prognostic factor in gastric cancer 
(Miyazaki et al., 2013), with high expression correlating with poor survival. In contrast, 
Giaginis et al. (2014) reported better survival associated with EphA4 expression in 
NSCLC patients, where expression was seen in low-grade tumours and associated with 
inflammation. The outcome of Eph receptor signalling may depend on the Ephrin ligands 
present, for example, Ephrin B3 inhibits the pro-apoptotic functions of EphA4 in adult 
neurogenesis (Furne et al., 2010), while Ephrin A1 acts antagonistically to EphA2 in the 
skin (Lin et al., 2010).   
A further potential tumour-suppressive role was described for EphA4 in regulating EMT 
and adhesion via the β1-integrin pathway in hepatoma cells (Yan et al., 2013): EphA4 
was down-regulated by MiR-10a, which was overexpressed in cancerous hepatoma 
tissues. Different effects of MiR-10a overexpression were seen in invasion and 
metastasis in vitro and in metastasis in vivo, perhaps relating to effects of EphA4 on the 
extracellular matrix (Yan et al., 2013). Yan et al. did not comment on the presence of 
Ephrin B3 or other Ephrin ligands, which could affect EphA4 signalling. This may also 
explain some of the differences seen between in vitro and in vivo effects of MiR-10a 
overexpression.  
EphA2 is perhaps the best studied Eph receptor in cancer, with high expression of this 
receptor frequently correlating with poor prognosis, for example in NSCLC, breast and 
pancreatic cancer (e.g. Duxbury et al. 2004; Brannan et al. 2009; Faoro et al., 2010; 
Kinch et al., 2003; Martin et al., 2008; Zhuang et al., 2010; Brantley-Sieders, 2012). In 
contrast to many findings of poor prognosis associated with EphA2 expression, 
favourable survival of patients expressing EphA2 and Ephrin A1 mRNA was reported in 
stage 1 NSCLC patients (Ishikawa et al., 2012). Higher EphA2 expression was reported 
more commonly in women, non-smokers and in tumours carrying EGFR mutations 
(Ishikawa et al., 2012). This is consistent with EphA2 as a target of EGFR signalling, but 
contrasts with the findings of Brannan et al (2009) who found higher EphA2 expression 
in smokers with K-ras but not EGFR mutations in NSCLC, and saw an association 
between increased EphA2 expression and poor prognosis. This indicates a tumour-
suppressor role for the Ephrin A1 ligand, demonstrating the different effects of ligand-
dependent and independent Eph/Ephrin signalling. Consistent with this, EphA2 and 
Ephrin A1 expression was shown to be mutually exclusive in breast cancer cell lines 
(Macrae et al., 2005). 
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EphA2 has been implicated in tumour initiation and progression (e.g. Zelinski et al. 2001; 
Duxbury et al. 2004; Brantley-sieders et al. 2008; Martin et al. 2008; Zhuang et al. 2010). 
Pro-tumour EphA2 signalling appears to be mediated in a mostly ligand independent 
manner (Brantley-sieders et al., 2008; Yang et al., 2011); Ephrin A1-dependent 
activation of EphA2 suppressed growth of prostate cancer cell line PC3 via inhibition of 
the Akt-mTORC1 pathway (Yang et al., 2011). This was consistent with the findings of 
Ishikawa et al (2012) in NSCLC. Knock down of EphA2 in glioma cell lines inhibited stem-
cell like properties, including self-renewal and stem cell marker expression, and also 
inhibited tumorigenesis of the cells in vivo. Stemness of the cells was inhibited by 
disrupting cross-talk with the Akt pathway, but this did not reduce tumorigenesis (Miao 
et al., 2014). As a role for ADAM17 in stemness was also described in HNSCC 
(Kamarajan et al., 2013; Hong et al., 2014), future investigation of a link between the 
ADAM17-EGFR-EphA2 signalling in cancer progression and stemness may be 
interesting.  
The different associations between EphA2 and EphA4 expression in terms of outcome 
or survival in different cancers demonstrate the complex and varying roles of Eph/Ephrin 
signalling. They may also indicate differential roles for EphA2 depending on the stage of 
tumour development and progression, and on the presence of Ephrin ligands. This also 
highlights the complexity of developing any potential therapies targeting the Eph/Ephrin 
pathway. However, targeting of EphB4 in a mouse model of oesophageal cancer 
appeared to be promising in preventing tumour progression (Hasina et al., 2013). 
Furthermore, inhibition of Ephrin B3 in NSCLC combined with ionising radiation 
treatment resulted in senescence, activation of cell-death pathways and alteration of the 
Akt pathway, a mechanism implicated in combined treatment with ionising radiation and 
staurosporine analogue PKC-142 to target radiation-resistant NSCLC cells (Ståhl et al., 
2013).  
As discussed in Chapter 5, EphB4 has been studied in cancer as a binding partner of 
Ephrin B3. In addition, EphB4 overexpression was identified in a number of cancers, 
including breast cancer (Wu et al., 2004), prostate cancer (Lee et al., 2005; Xia et al., 
2005), bladder cancer (Xia et al., 2006) and ovarian cancer (Kumar et al., 2007). EphB4 
mediated tumour cell survival, migration and invasion in vitro in addition to promoting 
tumour growth in a xenograft mouse model of breast cancer (Kumar et al., 2007). This 
likely occurred via ligand-independent signalling, as the presence of Ephrin B2 inhibited 
the viability of breast cancer cells. EphB4 is a substrate of ADAM17, and interestingly, 
its PMA-induced shedding was abrogated in iRhom2-/- MEFs (Maretzky et al., 2013) 
suggesting a further role for iRhom2 in regulating Eph/Ephrin signalling via ADAM17. 
EphB4 also appeared to be regulated by EGFR signalling in bladder cancer cell lines 
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and xenograft models, with EphA4 knock down reducing tumour volume by almost 80 %, 
and reducing in vitro migration, migration and angiogenesis (Xia et al., 2006).  
Increased expression of EphB4 was seen in OSCC and oesophageal adenocarcinoma 
(Hasina et al., 2013), as well as a correlation with the grade of the tumour. Hasina et al. 
(2013) also identified an increased gene copy number of EphB4 in a number of OSCC 
and adenocarcinoma tumour samples. EphB4-targeting siRNA and a small molecule 
inhibitor of EphB4 (AZ12489875-002) both inhibited proliferation and migration of OSCC 
and adenocarcinoma cell lines, and also reduced tumour growth in a chemically-induced 
oesophageal cancer mouse model. The development of the tumours in the mouse model 
was also associated with an increase in EphB4 expression (Hasina et al., 2013), 
consistent with a role for EphB4 in tumour growth.  
6.5.3 IGF-1 Receptor  
IGF-1R has also been implicated as a potential target for treatment of oesophageal  and 
gastrointestinal cancer (Piao et al., 2008; Adachi et al., 2014), and increased 
phosphorylation of IGF-1R in TOC keratinocytes compared to NEB1 control cells was 
seen in phospho-arrays shown in Chapter 4. Ligand binding and activation of IGF-1R 
results in downstream phosphorylation and activation of pathways including Akt and 
MAPK (Chitnis et al., 2008). IGF-1R expression is increased in a number of cancers 
(Baserga, 1994; Chitnis et al., 2008; Werner, 2012), including in a high percentage of 
oesophageal cancer samples (Ouban et al., 2003; Imsumran et al., 2007; Adachi et al., 
2014), and has been associated with Akt-mediated resistance to chemotherapy 
(Imsumran et al., 2007; Kyula et al., 2010; Adachi et al., 2014).  
IGF-1R is an important mediator of malignant transformation in many cells, often 
facilitating cancer progression after a ‘first hit’ driver event has occurred (Chitnis et al., 
2008; Werner, 2012). A number of clinical trials of therapies targeting IGF-1R in cancer 
are underway (http://www.clinicaltrials.gov/ct2/results?term=IGF-1R&Search=Search; 
accessed 21/7/14), including one phase II trial in oesophageal cancer testing IGF-1R-
targeting monoclonal antibody cuxitumumab in combination with chemotherapeutic 
agent paclitaxel (www.clinicaltrials.gov ref NCT01142388). However, targeting of IGF-1R 
can be complicated by its high homology to the insulin receptor (Imsumran et al., 2007). 
6.5.4 Desmosomes in cancer 
Dysregulation of adhesion molecules and cell-cell junctions is a critical step in the 
progression of cancer, with roles for proteins of AJ, TJ, connexins and desmosomes 
demonstrated in a wide range of cancers (Reynolds and Roczniak-Ferguson, 2004; 
Carneiro et al., 2012; Valenta et al., 2012; Ding et al., 2013; Gall and Frampton, 2013; 
Kwon, 2013; Runkle and Mu, 2013; Martin et al., 2014). Many desmosomal proteins have 
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been shown to be involved in intracellular signalling (Green and Simpson, 2007; 
Thomason et al., 2010), and desmosomes appeared dysregulated in TOC epidermis, 
which could suggest that dysregulation of desmosomal adhesion could be one of the 
mechanisms involved in development of OSCC in TOC.  
Desmosomes play a variety of roles in cancer through adhesion-dependent and 
independent processes. The increased processing of DSG2 by ADAM17 (Chapter 3; 
Brooke et al. 2014) could therefore play a role in OSCC development or progression. 
Alternatively, depletion of other desmosomal proteins due to DSG2 processing and/or 
increased EGFR signalling may have further downstream effects. DSG2 and PG play a 
role in mediating apoptosis and cell survival, for example (Brennan et al., 2007; Nava et 
al., 2007; Ryan et al., 2012).   
A role for DSG2 has been shown in a number of cutaneous cancers. Up-regulation of 
DSG2 was seen in basal cell carcinoma (BCC), SCC, sweat gland carcinoma and 
adenocarcinoma (Brennan and Mahoney, 2009). Re-localisation of DSG2 from the 
membrane to the cytoplasm and nucleus was seen in cutaneous SCC (Kurzen et al. 
2003; Brennan and Mahoney, 2009) and nuclear and cytoplasmic DSG2 was seen in 
mice overexpressing Dsg2 (Brennan et al., 2007). Furthermore, DSG2 was expressed 
more frequently in high-risk SCCs than low-risk SCCs (Kurzen et al., 2003), perhaps 
suggesting a role in cancer progression outside of adhesion in the desmosome.  
DSG2 overexpression in the suprabasal layers of transgenic mouse skin caused 
alteration in cytoskeletal organisation, cornified envelope hyperplasia and 
hyperproliferation. Over half of the mice developed benign papillomas by 6 weeks to 3 
months of age, and the mice were much more susceptible to chemical-induced 
carcinogenesis, although no increase in the invasiveness of the tumours was seen 
(Brennan et al., 2007).   
Other desmosomal proteins are also dysregulated in a number of other cancers, acting 
as tumour suppressors or mediating cancer development through adhesion-dependent 
and independent mechanisms (Brooke et al., 2012; Al-Jassar et al., 2013). Some recent 
examples include the following: Reduced expression of DSG3 correlated with worse 
survival in oesophageal SCC (Fang et al., 2014) with protein levels correlating with those 
of PG and DSP. Overexpression of DSG3 in Head and Neck cancer primary tumours 
and cell lines correlated with tumour stage, depth and extracapsular spread in lymph 
nodes (Chen et al., 2007), while DSG3 knock down resulted in PG translocation to the 
nucleus in head and neck cancer cell lines, where it regulated cell migration, invasion 
and cell growth via the TCF/LEF transcription factors (Chen et al., 2013).   
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Reduced PG mRNA was seen in prostate cancer samples (Shiina et al., 2005) resulting 
from methylation, partial methylation and LOH mechanisms. Down-regulation of 
desmocollins has also been reported in a number of cancers (e.g. Cui et al. 2011; Cui et 
al. 2012a; Cui et al. 2012b; Kolegraff et al. 2011) and loss of DSC3 due to promoter 
methylation was a predictor of poor clinical outcome in colon cancer (Cui et al., 2011). 
DSP was also shown to act as a tumour suppressor by inhibiting the Wnt/β-catenin 
pathway in human lung cancer (Yang et al., 2012).   
A switch between DSG2 and DSG3 expression was seen in OSCC (Teh et al., 2011), 
suggesting that further investigation of DSG expression and processing in the 
oesophagus may be of interest, particularly as increased DSG2 processing was seen in 
TOC keratinocytes (Chapter 3; Brooke et al. 2014). Isoform switching was also reported 
for desmocollins in colon cancer and colorectal dysplasia (Khan et al., 2006). The 
p53/p63 target gene Perp, which is required for desmosomal assembly (Attardi et al., 
2000; Ihrie et al., 2005), may also play a role in tumour development, as Perpfl/fl mice 
were resistant to papilloma development after treatment with TPA (Marques et al., 2005).   
6.5.5 iRHOM1 in cancer 
Roles for iRHOM1 have been demonstrated in breast cancer and HNSCC. siRNA 
knock down of iRHOM1 affected pathways downstream of EGFR, shown by reduced 
levels of the phospho-ERK and phospho-Akt in MDA-MDB-435 breast cancer cells and 
HNSCC 1483 cells (Yan et al., 2008). In addition, knock down of iRHOM1 reduced levels 
of phospho-EGFR and its downstream target p44/p42 MAPK following stimulation with 
GRP (Zou et al., 2009). Basal levels of p44/p42 MAPK phosphorylation were reduced, 
as well as the ability of serum-starved HNSCC 1483 cells to migrate into matrigel in 
response to GRP (Zou et al 2009).   
siRNA knock down of iRHOM1 in MDA-MB-435 breast cancer cell lines reduced growth 
and proliferation and increased levels of apoptosis. Similarly, in HNSCC cell line 1483, 
siRNA against iRHOM1 caused a reduction in proliferation and an increase in autophagy 
(Yan et al., 2008). In addition, delivery of iRHOM1 siRNA to xenograft tumours made with 
MDA-MDB-435 cells or HNSCC 1483 cells significantly inhibited tumour growth (Yan et 
al., 2008). iRHOM1 levels were reduced by around 50 % in the tumours. 
As discussed in section 6.4.2, iRHOM1 regulates HIF-1α stability in breast cancer (Zhou 
et al., 2014). Increased RHBDF1/iRHOM1 expression correlated with increases in HIF-
1α expression, and was associated with worse prognosis, faster progression, and poor 
response to chemotherapy (Zhou et al., 2014). Targeting of iRHOM1 and HSP90 may 
therefore be a possible way to overcome drug resistance in cancer, which is often 
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associated with hypoxia. Further investigation of the role of both iRHOM proteins in 
hypoxia may be of interest in future studies of cancer progression.  
6.5.6 Why do iRHOM2 mutations specifically cause Oesophageal 
SCC? 
While the data presented in this thesis and that described in Hosur et al (2014) support 
the hypothesis of iRHOM2-TOC and iRHOM2-cub GOF mutations being associated with 
dysregulated, accelerated wound healing in tissues subjected to stress, the oesophagus 
is not the only area of the GI tract subjected to high levels of stress, and incidence of 
other cancers does not appear to be increased in TOC (Ellis et al., 1994; Stevens et al., 
1996).  
This suggests that tissue-specific variation in expression of iRHOM2 and other tissue-
specific factors may play a role in OSCC development in TOC. Some examples may 
include tissue-specific regulators of iRHOM2/ADAM17 expression such as miRNAs, 
downstream mediators of the signalling pathways affected, and the balance of growth 
factor signalling in the tissues.   
Tissue specific expression of other proteins may also play a role. For example, the 
presence or absence of Ephrin ligands affects the function of Eph receptors which may 
function in ligand-dependent or independent manners. Expression of specific 
desmosomal cadherins such as DSG2 may also be a factor that could affect adhesion 
and cellular signalling, and isoform switching of DSG2 and 3 has been demonstrated in 
oesophageal cancer (Teh et al., 2011). Results in chapter 4 suggest that NOTCH 
signalling may also be dysregulated in TOC. NOTCH is known to act as a tumour 
suppressor in some tissues, but as an oncogene in others (South, 2012), so disruption 
of the balance of this signalling pathway could contribute to tissue-specific effects at 
different stages of cancer development and progression.   
6.6 ADAM17 as a therapeutic target 
Due to its wide range of substrates, and its role in regulating and mediating a number of 
signalling processes such as shedding of inflammatory molecule TNF-α, ADAM17 was 
identified as a promising target for the development of small molecule inhibitors. These 
compounds were developed for treatment of a number of conditions, including 
rheumatoid arthritis and cancer, and were developed with varying degrees of specificity: 
many also target MMPs and other ADAM family members (Moss, Sklair-Tavron and 
Nudelman, 2008; Arribas and Esselens, 2009; Rose-John, 2013). Inhibition of ADAM17 
proved promising in pre-clinical studies and animal models, but results from early clinical 
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trials have given disappointing results with respect to both efficacy and toxicity (Moss et 
al., 2008).  
6.6.1 The effect of ADAM17 loss-of-function in mice and humans 
A major concern in targeting ADAM17 is the high risk of toxicity and adverse events. 
ADAM17 knock-out in mouse is lethal (Peschon et al., 1998). Horiuchi et al. (2009) 
generated a conditional ADAM17 knock-out mouse using the SOX9 promoter to 
specifically knock-out ADAM17 in non-haematopoietic cells. The mice survived 6-9 
months (into adulthood), suffering from growth retardation, infertility, skin defects, bone 
loss and osteoporosis-like symptoms. The mice also suffered defects in the 
haematopoietic system, which did not result from lack of ADAM17 in haematopoietic 
cells (Horiuchi et al., 2009). This also suggests that ADAM17 inhibition may have severe 
consequences, particularly in long-term chronic therapy. 
As described previously, loss of ADAM17 function in humans appears to result in a less 
severe phenotype (Blaydon et al., 2011), although ADAM17 LOF does result in severe 
inflammatory skin and bowel disease, and a high incidence of infection (Blaydon et al., 
2011), again suggesting that there are likely to be a number of adverse events 
associated with ADAM17 inhibition. A number of the effects of ADAM17 inhibition are 
likely mediated through reduced EGFR signalling, as a similar phenotype was associated 
with a LOF mutation in EGFR (Campbell et al., 2014). 
6.6.2 ADAM17 therapy in cancer 
As described earlier in this chapter, ADAM17 is overexpressed in a number of cancers 
including breast cancer (Borrell-Pagès et al., 2003), and is associated with poor 
prognosis and disease progression (e.g. Sinnathamby et al., 2011; Stokes et al., 2010; 
Zhou et al., 2006; Narita et al., 2012; Ringel et al., 2006; Kornfeld et al., 2011; Chen et 
al., 2013; Hong et al., 2014; Kamarajan et al., 2013). The role of ADAM17 in many 
different aspects of cancer development and progression (section 6.6.1), such as 
migration and invasion (Chen et al., 2013; Giricz et al., 2013; Gao et al., 2013; Wang et 
al., 2013; Das et al., 2012), angiogenesis (Blanchot-Jossic et al., 2005; Tsai et al., 2009) 
and immune cell recruitment and modulation (e.g. Lin et al., 2001; Lin et al., 2006; Kenny 
and Bissell 2007; Talmadge et al., 2007; Ojalvo et al., 2009; Erreni et al., 2011; Scheller 
et al., 2011), may suggest that inhibition of ADAM17 would provide a multi-faceted 
approach to targeting tumours. Furthermore, the nature of cancer, and more acute 
therapeutic strategy, may suggest a greater tolerability to adverse events than in a 
chronic condition such as arthritis (Arribas and Esselens, 2009).  
ADAM17 has been successfully targeted in a number of cancer cell models in vitro and 
in vivo (Kenny & Bissell 2007; Chen et al. 2013; Das et al. 2012; Giricz et al. 2013). 
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Sinnathamby et al (Sinnathamby et al., 2011) also identified ADAM17 as a target for 
immunotherapy in breast, prostate and ovarian cancers through specific processing of 
an ADAM17 HLA-A2 restricted epitope by cancer cells but not normal cells (Sinnathamby 
et al., 2011). INCB3619 has been shown to work synergistically with chemotherapeutic 
agent paclitaxel to reduce tumour volume in a mouse model of NSCLC (Zhou et al., 
2006) and Richards et al (2012) reported a specific anti-ADAM17 antibody, D1(A12), 
which showed anti-tumour effects in an in vivo ovarian cancer mouse model.  
ADAM17 has also been associated with acquired resistance to chemotherapy and 
therapies targeting the EGFR pathways. Some examples include resistance to cisplatin 
in hepatocellular carcinoma via EGFR/PI3K/Akt signalling (Wang et al., 2013); resistance 
to gefitnib in NSCLC via up-regulation of HER-3 and Akt (Zhou et al., 2006); and 
resistance to 5-fluorouracil (5-FU) in in vitro and in vivo models of colorectal cancer 
(Kyula et al., 2010). This ADAM17-mediated 5-FU resistance in colorectal cancer cells 
was also associated with up-regulation of HER-3, although ADAM17 siRNA only 
appeared to result in a small reduction in HER-3 levels. ADAM17 siRNA did help to 
reduced tumour volume in a xenograft model and reduce phosphorylation of EGFRY1068, 
however (Kyula et al., 2010). These findings suggest that combining EGFR tyrosine 
kinase inhibitors with ADAM17 inhibition may help to overcome one mechanism of 
resistance (Arribas and Esselens, 2009). In support of this, combined EGFR and 
ADAM17 inhibition therapy in breast cancer cells in vitro and in in vivo xenograft models 
resulted in synergistic inhibition of cell and tumour growth (Witters et al., 2008), including 
reducing levels of phosphorylated HER-3 and Akt, which are associated with 
chemotherapy resistance (Witters et al., 2008). 
6.6.3 Could targeting the iRHOMs represent an alternative 
method of targeting ADAM17?  
Targeting of tissue-specific downstream effectors, or ADAM17 regulators such as the 
iRHOMs, or perhaps miRNAs, may provide a more targeted, tissue-specific approach 
and reduce side effects associated with ADAM17-targeting therapy. iRHOM1 knock-out 
in mouse had severe consequences, resulting in death approximately 6 weeks after birth 
(Christova et al., 2013). However, although associated with severe inflammatory 
syndromes in humans, knock-out of ADAM17 and EGFR appears less severe (Blaydon 
et al., 2011; Campbell et al., 2014), so the same could be true of iRHOM1 as it regulates 
many of the same pathways. iRHOM2 knock-out mice appear generally healthy 
(McIlwain et al., 2012; Hosur et al., 2014), although response to infection was altered 
(McIlwain et al., 2012). Tissue-specific blocking of iRHOM2 would lead to specific 
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inhibition of ADAM17 maturation in the immune cells, but iRHOM1 would allow 
processing of at least some ADAM17 in other tissues (Rose-John, 2013).    
iRHOM2 appears to play an important role in modulating the immune system. As 
discussed in chapter 4.3, iRhom2-/- mice were protected against septic shock and liver 
damage (McIlwain et al., 2012), consistent with Mohler et al (1994) who showed 
protection against septic shock with ADAM17 inhibition, However, the defence of the 
iRhom2-/- mice against L. monocytogenes was impaired, with mice succumbing to the 
infection much more quickly than WT mice (McIlwain et al., 2012). Furthermore, TOC 
keratinocytes showed reduced adhesion and invasion of S. aureus, which was reversed 
by ADAM17 inhibition (Brooke et al., 2014) and interestingly, PMA stimulation of TOC 
PBMCs, but not LPS stimulation, produced a dramatic increase in shedding of TNF-α. 
Overall, this suggests that iRHOM2 may be a potential target for treatment of septic 
shock, but that inhibiting iRHOM2 may result in greater susceptibility to other types of 
infection. Indeed, anti-TNF-α therapies for treating rheumatoid arthritis were shown to be 
associated with increased incidence of infection in a meta-analysis of clinical trials and 
publications relating to TNF-α therapy (Bongartz et al., 2006).  
The tissue-specific expression of iRHOM1 and iRHOM2, with absence of iRHOM1 in 
immune cells, means that rheumatoid arthritis is another potential target for ADAM17 
inhibition. Issuree et al (2013) demonstrated a role for iRHOM2 in mediating rheumatoid 
arthritis, as mice lacking iRHOM2 were protected against K/BxN inflammatory arthritis, 
which was associated with increased iRhom2/ADAM17-dependent shedding of TNF-α. 
iRHOM2 may also therefore provide a tissue-specific target for modulation of ADAM17 
activity in the tumour immune response, as modulation of iRHOM2 may be compensated 
by iRHOM1 activity in non-haematopoietic tissues. Furthermore, the rheumatoid joint is 
hypoxic, and iRHOM1 mediates hypoxia-induced responses in breast cancer (Zhou et 
al., 2014), suggesting that research into iRHOM2 in hypoxia may provide further insight 
into its role in rheumatoid arthritis, and also in cancer, where iRHOM1 and ADAM17 are 
known to mediate hypoxia and HIF-1α-induced resistance to chemotherapy (Zhou et al., 
2014).  
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6.7 Future Work 
A number of findings in this work suggest further investigation and follow-up studies may 
be of interest, as well as performing further repeats of the experiments presented to 
confirm the findings, many of which are preliminary. Areas for further investigation 
include the localisation of iRHOM2, uncovering further binding partners and roles for 
iRHOM2, and further investigation of the Eph/Ephrin and NOTCH signalling pathways in 
keratinocyte migration, proliferation and adhesion. Further investigation of these 
pathways in oesophageal cancer and other squamous cell cancers such as HNSCC 
would also be of interest.  
6.7.1 iRHOM2 localisation 
During ICC experiments presented in this thesis, the localisation of iRHOM2 appeared 
variable, and in both IHC and ICC, the staining had a punctate appearance. To further 
investigate the localisation of iRHOM2, further co-localisation of iRHOM2 could be 
performed with markers of cell compartments such as the ER, golgi and vesicular 
markers, as well as further cell-surface markers and a marker of lipid rafts such as 
caveolin to further dissect the precise subcellular localisation of iRHOM2. Future IHC 
and ICC studies could include isotype-matched negative controls where the sections or 
cells are incubated with an IgG to ensure that the antibody is not binding non-specifically 
to cell-surface proteins via the IgG domain. This could be further confirmed biochemically 
with subcellular fractionation, for example sucrose gradients.  
Further confirmation of co-localisation with iRHOM2 binding partners could include 
techniques such as fluorescence-resonance energy transfer (FRET) or the DuoLink® 
assay (Olink bioscience, Uppsalla, Sweden; Gullberg et al. 2010), another method of 
measuring the distance between two proteins and whether they are likely to interact. 
DuoLink® is a proximity ligation assay in which cells are treated with two probes against 
one or two primary antibodies. The probes are detected only if they are within a certain 
proximity of one another, thus confirming co-localisation. Co-immunoprecipitation with 
ADAM17 and any other binding partners could also be performed to see whether 
iRHOM2 protein-protein interactions are affected in TOC, and to determine whether the 
stability of the iRHOM2-ADAM17 interaction is also enhanced in TOC.  
Live cell imaging experiments with tagged iRHOM2, ADAM17 and any other iRHOM2 
binding partners identified would show more about iRHOM2 regulation and trafficking in 
different conditions, for example whether iRHOM2 is recycled, and how quickly WT and 
mutant iRHOM2 is degraded in human skin (compared with the findings of Hosur et al. 
2014) 
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Finally, further investigation of the tissue-specific localisation of iRHOM2 would be of 
interest, for example in cancerous and adjacent normal tissue, and how this compares 
with the localisation of iRHOM1. Investigation of the cell-surface localisation of iRHOM2 
in squamous tissues is an important question currently being addressed (Dr Thiviyani 
Maruthappu, CCR, Blizard Institute, QMUL) in addition to identification of iRHOM2 
binding partners such as type I keratins following a yeast two hybrid screen, which may 
uncover further functions of iRHOM2.  
6.7.2 Migration and wound healing 
To further investigate the downstream pathways mediating the change in the rate of 
migration in TOC keratinocytes, in vitro scratch and proliferation assays could be 
performed in the presence and absence of siRNA and inhibitors of various cell pathways, 
such as members of the Eph/Ephrin family (including EphA2, EphA4 and EphB4), 
Insulin-R and IGF-1R. Migration assays with ADAM17 and ADAM10 inhibitors have been 
carried out by Dr Matthew Brooke, confirming that the increased migration is largely 
dependent on ADAM17. Transwell migration (and invasion) assays could be performed 
to look further at the migration phenotype in TOC, and in OSCC and HNSCC cancer cell 
lines with high and low iRHOM2 and ADAM17 expression.   
Experimental tools to further these findings may include development of stable cell lines 
as transient transfection efficiency of iRHOM2 was low in this work; wound healing 
assays in 3D skin and oesophagus equivalents; and potentially in vivo wound healing 
assays in a mouse model overexpressing the iRHOM2-TOC mutations. This could 
perhaps be compared with iRhom2-/- and iRhom2cub/cub mice if they were available. As 
changes appear to be mediated by AREG (Brooke et al., 2014; Hosur et al., 2014), 
treatment of cells with exogenous AREG, or conditioned medium from TOC cells with or 
without AREG, iRHOM2 or ADAM17 siRNA could determine how much of the effect in 
TOC is due to AREG shedding. This could further determine how much of the AREG 
shedding is independent of ADAM17, which often needs a stimulus such as 
PMA/ionomycin or LPS for its activity to increase above basal levels, including in 
ADAM17 overexpressing mice (Yoda et al., 2013).  
As iRHOM2 expression appeared concentrated at the edge of some tumour tissues, 
staining of iRHOM2 and ADAM17 at the edge of scratches in wound-healing assays in 
keratinocytes and OSCC cell lines would be of interest; in addition to invasion assays 
with and without iRHOM2 and ADAM17 siRNA or inhibitors.  
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6.7.3 Adhesion and desmosomal dysregulation 
As the desmosomes were dysregulated in TOC, and the Eph/Ephrin pathway has also 
been associated with cellular adhesion, further investigation of adhesion in TOC would 
be interesting. Initially, further experiments to investigate DSG2 processing could be 
performed, to increase the number of experiments, and to determine how much of the 
dysregulation depends on the change in EGFR signalling by using EGFR and ADAM17 
inhibitors, and iRHOM2 siRNA.    
To look further at desmosomal regulation in TOC, it would also be interesting to 
investigate expression and localisation of the desmosomal cadherins DSG1 and 3 and 
DSC1, which were not investigated in this thesis. Due to their expression predominantly 
in the upper epidermal layers, this could be performed in 3D raft cultures to determine 
whether their expression differs in a 3D stratified tissue structure. EM of 3D cultures with 
TOC keratinocytes with and without ADAM17 inhibitors or siRNA or inhibitors could be 
performed to look at the desmosomal midline. This could also be performed following 
treatment with ADAM17 and EGFR inhibitors. Processing of DSG2 and other cadherins 
could be studied with western blotting, to determine whether the lack of midline is a direct 
effect of EGFR signalling, or also dependent on other iRHOM2-dependent pathways.  
Dispase and adhesion assays could be performed in vitro to measure cell-cell adhesion 
in the different conditions, and the adhesion of TOC and control cells to the cell culture 
dish could also be tested. Stretching of the cells in monolayer followed by dispase assays 
and light microscopy could be a way to see whether subjecting the cells to mechanical 
stress stimulates an increase in wound healing behaviour of the cells, as 
hyperproliferation is seen in areas of stressed skin in TOC. ELISA assays to look at 
shedding of ADAM17 substrates could help determine which molecules may be 
mediating the response. Live cell imaging with tagged desmosomal proteins co-
transfected with WT and mutant iRHOM2 (or in stable cell lines) to investigate trafficking 
and assembly of desmosomes and how this is affected by the TOC mutations. 
Exogenous AREG or EGF could be applied to the cells during the imaging and the time 
course of any remodelling captured, with or without EGFR inhibitors.  
6.7.4 iRHOM2-ADAM17 regulation of expression and activity 
Regulation of iRHOM2 appears to occur at least in part through ADAM17, as ADAM17 
knock down also reduced levels of iRHOM2. It would be interesting to look at levels of 
iRHOM1 in the HNSCC cell lines, as iRHOM1 can also traffick ADAM17 from ER to golgi, 
and has been shown to be altered in HNSCC cell lines and breast cancer.  
ChIP assays are currently being performed by Dr Anissa Chikh to look at which 
transcription factors bind to the promoters of iRHOM2, ADAM17 and iRHOM1. This could 
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be followed by treatment of the cells with transcription factors in combination with a 
luciferase reporter assay for ADAM17 and iRHOM2 (and iRHOM1) to directly measure 
transcription and look further at regulation of their expression. This could be performed 
in the presence and absence of siRNA targeting the iRHOMs and ADAM17, and could 
be performed in control and TOC keratinocytes to determine how the mutations in 
iRHOM and increased activity affect regulation of the expression of proteins in this 
pathway. 
Further investigation of post-transcriptional regulation of iRHOM2 and ADAM17 would 
also be of interest, for example, screening to identifty which microRNAs regulate 
iRHOM2 and ADAM17 expression in the skin and oesophagus. Proteins that regulate 
ADAM17 protein activity could also be investigated, such as TIMP3. This could also be 
investigated in the OSCC cell lines, and may explain some of the variability seen in 
ELISA assays presented in chapter 5.  
6.7.5 NOTCH1 signalling 
Preliminary data suggested enhanced NOTCH1 signalling in TOC, and a potential 
correlation between NOTCH1, iRHOM2 and ADAM17 expression in cancer cell lines. 
Further characterisation of NOTCH1 signalling in TOC and control keratinocytes could 
include subcellular fractionation and western blotting of total NOTCH1 and NOTCH NICD 
in the presence and absence of ADAM17 and ADAM10 inhibitors to confirm NOTCH1 
localisation, which would also be useful to look at iRHOM2 and ADAM17 localisation. 
Use of ADAM17 and ADAM10 inhibitors followed by western blotting of NOTCH1 NICD 
and total NOTCH1 would determine whether NOTCH processing is in part mediated by 
enhanced ADAM17 activity. This is also being performed by Dr Anissa Chikh, CCR, 
Blizard Institute, QMUL.  
qPCR and western blotting of downstream NOTCH genes, e.g. slug. In the presence and 
absence of EGFR inhibitors, and investigation of feedback between EGFR and NOTCH 
signalling in control and TOC keratinocytes may also reveal more about the role of 
NOTCH signalling in TOC. The Ctip2 transcription factor, for example, controls EGFR 
and NOTCH expression (Zhang et al., 2012). 
It would be of interest to investigate other members of the NOTCH family in TOC skin 
and oesophagus, and to look at ADAM10 in these cells to determine whether its 
expression is also related to NOTCH signalling, and also whether ADAM10 activity and 
expression are affected by enhanced ADAM17 activity in TOC. Hosur et al (2014) 
reported decreased mRNA levels of ADAM10 substrate egf in iRhom2cub/cub mice. 
Investigation of NOTCH ligand expression and the effect of siRNA targeting NOTCH1 
would also be interesting to determine whether ligand-dependent or independent 
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signalling or a combination of the two is modified in TOC (as ADAM10 has previously 
been reported to be the major regulator of ligand-dependent signalling and ADAM17 
implicated in ligand-dependent signalling; Bozkulak & Weinmaster 2009). Further, 
determination of how NOTCH signalling is affected by the changes in EGFR signalling 
in TOC would also be interesting.  
6.7.6 Further investigation of iRHOM2-ADAM17 in cancer 
Further, in vivo assays could be performed to assess tumourigenesis and to investigate 
how increases in the iRHOM2-ADAM17 pathway enhance development and progression 
of cancer. ADAM17 has also been implicated in angiogenesis and the tumour immune 
response, so further investigation of these pathways would be of interest. Looking at 
expression of and the effect of inhibiting PI3K-Akt-mTOR signalling and the relationship 
with ADAM17-EGFR signalling in TOC in cancer cell lines, perhaps in relation to drug 
resistance, would also be interesting, as well as investigating how iRHOM1 is involved, 
and whether iRHOM2 also plays a role in mediating hypoxia-response and drug 
resistance. 
Investigation of tumourigenesis and angiogenesis in vivo could also be performed, e.g. 
Xenografts experiments with stable cell lines overexpressing WT and mutant iRHOM2 
could be performed in the presence and absence of ADAM17 inhibitors or siRNA against 
iRHOM1 or iRHOM2. Chemical carcinogenesis studies in mice overexpressing ADAM17 
(Yoda et al., 2013) may also be interesting, and further research of the role of AREG, as 
ADAM17 overexpressing mice did not appear to have increased ADAM17 expression in 
all tissues (Yoda et al., 2013).  
Investigation of iRHOM1 and iRHOM2 expression in primary tumours, and their 
association with poor survival / drug resistance (as in Zhou et al. 2014), particularly 
OSCC tumours, could help determine the stages of cancer development at which 
iRHOM2 is important. Further study of the Eph/Ephrin and NOTCH signalling pathways 
in OSCC may also be logical, as both these pathways have been widely implicated in 
cancer. The IGF2-IGF2R ligand-receptor pair was also associated with worse prognosis 
in epithelial ovarian cancer (Sayer et al., 2005), and may be of interest in OSCC 
research, as IGF-1R has been associated with oesophageal cancer.  
6.7.7 Other potential future studies 
ADAM17 activity has been implicated in a number of other diseases and conditions. The 
potential link with ADAM17 and Insulin-R / IGF-1R signalling and in mediating insulin 
resistance suggest that this pathway may be relevant to diabetes. Further investigation 
of iRHOM2 in diabetes models may therefore be of interest. Other functions of the 
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iRHOMs, such as ERAD, would also be interesting in TOC, and could be studied with 
proteasome inhibitors, as in Hosur et al (2014) for example.   
Active rhomboid protease RHBDL2 also regulates EGF signalling, and many inactive 
protease-family enzymes regulate the same pathways as their active counterparts 
(Adrain and Freeman, 2012). This suggests that there may be some feedback between 
RHBDL2 and iRHOM activity. Furthermore, preliminary IHC suggested there may be 
some dysregulation of RHBDL2 in TOC, so this may be another avenue of future 
investigation. Further investigation of the effect of enhanced iRHOM2 stability in TOC on 
feedback to iRHOM1 expression and signalling would also be interesting, as iRHOM is 
involved in the regulation of ADAM17 trafficking.  
6.8 Summary and Conclusions 
Mutations in the inactive rhomboid protein iRHOM2 cause TOC, which is associated with 
enhanced ADAM17 trafficking and shedding of EGFR ligands, and desmosomal 
dysregulation (Blaydon et al., 2012; Brooke et al., 2014). This leads to enhanced 
migration and proliferation and an accelerated wound healing response in TOC 
keratinocytes. This work also suggested potential dysregulation in Eph/Ephrin signalling 
and the NOTCH signalling pathway, and enhanced barrier function and protection from 
infection have also been associated with TOC (Brooke et al., 2014). The iRHOM2 
mutations appear to result from enhanced iRHOM2 stability, leading to increased 
availability and may also lead to enhanced shedding of AREG (Brooke et al., 2014; Hosur 
et al., 2014). Regulatory mechanisms of iRHOM2 and ADAM17 expression also appear 
to be related, including in cancer cell lines, and a role for this pathway in both OSCC and 
HNSCC has been suggested. Some points for future investigation include the role of 
iRHOM2 at the cell surface, determining which proteins and pathways are mediating the 
downstream effect of enhanced migration, and why TOC is specifically associated with 
oesophageal cancer. 
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Appendix A: 
Control experiments and supporting 
results for Chapter 3 
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Appendix A1 Anti-RHBDF2 antibody epitopes and confirmation of cell-surface 
iRHOM2 localisation in the skin. A: Alignments of the protein sequences of iRHOM2 
isoforms 1 and 2 with the antibody epitopes for (i) the anti-RHBDF2 antibody used 
throughout the thesis (from Sigma-Aldrich), and (ii) the custom-made antibody shown in 
part B. B: Cell-surface staining of iRHOM2 in the epidermis with an additional antibody: 
custom made anti-RHBDF2 antibody R2437. Images were taken on the Zeiss Meta 510 
confocal microscope. iRHOM2 staining is shown in green, and DAPI nuclear staining 
shown in blue. 
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Appendix A2 Controls for co-localisation between iRHOM2 and CD68 in frozen 
skin sections. A: CD68 staining with rabbit and mouse secondary antibodies B: 
iRHOM2 staining with rabbit and mouse secondary antibodies. C: Negative controls 
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Appendix A3 Control staining from β-catenin-iRHOM2 co-localisation in TOC skin 
sections shown in figure 3.2.7. A: β-catenin plus Rb and Mo secondary antibodies, B: 
iRHOM2 plus Rb and Mo secondary antibodies, C: negative control staining.  
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Appendix A4 Control staining for iRHOM2-CD68 co-localisation shown in Chapter 
3. Control staining was carried out in normal breast skin. Brightness and contrast are 
increased by 20 %, as in figure 3.2.8 in Chapter 3. Rb and Mo refers to the species of 
the secondary antibody used (anti-Rabbit or anti-Mouse) 
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Appendix A5 Repeats of the iRHOM2-GFP overexpression studies shown in figure 
3.2.10. Western blots were carried out with cell lysates from NEB1 or HEK293T cells 
overexpressing WT or mutant iRHOM2-GFP as indicated, and were performed with 
either anti-iRHOM2 or anti-GFP antibodies, also as indicated.  
 
 
 
 
 
 
297 
 
 
 
Appendix A6 Controls and additional images for figure 3.2.12. A and B: Negative 
controls for E-Cadherin (A), and PG (B) co-localisation with iRHOM2-GFP-WT. C: Co-
localisation of overexpressed iRHOM2-GFP-P189L with E-Cadherin. D: co-localisation 
of iRHOM2-GFP-I186T with β-catenin. iRHOM2-GFP is shown in green, E-cadherin and 
β-catenin shown in red, and DAPI nuclear stain in blue. Images were taken on the Zeiss 
Meta 710 Confocal microscope.  
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Appendix A7 Individual repeats of the desmosome western blots in chapter 3 
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Appendix A8 DSG2 in normal Epidermis: IHC of DSG2 was performed in normal 
frozen epidermis sections with antibody 10D2. A: Normal skin epidermis from breast 
tissue, B: Sweat glandd in the same normal skin section, C: negative control. Brightness 
and contrast were increased by 10 % for each image. DSG2 is shown in green, DAPI 
nuclear stain shown in blue. Images were taken on the Zeiss Meta 710 Confocal 
microscope.  
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Appendix A9 DSG1 staining in control and TOC epidermis. A: IHC was performed 
with an antibody against DSG1 in normal skin from breast tissue, and TOC Patient 1, 
Patient 2 and Patient 3. B: Negative control staining. DSG1 is shown in green and DAPI 
nuclear stain in blue. Images were taken on the Zeiss Meta 710 Confocal microscope.  
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Appendix A10 DSG1 ICC in control and TOC keratinocytes. ICC was performed in 
MeAc fixed cells. A: DSG1-stained cells are shown in the presence (i) and absence (ii) 
of DAPI nuclear stain. B: Negative control staining. DSG1 is shown in green, and DAPI 
nuclear staining shown in blue. Images were taken with the Zeiss Meta 710 Confocal 
microscope. 
 
 
  
I† 
302 
 
 
 
Appendix A11 DSG2 localisation in control and TOC cells. ICC was performed with 
the DSG2 10D2 antibody in MeAc-fixed cells after culture in the presence of EGF (A). 
B: shows negative control staining. DSG2 is shown in green, and DAPI nuclear stain is 
shown in blue. Images were taken on the Zeiss Meta 710 Confocal microscope.  
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Appendix A12 Staining of desmogleins 1 and 2 in control and TOC epidermis. IHC 
was performed on frozen skin sections with antibody DSG3.10 which recognises DSG1 
and 2 (A). DSG1 and 2 are shown in green, in the presence or absence of DAPI nuclear 
stain which is shown in blue. Negative control staining is shown in B. Images were taken 
in the Zeiss Meta 710 confocal microscope.  
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Appendix A13 DSC2 staining in control and TOC epidermis. IHC showing DSC2 
staining in normal skin from breast, and TOC patients 1 and 2, as well as negative control 
staining, as indicated. The images marked with * are from patient 1, with the same 
brightness but increased zoom compared to the images on the left. The images marked 
with † are from patient 2, with reduced brightness and increased zoom compared with 
the images on the left. DSC2 is shown in green and DAPI nuclear stain shown in blue. 
Images were taken on the Zeiss Meta 710 confocal microscope.  
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Appendix A14 DSC2 localisation in control and TOC keratinocytes. ICC of DSC2 in 
control and TOC keratinocytes (A) shown in the presence and absence of DAPI nuclear 
stain, which is shown in blue. DSC2 is shown in green. Negative control staining is shown 
in B. Images were taken on the Zeiss Meta 710 confocal microscope.  
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Appendix A15 DSC3 in normal and TOC skin. A: Normal skin from breast, B: Normal 
Facelift skin, C: TOC patient 1, D: TOC patient 2, E: TOC patient 3, F: Negative control. 
All shown in the presence and absence of DAPI nuclear stain, in blue. DSC3 staining in 
shown in green. Images were taken on the Zeiss Meta 710 Confocal microscope.  
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Appendix A16 DSC3 localisation in control and TOC keratinocytes. ICC was 
performed against DSC3, in MeAc-fixed cells, shown in A, with negative control staining 
in B. DSC3 is shown in green, and DAPI nuclear stain in blue. Images were taken on the 
Zeiss meta 710 confocal microscope.  
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Appendix A17 PG localisation in control and TOC epidermis. IHC was performed in 
normal frozen skin from breast, and TOC interfollicular epidermis. A: PG staining, B: 
negative control staining. PG is shown in green, DAPI nuclear staining in blue. Images 
were taken on the Zeiss Meta 710 LSM confocal microscope.  
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Appendix A18 PG localisation in control and TOC keratinocytes. ICC with an 
antibody against PG in MeAc fixed cells (A), with negative controls shown in B. PG is 
shown in green and DAPI nuclear stain in blue. Images were taken on the Zeiss Meta 
710 confocal microscope.  
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Appendix A19 PKP1 IHC in frozen sections from control and TOC epidermis. IHC 
against PKP1 was performed in normal skin (NS) from breast (Br) and facelift (FL), and 
in the interfollicular frozen skin sections from TOC patients 1, 2 and 3 as indicated. PKP1 
is shown in green, DAPI nuclear stain in blue. Images were taken with the Zeiss Meta 
710 confocal microscope.  
 
311 
 
 
 
Appendix A20 PKP1 localisation in control and TOC keratinocytes ICC with an 
antibody against PKP1 in MeAc fixed cells (A), with negative controls shown in B. PKP1 
is shown in green and DAPI nuclear stain in blue. Images were taken on the Zeiss Meta 
710 confocal microscope.  
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Appendix A21 PKP2 localisation in control and TOC keratinocytes ICC with an 
antibody against PKP2 in MeAc fixed cells (A), with negative controls shown in B. PKP2 
is shown in green and DAPI nuclear stain in blue. Images were taken on the Zeiss Meta 
710 confocal microscope.  
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Appendix A22 DSP localisation in control and TOC epidermis. IHC with the DSP 
11-5F antibody in MeAc fixed sections (A), with negative controls shown in B. DSP is 
shown in green and DAPI nuclear stain in blue. Images were taken on the Zeiss Meta 
710 confocal microscope.  
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Appendix A23 DSP localisation in control and TOC keratinocytes ICC with the DSP 
11-5F antibody in MeAc fixed cells (A), with negative controls shown in B. DSP is shown 
in green and DAPI nuclear stain in blue. Images were taken on the Zeiss Meta 710 
confocal microscope.  
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Appendix A24 iRHOM2 is up-regulated in HaCaT keratinocytes following DSP 
knock-down in one experiment. Western blots showing A: DSP isoforms 1 and 2 with 
vinculin loading control, and B: iRHOM2 with GAPDH loading control. These findings 
were not reproducible. C: IHC with antibody DSG3.10, which recognises both DSG1 and 
2 in normal epidermis, epidermis with ADAM17 LOF mutations, and in TOC patient 4.  
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Appendix B: 
Control Experiments and Supporting 
results for Chapter 4 - iRHOM2 
signalling pathways in the skin 
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Appendix B1 Repeats of the ADAM17 and iRHOM2 siRNA knock-down 
experiments shown in chapter 4. 
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Appendix B2 Densitometry analysis of phospho-RTK arrays shown in chapter 4 
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Appendix B3 Repeats of EphA2 and EphA4 western blots in keratinocytes 
following culture in the presence or absence of EGF (RM+ or RM-) 
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Appendix B4 NOTCH1 S1, S2 and NICD localisation in control and TOC epidermis 
with AbCam ChIP grade antibody. Images from two experiments are shown as 
indicated. NOTCH1 is shown in green, DAPI nuclear staining in blue. Scale bars 
represent 20 μm. Images were taken on the Zeiss Meta 710 confocal microscope.  
NS, normal skin; Br, breast; P1-3, patients 1-3; TT, tummy tuck. 
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Appendix C: 
Control Experiments and Supporting 
results for Chapter 5 – iRHOM2 
localisation and expression in cancer 
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Appendix C1 Variable localisation of iRHOM2 within tissue sections in a biopsy 
from a frozen Breast Carcinoma. Images represent different regions of the same 
biopsy at magnifications of 40X (A, B, C) and 100X (D, E) in the presence (ii) and 
absence (i) of nuclear marker DAPI, shown in blue. iRHOM2 staining is shown in green. 
Image C is shown with and without DAPI, with the right hand images a close-up of the 
region indicated by the white box. Images were taken with the LSM 510 Confocal 
Microscope. Microscope settings were varied to achieve the best picture of the 
localisation. Red arrows indicate small, brighter areas of tissue staining, perhaps 
indicating infiltrating immune cells. White arrows show examples of plasma membrane 
staining.   
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Appendix C2 iRHOM2 localisation in Breast Ductal Carcinoma and Breast Lobular 
Carcinoma. Frozen sections were stained and images are taken from regions of the 
samples. Breast Ductal Carcinoma is shown in A-C, and breast lobular carcinoma shown 
in D-G. Images were taken at magnifications of 10X (A, D), 40X (C, E, F) 100X (B, G) 
with (i) and without (ii) DAPI nuclear stain, shown in blue. The images on the right in Ci 
and Cii are a close-up view of the region indicated by the white box on the left hand 
picture. Images were taken on the Zeiss LSM 510 Confocal microscope and the settings 
adjusted for each image to visualise iRHOM2 localisation. White arrows indicate possible 
plasma membrane staining, and orange arrows indicate regions and the edge of the 
tissue that appear to have brighter iRHOM2 staining. Red arrows show individual cells 
with particularly bright iRHOM2 staining, potentially infiltrating macrophages.  
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Appendix C3 iRHOM2 localisation in Neuroblastoma. Immunohistochemistry of 
iRHOM2 in a frozen Neuroblastoma section. Images were taken at 10X (A), 40X (B,C) 
and 100X (D and E). Orange arrows represent brighter staining at a tissue edge, white 
arrows represent possible plasma membranous staining. Images were taken on the LSM 
510 confocal microscope. Microscope settings were adjusted for each picture. Image Ei 
and ii, the right hand images are zoomed in images of the region of the left hand images 
indicated by the white box. 
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Appendix C4 iRHOM2 localisation in Endometrial adenocarcinoma. 
Immunohistochemistry of iRHOM2 in a frozen section from an adenocarcinoma. Images 
were taken using the LSM 510 Confocal microscope at a magnification of 10X (A) or 40X 
(B-D). Microscope settings were adjusted for each region of the section. Orange arrows 
indicate brighter iRHOM2 staining at the tissue edge, and red arrows indicate brighter 
iRHOM2 staining in individual cells, possibly infiltrating immune cells although these cells 
are smaller than those seen in other tissue sections. 
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Appendix C5 iRHOM2 localisation in Cervical Squamous Cell Carcinoma and Lung 
Carcinoma. Images were taken at magnifications of10X (A, F), 40X (B, G) and 100X (C, 
D, H, I). Red arrows represent individual cells staining brightly for iRHOM2 (likely 
infiltrating macrophages), and white arrows indicate plasma membranous staining. 
Images were taken on the LSM 510 Confocal microscope. Microscope settings were 
adjusted for each individual image.  
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Appendix C6 iRHOM1 (RHBDF1) mutations from the COSMIC database 
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Appendix C7 iRHOM2 (RHBDF2) mutations from the COSMIC database 
 
